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Summary 
Malaria is an acute febrile illness and one of the most prevalent infectious 
diseases in the world. It is caused by protozoan parasites of the genus 
Plasmodium that are transmitted to their mammalian hosts through the bite of an 
infected female Anopheles mosquito [1, 2]. In 2015, there were an estimated 214 
million cases of malaria, which resulted in 438 000 deaths, most of them occurring 
in sub-Saharan Africa [1]. Overall, 3.2 billion people are estimated to be at risk of 
being infected by Plasmodium and developing the disease [1]. 
Upon the bite of an infected mosquito, Plasmodium parasites, termed sporozoites 
at this stage of the lifecycle, are deposited under the skin of their mammalian host, 
and are carried by the circulatory system to the liver, where they traverse several 
hepatocytes before productively invading a final cell [3]. Inside hepatocytes, each 
sporozoite develops into an exoerythrocytic form (EEF), containing thousands of 
newly formed merozoites that are eventually released into the bloodstream where 
they invade red blood cells, initiating the symptomatic, erythrocytic stage of the 
disease [4].  
During the asymptomatic liver stage of Plasmodium infection, the parasite 
undergoes a remarkably rapid growth, with 104- to 105-fold replication of its 
genome [5, 6]. To support their rapid multiplication and supply their metabolic 
pathways, parasites scavenge nutrients from the host hepatocyte [7-10]. It was 
previously shown that glucose plays a crucial role during the liver stage of P. 
berghei, establishing the importance of the import of this nutrient through the 
parasite’s membrane hexose transporter (HT) for its replication inside liver cells 
[8]. On the other hand, microarray analyses of P. berghei-infected hepatoma cells 
and P. yoelii-infected mouse hepatocytes revealed that Plasmodium modulates 
the host cell’s transcriptome towards biosynthetic pathways and identified 63 
transport proteins or regulatory subunits whose expression is altered in infected 
cells [11]. 
We employed RNA interference (RNAi) to down-modulate the expression of a 
selected group of genes, in order to identify host cell membrane transporters that 
play a role during Plasmodium infection of hepatic cells. This approach led to the 
identification of glucose transporter 1 (GLUT1) and cationic amino acid transporter 
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2 (CAT2) as major players in this process and warranted further investigation of 
the host-parasite interaction in which they are involved. 
GLUT1 is one of the 14 members of the family of integral membrane glucose 
transporter (GLUT) molecules. It is expressed in liver cells and is overexpressed in 
various tumors [12, 13]. Glucose is transported by GLUT1 from the plasma into the 
cytosol of Plasmodium-infected erythrocytes, and is then taken up by the parasite 
via a parasite-encoded facilitative hexose transporter (HT) [14-16]. This 
transporter is also expressed during the liver and transmission phases of 
Plasmodium parasites, suggesting that glucose might be essential also for these 
stages [8, 17]. In this study, we employed rodent P. berghei parasites, a well-
established model of malaria infection, to investigate the uptake and utilization of 
glucose by Plasmodium liver stages. We established the importance of glucose 
availability for the intra-hepatic development of the malaria parasite. We observed 
that glucose uptake increases specifically in infected cells from 30 hours post-
infection onwards and identified GLUT1 as the major host transporter involved in 
glucose uptake by those cells. The importance of this molecule during hepatic 
infection was further validated by employing a specific GLUT1 inhibitor, both in 
vitro and in vivo. Finally, we demonstrated that P. berghei infection leads to a 
small depletion of intracellular ATP and enhances the translocation of GLUT1 to 
the cell membrane of infected hepatoma cells in a phosphoinositide 3-kinase 
(PI3K)-independent manner, contributing to the significantly higher uptake of 
glucose by infected cells, when compared with their non-infected counterparts. 
This increase in glucose uptake was not observed when hepatic cells were 
subjected to a variety of other stimuli, including temperature and oxidative stress, 
and viral infection, suggesting that it constitutes a specific response to 
Plasmodium infection. Overall, these data suggest that the extensive replication of 
intra-hepatic Plasmodium parasites leads to a decrease of intracellular glucose 
availability, consequently decreasing the host cells’ ATP levels. GLUT1 
translocation to the plasma membrane of Plasmodium-infected cells compensates 
for this decrease by enhancing glucose uptake and preventing further ATP 
depletion that could lead to cell death. 
CAT2, encoded by SLC7A2, is part of the CAT family of Na+-independent y+ 
transporters, which constitute the main mechanism of cellular uptake of cationic 
amino acids, such as arginine, lysine and ornithine [18-20]. Arginine is involved in 
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many metabolic pathways, including the synthesis of nitric oxide (NO), 
polyamines, agmatine, creatine, proline, glutamate, and urea [21]. Arginine and 
the arginase pathway have been implicated in several infections, including 
Trypanosoma spp., Leishmania spp., Toxoplasma gondii, Shistosoma mansoni, 
Candida albicans, and Helicobacter pylori (reviewed in [22]). Plasmodium 
parasites were also shown to express arginase, the first enzyme of the metabolism 
of arginine into polyamines, and to be dependent on polyamines for survival in the 
blood stage of infection [23-28]. Our results showed that the normal developmental 
process of liver stage P. berghei parasites is also dependent on arginine 
availability and that this arginine is acquired by the infected host cell mostly via the 
CAT2A and CAT2B transporters, the two splice variants encoded by the SLC7A2 
gene [29]. We also showed that the arginine taken up by the infected cell is mainly 
employed as a precursor of polyamine synthesis, to promote parasite growth. 
Because the inhibition of polyamine production by the host cell alone has no 
impact on P. berghei development in Huh7 cells, we hypothesize that the parasite 
relies mostly on its own polyamine synthesis pathway to fulfill its developmental 
needs. The bimodal hepatic infectivity behavior displayed by the arginase-KO P. 
berghei parasite partially supports this hypothesis but also suggests that the 
parasite may have compensatory mechanisms to guarantee its survival when this 
pathway is compromised.  
Finally, we investigated whether Plasmodium infection could be impaired by 
appropriate amino acid supplementation. Lysine, ornithine and valine have been 
described as arginase inhibitors and could therefore be employed to inhibit 
polyamine synthesis [30, 31]. Under these conditions, increasing the amount of 
arginine available might in turn enhance the production of NO, which was 
previously shown to kill malaria parasites in vitro [32-39]. For these reasons, we 
investigated the effect of these 4 amino acids, individually and in combination, on 
liver stage Plasmodium infection. Our data showed that P. berghei hepatic 
infection can be markedly inhibited in vitro and ex vivo through supplementation 
with lysine and valine, either alone or in combination. Importantly, we further 
showed that the simultaneous administration of lysine, valine and arginine in the 
drinking water of mouse models of P. berghei infection resulted in a striking 
decrease of in vivo liver parasite load. We showed that this decrease results from 
an impairment of parasite growth, as well as a significant reduction in the number 
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of P. berghei-infected hepatocytes, suggesting that this combination of amino 
acids effectively inhibits parasite growth and contributes to its elimination. Our data 
strongly suggest that the lysine and valine employed in the supplementation lead 
to arginase inhibition and consequent impairment of the synthesis of polyamines, 
which are important for parasite development. Concurrently, the extra arginine 
provided in the supplementation stimulates NO production by inducible NO 
synthase (iNOS), leading to parasite death. 
Overall, this dissertation highlights the relevance of glucose and arginine uptake 
and metabolism for parasite survival and intra-hepatic development in 
Plasmodium-infected cells. This work elucidates hitherto unknown host-parasite 
interactions and identifies a novel, drugless and non-toxic approach to modulate 
liver-stage of Plasmodium infection. 
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Resumo 
A malária é uma doença febril aguda e uma das doenças infecciosas mais 
prevalentes no mundo. É causada por parasitas protozoários do género 
Plasmodium, os quais são transmitidos aos seus hospedeiros mamíferos através 
da picada de um mosquito Anopheles fêmea infetado [1, 2]. Estima-se que em 
2015 ocorreram 214 milhões de casos de malária, dos quais resultaram 438 000 
mortes, a maioria das quais na África sub-Sahariana [1]. Globalmente estima-se 
que 3.2 biliões de pessoas corram o risco de serem infetadas pelo Plasmodium e 
desenvolverem a doença [1]. 
Aquando de uma picada por um mosquito infectado, os parasitas Plasmodium, 
denominados esporozoítos nesta fase do seu ciclo de vida, são depositados na 
pele do seu hospedeiro mamífero, e são transportados pela circulação sanguínea 
até ao fígado, onde atravessam diversos hepatócitos até invadirem 
produtivamente uma célula final [3]. Dentro dos hepatócitos, cada esporozoíto 
transforma-se numa forma exo-eritrocitária (EEF) contendo milhares de 
merozoítos recém-formados, que acabam por ser libertados para a corrente 
sanguínea, onde invadem os eritrócitos, dando início à fase eritrocitária, 
sintomática, da doença [4].  
Durante a fase hepática, assintomática, da infecção por Plasmodium, o parasita 
cresce de forma extremamente rápida, replicando o seu genoma 104 a 105 vezes 
[5, 6]. Para sustentar a sua rápida multiplicação e alimentar as suas vias 
metabólicas, os parasitas obtêm nutrientes a partir do seu hepatócito hospedeiro 
[7-10]. Foi anteriormente mostrado que a glucose desempenha um papel crucial 
durante a fase hepática de P. berghei, tendo sido demonstrada a importância do 
transporte deste nutriente pelo transportador de hexoses (HT) membranar do 
parasita para a replicação deste dentro das células hepáticas [8]. Por outro lado, 
estudos de transcriptómica de células de hepatoma infetadas por P. berghei e de 
fígados de ratinho infetados por P. yoelii mostraram que o parasita modula o 
transcriptoma da célula hospedeira no sentido de favorecer vias biossintéticas, e 
permitiu identificar 63 proteínas transportadoras cuja expressão está alterada em 
células infetadas [11]. 
Neste trabalho, utilizámos técnicas de RNA de interferência (RNAi) para diminuir a 
expressão de um grupo de genes selecionados, de modo a identificar 
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transportadores membranares das células hospedeiras envolvidos na infecção 
hepática por Plasmodium. Esta abordagem conduziu à identificação do importante 
papel do transportador de glucose 1 (GLUT1) e do transportador de aminoácidos 
catiónicos 2 (CAT2) neste processo, abrindo caminho para uma investigação mais 
aprofundada das interações hospedeiro-parasita em que estão envolvidos. 
O GLUT1 é um de 14 membros da família de moléculas membranares 
transportadoras de glucose (GLUT), sendo expresso em células hepáticas e 
sobre-expresso em diversos tumores [12, 13]. A glucose é transportada pelo 
GLUT1 do plasma para o citosol dos eritrócitos infetados por Plasmodium, sendo 
depois transportado para o parasita através de um transportador de hexoses 
parasitário (HT) [14-16]. Este transportador também é expresso durante as fases 
hepáticas e de transmissão de parasitas Plasmodium, sugerindo que a glucose 
poderá também ser essencial nestas fases [8, 17]. No presente estudo, utilizámos 
parasitas P. berghei de roedores, um modelo bem estabelecido de infeção de 
malária, para investigar a aquisição e utilização da glucose por parasitas 
Plasmodium hepáticos. Demonstrámos a importância da disponibilidade de 
glucose para o desenvolvimento intra-hepático do parasita da malária. 
Observámos que durante o desenvolvimento hepático de P. berghei, a aquisição 
de glucose aumenta especificamente em células infetadas a partir de 30 horas de 
infeção, e identificámos o GLUT1 como sendo o principal transportador 
responsável pela entrada de glucose nessas células. A importância desta 
molécula durante a infeção hepática foi adicionalmente validada através da 
utilização de um inibidor específico de GLUT1, quer in vitro, quer in vivo. 
Finalmente, demonstrámos que a infeção por P. berghei leva a uma pequena 
depleção do ATP intracelular e conduz à translocação de GLUT1 para a 
membrana celular de células de hepatoma infetadas, num processo independente 
da cinase PI3K. Isto contribui para que o aumento da aquisição de glucose seja 
significativamente maior nas células infetadas do que nas não-infetadas. Este 
aumento de aquisição de glucose não foi observado quando as células hepáticas 
foram sujeitas a diversos outros estímulos, incluindo stress de temperatura, stress 
oxidativo, e infeção viral, sugerindo que se trata de uma resposta específica à 
infeção por Plasmodium. Globalmente, estes dados sugerem que a enorme taxa 
de replicação dos parasitas Plasmodium intra-hepáticos conduz a uma diminuição 
da disponibilidade de glucose intracelular, o que leva ao decréscimo dos níveis de 
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ATP da célula hospedeira. A translocação do GLUT1 para a membrana celular 
compensa esta diminuição, aumentando a aquisição de glucose e impedindo uma 
maior depleção de ATP, que poderia conduzir à morte celular. 
O CAT2, codificado pelo gene SLC7A2, faz parte da família CAT de 
transportadores y+ independentes de Na+, que constituem o principal mecanismo 
de aquisição celular de aminoácidos catiónicos, tais como a arginina, a lisina e a 
ornitina [18-20]. A arginina está envolvida em diversas vias metabólicas, incluindo 
a síntese de óxido nítrico (NO), poliaminas, agmatina, creatina, prolina, glutamato 
e ureia [21]. A arginina e a via da arginase foram já implicadas em diversas 
infeções, incluindo Trypanosoma spp., Leishmania spp., Toxoplasma gondii, 
Shistosoma mansoni, Candida albicans, e Helicobacter pylori (revisto em [22]). No 
que diz respeito a parasitas Plasmodium, foi demonstrado que eles expressam 
arginase, a primeira enzima do metabolismo de arginina a poliaminas, e que 
dependem de poliaminas para a sua sobrevivência durante a fase sanguínea da 
infeção [23-28]. Os nossos resultados mostram que o processo de 
desenvolvimento normal de parasitas P. berghei hepáticos também depende da 
disponibilidade de arginina, a qual é adquirida pela célula hospedeira 
principalmente através de transportadores CAT2A e CAT2B, as duas variantes 
codificadas pelo gene SLC7A2 [29]. Também demonstrámos que a arginina 
adquirida pela célula infectada é utilizada principalmente como precursor da 
síntese de poliaminas, para permitir o crescimento do parasita. O facto de a 
inibição da produção de poliaminas apenas pela célula hospedeira não ter 
qualquer impacto no desenvolvimento de P. berghei em células Huh7, sugere a 
hipótese de que o parasita depende principalmente da sua própria via de síntese 
de poliaminas para preencher as suas necessidades de desenvolvimento. O 
comportamento bimodal de infectividade hepática apresentado pelo parasita P. 
berghei arginase-KO sustenta em parte esta hipótese mas também sugere que o 
parasita poderá dispor de mecanismos compensatórios para assegurar a sua 
sobrevivência quando essa via está comprometida. 
Finalmente, investigámos se a infeção por Plasmodium poderia ser inibida através 
de uma suplementação adequada com aminoácidos. A lisina, a ornitina e a valina 
foram identificadas como inibidores da arginase, podendo pois ser utilizadas para 
inibir a síntese de poliaminas [30, 31]. Nessas condições, um aumento na 
quantidade de arginina disponível poderia por sua vez aumentar a produção de 
Resumo 
VIII 
 
NO, o qual se demonstrou previamente ser capaz de matar parasitas da malária 
in vitro [32-39]. Por estas razões, investigámos o efeito destes 4 aminoácidos, 
individualmente e em combinação, na infeção hepática por Plasmodium. Os 
nossos resultados mostraram que a infeção hepática por P. berghei pode ser 
fortemente inibida in vitro e ex vivo pela suplementação com lisina e valina, quer 
individualmente, quer em combinação. Crucialmente, mostrámos ainda que a 
administração simultânea de lisina, valina e arginina na água de modelos 
roedores de infeção por P. berghei conduziu a um enorme decréscimo da carga 
parasitária hepática in vivo. Mostrámos que este decréscimo resulta de uma 
inibição do crescimento do parasita, a par de uma significativa diminuição do 
número de hepatócitos infetados por P. berghei, sugerindo que esta combinação 
de aminoácidos inibe eficazmente o desenvolvimento do parasita e contribui para 
a sua eliminação. Os nossos dados sugerem fortemente que a lisina e a valina 
empregues na suplementação conduzem à inibição da arginase e à consequente 
inibição da síntese de poliaminas necessárias ao desenvolvimento do parasita. 
Concomitantemente, a arginina fornecida na suplementação estimula a produção 
de NO pela enzima iNOS, conduzindo à morte do parasita. 
Globalmente, esta dissertação demostra a relevância da aquisição e metabolismo 
da glucose e arginina para a sobrevivência e o desenvolvimento intra-hepático do 
parasita em células infetadas por Plasmodium. Este trabalho elucida novas 
interacções hospedeiro-parasita e identifica uma nova abordagem para modular a 
infeção hepática por Plasmodium sem recorrer ao uso de fármacos e sem 
toxicidade associada. 
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Malaria – general considerations 
Malaria is an acute febrile illness and one of the most prevalent infectious 
diseases in the world [1, 2]. It is caused by a protozoan parasite of the genus 
Plasmodium that is transmitted through the bite of an infected female Anopheles 
mosquito [1, 2]. There are five species of Plasmodium that can cause malaria in 
humans [1, 40, 41]. Four of these (Plasmodium falciparum, P. vivax, P. malariae 
and P. ovale) are human malaria species, which are spread from one person to 
another by the bite of an infected mosquito [1, 2, 40]. Additionally, in recent years, 
human cases of malaria have also been recorded due to P. knowlesi, a species 
that causes malaria among monkeys, and occurs in certain forested areas of 
South-East Asia [1, 42, 43]. 
P. falciparum and P. vivax malaria pose the greatest public health challenge [1, 2, 
40, 41]. P. falciparum is most prevalent in Africa but also occurs in South and East 
Asia, South America, the Caribbean and the Middle East, and is responsible for 
most deaths from malaria [1, 40, 42, 44]. P. vivax has a wider geographic 
distribution because it can develop in the Anopheles mosquito vector at lower 
temperatures and survive at higher altitudes and in cooler climates [1, 40, 42, 44, 
45]. Additionally, it can generate cryptic forms, known as hypnozoites, which can 
remain dormant for long periods of time as potential reservoirs of infection, leading 
to disease relapses after the initial symptomatic infection has been treated [1, 40, 
44]. Although P. vivax can occur throughout Africa, the risk of infection with this 
species in this continent is lower, because of the absence of the Duffy gene in 
many African populations, which codes for a protein necessary for red blood cell 
invasion by P. vivax [1, 46]. Recently, however, several reports have surfaced, 
describing P. vivax mono and mixed malaria parasite infections in Duffy-negative 
individuals from several countries, such as Brazil, Angola, Equatorial Guinea, 
Mauritania, Cameroon and Ethiopia [46-50]. P. ovale and P. malariae are two rare, 
nonlethal parasites, most commonly found in Africa and Papua New Guinea [42, 
45]. 
In a non-immune individual, malaria symptoms include fever, headache, chills, 
sweating, fatigue and vomiting, and appear seven days or more after the infective 
mosquito bite [2, 51, 52]. If not treated within 24 hours, P. falciparum malaria can 
progress to severe illness, defined as a malaria episode with signs and symptoms 
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of organ dysfunction or high levels of parasitaemia, which often leads to death [2, 
40, 52]. Children with severe malaria frequently develop severe anaemia, 
respiratory distress, metabolic acidosis and/or cerebral malaria [2, 51]. In pregnant 
women, malaria increases the risk of maternal death, miscarriage, stillbirth, and 
low birth weight, as well as the associated risk of neonatal death [2]. In endemic 
countries, partial immunity develops over years of exposure [2, 52]. Although this 
does not provide complete protection, it does reduce the risk of developing severe 
disease [2, 52].  
The History of Malaria 
From Superstition to Disease 
Possible references to malaria may be traced back to antiquity considering its 
clinical signatures, specifically, recurrent periodic fevers and splenomegaly [53, 
54]. The most ancient records were found in a Chinese document from about 2700 
BC, clay tablets from Mesopotamia from 2000 BC, Egyptian papyri from 1570 BC 
and Hindu texts as far back as 6 BC [53-55]. Numerous other ancient Chinese 
documents provided valuable information about how the infection was transmitted 
[53]. Indeed, two documents dating back as far as the period 476 to 221 BC 
mentioned that malaria was caused by mosquito bites, especially during the late 
summer and early autumn [53]. Nonetheless, in ancient times malarial 
manifestations were usually attributed to supernatural influences, namely to the 
anger of a deity or to the devils that governed the destiny of men and nature; their 
curses could be inactivated through specific rites, sacrifices, exorcisms or magic 
potions [53, 54]. 
The early Greeks, including Homer in about 850 BC, Empedocles of Agrigentum in 
about 550 BC, and Hippocrates in about 400 BC, were well aware of the 
characteristic poor health, fevers and enlarged spleens seen in people living in 
marshy places [55, 56]. In fact, Hippocrates was the first physician who described 
the malarial paroxysm (chills, fever, sweats and exacerbation) and the different 
clinical types of malaria depending on the periodicity of the fevers (tertian and 
quartan fever, depending on whether the person has fever every 3 or 4 days, 
respectively) [53, 54, 56]. 
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Throughout history, several designations were used to describe malaria: ägue, 
paludisme, Wechselfieber, Dardag Kolle, triasuchka, likhoradka, the fever, febris 
ardens, accessia, paludal fever, fiève äigue, marsh fever, seasonal fevers, fever of 
summer/fall (estivoautumnal fever), autumnal fever, intermittent fever, periodical 
fever, the quakes, the Bailiff of the Marshes, Lord John's fever and Old Johnny 
Axey [53, 56]. The word malaria used nowadays derives from the Italian words 
mal'aria meaning bad air, evil air or corrupted air, since for hundreds of years the 
supposition of the miasmatic nature of the illness was widely spread [53-56]. The 
first attested mention of the term mal aere dates from 1440 [53]. Malaria, the finally 
settled word for the disease, was used for the first time in the first half of the 
nineteenth century [53]. The overlapping clinical features between malaria and 
typhoid fever created difficulties in the diagnosis of malaria by clinicians, hence the 
usage of the term typhomalaria was widespread for several decades [56]. This 
term was mostly abandoned when William Osler described the specific differences 
in the clinical features of each disease, and established the susceptibility of the 
malaria parasite to quinine as a simple clinical test for malaria [56, 57]. 
Discovery of Plasmodium parasites – the Erythrocytic Stage  
With the discovery of bacteria by Antonie van Leeuwenhoek in 1676, the 
incrimination of microorganisms as causes of infectious diseases and the 
development of the germ theory of infection by Louis Pasteur and Robert Koch in 
1878-1879, the search for the causative agent of malaria deepened [55]. At first, it 
was thought that malaria was caused by a bacterium present in marshy waters, 
Bacillus malariae, but this theory was proven wrong by Alphonse Laveran, a 
French military surgeon, in 1880 [53-55]. Starting from the known fact that the 
spleens of malaria patients contained a dark pigment, Laveran began to look for 
pigment in the fresh unstained blood of 200 patients and observed it first in 
leucocytes and then in red blood cells, exclusively in patients with malaria [55, 57]. 
He observed several different forms of erythrocytic organisms including crescents, 
spherical motionless bodies with pigment, spherical moving bodies with pigment 
and bodies that extruded flagella-like structures, all of which he thought were on 
the outside of the red blood cells (Fig. 1.1) [55, 57]. He also suggested a course of 
events that began with clear spots that grew, acquired pigment and filled the cell, 
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which then burst, coinciding with the fevers associated with malaria [55]. Laveran 
quickly realized that he had found a parasitic protozoan which he called Oscillaria 
malariae [55]. He presented his findings to the French Academy of Medical 
Sciences and, after overcoming the skepticism of all microbiologists, zoologists 
and malariologists of his time, he was awarded the Nobel Prize for Medicine in 
1907 [55, 58]. 
 
Figure 1.1 - Laveran’s drawings of malaria parasites. From [57]. 
At around the same time, the Russian physiologist Vassily Danilewsky observed a 
number of parasites, including trypanosomes and others, that he identified as 
“pseudovacuoles”, later confirmed as unstained malaria parasites, while examining 
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the blood of birds and reptiles in the Ukraine [55]. In fact, by 1885 Danilewsky had 
recognised the three most common genera of intraerythrocytic blood parasites of 
birds (Plasmodium, Haemoproteus and Leucocytozoon) [55]. However, as he had 
published much of his work in Russian, only in 1889 did this information become 
widely available in French [55]. The accidental discovery of a methylene blue-
eosin stain by Dimitri Leonidovitch Romanowsky in 1891 greatly facilitated the 
search for other malaria parasites in reptiles, birds and mammals [55, 59]. This 
stain became popular at the beginning of the twentieth century and nowadays 
remains the basis of blood stains, such as Leishman’s, Giemsa’s and Wright’s 
[55]. 
By 1890, with the contributions of Marchiafava, Bignami and Golgi, it was well 
established that malaria was caused by a protozoan parasite that invaded and 
multiplied in red blood cells, that there were three species with specific 
periodicities responsible for benign tertian (Haemamoeba vivax), malignant tertian 
(Laverania malariae) and quartan malaria (Haemamoeba malariae), currently 
known as P. vivax, P. falciparum and P. malariae, respectively, and that the 
paroxysms of fever coincided with the rupture and release of merozoites into the 
bloodstream [54, 55, 57]. P. ovale, a fourth species that resembled P. vivax, was 
only described in 1922 by John Stephens while working in West Africa [55]. 
The Mosquito Stage 
Throughout centuries, circumstantial evidence accumulated suggesting that 
mosquitoes could be the explanation for how the parasite spread from one human 
to another [55]. By 1883, the American physician Albert King had assembled 19 
facts in support of this theory [57]. 
The first person to provide definitive proof that mosquitoes carried malaria was 
Ronald Ross while working in India in 1897 [54, 55, 57, 60]. Under the tutelage of 
his mentor, Patrick Manson, he discovered that culicine mosquitoes transmitted 
the avian malaria parasite Plasmodium relictum [55, 60]. He found that after 
feeding on infected birds, the mosquitoes developed pigmented bodies in their 
guts, which he called “spores”, leading him to conclude that the mosquitoes would 
take up male and female gametocytes from the infected bird, very similarly to what 
had been described by William MacCallum for the haematozoan Haemoproteus 
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columbae [55, 60]. These gametocytes would undergo fertilization in the mosquito 
gut, developing into spores, within which rod-like structures were produced that 
invaded the mosquito’s salivary glands and were injected into a new host when the 
infected mosquito fed [55, 60]. Later, when working in Sierra Leone in 1899, he 
observed that mosquitoes fed on a malaria patient also contained spores in their 
guts, proving that the human malaria parasites were transmitted by anopheline 
mosquitoes [53, 55, 61]. Ross was awarded the Nobel Prize for Physiology and 
Medicine in 1902 [53, 58]. 
Bignami and Grassi had reached the same conclusions one year earlier in sites 
near Rome and in Sicily, where malaria was present; they fed local Anopheles 
claviger mosquitoes on infected patients and subsequently transmitted the 
infection to uninfected individuals through the bite of the same mosquitoes [54, 55, 
57, 62]. These observations were confirmed by Manson in London by using P. 
vivax-infected A. maculipennis mosquitoes to infect two healthy volunteers, one of 
them his own son [55, 57]. Over the next two years Bignami, Grassi and 
Bastianelli proved that only female Anopheles mosquitoes could transmit malaria 
and described the whole blood-mosquito life cycles of P. vivax, P. falciparum and 
P. malariae [53-55, 62]. The discovery of the role of mosquitoes in the 
transmission of malaria was essential because it raised the possibility of 
controlling the disease by reducing contact with infected mosquitoes, a malaria 
control strategy that is still used presently [55]. 
Plasmodium’s Elusive Exoerythrocytic Stage 
At this point in time, although the blood and mosquito stages were mostly 
understood, nobody knew where the parasites developed in the first days after 
infection, during which they could not be seen in the blood [55]. Grassi and his 
colleagues, in the late 1890’s, were the first ones to postulate that another 
developmental stage should exist in cells other than red blood cells, possibly white 
blood cells [55]. Their theory was quickly abandoned due to what is nowadays 
known as “Schaudinn’s fallacy” [55]. In 1903, the German scientist Fritz Schaudinn 
described the direct penetration of red blood cells by P. vivax sporozoites, without 
further development [55, 57]. Even though, in 1898, MacCallum had observed 
developmental stages of P. relictum in the liver and spleen of infected birds and no 
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one else was able to reproduce Schaudinn’s results, his ideas dominated the 
scientific opinion for over 40 years [55, 57]. 
It was only in 1937 that Sydney James and Parr Tate conclusively demonstrated 
that in sporozoite-induced P. gallinaceum infections in chickens, a phase of 
multiplication in cells of the reticuloendothelial system preceded the appearance of 
parasites in the blood [55, 63]. One decade later, Henry Shortt and Cyril Garnham, 
working in London, finally confirmed that in primates this exoerythrocytic phase 
occurs in the liver [55, 57, 64]. Their clue came from the monkey parasites 
Hepatocystis kochi; while being related to malaria parasites, they do not have an 
erythrocytic stage in their life cycles, only an exoerythrocytic stage in the 
parenchyma cells of the liver [55, 65]. Shortt and Garnham found exoerythrocytic 
stages in the livers of rhesus monkeys seven days after the bites of five hundred 
A. maculipennis atroparvus mosquitoes infected with P. cynomolgi [55, 66]. In 
subsequent years, they found exoerythrocytic forms of P. vivax, P. falciparum and 
P. ovale in human volunteers [55, 67-69]. The exoerythrocytic stages of P. 
malariae were only demonstrated experimentally in infected chimpanzees in 1960 
by Robert Bray [55, 70]. It took nearly 70 years for the elucidation of the life cycle 
of the human malaria parasites to be almost complete [55]. The last piece of the 
puzzle, the dormant exoerythrocytic stages of P. vivax, called hypnozoites, was 
described by Wojciech Krotoski in 1982 [55, 71]. 
Malaria in Portugal 
In Portugal, in the beginning of the 1900’s, malaria was mostly endemic in the 
alluvial valleys of the main rivers with extensive rice cultivation, where the 
mosquito A. atroparvus had its breeding places [72]. Control programs in the 
Tagus river basin were initiated in 1931 and, seven years later, the Institute for 
Malaria Research and Training (Instituto de Malariologia) was established by the 
Rockefeller Foundation, under the direction of Francisco Cambournac [72]. Only in 
the 1950’s were plans for eradication of the disease with 
dichlorodiphenyltrichloroethane (DDT) spraying put into motion [72, 73]. By 1958 
transmission of the infection was interrupted in nearly all areas of Portugal and the 
country was placed in the maintenance phase of malaria eradication [72, 73]. The 
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certification of malaria eradication was confirmed by the World Health 
Organization (WHO) in 1973 [72, 73]. 
Nowadays, the only cases of malaria in Portugal are imported [74]. Approximately 
40 to 50 cases are notified every year, mostly due to the increasing international 
travel and expatriation to sub-Saharan countries where malaria is endemic [74]. In 
fact, from 2009 to 2012, there was a 60% increase in malaria hospitalizations, 
contradicting the declining trend observed since 2003 in Europe [74]. This raises 
the possibility of reappearance of autochthonous malaria, which has already 
occurred in other European countries once officially considered malaria-free like 
France, Spain, Italy, and Greece [74]. Malaria might be spread by A. atroparvus, 
which is widely distributed in Portugal and might be susceptible to African P. vivax 
strains, despite being non-susceptible to the African P. falciparum strains [74]. 
Antimalarials with History 
Over the centuries, several antimalarial compounds with different origins and 
efficacies have been used to treat malaria. 
One of the most famous antimalarials is quinine. Quinine is the main alkaloid 
extracted from the powdered bark from the cinchona tree from South America [42, 
54, 59]. The name of the tree resulted from the successful treatment of the 
countess of Chinchon, wife of the Spanish Vice-king of Peru, who was suffering 
from fever [54]. In 1633, an Augustinian monk called Calancha, from Lima, Peru, 
was the first to report that the powder of the cinchona plant “given as a drink cures 
fever and tertian” [54]. Cinchona was imported into Europe by the Jesuit Fathers to 
cure fever and, for almost two centuries, the bark of the cinchona tree was used in 
medicine as a powder [54]. Quinine was finally isolated in 1820 by Pelletier and 
Caventou [54]. Although its mode of action remains incompletely understood, it is 
thought to inhibit the formation of hemozoin in the digestive vacuole (DV) of blood 
stage Plasmodium parasites, a process indispensable for the disposal of the heme 
generated by the digestion of host’s hemoglobin [42, 75, 76]. The quinoline moiety 
of quinine, essential for the antimalarial properties of the compound, is present in 
the numerous analogues synthesized subsequently, including chloroquine (CQ) 
and primaquine (PQ) [42]. 
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Chloroquine (CQ) is a quinoline analogue that was found during a collaborative 
program of research into antimalarial drugs during the Second World War [42, 54]. 
At the end of the war, however, it was discovered that the same compound had 
been synthesized and studied under the name of Resochin by the German 
researcher Johann “Hans” Andersag and his coworkers at the Bayer laboratories 
since 1934, but it had been rejected because it was considered too toxic for 
human use [54, 59, 77]. CQ can freely diffuse across membranes in its neutral 
form, allowing it to concentrate inside the acidic DV of Plasmodium parasites 
inside red blood cells (RBCs) and prevent hemozoin formation [78-81]. It was used 
as first-line antimalarial therapy for many years due to its effectiveness and 
relatively low cost, but after 20 years of use resistant Plasmodium strains 
eventually appeared in Southeast Asia, South America and the Western Pacific 
region, and spread progressively throughout malaria-endemic areas  [42, 59, 78, 
82]. The primary determinant for CQ resistance was shown to be the P. falciparum 
CQ resistance transporter (PfCRT), which is involved in excreting CQ from the DV 
[78, 83]. 
Primaquine (PQ) is an 8-aminoquinoline [42, 84]. Its first mass use occurred in the 
1950s during the Korean War to eliminate long latency P. vivax infections [84, 85]. 
Since then, it has been administered to millions of people, mostly in China, 
Azerbaijan, Tajikistan, Northern Afghanistan and North Korea [84]. Despite its 
weak asexual stage activity, PQ is able to kill mature gametocytes of P. falciparum 
(with a single dose) and developing parasites of all species in the liver, and is 
currently the only clinically available drug that is active against hypnozoites from P. 
vivax and P. ovale [1, 42, 84, 86-89]. Unfortunately, PQ has a short plasma half-
life (approximately 6 hours) as a result of oxidative deamination to 
carboxyprimaquine, and causes mild to severe and possibly fatal acute hemolytic 
anemia, particularly in patients bearing an inborn deﬁciency of glucose-6-
phosphate dehydrogenase (G6PD), which has an 8% average prevalence in 
malaria-endemic regions [42, 44, 84, 86, 90]. Recently, a mutation in the human 
cytochrome P-450 2D6 enzyme with a serious impact on PQ metabolism and 
decreasing its efficacy against relapse was uncovered [44, 91]. 
Artemisinin (ART) is the endoperoxide of a sesquiterpene lactone derived from the 
infesting plant Qing hao, also known as sweet or annual wormwood [54, 92]. The 
medical properties of this plant were well known by the Chinese more than 2000 
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years ago [54]. In 340 AD, Ge Hong prescribed tea of Qing hao as a remedy for 
feverish attacks and in 1596, Li Shizhen recommended it for the relief of the 
symptoms of malaria [54]. The antimalarial component, artemisinin, was extracted 
and crystallized in 1972 by Chinese researchers from ‘project 523’ [54, 92]. One of 
these researchers, Tu Youyou, was recently awarded the 2015 Nobel Prize in 
Physiology or Medicine [58]. It is a potent treatment for malaria due to its low 
toxicity, rapid killing of malaria parasites in several stages of their life cycle and its 
nanomolar potency in vivo against P. falciparum, including multi-resistant strains. 
However, it has low solubility in water and oil and a very short half-life of only 2 
hours in vivo [42, 92-97]. Nowadays, ART has been replaced by three more 
powerful semi-synthetic derivatives: dihydroartemisinin (DHA), artemether and 
artesunate [42, 54]. In addition, to overcome their short half-lives, ART-based 
combination therapies (ACTs), in which a potent, short-acting ART derivative is 
simultaneously administered with one or more longer-acting drug with independent 
mode of action, are the current first-line antimalarials recommended by the WHO 
[42, 78, 98, 99].  
The Public Health Challenge Currently Posed by Malaria 
Nowadays, malaria exerts a heavy burden on several low- and lower-middle-
income countries, especially in Africa [1, 100]. Within malaria-endemic countries, 
the poorest communities are the most severely affected, having the highest risks 
associated with malaria and the least access to effective services for prevention, 
diagnosis and treatment [1, 101]. 
The 2015 World Malaria Report, which summarizes information received from 96 
malaria-endemic countries, estimated that 3.2 billion people are at risk of being 
infected by Plasmodium and developing malaria [1]. In 2015, there were an 
estimated 214 million cases of malaria, which resulted in 438 000 deaths, 90% of 
which in sub-Saharan Africa (Table 1.1) [1]. The number of malaria deaths in 
children aged under 5 years is estimated to have decreased to 306 000, which 
accounts for only 10% of total child deaths in sub-Saharan Africa [1]. As a result, 
malaria is no longer the leading cause of death among children in this region [1]. 
Substantial progress has been accomplished in the past few years, with a 60% 
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reduction in global malaria deaths between 2000 and 2015 due to an increase in 
international and domestic funding for malaria control and elimination [1]. 
Table 1.1 - Estimated malaria cases and deaths, by WHO region, 2000–2015. 
From [1]. 
 
Besides the significant impact on the demographic structure of endemic countries 
caused by the preferential mortality of infants and children, malaria has a profound 
impact on households, health systems and national economies [100-102]. 
At the household level, malaria imposes both direct and indirect costs [100, 103]. 
Direct costs include time lost from work, as well as medical treatment and 
prevention costs, while indirect costs include loss of work efficiency and work 
reallocation within the household [100-103]. In the case of the children, indirect 
costs include nutritional deficiencies, cognitive and educational disabilities and 
physical retardation [100-102]. Notably, malaria is responsible for 15% of health-
related absenteeism from school, contributing to poor educational performance 
and high failure and school drop-out rates [101, 102, 104].  
Public health systems of endemic countries spend a high proportion of their 
resources on malaria treatment [102]. Additionally, malaria has an adverse impact 
on foreign investment, tourism and trade in endemic countries, impairing their 
economic linkage with the rest of the world [101, 102]. 
Ultimately, malaria costs Africa more than US$12 billion annually and is estimated 
to have slowed down economic growth in African countries by as much as 1.3% 
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per year [54, 100, 101, 105]. Malaria is, therefore, a cause of poverty; conversely, 
poverty promotes malaria transmission [101, 102]. 
 
Strategies for Malaria Control and Elimination  
Prevention 
Malaria interventions comprise vector control, which reduces transmission by the 
mosquito vector from humans to mosquitoes and then back to humans and can be 
achieved using insecticide-treated mosquito nets (ITNs), long-lasting nets (LLNs) 
or indoor residual spraying (IRS); chemoprevention, which prevents blood stage 
infections in humans; and case management, which includes diagnosis and 
treatment of infections [1, 2]. 
ITNs and IRS are currently the preferred methods of malaria vector control and, in 
many cases, are used together in the same households, conferring increased 
protective benefits [106]. In 2015, 67% of the population at risk in sub-Saharan 
Africa had access to an ITN and, in 2014, 116 million people were protected from 
malaria through the use of IRS [1]. IRS makes use of 12 WHO-approved 
insecticides from 4 different classes, namely organochlorines (namely, DDT), 
organophosphates, carbamates and pyrethroids [106, 107]. On the other hand, 
ITNs show a high degree of personal protection but rely mainly on pyrethroids, to 
which malaria vectors in most countries around the world have acquired resistance 
[1, 108-118]. 
Chemoprevention is particularly important for pregnant women and young children 
[1, 86]. Intermittent preventive treatment in pregnancy (IPTp), through the 
administration of sulfadoxine-pyrimethamine (SP) during the second and third 
trimester of pregnancy, has been shown to reduce severe maternal anaemia, low 
birth weight and perinatal mortality [1, 54, 86, 119]. In 2014, only 17% of the 
pregnant women received the recommended three or more SP doses [1]. For 
children, the WHO recommends the implementation of seasonal malaria 
chemoprevention (SMC) with amodiaquine plus SP (AQ+SP) and intermittent 
preventive treatment for infants (IPTi) with SP [1, 86]. SMC can be used in children 
aged 3–59 months living in areas of highly seasonal malaria transmission and it 
works by maintaining therapeutic antimalarial drug concentrations in the blood 
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during periods of greatest malaria risk [1, 86]. IPTi is delivered at routine infant 
immunization, providing protection in the first year of life against clinical malaria 
and anaemia [1, 86]. In 2014, only 8 countries had adopted SMC and only one 
country, Chad, had adopted IPTi [1]. 
Chemoprophylaxis is also recommended for travelers from non-endemic countries 
to countries with ongoing local malaria transmission, preferably in addition to 
other personal protective measures, such as the use of insect repellents, ITNs, 
long sleeves and long pants [52, 120]. Currently, the most common prophylactic 
drugs for travelers are CQ, Proguanil, Atovaquone/Proguanil (known as 
Malarone), Doxycycline, Mefloquine and PQ [120, 121]. The preventive drug 
recommended varies with the country of origin and the availability of antimalarial 
drugs in that country, the species of Plasmodium and the presence or not of drug 
resistance in the country of destination, as well as, the time the traveler will spend 
there [52, 120]. 
There is still no licensed vaccine available against malaria, mainly due to the 
complex life cycle of Plasmodium, which makes the selection of targeted antigens 
more challenging, and by our lack of understanding of the immune response 
against malaria [1, 51, 122]. Even so, four candidate vaccines are currently 
undergoing field trials: three of these are in Phase 2B clinical trials and one, the 
RTS,S/AS01 vaccine, has completed Phase 3 trials [1, 123, 124]. This vaccine is 
based on the repetitive sequence of 4 amino acids of the P. falciparum surface 
circumsporozoite protein (CSP) and its administration led to a 46% reduction in 
malaria incidence in children and a 27% reduction in infants [1, 54, 122-124]. The 
RTS,S/AS01 candidate vaccine, known as MosquirixTM, was reviewed for its 
quality, safety and efficacy by the European Medicines Agency (EMA) earlier this 
year and was considered to have a favourable risk-benefit balance for active 
immunization of children aged 6 weeks up to 17 months [122, 125].  WHO’s 
Strategic Advisory Group of Experts on Immunization (SAGE) and the Malaria 
Policy Advisory Committee (MPAC) recommend that pilot implementations should 
be the next step with this vaccine and regard it as a complementary tool that could 
potentially be added to, but not replace, the core package of proven malaria 
preventive measures [126]. Nonetheless, efforts towards the generation of a 
vaccine with higher efficacy levels are still ongoing [122]. 
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Diagnostic and Treatment 
Early diagnosis and treatment of malaria reduces disease and prevents deaths [2]. 
The WHO recommends that all patients with suspected malaria (i.e., people who 
had fever for a week or more in an area of malaria transmission) should be 
examined for evidence of infection with Plasmodium parasites by either 
microscopy or a rapid diagnostic test (RDT) [1, 2, 86]. The accuracy of the 
diagnostic test by microscopy depends on the expertise of the personnel [52, 127]. 
RDTs rely on the detection of two major antigens: the histidine-rich protein-2 
(HRP-2) / aldolase system and the Plasmodium lactate dehydrogenase (pLDH) 
system [52, 127]. Although these RDTs have limited sensitivity to non-falciparum 
and non-vivax Plasmodium species, respectively, they are quick and easy to 
perform, contrary to microscopy, which requires significant expertise [52, 127]. In 
general, RDTs detecting HRP2 are most commonly used, because they are less 
expensive, more stable across a wider temperature range and have a lower 
detection threshold than pLDH-based tests [127, 128]. Other alternatives for 
malaria diagnosis are DNA/RNA-based detection techniques, such as the 
polymerase chain reaction (PCR), which is considered to have the most sensitive 
parasite detection level [127, 129]. However, it requires trained staff and 
specialized equipment, which are seldom available in resource-poor settings [127, 
130, 131]. 
By the end of 2013, ACTs were adopted as national policy for first-line treatment of 
P. falciparum uncomplicated malaria, as recommended by the WHO [1, 52, 86]. 
The five ACTs currently in use are artemether plus lumefantrine, artesunate plus 
AQ, artesunate plus mefloquine, artesunate plus SP, and dihydroartemisinin plus 
piperaquine [2, 42, 52]. The choice of the ACT is usually based on the therapeutic 
efficacy of the combination in the country or area of intended use [2, 52]. 
Importantly, although the transmission of the parasite is reduced by decreasing the 
amount of gametocytes in the blood of subjects treated with an ACT, they can still 
transmit malaria [52, 86]. The only licensed drug that can completely prevent 
transmission of P. falciparum is PQ [1, 42, 84, 86-89]. As for the treatment of 
severe malaria, quinine, which has a fatality rate around 10% and is difficult to 
administer, remains the official first-line treatment in most countries, even though 
artesunate was shown to function better [52, 54, 132]. 
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All African countries have reported P. falciparum resistance to CQ treatment and 
resistance to SP is increasing [52, 133, 134]. In fact, in many areas along the 
Cambodia-Thailand border, P. falciparum has become resistant to most available 
antimalarial medicines, the most worrisome being the reports of changes in 
sensitivity to ART since 2007 [1, 133, 135, 136]. It is arguable whether this lower 
sensitivity to ART can be considered resistance because, even though there is a 
slower parasite clearance due to the reduced susceptibility of ring-stage parasites, 
the parasites are still eliminated [133, 135-141]. But the fact is that, on the 
Thailand-Myanmar border, the geometric mean half-life for parasite clearance 
increased from 2.6 hours in 2001 to 3.7 hours in 2010, as compared with a half-life 
of 5.5 hours in western Cambodia between 2007 and 2010 (Fig. 1.2) [133, 142, 
143]. Recently, this slow clearance has been linked with point mutations in the 
“propeller” region of a P. falciparum kelch protein gene on chromosome 13 
(kelch13) [143, 144]. Nevertheless, ACTs have generally remained clinically and 
parasitologically efficacious, provided the partner drug remains efficacious and the 
treatment is prolonged from 3 to 6 days [1, 133]. 
 
Figure 1.2 – Distribution of Plasmodium clearance time with ART treatment in 
Southeast Asia and its association with kelch13 mutations. Adapted from [133]. 
CQ is still used in 10 Central American and Caribbean countries for the treatment 
of P. vivax malaria, where it remains efficacious [1, 78]. Alternatively, both CQ and 
ACTs can be combined with a 14-day course of PQ for the radical cure of P. vivax 
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malaria, the latter being the only licensed drug effective against hypnozoites of P. 
vivax [2, 44, 84, 86]. Confirmed P. vivax resistance to CQ has been emerging at 
least since 1990 and, currently, has been detected in 10 countries; ACTs are now 
recommended for the treatment of CQ-resistant P. vivax [1, 44].  
Plasmodium Life Cycle 
As previously mentioned, Plasmodium parasites cycle between a mosquito vector 
and a vertebrate host, and are obligate intracellular pathogens within the latter 
(Fig. 1.3) [5, 6, 51]. 
 
Figure 1.3 – Life cycle of the Plasmodium parasite. 
Upon a bite of an infected female Anopheles mosquito, Plasmodium parasites, 
termed sporozoites at this stage, are deposited under the skin of the mammalian 
host [5, 40, 41, 145, 146]. Sporozoites then use a form of locomotion known as 
gliding motility to reach the host’s vasculature, and a form of host interaction (cell 
traversal) to enter circulation [5, 40, 41, 145, 146]. Within a few minutes to a few 
hours after inoculation, these highly motile forms are passively carried to the liver 
by the circulatory system, where they traverse several hepatocytes before 
invading a final cell [5, 40, 41, 145, 147]. Recently, it was shown that sporozoites 
traverse cells inside transient vacuoles that precede PV formation [148]. 
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Sporozoites initially invade cells inside transient vacuoles by an active moving 
junction-independent process and then, using pH sensing and perforin-like protein 
1 (PLP1), they exit these vacuoles and, only then, enter the PV [148]. Once 
established inside hepatocytes, each sporozoite develops into an exoerythrocytic 
form (EEF), through a process called schizogony [5, 40, 41, 145]. This pre-
erythrocytic phase of infection is completely asymptomatic and lasts 5-17 days in 
humans, depending on the Plasmodium species [6, 40, 41]. Once parasite 
replication and cellularization are completed, the newly formed haploid parasites 
(termed merozoites) are packaged into vesicles called merosomes, which are then 
released into the bloodstream and eventually burst in the vasculature of the lung, 
releasing merozoites that will initiate the erythrocytic stage of infection [5, 40, 41, 
51, 149, 150]. The liver stage of Plasmodium infection will be further detailed in a 
section below. 
P. vivax and P. ovale are capable of forming dormant pre-erythrocytic forms, 
called hypnozoites, which hugely magnify their epidemiological and clinical 
complexity [6, 44, 51, 151]. These dormant parasites can cause multiple clinical 
attacks (called relapses) for up to about 2 years [40, 44, 51]. The risk, timing, and 
frequency of the relapses appear to coincide with both a relatively high likelihood 
of encountering a different strain of the parasite in the blood and of the presence 
of anopheline mosquitoes in the environment, in which sexual recombination with 
that other strain may occur [44].  
During the symptomatic erythrocytic stage of infection, the parasites use the 
erythrocytes as sites of asexual replication, with cycles of replication of 24, 48 or 
72 hours, depending on parasite species [40, 51]. The parasite progresses from a 
ring-stage, which is the earliest form of the parasite that is established following 
invasion of the red blood cell by a merozoite, to a more metabolically active 
trophozoite and, finally, to a schizont, characterized by asexual replication and cell 
division [51, 152]. At the end of each cycle, the newly formed merozoites burst 
from the erythrocytes and infect more cells, leading to the classic symptoms of the 
disease [6, 40, 51, 149]. Plasmodium blood stages extensively remodel their 
erythrocyte host cell, establishing several endomembrane structures, such as the 
Maurer’s clefts, Schueffner’s dots, J-dots and the tubovesicular network (TVN) [6, 
153-156]. These structures allow the export of virulence factors, such as the P. 
falciparum erythrocyte membrane protein 1 (PfEMP1) family, that mediate 
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adhesion of the infected cell to the vascular endothelium and avoid parasite 
clearance by the spleen [157]. 
Throughout the blood stage of infection, some parasites differentiate into the 
sexual forms, called gametocytes, which are eventually taken up by an uninfected 
female Anopheles mosquito [51, 152]. This process of gametocytogenesis occurs 
in only a small proportion of blood stage parasites, but is an essential step in the 
Plasmodium life cycle, as it ensures continued transmission [152, 158]. Following 
ingestion by the mosquito, gametocytes experience a drop in temperature, a 
change in pH and exposure to xanthurenic acid, which together trigger their 
maturation into gametes in the mosquito midgut [152, 159]. These gametes then 
fuse, forming diploid zygotes that develop into ookinetes before burrowing into the 
midgut epithelium and develop into oocysts [51, 152, 160]. The oocysts burst after 
one or two weeks of incubation in the midgut and release sporozoites into the 
hemolymph [51, 152, 160]. Finally, these sporozoites invade the salivary glands 
and are then transmitted to the next mammalian host that is bitten [51, 160]. 
The Pre-Erythrocytic Stage of Plasmodium Infection 
The pre-erythrocytic stage of Plasmodium infection includes all the steps since 
Plasmodium sporozoite deposition under the skin of the mammalian host until the 
release of the first generation merozoites into the bloodstream, where they will 
invade red blood cells and initiate the erythrocytic stage of infection. The pivotal 
stage of pre-erythrocytic infection occurs in the liver. Sporozoites selectively infect 
hepatocytes because these cells are able to support their massive replication, 
ensuring life cycle progression with the release of red blood cell-infectious 
merozoites [6]. This hepatic stage of Plasmodium infection takes 5-17 days in 
humans and constitutes an appealing target for the development of an anti-
malarial vaccine or prophylactic drug because it would act before the onset of 
pathology [5, 40, 149, 161]. 
The present section of this thesis is divided in two parts. The first part addresses 
the most commonly used tools to investigate Plasmodium hepatic infection. In the 
second part, each step of the pre-erythrocytic stage of infection is described in 
detail. Liver structure and metabolism are outlined in the following section of the 
thesis. 
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Experimental Address of Plasmodium Hepatic Infection 
The study of human malaria relies mainly on epidemiological analyses, population 
genetics, clinical studies of patients, and post-mortem biopsies [40]. This entails 
several limitations, such as the difficult access to post-mortem tissues and the lack 
of proper control subjects for most studies [40]. Additionally, the data obtained 
from post-mortem studies represents solely the end stage of a long process; 
consequently, it is not informative of the sequence of events that led to pathology, 
particularly the liver stage of infection [40, 41]. Therefore, several models have 
been developed to enable effective experimental approaches to study hepatic 
Plasmodium infection [41]. 
Rodent parasite models 
P. berghei was the first rodent malaria parasite identified and was isolated from 
wild rodents in Central Africa by Ignace Vincke and Marcel Lips in 1948 [41, 55]. It 
was subsequently adapted to mice, rats, hamsters and gerbils and it can be easily 
maintained in laboratory-bred mosquitoes such as A. stephensi [55]. Since then 
three other species, P. yoelii, P. vinckei and P. chabaudi, have been identified, 
isolated and adapted to laboratory rodents [41, 55]. Several strains of each 
parasite are currently available, with distinct courses and outcomes of infection, 
depending on the host-mouse strain combination [40]. 
In vitro hepatic infection systems 
Liver stage malaria research has made use of several cell lines, which are easy to 
maintain and propagate in the laboratory, have a well-defined genome and 
transcriptome, and are very permissive to genetic manipulation [41]. The cell lines 
most commonly used with rodent Plasmodia are HepG2, Huh7 and Hepa1-6; 
HepG2 and HC04 cells are used for P. vivax infections, being HC04 the only cell 
line known to support in vitro growth of P. falciparum [162-166]. However, one 
negative aspect of cell lines is the fact that they are modified, immortalized cells 
that may have lost some of the features of the cells they were derived from [41]. 
An alternative approach relies on the ex vivo use of primary hepatocyte cultures, 
which retain more characteristics of liver hepatocytes [41, 167]. Primary 
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hepatocytes can either be acquired commercially or purified in the laboratory [41, 
168]. 
In vivo infection models 
The use of mosquito-borne human-infective Plasmodium species in the laboratory 
poses obvious safety concerns and several technical challenges [41]. Hence, most 
liver stage malaria research has employed parasite species that infect other 
mammals, namely rodents and non-human primates [41]. 
Mouse models of malaria infection have been used for several decades, as they 
can be infected by a variety of Plasmodia that mimic human parasites [41, 169]. 
They are particularly useful for understanding of the basic biology of the parasite, 
the response of the organism to infection as a whole, and to perform drug delivery 
or toxicity studies [40, 41]. Distinct courses and outcomes of infection can be 
obtained, depending on the host-mouse model and the parasite used [40, 41]. 
Although the heterogeneity in outcome observed with different parasite and mouse 
combinations generates concerns about the translational utility of animal models in 
understanding human malaria, it can also be considered a reflection of the 
diversity of the human pathology [40, 169, 170]. The availability of 
inbred/congenic/transgenic animals and the ability to manipulate and control 
different aspects of the host, including the immune system, make the mouse 
model a precious tool [40, 151]. Additionally, the use of rodent models enables 
maintaining the entire life cycle of the parasite in controlled and optimized 
laboratory conditions [40, 41]. 
Nevertheless, the results obtained with mouse models should be interpreted with 
caution because mice are physiologically and genetically different from humans 
and the Plasmodium species infecting each host are highly divergent [40, 161, 
169, 170]. In fact, rodent malaria parasites have only around 70% and 60% 
identity in nucleotide and protein sequence, respectively, with P. falciparum [151]. 
Consequently, not all aspects of P. falciparum biology can be modeled using 
rodent malaria models [171]. P. falciparum exhibits a diversity of unique traits and 
harbors several genes that lack orthologous genes in the rodent Plasmodium 
parasites [171]. Additionally, many rodent parasite genes diverge functionally from 
their human parasite orthologs or have different times of expression [171]. 
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Besides humans, only large apes, including gorillas and chimpanzees, and 
possibly other smaller, non-human primate species, are natural hosts for P. 
falciparum and P. vivax [41, 151, 171]. However, their use is hampered by ethical 
and economic constraints [41, 151, 171]. Recently, mouse models with human 
tissues (liver and blood) have been developed to enhance our biological 
knowledge of human parasites, allowing their study in a physiologically relevant 
model [151, 161, 171]. These humanized mouse models share a set of mutations 
and genetically deficient backgrounds for immunocompromised status that 
facilitate engraftment with human cells and have already been shown to support 
the development of blood and liver stages of P. falciparum, when transplanted with 
human RBCs or hepatocytes, respectively [161, 171]. A mouse with a dual 
humanization of the erythrocytic and hepatic compartments would support the 
entire mammalian life cycle stages of human malaria parasites, enabling to study 
all the transition points in the cycle, to assess the safety of live-attenuated vaccine 
strains and to test pre-clinically the efficacy of therapeutics blocking different parts 
of the parasite life cycle in vivo [151, 171]. To date, only one study has 
recapitulated P. falciparum entire life cycle in vivo [151, 172]. In order to study 
immune responses and vaccine immunogenicity and efficacy, these humanized 
mouse models still need further improvement [171]. 
The First Step of Plasmodium Infection – The Skin 
Sporozoites residing in the mosquito salivary glands exit with the saliva into the 
skin of the vertebrate host as the mosquito probes for blood [147]. Salivation stops 
when the mosquito begins to take in blood [173-175]. Consequently, sporozoites 
are primarily deposited into the dermis of the skin and not directly into the 
bloodstream [173-175]. A single infected mosquito can inject between 0 and 1300 
sporozoites, with the average inoculum being approximately 125 sporozoites 
[176]. However, these numbers correspond to laboratory-raised mosquitoes where 
infection is optimized and salivary gland sporozoite numbers tend to be high [147]. 
In the field, mosquitoes harbor lower numbers of parasites, and therefore, it is 
likely that the inoculum is smaller than 100 sporozoites [177, 178]. 
To exit the skin, sporozoites move randomly using gliding motility until they contact 
with endothelial cells of the blood system [147, 175, 179, 180]. They glide around 
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and along these vessels, enter them by a cell traversal process, and are swiftly 
carried away by the blood circulation [147, 179]. Although some sporozoites leave 
the injection site very rapidly, many take up to 2 to 3 hours to exit the dermis and 
enter the bloodstream [181]. Fifteen to 20% of the inoculated sporozoites do not 
enter the bloodstream and, instead, reach the lymphatic circulation and go to the 
draining lymph node, where they are eliminated by the immune system [179, 181, 
182]. Finally, 0.5-5%, of the inoculated sporozoites were shown to remain in the 
dermis and begin to develop into exoerythrocytic stages at the inoculation site 
[183, 184]. This has only been observed using laboratory rodent malaria parasites 
[147]. Hence, it is possible that the development of exoerythrocytic parasite forms 
in the skin results either from a non-optimal host-parasite combination or is an 
evolutionary remnant from the common ancestry with the avian malaria parasites 
[147]. Notably, parasites developing in the skin are not able to initiate a blood 
stage infection; even though the merozoites seem fully mature, they are probably 
unable to penetrate the closed endothelium of the blood vessels [147, 183, 184]. 
Sporozoites that remain at the inoculum site are possibly destroyed by the innate 
immune cells, contributing to the initiation of the immune response [40, 147]. In the 
end, only 10 - 25% of the inoculated sporozoites reach and develop within the liver 
[185, 186]. 
The Arrival to the Liver – Plasmodium’s Cell Traversal Ability 
Liver sinusoids have a fenestrated endothelium and are lined with liver-resident 
macrophages called Kupffer cells [5]. Once the sporozoites injected by an infected 
mosquito reach the blood capillaries in the liver, parasites traverse liver sinusoidal 
endothelial cells (LSECs) or Kupffer cells to exit the bloodstream and gain access 
to the hepatocytes [5, 6, 187-189]. Kupffer cells have been shown to undergo 
apoptosis after exposure to sporozoites [5, 190]. Thus, the traversal of these cells 
might constitute a strategy to resist phagocytosis [5, 190]. 
After traversing the sinusoidal barrier, sporozoites traverse several hepatocytes 
before invading one that will serve as host cell (Fig. 1.4) [145]. The role of this 
migration process is still unclear but it was postulated to render the sporozoites 
competent for invasion and/or the host cell permissive to infection [5, 191]. 
Sporozoites that have traversed cells were shown to be more infectious than non-
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traversing parasites, probably due to induction of exocytosis of apical organelles 
necessary for invasion [191]. On the other hand, during traversal, sporozoites are 
exposed to increased levels of potassium inside the traversed cells which reduces 
their cell passage activity and enhances their infectivity [192]. Finally, 
wounded/traversed hepatocytes secrete hepatocyte growth factor (HGF), which 
conditions neighbouring cells to be more susceptible to infection [193]. 
Nevertheless, mutant parasites lacking one of the proteins that are known to be 
involved in cell traversal, namely sporozoite microneme protein essential for cell 
traversal (SPECT), PLP1, cell traversal protein for ookinetes and sporozoites 
(CelTOS) and phospholipase (PL), are able to infect cells in vitro with efficiencies 
similar to those of wild type parasites, suggesting that traversal is not a pre-
requisite for cell invasion by sporozoites [194-199]. Another hypothesis as to how 
the sporozoite switches to an infectious mode is related to their interaction with 
highly sulfated-heparan sulfate proteoglycans (hsHSPGs) present on hepatocytes 
[6, 200]. Exposure to hsHSPGs induces the proteolytic cleavage of the N-terminus 
of the surface CSP by a parasite cysteine protease, exposing the type I 
thrombospondin repeat (TSR), a cell adhesive domain that is otherwise masked, 
and thus allows the sporozoite to shift to an invasive state [147, 201]. 
The Process of Hepatocyte Invasion 
Similarly to gliding motility, the invasion process relies on the actin-myosin motor 
beneath the parasite’s plasma membrane and requires the formation of a moving 
junction to form an interface between the parasite and the hepatocyte [5, 147]. The 
proteins necessary for host cell invasion are stored and released from specialized 
apical organelles called micronemes [5]. One such protein is thrombospondin-
related anonymous protein (TRAP), which connects host cell and parasite by using 
its cytoplasmic tail to bind parasite actin via aldolase and its extracellular adhesive 
domains to bind hepatocytes, as has been shown using both gene deletion and 
mutagenesis of functional domains [5, 147, 202, 203]. TRAP is secreted from 
micronemes at the sporozoite’s anterior end and is translocated to the posterior 
end, thus providing the propulsion used by the sporozoite during invasion [5, 147, 
203]. Parasite proteins stored in the rhoptries, another type of secretory organelle, 
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might also be involved in the hepatocyte invasion process because of their 
demonstrated roles in invasion of red blood cells by merozoites [5, 204]. 
Several host factors are also important for invasion of hepatocytes. The actin 
nucleating complex Arp2/3 is required for the parasite-induced formation of a ring-
shaped F-actin structure in the host cell at the moving junction [205]. A successful 
invasion requires de novo polymerization of host actin at the entry site, which is 
likely involved in anchoring the tight junction so that the parasite can pull upon it to 
penetrate the host cell [5]. The tetraspanin cluster of differentiation 81 (CD81), 
present in cholesterol-rich lipid rafts on the surface of hepatocytes, has been 
shown to be involved in sporozoite invasion by some species of Plasmodium [5, 
6]. HepG2 cells expressing CD81 are more permissive to invasion by P. yoelii; on 
the other hand, CD81 is not required for invasion by P. berghei and its presence is 
necessary but not sufficient for invasion by P. falciparum [206-209]. Scavenger 
receptor BI (SR-BI) is a high-density lipoprotein receptor that, along with CD81, is 
present in cholesterol-rich microdomains on the hepatocyte surface and is 
necessary for efficient sporozoite invasion [210, 211]. SR-BI normally functions to 
facilitate the uptake of high-density lipoprotein cholesteryl-esters, and thus may 
indirectly promote sporozoite invasion by providing the cholesterol necessary for 
appropriate CD81 cell-surface localization [5, 6]. Another hepatocyte receptor, c-
Met, has been implicated in hepatocyte infection by P. berghei but not by P. 
falciparum or P. yoelii [193, 212]. 
Host-Parasite Interface - The Parasitophorous Vacuole 
During the invasion of hepatocytes, the parasite forms a parasitophorous vacuole 
(PV), within which it resides throughout its liver stage development (Fig. 1.4) [5, 6]. 
The sporozoites that enter hepatocytes without a PV are rapidly cleared by host 
cells through a Bcl-2-dependent apoptosis mechanism, whereas the sporozoites 
that form a PV render host cells less susceptible to apoptosis [213-215]. The PV 
membrane (PVM) is porous, allowing the entrance of small host factors into the 
vacuole [5, 6, 216]. It is derived from the host plasma membrane, which is 
significantly remodeled with proteins of parasite origin [5, 6, 216]. 
The parasite proteins P36 and P52 (P36p) are involved in the formation of the PV, 
as a P. yoelii p52/p36 double gene knockout and P. berghei and P. falciparum p52 
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single gene deletion are unable to form a PVM and arrest early in liver stage 
development [213, 217, 218]. Very recently, it was shown that the hepatocyte 
EphA2 receptor is likely to play a role in establishing a PV, probably via an 
interaction with P36 [219]. A secreted protease from P. yoelii, rhomboid 1 (ROM1), 
was found to be involved in liver stage PV formation, with 50% of rom1 knockout 
parasites developing abnormal vacuoles and aborting growth within the first 12 
hours of infection [220]. Several liver stage PVM-resident proteins have been 
identified, including upregulated in infectious sporozoites (UIS) 3, UIS4, exported 
protein 1 (EXP1), and two members of the early transcribed membrane protein 
(ETRAMP) family [221-223]. These PVM-resident proteins might have a role on 
parasite growth and survival, as evidenced by the deletion mutants of UIS3 or 
UIS4 that are not able to develop beyond early liver stages in vivo [5]. Both UIS3 
and UIS4 have their carboxyl-termini in direct contact with host hepatocyte, 
therefore they are likely involved in host-parasite interactions [5]. In fact, UIS3 was 
shown to bind host liver fatty acid binding protein (L-FABP), indicating an 
involvement in the uptake of fatty acids by the parasite [9]. It is likely that other 
PVM proteins are also involved in nutrient uptake or other forms of host cell 
manipulation [5]. 
Plasmodium Hepatic Schizogony 
After the successful invasion of a hepatocyte, each sporozoite dedifferentiates 
from an invasive form to an active replicative form, the liver stage trophozoite (Fig. 
1.4) [5, 6]. This process takes approximately one-third of the time the parasite 
spends inside the hepatocyte and begins with the breakdown of the sporozoite’s 
inner membrane complex, a cytoskeletal structure located beneath the plasma 
membrane, which leads to the formation of a central spherical bulb around the 
nucleus with the simultaneous retraction of the sporozoite’s two distal ends [216, 
224]. Simultaneously, the parasite expels the remnants of its invasion machinery 
by an active exocytic process, retaining only those organelles that are necessary 
for parasite replication [5]. Dedifferentiation to a trophozoite was shown to be 
triggered by extracellular bicarbonate concentrations and a raise in temperature 
that mimic host conditions, leading to increased intracellular calcium levels, 
especially in the centre of the spherical bulb [225, 226]. Additionally, the 
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translational repression of specific mRNAs packaged into storage granules also 
plays a major role in sporozoite transformation [5]. 
Once dedifferentiated, the trophozoite enters schizogony, a process during which 
it undergoes rapid growth with 104- to 105-fold replication of its genome, ultimately 
forming a multinucleate syncytium (Fig. 1.4) [5, 6]. During nuclear division, the 
apicoplast and mitochondrion become two extensively branched and intertwining 
structures that undergo morphological and positional changes before segregating 
into individual merozoites [227]. This cellular and genomic expansion happens at a 
remarkable speed, taking only 2 days for the rodent-infective P. yoelii and P. 
berghei parasites [5]. 
To support their rapid multiplication, parasites derive nutrients from the host 
hepatocyte both by passive diffusion through pores in the PVM and by active 
processes such as those that take up glucose, fatty acids and cholesterol [7-10]. 
Indeed, microarrays of P. berghei-infected hepatoma cells and P. yoelii-infected 
mouse hepatocytes revealed that the parasite modulates the host cell’s 
transcriptome towards biosynthetic pathways including carbohydrate and fatty acid 
metabolism [11]. Recently, it was demonstrated that the developing EEF 
scavenges phosphatidylcholine from their hepatocyte host [228]. Liver stage 
parasites also scavenge PI(3,5)P2 by sequestration of late endosomes and 
lysosomes around their PVM and subsequent fusion with the TVN during 
development [229-231]. Iron availability also plays a role on Plasmodium liver 
development. It was shown that blood stage parasite density above a certain 
threshold can inhibit the next wave of sporozoite invasion and development 
through modulation of hepcidin, the host iron regulatory hormone, to redistribute 
iron away from the liver [232]. Certainly, several other nutrients are also acquired 
from the host to sustain parasite growth and development. 
Merozoite Formation and Release 
Formation of the individual hepatic merozoites occurs through several 
invaginations of the parasite plasma membrane that eventually package the 
individual daughter merozoites with a single nucleus and the necessary organelles 
[5]. This massive expansion of the parasite plasma membrane relies on the 
endogenous generation of fatty acids via the type II fatty acid synthesis (FAS-II) 
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pathway in the apicoplast [5]. The components of this pathway were shown to be 
upregulated in liver stages; if deleted, rodent malaria parasites arrest their liver 
stage development before merozoite formation, indicating that fatty acid synthesis 
is essential for late liver stage development [233-235]. 
Plasmodium-specific apicoplast protein important for liver merozoite formation 
(PALM) was also implicated in efficient merozoite formation and segregation 
because its absence results in a significant defect in late liver stage development 
[236]. In fact, the apicoplast seems to play an important role in the development of 
the parasite given that using antibiotics to inhibit the bacterial-like protein 
translation processes of this organelle hinders its development and, consequently, 
disrupts the maturation of the parasite [236]. 
During merozoite formation, the cysteine protease-dependent degradation of the 
PVM leads to the release of merozoites into the host cell cytoplasm [237]. These 
cysteine proteases are probably serine repeat antigen (SERA) proteases, which 
are present in all Plasmodium species and are essential for merozoite egress from 
erythrocytes and sporozoite egress from oocysts in the mosquito midgut [238]. In 
fact, P. berghei proteases SERA-1 and SERA-3 were found in the hepatocyte 
cytoplasm during merozoite development, probably due to PVM breakdown [239, 
240]. Nevertheless, it is still unknown if these proteases are involved in the 
breakdown of the PVM or whether they play a role during merozoite release from 
the hepatocyte [5]. 
Following the breakdown of the PVM, from a few to several thousand merozoites 
are packaged into vesicles termed merosomes that are extruded from the infected 
hepatocyte into the liver sinusoids (Fig. 1.4) [237, 241]. The parasite induces a 
non-apoptotic/non-necrotic cell death program in the hepatocyte causing it to 
detach from surrounding tissue and delays the fragmentation of the host genomic 
DNA [5, 237]. Additionally, it inhibits phosphotidylserine display on the outer leaflet 
of the plasma membrane of these dying hepatocytes, as well as, on the surface of 
merosomes, whose membrane is comprised of the host hepatocyte plasma 
membrane [242]. This allows the merozoites to evade detection by immune cells 
present in the liver [5]. Merosomes then travel passively in the bloodstream and 
burst in the narrow vasculature of the lung, releasing merozoites that initiate blood 
stage infection [150]. 
General Introduction               Chapter I 
30 
 
 
Figure 1.4 – The liver stage of Plasmodium parasites. After traversing the 
endothelium, each sporozoite traverses several hepatocytes until it productively 
invades one, with formation of a PV. Then, it actively expels and disassembles 
organelles involved in the invasion process and dedifferentiates into a 
trophozoite. Liver stage parasites scavenge nutrients from the hepatocyte and 
extensively replicate their genome and organelles, which are segregated during 
schizogony into each of the newly formed merozoites. Late in schizogony, the 
PVM breaks down and merozoites are enclosed in merosomes, which are 
released into the liver sinusoid, enter circulation and eventually burst in the lung 
microvasculature to release the merozoites. Infections by P. vivax and P. ovale 
also produce hypnozoites that can reactivate months or years later. From [5]. 
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Liver Structure and Metabolism 
Liver Anatomy 
The liver is the largest gland in the body, accounting for 2 to 5% of body weight 
[243-245]. It sits in the right upper abdominal cavity beneath the diaphragm and is 
protected by the rib cage and by a thin connective tissue capsule known as 
Glisson’s capsule [244, 245]. 
This organ has a dual blood supply consisting of the hepatic artery, which delivers 
around 25% of the blood supply, and the portal vein that accounts for the 
remaining 75% [245]. All nutrients absorbed by the intestinal system reach the 
liver through the portal vein and are processed through the hepatic metabolism of 
glucose, lipids and proteins [245, 246]. 
The liver possesses a repeated, multicellular architecture, composed of five types 
of specialized cells, classifiable into parenchymal (hepatocytes) and 
nonparenchymal cells (sinusoidal endothelial cells, Kupffer cells, biliary ductal cells 
and stellate cells) [243-245]. The vast majority of liver functions, including 
synthesis and storage functions and filtration of the portal venous blood, are 
mediated by the hepatocytes, which constitute about two-thirds of the liver cell 
mass [243-245]. These cells are structurally and functionally polarized, with three 
distinct membrane domains, sinusoidal (basal), lateral and canalicular (apical) 
[245, 247]. Kupffer cells are the specialized liver macrophages, responsible for 
immunological and phagocytic functions [248]. Bile duct epithelial cells are 
involved in the transport of bile and maintenance of its pH [249]. Finally, hepatic 
stellate cells store retinoids (retinol and retinyl esters) in perinuclear fat droplets 
and have been implicated in the pathological remodeling process associated with 
hepatic fibrosis [250, 251]. 
The liver parenchyma is arranged in hexagonal lobules in a honey-comb-like 
pattern; at the periphery of each lobule, branches of the hepatic artery, portal vein 
and bile duct form three to six portal triads (Fig. 1.5A) [244, 245, 252, 253]. Both 
portal vein venules and portal arterioles of each portal triad branch into the lobules 
to form the sinusoids, blood vessels with fenestrated, discontinuous endothelium 
that serve to provide nutrients and oxygen to the surrounding hepatocytes [244, 
245, 253]. The sinusoids are positioned radially in the liver lobule and ultimately 
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converge and form the central vein at the center of the lobule [244, 245]. The 
direction of blood flow of each liver lobule is from the periphery to the center, 
generating a gradient in oxygen, nutrients, hormones and growth factors (Fig. 
1.5B) [243, 245]. 
Hepatocytes are the building blocks of the liver lobules [245, 253]. They are 
arranged in liver cell plates and positioned radially with individual sinusoidal 
capillaries (Fig. 1.5B) [243-245, 254]. This unique architectural arrangement allows 
for bi-directional permeability and exchange of materials from both the hepatocyte 
and blood [245, 253]. The space of Disse is a subendothelial area that separates 
the endothelial cells from the hepatocytes [244, 245]. Many hepatic 
nonparenchymal cells are located in the sinusoids and space of Disse, allowing for 
efficient immune surveillance as well as other metabolic functions [245].  
 
Figure 1.5 - Liver structure and cell types. A) The liver is organized in many 
lobules, its functional units. The portal triad consists of a portal vein, hepatic 
artery and biliary duct. Hepatocyte cords are separated by sinusoids that carry 
blood from the portal triads to the central vein. B) Within each lobule are a 
number of sinusoids, which are discontinuous vessels built from specialized 
fenestrated endothelial cells of the liver. Stellate cel ls are located in the space of 
Disse between the hepatocyte cords and sinusoids. Kupffer cells also reside in 
sinusoids. Hepatocytes secrete bile salts into the bile canaliculi that lead to the 
bile duct. Cholangiocytes are the epithelial cells lining the bile ducts. From [255]. 
Liver Zonation 
The liver cell plate consists of 15–25 hepatocytes that extend from the portal triad 
to the hepatic venule [245, 253]. Although histologically indistinguishable, each 
hepatocyte specializes in certain metabolic functions based on its position along 
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the porto-central axis of the liver lobule, which determines their fate as either 
periportal or perivenous hepatocytes [245, 253, 256]. Zone 1 is composed by six 
to eight periportal hepatocytes that surround the portal triad and are in close 
contact with the afferent blood [245]. Close to the efferent centrilobular vein, two to 
three perivenous hepatocytes are considered zone 3 [245]. The midlobular 
population of six to ten hepatocytes make up zone 2 [245]. The concept of 
zonation, in which opposing or complementary metabolic pathways are carried out 
within distinct non-overlapping regions of the liver lobule, was proposed by 
Jungermann thirty years ago [245, 253, 257]. This metabolic zonation is thought to 
contribute to the maintenance of optimal metabolic homeostasis and to optimize 
liver function [253]. 
The zonated functions include glucose metabolism, ammonia detoxification, 
metabolism of drugs and xenobiotics, lipid metabolism, synthesis of bile acids and 
the metabolism of several amino acids [245, 253]. In the case of glucose 
metabolism, gluconeogenesis is mostly periportal whereas glycolysis is mostly 
perivenous [245, 256]. Ammonia detoxification relies firstly on periportal 
hepatocytes and, later, on perivenous hepatocytes [245, 258, 259]. The 
metabolism of drugs and xenobiotics occurs mostly in the perivenous area [245, 
257]. Importantly, not all hepatic processes are zonal [245]. For example, the 
synthesis of transthyretin and transferrin transporters and albumin appears to 
occur in all hepatocytes [245]. 
Functional zonation is mainly controlled by differential expression of genes 
encoding the enzymes responsible for the functions concerned [245, 260]. This 
control may involve transcriptional or posttranscriptional regulation along the 
portocentral axis [245]. The Wnt/β-catenin pathway is one critical player in liver 
zonation [253, 261-263]. The transcription factor Hnf4α is also a modulator of the 
zonal expression of genes, acting through cross-talk with the Wnt pathway [245, 
264]. 
Liver Function 
The liver functions as a metabolic hub, performing a complex array of more than 
500 functions, including synthesis of serum proteins, metabolism of amino acids, 
lipids and carbohydrates and detoxification of xenobiotic compounds [243, 245]. 
For the sake of simplicity, only glucose and protein metabolisms will be introduced. 
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Hepatic Glucose Metabolism 
The liver plays a unique role in controlling carbohydrate metabolism by 
maintaining glucose concentrations in a normal range through a tight regulation of 
glucose breakdown, synthesis and storage as glycogen in hepatocytes [245]. 
Additionally, it acts as a sensory organ; the intrahepatic sensory-effector nerves 
detect glucose concentration gradients between the hepatic artery and the portal 
vein and, subsequently, generate a cholinergic signal for an insulin-dependent net 
hepatic glucose uptake [265, 266]. 
Blood glucose enters hepatocytes mainly via plasma membrane glucose 
transporter 2 (GLUT2), a high capacity transporter that also mediates glucose 
release [245, 246, 267]. Upon uptake, glucose is phosphorylated by glucokinase 
(GCK), the rate-limiting enzyme for further glucose utilization, to generate glucose 
6-phosphate (G6P) (Fig. 1.6) [245, 246, 268]. G6P is then channeled to several 
pathways such as glycogen synthesis, glycolysis and pentose phosphate pathway  
(PPP) in the fed state, or is transported into the endoplasmic reticulum (ER) and 
dephosphorylated by glucose-6-phosphatase (G6Pase) to release glucose in the 
fasted state [246]. 
Glycogen Metabolism 
With 10% of its weight, the liver has the highest specific glycogen content of any 
tissue [245]. Glycogen is synthesized from G6P by glycogen synthase in the fed 
state and is metabolized by glycogen phosphorylase in the fasted state, both 
enzymes regulated by phosphorylation [245, 246, 269].  
In the fed state, pancreatic β-cells secret insulin, that stimulates the synthesis of 
glycogen and suppresses glycogenolysis, the process of glycogen breakdown 
[246, 270]. Glycogen synthesis is also stimulated by the GI-secreted fibroblast 
growth factor 15/19 (FGF15/19) [246, 271]. In the fasted state, glucagon and 
catecholamines, such as epinephrine and norepinephrine, are secreted by 
pancreatic α-cells and the adrenal medulla, respectively, and stimulate glycogen 
breakdown [246, 272]. 
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Figure 1.6 - Pathways of hepatic glucose metabolism. A) Simplified scheme 
depicting the major biochemical pathways activated during postprandial  glucose 
consumption and storage. B) Simplified scheme depicting the major biochemical 
pathways activated during post-absorptive glucose production. Acetyl-CoA, 
acetyl-coenzyme A; GCK, glucokinase; GLUT2, glucose transporter 2; TCA, 
tricarboxylic acid. From [273]. 
Glycolysis 
In the fed state, when glucose is abundant, glycolysis is the preferred pathway for 
energy supply by hepatocytes [246]. The generated glycolytic intermediates are 
completely oxidized in the tricarboxylic acid (TCA) cycle to generate adenosine 
triphosphate (ATP) and are used to synthesize lipids, amino acids and other 
important molecules (Fig. 1.6A) [245, 246]. The glycolytic flux is mainly controlled 
by four kinases, GCK, 6-phosphofructo-1 kinase (PFK), liver pyruvate kinase (L-
PK) and pyruvate dehydrogenase kinases (PDKs), whose levels and activity 
increase after food ingestion [274]. 
Hepatic glycolysis is also controlled by insulin and glucagon. In the fed state, 
insulin stimulates glycolysis while in the fasted state, glucagon inhibits it; both act 
via a single enzyme called bifunctional 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase (PFK-2/FBP-2) [275, 276]. 
Pentose Phosphate Pathway (PPP) 
The PPP, also known as the hexose monophosphate shunt or the 
phosphogluconate pathway, branches from glycolysis at the first committed step 
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and consumes G6P as a primary substrate [277]. Besides generating 
phosphopentoses and ribonucleotides, the PPP plays a pivotal role in the cellular 
redox state because it is a major source of nicotinamide adenine dinucleotide 
phosphate (NADPH) [277]. 
The PPP comprises two branches: the oxidative branch and the nonoxidative 
branch [277-279]. The oxidative branch generates NADPH and ribonucleotides via 
three irreversible reactions [277-279]. The non-oxidative branch comprises a 
series of reversible reactions that recruit additional glycolytic intermediates, such 
as fructose-6-phosphate (F6P) and glyceraldehyde-3-phosphate (G3P), which can 
be converted into pentose phosphates and vice versa [277-279]. 
Gluconeogenesis 
The liver produces glucose through glycogenolysis in short-term fasting (2-6 hours 
after a meal) [245, 246]. In more prolonged fasting, after depletion of hepatic 
glycogen, hepatocytes start synthesizing glucose through gluconeogenesis using 
lactate, pyruvate, glycerol and amino acids, such as alanine (Fig. 1.6B)  [245, 246, 
272]. 
The rate of gluconeogenesis is determined by the availability of its substrates, 
which are either generated within the liver or delivered through the circulation from 
extra-hepatic tissues, such as skeletal muscle and adipose tissue, and by the 
activity of the unidirectional enzymes, phosphoenolpyruvate carboxylase 
(PEPCK), fructose-1,6-bisphosphatase (FP2ase) and G6Pase [245, 246, 272]. 
Gluconeogenesis is a highly regulated process. Insulin is a very well-known 
suppressor of gluconeogenesis [245, 246, 280]. On the other hand, glucagon, 
whose secretion is higher in the fasted state and during exercise, is a stimulator 
[245, 281]. Several GI hormones, including glucagon-like peptide 1, FGF15/19 and 
serotonin, also regulate this process [246, 282, 283]. 
Hepatic Protein Metabolism 
Under steady-state conditions the body cannot store protein [245]. All amino 
groups of the protein component of the food have to be deaminated [245]. The 
resulting ammonia has to be detoxified and excreted (mainly as urea), whereas 
the carbohydrate component is metabolized or stored as glycogen or fat [245]. 
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The liver is the main responsible for the detoxification of the ammonia generated 
by metabolization of amino acids in the intestines, converting 75% of it into urea 
[245, 284]. Several amino acids, such as alanine and glutamine, are also directly 
used in hepatic urea synthesis [245, 253]. Although relatively independent from 
feeding, the capacity to synthesize urea corresponds directly to the protein content 
of the food [284-286]. 
Urea excretion via the urine accounts for 70-80% of the urea synthesized [287-
289]. The remaining is lost through the gut or reabsorbed in the form of ammonia 
to reenter the urea cycle, or rescued for amino acid synthesis via microbial urease 
[287, 289-291]. 
The liver is also able to produce amino acids, such as glutamine or, alternatively, 
to convert some amino acids into others [284, 292, 293]. Distinct hepatocytes 
express the enzymes involved in hepatic ammonia and glutamine metabolism 
[245]. Urea cycle enzymes are found in periportal hepatocytes, whereas glutamine 
synthesis is mostly confined to pericentral hepatocytes [294, 295]. Enzymes 
involved in the metabolism of histidine, histamine, glycine and serine are mostly 
periportal [253, 260]. 
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Plasmodium Metabolism 
Most of what is known about Plasmodium metabolism regards the blood stage of 
infection. Information concerning mosquito and liver stages has arisen more 
recently. In the following two sections, the parasite´s carbon and polyamine 
metabolisms will be addressed. 
Carbon Metabolism 
Glucose is the major carbon source for Plasmodium blood stage parasites [296, 
297]. In fact, the glucose consumption rate of an erythrocyte is estimated to 
increase up to 100-fold when containing the metabolically active trophozoite and 
schizont stages of Plasmodium [297, 298]. 
Most of the glucose consumed by the malaria parasite is incompletely oxidized to 
lactic acid, which is excreted; other metabolites include pyruvate, alanine and 
glycerol, the latter being an unusual product of anaerobic catabolism of glucose 
only found in yeast and other protozoan parasites, such as Leishmania and 
Trypanosomes [296, 299-301]. Only a small fraction is completely oxidized to 
carbon dioxide, suggesting that blood stage Plasmodium relies primarily on 
glucose fermentation for energy supply [297, 302, 303]. Similarly to all proliferating 
cells, Plasmodium parasites also utilize glucose to synthesize nucleic acids and 
NADPH via the PPP [304-307]. Among the other sugars, only fructose can support 
Plasmodium growth, but at a reduced rate [15, 308]. 
As previously mentioned, blood stage malaria parasites generate energy mainly 
through anaerobic glycolysis. However, a canonical oxidative TCA cycle is also 
active and uses both glucose and glutamine as carbon sources [309, 310]. 
Glutamine-derived carbon enters the cycle via α-ketoglutarate, whereas glucose 
provides oxaloacetate and acetyl-CoA [309-311]. Glucose-derived acetyl-CoA is 
also used in the synthesis of UDP-N-acetyl-glucosamine, which is involved in the 
production of glycophosphatidylinositol (GPI) anchors of glycoconjugated proteins 
[312]. Knockout parasites for the TCA cycle enzymes grow normally in asexual 
blood stages but their life cycle progression is halted at later stages, such as 
gametocyte and mosquito stages [313]. 
Plasmodium parasites lack the ability to generate carbohydrate stores such as 
glycogen and, for that reason, they are dependent on a constant and abundant 
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supply of glucose [297, 302, 303, 314]. This is achieved by the presence of sugar 
transporters on the erythrocyte and on the parasite plasma membranes [17, 315]. 
Glucose is first transported from the blood plasma into the erythrocyte cytosol by 
GLUT1, the most abundant facilitative glucose transporter in the erythrocyte 
membrane [315, 316]. Glucose molecules then pass from the erythrocyte 
cytoplasm to the vacuolar space through high-capacity, low selectivity channels 
present in the PVM [317]. Finally, glucose uptake into the parasite is mediated by 
a facilitative hexose transporter (HT) [315, 318]. Inhibition of HT by 3-O-[undecyl-
10-en]-1-yl-D-glucose, also known as compound 3361, highly impacts P. 
falciparum in vitro survival and suppresses P. berghei parasitaemia in vivo [16]. 
Deletion of this gene is lethal for the parasite, further proving its essentiality for 
asexual blood stages [7, 17].  
Glucose also plays a pivotal role in other stages of the parasite’s life cycle. The 
hemolymph of A. stephensi is rich in glucose and in the storage carbohydrate 
trehalose; likewise, the liver of the mammalian host is rich in glucose and glycogen 
[245, 319]. Additionally, HT is expressed throughout development in the mosquito 
vector, as well as during the liver stage [8, 17, 233, 320, 321]. Inhibition of glucose 
uptake with compound 3361 affects both these stages of the parasite life cycle [7, 
8]. Finally, glucose concentration in the culture medium was established as a key 
factor for P. berghei development into infective merozoites inside hepatoma cells 
[322]. 
Polyamines Metabolism 
Polyamines (putrescine, spermidine and spermine) are low molecular weight 
organic cations that are synthesized in all cells but occur in particularly high 
concentrations in rapidly proliferating cells, such as cancer cells and protozoan 
parasites [323-325]. These molecules and their derivatives have the ability to 
interact electrostatically with most polyanionic macromolecules in the cells and 
thereby mediate several important cellular processes, including cellular 
differentiation and proliferation, embryonic development and stress responses 
[326-329]. 
Polyamine biosynthesis pathways start with the conversion of L-arginine into L-
ornithine by arginase, which is then metabolized into putrescine (1,4-
diaminobutane) by ornithine decarboxylase (ODC) [329, 330]. In parallel, S-
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adenosylmethionine decarboxylase (AdoMetDC) catalyses the formation of 
decarboxylated S-adenosylmethionine (AdoMet) [331, 332]. AdoMet then donates 
the aminopropyl group for the conversion of putrescine into spermidine and, 
subsequently, of spermidine into spermine, by spermidine synthase (SpdS) and 
spermine synthase (SpmS), respectively [331-333].  
Polyamines make up 14% of the total metabolome of isolated intraerythrocytic 
Plasmodium parasites and their availability is essential for the survival and rapid 
proliferation of the parasite [328, 329, 334]. This pool of polyamines is mainly 
composed of putrescine and spermidine [26, 329]. Spermine is only present in 
very low levels because the parasite lacks a SpmS; however, its SpdS is 
somewhat promiscuous and can also metabolize spermidine into spermine [328, 
329, 335]. The most distinctive feature of polyamine biosynthesis in the malaria 
parasite is that a single open reading frame encodes the two rate-limiting enzymes 
in the pathway, ODC and AdoMetDC, originating a unique protein, 
AdoMetDC/ODC [328, 329, 336]. Even though each decarboxylase active site 
functions independently of the other, ODC activity seems to be allosterically 
stimulated by the presence of the AdoMetDC domain and, conversely, AdoMetDC 
activity is inhibited by the presence of the ODC domain, resulting in the production 
of equimolar levels of putrescine and AdoMet [337-339]. 
Polyamine metabolism can be targeted either by preventing intracellular polyamine 
biosynthesis with enzyme inhibitors or by competitively displacing the functional 
polyamine pool within cells with non-functional polyamine analogues [324, 329]. 
Inhibition of AdoMetDC/ODC with ODC inhibitors, the most well-known being α-
difluoromethylornithine (DFMO), has a cytostatic effect on P. falciparum 
proliferation in vitro that is reversible by exogenous polyamines; additionally, it is 
not curative in an in vivo infection with P. berghei [26, 328, 340, 341]. Similar 
results were obtained when inhibiting the AdoMetDC activity of the bifunctional 
protein with the compound MDL 73811 [328, 342]. Co-inhibition of both 
decarboxylase activities displays a non-synergistic but additive effect on infection 
[340, 342]. Although not so extensively studied, inhibition of SpdS also impacts P. 
falciparum growth in vitro [28, 335]. Polyamine analogues inhibit P. falciparum and 
P. berghei growth in vitro and in vivo, respectively [343-345]. Notably, 
administration of one of the bis(benzyl)polyamine analogs, MDL 
27695,  in combination with DFMO, effectively cured 47 out of 54 mice infected 
Chapter I  General Introduction 
41 
 
with P. berghei; these mice were found to be immune upon re-challenge with the 
same P. berghei strain 4 months after the initial infection [343]. 
The cytostatic effects of the inhibitors of both activities of the AdoMetDC/ODC 
enzyme and of SpdS are probably due to the ability of the parasite to take up 
exogenously provided polyamines to replenish intracellular pools [328, 329]. Both 
putrescine and spermidine can be taken up into the parasite via a saturable 
temperature-dependent process, with competition between different polyamines, 
the precursor ornithine and other basic amino acids [346]. This transport is 
dependent on extracellular pH and on the parasite’s membrane potential but 
independent of extracellular Na+ concentration [346]. Putrescine and spermidine 
uptake is increased when polyamine biosynthesis is inhibited [346]. 
The polyamine biosynthesis pathway is likely to play an important role on other 
stages of Plasmodium life cycle. DFMO was shown to impair exoerythrocytic 
development of P. berghei both in mice and in cultured human hepatoma cells 
[347]. Similarly, DFMO also impacts the sporogonous cycle of P. berghei in 
Anopheles mosquitos [348]. 
Parasites scavenge nutrients from the host hepatocyte to feed into their metabolic 
pathways and support their rapid multiplication. It is, therefore, expected that this 
utilization of nutrients by the parasite, making them unavailable for the host cell, 
will affect the cell’s metabolism. 
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Thesis Aims 
During the liver stage of Plasmodium infection, the parasite undergoes a 
remarkably rapid growth, with 104- to 105-fold replication of its genome, ultimately 
forming thousands of new parasites [5, 6]. In order to support their rapid 
multiplication and feed their metabolic pathways, parasites scavenge nutrients 
from the host hepatocyte [7-10, 228-232, 322]. 
The host lab previously showed that glucose plays a crucial role during the liver 
stage of P. berghei, establishing the importance of the import of this nutrient 
through the parasite’s membrane hexose transporter (HT) for its replication inside 
liver cells [8]. On the other hand, a previous microarray study from the host lab 
showed that Plasmodium development inside hepatic cells induces the 
coordinated and sequential expression of host genes [11]. Prominent among these 
are genes encoding membrane transporters, including several genes involved in 
amino acid transport, whose expression is consistently altered in infected cells.  
These observations led to the formulation of two hypotheses, which the present 
thesis aimed to address: the uptake of glucose by the host cell constitutes a 
crucial requirement for the parasite’s ability to develop normally; and, the intra-
hepatic Plasmodium parasites modulate host membrane transporters, most likely 
to ensure their own survival and development. 
At the onset of this work, we established a number of specific aims. Firstly, to 
employ an RNA interference (RNAi)-based approach to identify, from among a 
panel of selected genes encoding the membrane transporters that might play a 
role during Plasmodium infection of liver cells. Secondly, to characterize the 
molecular function of these transporters and the role of their downstream 
metabolic pathways during the parasite’s intracellular development. And, finally, to 
identify molecular targets and infection modulation strategies that can impact 
Plasmodium development or survival during the hepatic stage of the parasite’s life 
cycle. 
The pursuit of these objectives relied upon the use of an extensive array of 
methodological approaches and experimental tools, including established in vitro, 
ex vivo and in vivo infection models, selected transgenic rodent models, RNAi, 
immunofluorescence microscopy, flow cytometry and quantitative real-time PCR 
techniques, and the use of specific competitors and inhibitors of the transport 
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proteins identified and of the enzymes of the downstream pathways, as well as 
nutrient depletion and supplementation studies. With these approaches, we 
expected to unravel novel host transport proteins and metabolic pathways that 
play a crucial role on Plasmodium exoerythrocytic development, and which may 
constitute suitable targets for malaria prophylaxis and thereby contribute to the 
development of new intervention strategies against this disease. 
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Introduction 
Glucose is the primary source of energy and a key substrate for most cells. 
Glucose and other carbohydrates are transported into cells by members of a 
family of integral membrane glucose transporter (GLUT) molecules. To date 14 
members of this family, also called the solute carrier 2A (SLC2A) family, have 
been identified, which are divided into several families (classes I to III) based on 
their transport characteristics and sequence similarities [349, 350]. 
GLUT1 is a class I facilitative glucose transporter expressed in liver cells and 
overexpressed in various tumors [12, 13]. GLUT1 expression is highest in the 
human erythrocyte membrane, and has been shown to play a critical role in 
cerebral glucose uptake [351]. GLUT1 is also a receptor for the human T cell 
leukemia virus (HTLV) and GLUT1-mediated glucose transport in T-cells has been 
shown to regulate HIV infection [352, 353]. 
As mentioned in the Plasmodium Metabolism section on the general introduction 
of this thesis, blood stages of malarial parasites are dependent on glycolysis as 
their main ATP source, a process that has recently been modeled for the human 
malaria parasite P. falciparum [315, 354-356]. Glucose has been shown to be 
transported from human blood plasma into the erythrocyte cytosol by GLUT1, and 
then taken up by the parasite via a parasite-encoded facilitative hexose transporter 
(PfHT) [14-16]. This finding supports novel chemotherapeutic interventions that 
target PfHT [316, 357]. Furthermore, studies in the rodent malaria model, P. 
berghei, found that the orthologous hexose transporter (PbHT) is expressed not 
only throughout the parasite's development within the mosquito vector, but also 
during liver and transmission stages [8, 17]. 
During their extensive intra-hepatic replication, developing Plasmodium parasites 
likely require the availability of large amounts of nutrients and energy. The 
availability of appropriate amounts of glucose in infected hepatic cells is thus 
expected to play an essential role in the development of liver stage Plasmodium 
parasites. In fact, inhibition of PbHT by compound 3361, a specific inhibitor of 
plasmodial HTs, impairs hepatic P. berghei development, supporting the 
essentiality of glucose uptake for Plasmodium liver stages [8]. Accordingly, a 
recent study established D-glucose concentration in the culture medium as a key 
factor for in vitro hepatic parasite development [322]. 
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In this study, we employed rodent P. berghei parasites, a well-established model 
of malaria infection, to elucidate the uptake and utilization of glucose by 
Plasmodium liver stages [41]. We confirmed the importance of glucose availability 
for the intra-hepatic development of the malaria parasite. We also investigated the 
glucose requirements during the course of P. berghei development in hepatic cells 
as well as the host molecular receptors involved in glucose uptake by those cells. 
The importance of GLUT1 in glucose uptake by infected hepatic cells was 
validated with a specific inhibitor, both in vitro and in vivo. Finally, we demonstrate 
that P. berghei infection leads to a small intracellular ATP depletion and enhances 
the translocation of GLUT1 to the cell membrane of infected hepatoma cells, which 
contribute to their significantly higher uptake of glucose comparing to non-infected 
cells. This higher glucose uptake was not observed with any of the other stimuli 
tested, suggesting specificity to Plasmodium infection. 
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Materials and Methods 
Chemicals 
RPMI 1640, PBS pH 7.4, trypsin, fetal bovine serum (FBS), non-essential amino 
acids, penicillin/streptomycin, glutamine, HEPES pH 7, OptiMEM and 
Lipofectamine RNAiMAX were purchased from Gibco/Invitrogen. All other 
chemicals were obtained from Sigma, unless otherwise specified. 
Cells 
Huh7 cells, a human hepatoma cell line, and mouse embryonic fibroblasts (MEFs) 
were cultured in RPMI 1640 or DMEM medium, respectively, supplemented with 
10% FBS, 1% non-essential amino acids, 1% penicillin/streptomycin, 1% 
Glutamine and 1% HEPES, pH 7 and maintained at 37°C with 5% CO2. 
Mice 
C57BL/6 mice were purchased from Charles River and housed in a 12 hour night-
light cycle. All animal experiments were performed in strict compliance to the 
guidelines of our institution´s animal ethics committee and the Federation of 
European Laboratory Animal Science Associations (FELASA). 
Parasites 
Green fluorescent protein (GFP)-, red fluorescent protein (RFP)-, or luciferase-
expressing P. berghei ANKA sporozoites were dissected in non-supplemented 
RPMI medium from the salivary glands of infected female A. stephensi 
mosquitoes, bred at Instituto de Medicina Molecular (Lisbon, Portugal), prior to 
being employed for in vitro and in vivo infections [358, 359]. 
Overall in vitro infection by luminescence 
Overall hepatic infection was determined by measuring the luminescence intensity 
in Huh7 cells infected with a ﬁreﬂy luciferase-expressing P. berghei line, as 
previously described [358]. Brieﬂy, Huh7 cells (1.0x104 per well) were seeded in 
96-well plates the day before infection. Sporozoite addition was followed by 
centrifugation at 1800xg for 5 minutes and the medium was replaced 
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approximately 2 hours after infection by the appropriate medium. Parasite infection 
load was measured 48 hours after infection by a bioluminescence assay (Biotium) 
using a multiplate reader Infinite M200 (Tecan). The effect of the different 
treatments on the viability of Huh7 cells was assessed by the CellTiter-Blue assay 
(Promega) according to the manufacturer's protocol. 
Quantification of P. berghei invasion and development by flow 
cytometry 
Invasion of hepatoma cells and intracellular parasite development were assessed 
by determining the percentage of GFP+ cells 2 hours after infection with a GFP-
expressing P. berghei line and by measuring the intensity of the GFP signal of the 
infected cells 48 hours after infection, respectively, as previously described [163]. 
Huh7 cells (5.0x104 per well) were seeded in 24-well plates the day before 
infection. The medium was replaced by the appropriate medium 1 hour prior or 2 
hours after infection, for invasion and development quantification, respectively. 
Cells were then collected for flow cytometry analysis at 2 hours or 48 hours after 
infection and analyzed on a Becton Dickinson FACSCalibur. Data acquisition and 
analysis were carried out using the CELLQuest (version 3.1.1 f1, Becton 
Dickinson) and FlowJo (version 6.4.7, FlowJo) software packages, respectively. 
Immunofluorescence imaging of P. berghei in Huh7 cells 
For  immunofluorescence microscopy analyses,  cells  were  seeded  on   glass 
coverslips  in  24‐well  plates  and  infected  with  sporozoites  as described above. 
Forty-eight hours after infection, cells were rinsed with 1x PBS and fixed with 4% 
paraformaldehyde (PFA; Santa Cruz Biotechnology) for 20 minutes at room 
temperature and stored at 4°C in PBS 1x until being stained. Cells were incubated 
with the permeabilization/blocking solution (0.1% triton X-100, 1% bovine serum 
albumin (BSA) in 1x PBS) for 30 minutes at room temperature. Parasites were 
stained with a parasite specific anti-Heat Shock Protein 70 (Hsp70) antibody (2E6; 
dilution 1:100) and an anti-UIS4 antibody (dilution 1:1000) for 1 hour at room 
temperature, followed by three washes with permeabilization/blocking solution. 
Cells were further incubated in a 1:400 dilution of anti‐mouse Alexa‐Fluor 488 
(Jackson ImmunoResearch Laboratories) or anti-goat Alexa-Fluor 568 (Life 
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Technologies) secondary antibodies in the presence of a 1:1000 dilution of 
Hoechst 33342 (Invitrogen) for nuclei staining. An additional three washes were 
carried out with permeabilization/blocking solution. Coverslips were mounted on 
microscope slides with Fluoromount (SouthernBiotech). Confocal images were 
acquired using a Zeiss LSM 710 confocal microscope. Widefield images for size 
determination were acquired in a Zeiss Axiovert 200M microscope. Images were 
processed with ImageJ software (version 1.47).   
Quantification of glucose uptake by flow cytometry 
Glucose uptake into Huh7 cells was quantified by flow cytometry using a 
fluorescent D-glucose derivative, 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-
deoxy-D-glucose (2-NBDG; Molecular Probes, Life Technologies) as a tracer [360, 
361]. Shortly, Huh7 cells (1.0x104 per well) were seeded in 96-well plates the day 
before infection with RFP-expressing P. berghei sporozoites. At several time 
points after infection, the medium was replaced by RPMI without glucose 
supplemented with 1 mM of glucose and 0.1 mM of 2-NBDG, and cells were 
incubated for 5 min at 37°C to allow uptake. Cells were then collected for flow 
cytometry analysis and analyzed on a BD LSR Fortessa flow cytometer with the 
DIVA software (version 6.2). Analysis was carried out using the FlowJo software 
(version 6.4.7, FlowJo). 
Temperature shocks and ethanol-induced oxidative stress 
Huh7 cells (1.0x104 per well) were seeded in 96-well plates and incubated at 37°C 
for 48 hours. To induce a mild cold stress response, one of the plates was 
incubated at 27°C for 1 hour [362]. To induce a heat stress response, another 
plate was incubated at 43°C for 1 hour [363]. Control plate was maintained at 
37°C. Ethanol-induced oxidative stress was attained by incubating Huh7 cells in 
complete RPMI with 50 mM of ethanol for 24 hours [364, 365]. Following 
temperature shocks and ethanol-induced oxidative stress, the uptake of 2-NBDG 
by the cells was determined as previously described. 
Stress induced by viral infection 
Huh7 cells (5.0x104 per well) were seeded in 24-well plates and, on the following 
day, were infected with 0.01, 1 and 5 plaque-forming units (PFU)/cell of wild type 
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murine gammaherpesvirus 68 (MHV68) or YFP-expressing MHV68 (MHV68-YFP) 
[366]. Twenty-four hours later, the uptake of 2-NBDG by the MHV68-infected cells 
was determined as previously described. The percentage of MHV68-infected cells 
in each condition was estimated by determining the percentage of YFP+ cells after 
infection with the same amount of PFU/cell of MHV68-YFP. 
Assessment of the impact of glucose transporters on Plasmodium 
infection by RNA interference (RNAi) 
Down-modulation of the genes encoding selected glucose transporters employed 
short hairpin RNAs (shRNAs). All shRNAs were purchased from the MISSION 
TRC library (Sigma) in the form of bacterial glycerol stocks which were grown to 
obtain the purified plasmids. Each gene was targeted by using three distinct 
shRNAs, used individually (Table 2.1). For the lentiviral production, HEK 293FT 
cells (2.0x104 per well) were seeded in 96-well plates. On the following day, cells 
were transfected with the packaging vectors and each individual shRNA plasmid in 
a final concentration of 100 ng/well using the FuGENE 6 reagent (Promega), 
according to the manufacturer’s instructions. The lentiviral particles were collected 
in the supernatant of these cells approximately 60 hours after transfection and 
stored at - 80°C. For the transduction of Huh7 cells and subsequent generation of 
cell lines with stable knockdown of the genes of interest, cells (1.0x105 per well) 
were seeded in 12-well plates. On the following day, the medium was replaced by 
400 µL of supplemented RPMI with 8 µg/mL of polybrene, on top of which were 
added 100 µL of lentiviral particles-containing supernatant (approximate MOI of 
1:1) and the plates were centrifuged for 30 minutes at 1200xg and 37°C. Twenty-
four hours after transduction, the medium was replaced by supplemented RPMI 
with 5 µg/mL of puromycin (Calbiochem) for the selection of the transduced cells 
which were allowed to grow for at least a week before being used for infections 
with luciferase- or GFP-expressing P. berghei sporozoites to determine overall 
infection and parasite development by luminescence, flow cytometry and 
microscopy, as described above. Cells transduced with lentiviral particles carrying 
a negative control shRNA (SHC002) not targeting any annotated gene in the 
human genome were used as negative control. A stable cell line with the 
knockdown of SR-BI was used as positive control in the luminescence assays 
[210]. The knockdown efficiency of each shRNA sequence (Table 2.1) was 
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assessed by quantitative PCR (qPCR) with specific primers for each gene (Table 
2.2). 
siRNA transfection 
4.0x104 Huh7 cells were reverse-transfected with 30nM of target specific (human 
AMPK α1: ref. L-005027-00-0005; human AMPK α2: ref. L-005361-00-0005) or 
control siRNA sequence pools (ON-TARGETplus SMARTpool, Dharmacon), using 
Lipofectamine RNAiMAX (Gibco/Invitrogen) according to the manufacturer´s 
instructions. Twenty-four hours after transfection, the cells were infected with 
3.0x104 GFP-expressing P. berghei sporozoites. Cells were collected for flow 
cytometry analysis at 48 hpi and analyzed on a BD LSR Fortessa flow cytometer 
with the DIVA software (version 6.2). Analysis was carried out using the FlowJo 
software (version 6.4.7, FlowJo). The efficiency of knockdown was assessed with 
specific primers by qPCR (Table 2.2). 
FACS-sorting of P. berghei-infected and non-infected Huh7 cells 
Huh7 cells (1.0x105 per well) were seeded in 24-well plates and infected 24 hours 
later with 1.0x105 GFP-expressing P. berghei sporozoites. Cells were collected at 
2 hpi and FACS-sorted on a BD FACSAria III Cell Sorter (BD Biosciences). Non-
infected and GFP-expressing P. berghei-infected cells were gated on the basis of 
their different fluorescence intensity, as previously established, and collected 
simultaneously [11, 163]. Immediately after FACS-sorting, both infected and non-
infected cells were washed and seeded in 24-well plates at a density of 1.5x105 
per well. Infected cells were diluted 1:1 with non-infected cells to allow replicates. 
Cells were then incubated until being collected at 30 or 48 hpi. In the case of the 6 
hpi time point, P. berghei-infected cells were FACS-sorted at this time, diluted 1:1 
with non-infected cells, pelleted, snap-frozen and stored until RNA extraction using 
the High Pure RNA Isolation kit (Roche) according to the manufacturer´s 
instructions. 
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Table 2.1 - List of shRNA sequences used, with the corresponding knockdowns. 
Protein Gene Gene ID Sequence Clone ID Oligonucleotide Sequence Knockdown 
GLUT1 SLC2A1 NM_006516 
#01 TRCN0000043583 CCGGGCCACACTATTACCATGAGAACTCGAGTTCTCATGGTAATAGTGTGGCTTTTTG 90% 
#02 TRCN0000043584 CCGGGCGGAATTCAATGCTGATGATCTCGAGATCATCAGCATTGAATTCCGCTTTTTG 80% 
#03 TRCN0000043585 CCGGCTTCTATTACTCCACGAGCATCTCGAGATGCTCGTGGAGTAATAGAAGTTTTTG 40% 
 
SLC2A2 NM_000340 
#01 TRCN0000043598 CCGGGCCCACAATCTCATACTCAATCTCGAGATTGAGTATGAGATTGTGGGCTTTTTG 0% 
GLUT2 #02 TRCN0000043600 CCGGGCAAACATTCTGTCATTAGTTCTCGAGAACTAATGACAGAATGTTTGCTTTTTG 45% 
 #03 TRCN0000043601 CCGGCGACGTTCTCTCTTTCTAATTCTCGAGAATTAGAAAGAGAGAACGTCGTTTTTG 70% 
 
SLC2A3 NM_006931 
#01 TRCN0000043614 CCGGCCTGAGAAGATCATAAAGGAACTCGAGTTCCTTTATGATCTTCTCAGGTTTTTG 80% 
GLUT3 #02 TRCN0000043615 CCGGAGTAGCTAAGTCGGTTGAAATCTCGAGATTTCAACCGACTTAGCTACTTTTTTG 95% 
 #03 TRCN0000043617 CCGGCCCAGATCTTTGGTCTGGAATCTCGAGATTCCAGACCAAAGATCTGGGTTTTTG 60% 
 
SLC2A4 NM_001042 
#01 TRCN0000043629 CCGGCCTTCTTAAGAGTACCTGAAACTCGAGTTTCAGGTACTCTTAAGAAGGTTTTTG 90% 
GLUT4 #02 TRCN0000043630 CCGGCTTGAGTATTTAGGGCCAGATCTCGAGATCTGGCCCTAAATACTCAAGTTTTTG 60% 
 #03 TRCN0000043632 CCGGGTGATTGAACAGAGCTACAATCTCGAGATTGTAGCTCTGTTCAATCACTTTTTG 80% 
 
SLC2A9 NM_001001290 
#01 TRCN0000043683 CCGGACGTTGGACAATTATGTCAAACTCGAGTTTGACATAATTGTCCAACGTTTTTTG 70% 
GLUT9 #02 TRCN0000043684 CCGGCGCTTCATCATGGGCATAGATCTCGAGATCTATGCCCATGATGAAGCGTTTTTG 25% 
 #03 TRCN0000043685 CCGGCCATACCTGTTTGGAGTGATTCTCGAGAATCACTCCAAACAGGTATGGTTTTTG 70% 
SR-BI SCARB1 NM_005505  TRCN0000056966 CCGGGCAAGGTTGACTTCTGGCATTCTCGAGAATGCCAGAAGTCAACCTTGCTTTTTG 85% 
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In vivo WZB117 treatment and P. berghei sporozoites infection and 
quantification of parasite liver load by qPCR 
Six weeks old male C57BL/6 mice were injected intraperitoneally (i.p.) with 10 
mg/kg of WZB117 in PBS/DMSO 1:1 (v/v), or with vehicle alone, immediately 
before intravenous (i.v.) injection of 3.0x104 GFP-expressing P. berghei 
sporozoites [367]. The administration of the drug or vehicle was repeated at 15 
and 30 hours post-infection (hpi) and the livers were collected at 44 hpi and 
homogenized in 3 mL of denaturing solution (4 M guanidine thiocyanate; 25 mM 
sodium citrate pH 7, 0.5% N-lauroylsarcosine and 0.7% β mercaptoethanol in 
DEPC-treated water). Total RNA was extracted from the livers with the NZY Total 
RNA Isolation Kit (NZYTech), according to the manufacturer's protocol, and 
parasite load was quantified by qPCR using primers specific to P. berghei 18S 
RNA (Table 2.2). Mouse Hprt expression was used for normalization. 
Immunohistochemical staining of liver sections 
For microscopy, PFA-fixed liver lobes were cut in 50 μm sections and were 
incubated in permeabilization/blocking solution (1% w/v BSA, 0.5% v/v Triton-
X100 in PBS) at room temperature for 1 h, followed by a 2 h incubation at room 
temperature with an anti-UIS4 antibody (dilution 1:500). Slices were further 
incubated in a 1:300 dilution of anti-GFP-Alexa488 antibody (Invitrogen) and anti-
goat Alexa-Fluor 568 (Invitrogen) in the presence of a 1:1000 dilution of Hoechst 
33342 (Invitrogen) and a 1:100 dilution of Phalloidin-660 (Invitrogen) for actin 
staining for 1 h. After washing, slices were mounted on microscope slides with 
Fluoromount (SouthernBiotech). Images were acquired and processed as 
previously described. 
RNA extraction and quantification   
RNA was extracted from cultured Huh7 cells using the High Pure RNA Isolation kit 
(Roche) according to the manufacturer´s instructions. The amount of RNA in each 
sample was assessed with a NanoDrop® ND‐1000 spectrophotometer.  
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cDNA synthesis and qPCR   
Complementary DNA (cDNA) was synthesized from 1 μg of RNA using the Roche 
cDNA synthesis kit, according to the manufacturer´s instructions. The cDNA was 
synthesized employing the following thermocycling parameters: 25°C for 10 
minutes, 55°C for 30 minutes, and 85°C for 5 minutes. qPCR reaction 
was performed in a total volume of 20 µL in a ABI Prism 7500 Fast system 
(Applied Biosystems) using the iTaqTM Universal SYBR® Green kit (BioRad) as 
follows: 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles at 95°C for 15 seconds 
and 60°C for 1 minute, melting stage was done at 95°C for 15 seconds, 60°C for 1 
minute, and 95°C for 30 seconds. Primers for the housekeeping gene 
hypoxanthine-guanine phosphoribosyltransferase (HPRT) were used for 
normalization in all experiments (Table 2.2). For qPCR, the delta-delta 
CT relative quantification method was used.  
Table 2.2 - List of primer sequences used. 
Gene forward primer (5’ - 3’) reverse primer (5’ - 3’) 
SLC2A1 CGTCGCCACCCGCGTAC AACTCCTCGATCACCTTCTGGGG 
SLC2A2 AGATAAGGTCACTGGGACCCTGGT GCTTTTCGGTCATCCAGTGGAACA 
SLC2A3 GGACGTGGAGAAAACTTGCTGCTG GCCGATTGTAGCAACTGTGATGGCA 
SLC2A4 AGACGAGATGCCGTCGGGCT TGTTCAATCACCTTCTGAGGGGCA 
SLC2A9 CAAGAGCTGTGAAAGCCTTCC ATGGTGACAATCACGGTGACC 
SCARB1 AGAATAAGCCCATGACCCTGAA TGAGCTCAGCAAATAATCCGAA 
AMPK α1 AGGAGAGCTATTTGATTATATCTGTAAGAATG ACACCAGAAAGGATCTGTTGGAA 
AMPK α2 CGGCTCTTTCAGCAGATTCTGT ATCGGCTATCTTGGCATTCATG 
Pb18S AAGCATTAAATAAAGCGAATACATCCTTAC GGAGATTGGTTTTGACGTTTATGTG 
HPRT TTTGCTGACCTGCTGGATTAC CAAGACATTCTTTCCAGTTAAAGTTG 
Determination of ATP levels inside single cells by live microscopy 
Huh7 cells (2.0x105 cells) were seeded on glass bottom microwell dishes 
(MatTek). The following day, 1 µg of ATeam plasmid carrying the ATP indicator 
(pRSET-AT1.03) was transfected into the cells with FuGENE 6 (Roche) according 
to the manufacturer’s instructions [368]. Twenty-four hours after transfection, cells 
were infected with RFP-expressing P. berghei sporozoites and, at selected time 
points of infection, were visualized at 37°C on a Zeiss LSM 710 confocal 
microscope as described previously [369]. Huh7 cells incubated for 6 hours in 
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RPMI without glucose with 10 mM of galactose and 10 µM of Oligomycin were 
used as positive controls for ATP depletion. Image analysis was performed using 
the ImageJ software (version 1.47). The Venus/CFP emission ratio was calculated 
for each cell dividing its mean intensity in the Venus channel by the mean intensity 
in the CFP channel. 
Quantification of GLUT1 at the plasma membrane of infected cells by 
flow cytometry 
Huh7 cells (1.0x104 per well) were seeded in 96-well plates and were infected with 
RFP-expressing P. berghei sporozoites on the following day. Thirty and 48 hours 
after infection, cells were detached using PBS containing 1 mM EDTA, centrifuged 
at 4°C, and the cell pellet was resuspended in cold RPMI containing 10% FBS. 
Cells were further incubated with supernatant obtained from 293T cells transfected 
with a vector encoding the HRBD-EGFP fusion protein (dilution 1:50 in PBS with 2% 
FBS) [352, 370]. Following incubation at 37°C for 30 minutes, cells were harvested 
by centrifugation, washed one time with PBS with 2% FBS, resuspended in the 
same buffer and analyzed with a BD LSR Fortessa cytometer with the DIVA 
software (version 6.2). Huh7 cells incubated overnight in complete RPMI with 250 
µM of cobalt (II) chloride (CoCl2) were used as positive controls [371]. Analysis 
was carried out using the FlowJo software (version 6.4.7, FlowJo).  
Statistical Analyses 
Statistical analyses were performed using the GraphPad Prism 5 software. One-
way ANOVA, Two-way ANOVA, Chi-Square, Mann-Whitney U test or Student’s t-
test were used for significance of differences observed, as indicated in each figure. 
ns – not significant, * p < 0.05, ** p < 0.01 and *** p < 0.001. 
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Results 
Effect of glucose on P. berghei hepatic infection 
In order to evaluate glucose requirements throughout the liver stage of infection, 
Huh7 cells, a human hepatoma cell line, were infected with luciferase-expressing 
P. berghei sporozoites in the presence of varying concentrations of glucose. 
Glucose concentrations ranged from 1.25 to 20 mM, which includes and expands 
the physiological range of glucose concentrations, 2.5-10 mM [372]. 
Luminescence intensity, a correlate of parasite load, and cell viability were 
measured near the end of hepatic parasite development, at 48h after infection 
[358]. Our results show that an increase in glucose availability correlates with an 
increase of overall Plasmodium infection (Fig. 2.1A). In contrast, any glucose 
concentration below the standard medium ≈10 mM concentration significantly 
impairs infection (Fig. 2.1A), demonstrating that glucose is required for a 
successful hepatic Plasmodium infection. Cell viability was not affected by the 
presence of an excess of glucose in the medium, but decreased for 2.5 and 1.25 
mM of glucose (Fig. 2.1A). 
In order to dissect how glucose influences hepatic infection, we employed an 
established flow cytometry-based approach that makes use of GFP-expressing P. 
berghei parasites to determine the number of infected cells and to measure 
parasite development [163]. The analysis of cells 2 hours after sporozoite addition, 
when the invasion process is virtually completed, shows that glucose 
concentration does not affect the ability of parasites to invade cells (Fig. 2.1B) 
[163]. Conversely, when cells were analyzed 48 hours after infection, a glucose-
dependent increase in parasite development was observed (Fig. 2.1C). These 
results also showed that the number of infected cells is higher at 20 mM glucose 
concentration than at glucose concentrations below the physiological range, 
suggesting that glucose availability influences the survival of infected cells. These 
results were further confirmed by immunofluorescence microscopy analysis, which 
demonstrated that parasite size is proportional to the amount of glucose in the 
medium and that the survival of intra-hepatic parasites 48 hours after infection 
depends on the availability of glucose (Fig. 2.1D, E). In fact, at low glucose 
concentrations, not only are most parasites very small (<50 µm2) but also the 
GLUT1-mediated glucose uptake during Plasmodium hepatic infection                                                           Chapter II 
58 
 
number of infected cells is very low. Increasing concentrations of glucose lead to 
higher numbers of parasites and favor parasite growth, with approximately 40% of 
the parasites being larger than 200 µm2 at 10 and 20 mM glucose (Fig. 2.1E). 
Overall, these results demonstrate that glucose availability plays an important role 
in the intra-hepatic development and survival of Plasmodium parasites.  
 
Figure 2.1 - Glucose availability highly impacts P. berghei hepatic infection. (A) 
Huh7 cells were infected with luciferase-expressing P. berghei sporozoites and the culture 
medium was replaced 2 hpi by medium with different concentrations of glucose. Parasite 
load (luminescence) and cell viability were assessed after 48 hours. Representative 
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experiment out of 2 independent experiments. Error bars represent SD. One-way ANOVA 
with post-test Dunnett. (B) The culture medium of Huh7 cells was replaced by medium 
with different concentrations of glucose 1 hour prior to infection with GFP-expressing 
sporozoites. Cell invasion was quantified by determining the percentage of GFP+ cells 2 
hpi by flow cytometry. Representative experiment out of 2 independent experiments. Error 
bars represent SD. One-way ANOVA with post-test Dunnett. (C) Huh7 cells were infected 
with GFP-expressing P. berghei sporozoites and the culture medium was replaced 2 hpi 
by media with different concentrations of glucose. Parasite development and the total 
number of infected cells were assessed by flow cytometry by determining the 
fluorescence intensity and the number of GFP+ cells at 48 hpi, respectively. 
Representative experiment out of 5 independent experiments. Error bars represent SD. 
One-way ANOVA with post-test Dunnett. (D) For each glucose concentration, the EEFs in 
the acquired fluorescent microscopy images were counted and their area was determined. 
EEFs were divided into 5 different size classes. Pool of 2 independent experiments. Chi-
square test. (E) Representative confocal images of Huh7 cells infected with sporozoites 
and incubated in medium with different concentrations of glucose for 48 hours. The cells 
were immunostained with anti-UIS4 (red), anti-HSP70 (green) and Hoechst (blue). Scale 
bar, 10 µm. ns - not significant, * p < 0.05, ** p < 0.01 and *** p < 0.001. 
Glucose uptake is specifically increased in hepatic cells containing 
replicating P. berghei parasites 
Having demonstrated a fundamental role for glucose during intra-hepatic P. 
berghei development, we then sought to determine whether glucose uptake is 
specifically enhanced in infected cells and whether this is linked to parasite 
replication within these cells. To this end, we employed flow cytometry to monitor 
the uptake of a fluorescent glucose derivative, 2-NBDG, by P. berghei-infected 
cells [360, 361]. Huh7 cells were incubated with 2-NBDG and analyzed at different 
time points following addition of RFP-expressing P. berghei sporozoites. The 
uptake of 2-NBDG was measured as an increase in green fluorescence intensity, 
whereas parasite development was monitored as a function of red fluorescence 
intensity. The latter enables distinguishing the population of cells containing 
replicating parasites from a smaller population of cells containing parasites whose 
development is impaired (Fig. 2.2A) [163]. Our results clearly show that glucose 
uptake is highly increased in cells containing developing parasites, from 30 hpi 
onwards (Fig. 2.2B). A smaller increase in glucose uptake is also observed at 
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around the same time in non-infected cells and in cells containing non-developing 
parasites, present in the same well (Fig. 2.2B). 
 
Figure 2.2 - Glucose uptake is increased in hepatoma cells containing developing P. 
berghei parasites. (A) Huh7 cells were infected with RFP-expressing P. berghei 
sporozoites and incubated with medium with 2-NBDG, a fluorescent glucose derivative, at 
different time points of infection. Dot plot represents non-infected and infected (RFP+) 
cells of one replicate from the 48 hours time point. Left histogram shows the different 
fluorescence intensity displayed by non-developing (RFPlow) and developing (RFPhigh) 
parasites. Right histogram exemplifies the 2-NBDG uptake by the different cell 
populations (non-infected, non-developing and developing parasites), assessed as an 
increased fluorescence intensity in the green channel. (B) 2-NBDG uptake by the several 
cell populations, normalized to cell size, at different time points of infection, assessed by 
flow cytometry. Error bars represent SD. Two-way ANOVA with post-test Bonferroni. ** 
p < 0.01 and *** p < 0.001. 
Since it is known that hepatic glucose uptake and metabolism are influenced by 
factors such as feeding/fasting, exposure to low/high temperature, exercise, 
oxidative stress, several liver pathologies, such as steatosis and non-
alcoholic fatty liver disease (NFLD), and liver infections, for example, by hepatitis 
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C virus (HCV), we sought to assess the specificity of the P. berghei-induced 
increase in glucose uptake by infected Huh7 cells [373-379]. To this end, we 
measured 2-NBDG by Huh7 cells subjected to conditions known to induce low-
temperature stress in various types of mammalian cells, high-temperature stress in 
a chicken hepatocellular carcinoma cell line or oxidative stress in rat hepatocytes 
[362-365] (Fig. 2.3). 
 
 
Figure 2.3 – The increased glucose 
uptake by P. berghei-infected cells is 
not recapitulated by exposure to 
temperature or oxidative stresses. 2-
NBDG uptake by naïve Huh7 cells, cells 
containing developing P. berghei 
parasites and cells subjected to low-
temperature, high-temperature and 
ethanol-induced oxidative stresses, 
assessed by flow cytometry. Pool of 2 
independent experiments. Error bars 
represent SD. One-way ANOVA with 
post-test Dunnet. ns - not significant and 
*** p < 0.001. 
 
Finally, we infected Huh7 cells with the wild type MHV68 at different MOI and did 
not observe any increase on 2-NBDG uptake 24 hours after infection (Fig. 2.4A). 
The percentage of virus-infected cells was estimated by infecting Huh7 cells with 
MHV68-YFP with the same MOI as the wild type and determining the percentage 
of YFP+ cells 24 hours later by flow cytometry (Fig. 2.4B) [366]. Our data show that 
2-NBDG is neither affected by any of the stress-inducing treatments employed, nor 
by any of the conditions of viral infection assessed, suggesting that the increase in 
glucose uptake by P. berghei-infected cells is not the result of an unspecific 
response to stress or to infection. Overall, these results show that P. berghei 
development inside infected Huh7 leads to a specific enhancement of glucose 
uptake by these cells. 
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Figure 2.4 – Infection with MHV68 does not increase glucose uptake by virus-
infected cells. (A) 2-NBDG uptake by naïve Huh7 cells and cells infected with MHV68 at 
different MOI, assessed by flow cytometry. (B) Percentage of YFP+ cells 24 hours after 
infection with different loads of MHV68-YFP, assessed by flow cytometry. 
RNAi study implicates GLUT1 in glucose uptake by P. berghei-infected 
hepatic cells 
The results so far suggest that infection of hepatic cells by Plasmodium modulates 
the uptake of glucose by these cells, possibly through the enhancement of the 
activity of membrane glucose transporters in the cell. To ascertain this, we decided 
to carry out a small-scale RNAi study to evaluate the effect of the down-regulation 
of the expression of 5 membrane glucose transporters on P. berghei infection (see 
Table 2.1 from the Materials and Methods section). The screen included all class I 
GLUT transporters (GLUT1-4) as well as GLUT9, a major regulator of influx in 
HepG2 hepatoma cells [380].  
Huh7 cells stably expressing shRNA sequences targeting the selected genes were 
constructed to be used throughout the RNAi study. The study proceeded in 3 
consecutive steps, employing different established methods to measure hepatic 
infection by Plasmodium.  In the first step, 3 shRNA sequences were used to 
silence each of the selected genes and the resulting stable cell lines were infected 
with luciferase-expressing P. berghei sporozoites. Forty-eight hours later, the 
parasite load in these cells was determined by measuring the bioluminescence of 
cell lysates. Each sequence was used in at least 4 independent experiments and a 
shRNA targeting SR-BI was employed as a positive control for infection decrease 
[210]. GLUT1 emerged as the transporter whose knockdown leads to the 
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strongest decrease in infection, with GLUT4 and GLUT9 knockdown yielding a 
more moderate effect (Fig. 2.5A). We then carried out a second step of the RNAi 
study, where the expression of only GLUT1, GLUT4 and GLUT9 was silenced 
prior to infection with GFP-expressing P. berghei parasites. The extent of parasite 
development was assessed 48 hours later by flow cytometry determination of GFP 
intensity [163]. The results showed that the knockdown of GLUT1 leads to the 
strongest impairment of parasite development among the transporters assessed 
(Fig. 2.5B). Therefore, GLUT1 was selected for a final confirmation step using the 
three shRNA sequences targeting the GLUT1-encoding gene and assessment of 
parasite development by immunofluorescence microscopy (Fig. 2.5C). 
Interestingly, these imaging data demonstrated that parasite size correlates with 
the expression levels of GLUT1, suggesting that GLUT1-mediated glucose uptake 
is required for the parasite’s replication. 
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Figure 2.5 - GLUT1 knockdown significantly impairs P. berghei intra-hepatic 
development. (A) Huh7 cells with stable knockdown of one of the 5 GLUTs tested were 
infected with luciferase-expressing P. berghei sporozoites and parasite load 
(luminescence) was assessed after 48 hours. A scrambled shRNA sequence was used as 
a negative control and a cell line with stable knockdown of SR-BI as positive control. Pool 
of 4 independent experiments. Error bars represent SEM. (B) Huh7 cells with the 
knockdown of GLUT1, GLUT4 or GLUT9 were infected with GFP-expressing P. berghei 
sporozoites and parasite development was assessed by flow cytometry at 48 hpi. Pool of 
3 independent experiments. Error bars represent SEM. (C) Quantification of the area of 
the EEFs in each of the 3 different cell lines with GLUT1 knockdown at 48 hpi by 
immunofluorescence microscopy. The knockdown efficiency of each shRNA sequence is 
indicated. Pool of 3 independent experiments. All panels: one-way ANOVA with post-test 
Dunnett. ns - not significant, * p < 0.05 and *** p < 0.001. 
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To further establish a link between the uptake of glucose by GLUT1 and 
Plasmodium infection, we assessed the difference of 2-NBDG uptake by infected 
and non-infected Huh7 cells expressing the same three GLUT1-targeting shRNA 
sequences as above. As previously shown, infected control cells were found to 
uptake significantly more fluorescent glucose than their non-infected counterparts 
at 48 hpi. However, this difference in 2-NBDG uptake by infected and non-infected 
cells was reduced by up to 40% in the GLUT1-knockdown stable cell lines, a 
decrease that is proportional to the extent of the down-modulation of GLUT1 (Fig. 
2.6A). Only when GLUT1 expression is 90% reduced, we can see a decrease in 
glucose uptake by non-infected cells, thus it seems that GLUT1 knockdown 
primarily affects glucose uptake by infected cells (Fig. 2.6B). As control, we 
assessed the 2-NBDG uptake following knockdown of GLUT2, the main glucose 
transporter in the liver, showing that the down-modulation of the expression of this 
transporter does not affect 2-NBDG uptake by infected cells (Fig. 2.6A).  
 
Figure 2.6 - GLUT1 knockdown significantly impairs glucose uptake into P. berghei-
infected cells. (A) Difference of 2-NBDG uptake in the several cell lines with GLUT1 
knockdown by developing parasites-containing cells and non-infected cells at 48 hpi, 
assessed by flow cytometry. A cell line with the knockdown of GLUT2 was used as a 
control. Pool of 4 independent experiments. Error bars represent SEM. (B) 2-NBDG 
uptake only by non-infected cells in the several cell lines with GLUT1 knockdown at 48hpi, 
assessed by flow cytometry. Pool of 4 independent experiments. Error bars represent 
SEM. Both panels: one-way ANOVA with post-test Dunnett. ns - not significant, * p < 0.05, 
** p < 0.01 and *** p < 0.001. 
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To provide a chemical validation of the results obtained by the previously 
employed genetic approach, we assessed infection, parasite development, and 2-
NBDG uptake by infected cells, in the presence of WZB117, a specific inhibitor of 
GLUT1-mediated glucose transport [367]. Our results show a clear dose-
dependent effect of WZB117 on P. berghei infection of Huh7 cells (Fig. 2.7A), 
which correlates to a decreased parasite development, as assessed by flow 
cytometry (Fig. 2.7B).  Similarly, 2-NBDG uptake by infected cells is affected in a 
dose-dependent manner (Fig. 2.7C). Taken together, these data indicate that the 
membrane transporter GLUT1 has a pivotal contribution to glucose uptake by the 
infected host cell, as required by the replicating parasite during its hepatic 
developmental process. 
 
Figure 2.7 – Chemical inhibition of GLUT1-mediated glucose transport with WZB117 
impairs P. berghei intra-hepatic development and glucose uptake by infected cells. 
(A) Huh7 cells were infected with luciferase-expressing P. berghei sporozoites and 2 
hours later the culture medium was replaced by medium with increasing concentrations of 
WZB117. Parasite load (luminescence) was assessed at 48 hpi. Representative 
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experiment out of 2 independent experiments. Error bars represent SD. (B) Huh7 cells 
were infected with RFP-expressing P. berghei sporozoites and 2 hours later the culture 
medium was replaced by medium with increasing concentrations of WZB117. Parasite 
development was assessed by flow cytometry at 48 hpi. Pool of 2 independent 
experiments. Error bars represent SD. (C) 2-NBDG uptake by RFP-expressing P. berghei-
infected cells at 48 hpi after treatment with increasing concentrations of WZB117, 
assessed by flow cytometry. Pool of 2 independent experiments. All panels: one-way 
ANOVA with post-test Dunnett. ns - not significant, * p < 0.05, ** p < 0.01 and *** p 
< 0.001. 
Finally, we evaluated the role of GLUT1 on Plasmodium hepatic infection in vivo. 
C57BL/6 mice received three i.p. injections of 10 mg/kg of WZB117 in PBS/DMSO 
1:1 (v/v), or vehicle alone, the first administration being immediately before the i.v. 
injection of 3.0x104 GFP-expressing P. berghei sporozoites, and the other two at 
15 and 30 hpi [367]. Livers were collected at 44 hpi and parasite load was 
determined by qPCR. Our results show a statistically significant 50% reduction on 
P. berghei liver load upon treatment with WZB117 (Fig. 2.8A). This decrease is 
mainly explained by a reduction in the number of parasites per area of liver (Fig. 
2.8C), although a small effect on parasite size was also observed (Fig. 2.8B and 
D). Even though GLUT1 is not the main glucose transporter in the liver, its 
inhibition with WZB117 has a high impact on the survival of P. berghei parasites in 
vivo. Because GLUT1 is only at the membrane of the few pericentral hepatocytes 
of each chord, we hypothesize that the parasites inside these specific hepatocytes 
might be preferentially targeted by the treatment with this inhibitor. 
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Figure 2.8 – In vivo inhibition of GLUT1-mediated glucose transport with WZB117 
decreases the number of P. berghei parasites in the liver of C57BL/6 mice. (A) Mice 
received three doses of 10 mg/kg of WZB117 i.p., the first immediately before infection 
with P. berghei sporozoites and the other two at 15 and 30 hpi. Parasite load was 
assessed at 44 hpi by qPCR. Pool of 3 independent experiments. Vehicle: n = 15 mice; 
WZB117-treated: n = 12 mice. Two-tailed Mann-Whitney test. (B) A liver lobe of one 
mouse from each group was cut in 50μm sections and the parasites were stained with 
anti-UIS4 (red) and Hoechst (blue) for area determination by fluorescence microscopy. 
Representative experiment out of 2 independent experiments. Two-tailed Mann-Whitney 
test. (C) Number of parasites observed per area of liver in the control (vehicle) or the 
WZB117-treated mouse. Two-tailed Mann-Whitney test. (D) Representative confocal 
images of P. berghei parasites in both groups of mice. Scale bar, 10 µm. * p < 0.05 and 
*** p < 0.001. 
GLUT1 expression is not enhanced in Plasmodium-infected cells 
Having established a role for GLUT1 on the specific uptake of glucose by infected 
cells, we hypothesized that Plasmodium infection might lead to an increase in the 
expression of that transporter. To address this, we compared GLUT1 expression 
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levels in non-infected and infected Huh7 cells at 6, 30 and 48 hpi with GFP-
expressing P. berghei parasites. Following the separation of infected and non-
infected cells by fluorescence-activated cell sorting (FACS), cells were analyzed 
by qPCR, employing GLUT1-specific primers (see Table 2.2) [11]. The data 
showed no significant differences in GLUT1 expression between infected and non-
infected cells, at the selected time points (Fig. 2.9). As such, we concluded that 
the increase in GLUT1-mediated glucose uptake by Plasmodium-infected cells 
does not result from an infection-induced enhancement of the expression of this 
transporter. 
 
 
Figure 2.9 - GLUT1 expression is not 
altered in P. berghei-infected cells. 
Quantification of GLUT1 transcriptional 
expression on sorted infected and non-
infected Huh7 cells by qPCR. Each time 
point is a pool of 2 independent sortings. 
Error bars represent SD. Two-tailed Mann- 
Whitney test. ns – not significant. 
 
P. berghei development leads to cytoplasmic ATP depletion 
It has been shown that cytoplasmic ATP interacts with GLUT1 to induce 
conformational changes that inhibit GLUT1-mediated glucose transport [381, 382]. 
This modulation by ATP is inhibited by AMP and ADP [383].  We thus wondered 
whether the observed increase in glucose uptake by Plasmodium-infected cells 
would correlate to a decrease in ATP levels in these cells. To investigate this, we 
employed a fluorescence resonance energy transfer (FRET)-based indicator for 
ATP (ATeam), composed of the  subunit of the bacterial FoF1-ATP synthase 
sandwiched by the cyan- and Venus fluorescent proteins (CFP and Venus, 
respectively), which enables monitoring intracellular ATP levels as a function of 
the Venus/CFP ratio [368]. Using RFP-expressing P. berghei parasites and live 
fluorescence microscopy, we specifically monitored ATP levels in non-infected and 
infected cells at 30 and 48h after infection. Interestingly, we observed that ATP 
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levels of infected cells were significantly lower than those of naïve cells (Fig. 2.10). 
In agreement with the results in Figure 2.2B, we also detected a smaller but 
significant ATP reduction in the non-infected cells present in the same well, when 
compared to naïve cells (Fig. 2.10). These results indicate that intra-hepatic 
parasite development leads to a small but significant decrease in the ATP/AMP 
ratio inside the host cell, which could result in the well-described ATP/ADP/AMP-
driven conformational changes in GLUT1 and ultimately lead to an increased 
glucose uptake [381-383]. 
 
Figure 2.10 - P. berghei development inside Huh7 cells results in a decreased 
ATP/AMP ratio. Huh7 cells were transfected with an ATP probe, AT1.03, and infected 
with RFP-expressing P. berghei sporozoites. Thirty and 48 hpi, the Venus/CFP emission 
ratio in the cytoplasm of each individual cell (non-infected and cells containing developing 
parasites) was calculated from the fluorescent images acquired in both channels. Huh7 
cells incubated in RPMI without glucose with 10 mM of galactose and 10 µM of oligomycin 
were used as positive controls for ATP depletion. Pool of 2 and 3 independent 
experiments for the 30 hours and 48 hours time points, respectively. One-way ANOVA 
with post-test Tukey. * p < 0.05 and *** p < 0.001. 
A pathogen-induced decrease in cytoplasmic ATP is typically associated with 
activation of AMP-activated protein kinase (AMPK) [384]. Also, an enhancement of 
glucose transport by GLUT1 transporters preexisting in the plasma membrane has 
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been associated with stimulation of AMPK activity [385, 386]. Thus, we next 
compared 2-NBDG uptake by infected and non-infected wild type (WT) and 
AMPK-deficient (knockout for both α1 and α2 AMPK subunits, AMPK-dKO) mouse 
embryonic fibroblasts (MEFs). Crucially, 2-NBDG uptake was not impaired by 
AMPK-deletion (Fig. 2.11A), suggesting that this kinase does not play a role in the 
increase of glucose uptake in Plasmodium-infected hepatic cells. This was further 
confirmed by measuring P. berghei infection of Huh7 cells and 2-NBDG uptake by 
infected and non-infected cells, following the knockdown of the expression of both 
the α1 and the α2 subunits of AMPK by RNAi. Our results show that the effective 
knockdown of gene expression (Fig. 2.11B) did not impair parasite development 
(Fig. 2.11C), nor did impact the uptake of 2-NBDG by infected cells (Fig. 2.11D). 
Collectively, these results rule out a role for AMPK in the increased uptake of 
glucose by cells containing developing Plasmodium parasites. 
 
Figure 2.11 – Increased GLUT1-dependent glucose uptake into P. berghei-infected 
cells is independent of AMPK. (A) WT and AMPK-dKO MEFs were infected with RFP-
expressing sporozoites and incubated with medium with 2-NBDG, 48 hours after infection. 
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The difference of 2-NBDG uptake by cells containing developing parasites and non-
infected cells was assessed for both cell lines by flow cytometry. Pool of 2 independent 
experiments. Error bars represent SD. Two-tailed unpaired t-test. (B) Knockdown 
efficiency upon transfection in Huh7 cells of the siRNAs used against the α1 and α2 
subunits of AMPK. (C) Huh7 cells with the knockdown of α1 or/and α2 subunits of AMPK 
were infected with GFP-expressing P. berghei sporozoites and parasite development was 
assessed by flow cytometry at 48 hpi. Pool of 2 independent experiments. Error bars 
represent SD. One-way ANOVA with post-test Dunnett. (D) 2-NBDG uptake at 48 hpi by 
developing parasites-containing cells with the knockdown of α1 or/and α2 subunits of 
AMPK, assessed by flow cytometry. Representative experiment out of 2 independent 
experiments. Error bars represent SD. One-way ANOVA with post-test Dunnett. ns - not 
significant, *** p < 0.001. 
P. berghei infection leads to GLUT1 translocation to the plasma 
membrane 
It has been shown that GLUT1 translocation to the plasma membrane may be 
triggered by different factors, such as ischemia and insulin, in a phosphoinositide 
3-kinase (PI3K)-dependent fashion [387, 388]. Although no effect on parasite load 
(Fig. 2.12A and B), nor on the specific uptake of glucose by infected cells (Fig. 
2.12C and D), was observed in the presence of increasing concentrations of 
insulin or of the PI3K irreversible inhibitor, Wortmannin, we hypothesized that 
there could exist a PI3K-independent mechanism responsible for the translocation 
of GLUT1 to the membrane of P. berghei-infected cells that could contribute to the 
observed increase in GLUT1-mediated glucose uptake upon infection. 
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Figure 2.12 - PI3K stimulation or inhibition does not impact P. berghei infection of 
Huh7 cells neither does it alter glucose uptake by infected cells. Huh7 cells were 
infected with luciferase-expressing P. berghei sporozoites and 2 hours later were treated 
with different concentrations of (A) insulin or (B) Wortmannin. Parasite load 
(luminescence) was assessed after 48 hours. Representative experiment out of 2 and 
pool of 3 independent experiments, respectively. Error bars represent SD. To evaluate 
possible effects on glucose uptake, Huh7 cells were infected with RFP-expressing P. 
berghei sporozoites and the treatment with different concentrations of insulin (C) and 
Wortmannin (D) was initiated 2 hpi. 2-NBDG uptake by developing parasites-containing 
cells was assessed at 48 hpi by flow cytometry. Pool of 2 independent experiments for 
both insulin and Wortmannin. Error bars represent SD. All panels: one-way ANOVA with 
post-test Dunnett. ns - not significant. 
To compare the amount of GLUT1 present on the membrane of infected and non-
infected cells, Huh7 cells were infected with RFP-expressing P. berghei parasites 
and incubated with the fusion peptide HRBD-EGFP (consisting of the Receptor 
Binding Domain of the human T cell leukemia virus fused to enhanced green 
fluorescent protein), which specifically binds to GLUT1 at the cell membrane [352, 
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370]. CoCl2 was used as positive control as it has been shown to enhance GLUT1 
translocation to the plasma membrane [371]. Flow cytometry analysis showed a 
small, non-significant increase in the amount of membrane-located GLUT1 in both 
non-infected and infected cells at 30 hpi, relative to naïve cells (Fig. 2.13). 
However, at 48 hpi, the amount of GLUT1 on the membrane is specifically and 
significantly enhanced in infected cells (Fig. 2.13). This suggests that an 
enhancement of GLUT1 availability at the plasma membrane facilitates the uptake 
of glucose required for the later stages of parasite development, the time at which 
there is a dramatic increase in glucose uptake (Fig. 2.2B). Overall, these data 
support the notion that P. berghei development inside hepatic cells results in the 
PI3K-independent translocation of GLUT1 to the host cell's membrane, leading to 
increased glucose uptake. 
 
Figure 2.13 - P. berghei development inside Huh7 cells results in an increased 
GLUT1 content at the plasma membrane. Huh7 cells were infected with RFP-
expressing sporozoites and, at 30 and 48 hpi, were incubated with the HRBD-EGFP peptide 
that binds specifically to GLUT1 at the surface of the cells and were analysed by flow 
cytometry. Huh7 cells incubated overnight in complete RPMI with 250 µM of CoCl2 were 
used as positive controls. Pool of 2 and 4 independent experiments for the 30 hours and 
48 hours time points, respectively. Error bars represent SEM. One-way ANOVA with post-
test Tukey. ns - not significant, * p < 0.05 and *** p < 0.001.  
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Discussion 
Glucose is ubiquitously used as the common currency of metabolism, and the 
ability to transport this hexose across the plasma membrane is a feature of nearly 
all cells [389]. Although GLUT2 is the major glucose transporter of hepatocytes, 
where it is involved in glucose uptake and release in the fed and fasted states, 
respectively, GLUT1 is also present in the liver, where it is transcribed and 
expressed by both periportal and perivenular hepatocytes [349, 350, 390]. 
Interestingly, membrane localization of GLUT1 under basal conditions is restricted 
to hepatocytes proximal to the hepatic venule [12, 391]. Since the liver cell plate is 
perfused unidirectionally from portal to hepatic venule, the concentration of several 
substrates, such as oxygen and glucose, decreases as blood moves closer to the 
hepatic venule [391]. This is consistent with the observation that GLUT1 
expression is enhanced by a decrease in circulating glucose levels as well as by 
hypoxia [392, 393]. Importantly, it has recently been shown that hypoxia enhances 
liver stage infection by malaria parasites, an effect that is also observed following 
treatment with an activator of hypoxia inducer factor (HIF)-1α or with the hypoxia 
mimetic CoCl2 [394]. Interestingly, increased HIF-1α levels have been shown to 
upregulate expression of GLUT1 and CoCl2 has been shown to enhance GLUT1 
translocation to the plasma membrane (Fig. 2.13) [371, 395]. In this context, our 
results suggest that the high capacity GLUT1 transporter provides a crucial link to 
explain the observed preferential infectivity of hypoxic liver cells by Plasmodium 
parasites. Indeed, our in vivo data support this hypothesis, as the chemical 
inhibition of GLUT1-mediated glucose uptake had a considerable impact on the 
survival of P. berghei parasites (Fig. 2.8). Although it has been suggested that the 
effect of hypoxia on liver stage parasite development might be mediated by the 
AMPK pathway, our data do not indicate any effect of AMPK on parasite 
development nor on glucose uptake by infected cells (Fig. 2.11) [396]. This is also 
in agreement with the results of our previously published kinome RNAi screen, 
which did not identify AMPK as one of the kinases implicated on infection of 
hepatoma cells by P. berghei [397]. 
Our data suggest a model in which the extensive replication of intra-hepatic 
parasites leads to a depletion in intracellular glucose concentration and, 
consequently, affects the host cells’ ATP levels due to the lack of its main 
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substrate. This effect is compensated for by an increase in glucose uptake that 
results from the likely activation of GLUT1 transporters at the plasma membrane 
via AMP-dependent conformational changes and from GLUT1 translocation to the 
plasma membrane that, consequently, do not allow further decrease in ATP levels 
that could lead to cell death (Fig. 2.14). Still, the levels of ATP are not completely 
restored in infected cells, possibly contributing to the activation of the GLUT1 
transporters at the plasma membrane via AMP-dependent conformational 
changes in the transporter (Fig. 2.10) [381-383]. 
 
Figure 2.14 - Representative model of GLUT1-mediated glucose uptake during 
hepatic infection by Plasmodium. 
The increased glucose uptake by infected cells likely leads to the depletion of this 
nutrient from the culture medium, which results in a similar, albeit weaker, 
response by neighboring non-infected cells. In fact, these cells also display a small 
decrease in ATP levels, as well as some, although not statistically significant, 
GLUT1 translocation to the membrane (Fig. 2.11 and Fig. 2.13) and a slight 
increase in glucose uptake from 30 hours of infection onwards (Fig. 2.2B). 
Importantly, as infection progresses, the amount of GLUT1 on the membrane 
increases specifically in infected cells (Fig. 2.13), presumably to maintain their 
energetic balance despite the expectedly high glucose consumption by developing 
parasites [8]. This is in agreement with the observation that ATP levels in infected 
cells do not appear to change over the time of infection (Fig. 2.10). Finally, we also 
showed that P. berghei infection of hepatoma cells is neither affected by addition 
of insulin, nor by inhibition of PI3K (Fig. 2.12). This is consistent with the fact that, 
although both ischemia and insulin have been shown to promote GLUT1 (and 
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GLUT4) translocation to the membrane in rat hearts, PI3K is only involved in the 
insulin-induced signaling, but not in the ischemia-mediated signaling, leading to 
GLUT1 translocation [388]. Very recently, phosphorylation of GLUT1 by protein 
kinase C (PKC) has been shown to lead to the rapid increase in glucose uptake 
and enhanced cell surface localization of GLUT1 induced by 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) [398]. Whether a similar mechanism may be at play 
during P. berghei infection of hepatic cells is currently under investigation. 
The liver displays the capacity to remove 30-40% of the glucose presented to it 
following glucose ingestion and therefore must be considered a significant site of 
postprandial glucose removal [399]. Interestingly, a recent case-control study in 
Ghana found that patients with type 2 diabetes mellitus had a 46% increased risk 
for infection with P. falciparum [400]. The authors of this study offer a number of 
possible explanations for this observation, including impaired immune responses, 
an increased number of infectious mosquito bites, and enhanced parasite growth 
in the blood of type 2 diabetes mellitus patients [400]. Thus, our results suggest 
the possibility that the elevated amounts of circulating glucose displayed by 
diabetic patients may also promote parasite development in the liver, thereby 
contributing to the increased risk of appearance of clinically relevant malaria. 
Further investigation of the link between diabetes and malaria is clearly warranted 
by the fact that sub-Saharan Africa currently faces the world’s highest increase in 
type 2 diabetes mellitus [401]. 
This work addresses the role of glucose during hepatic infection by Plasmodium 
from a molecular point of view. It identifies GLUT1 as a major player in glucose 
uptake by infected cells and shows that its function as a glucose transporter is 
modulated in cells containing replicating parasites. These findings contribute to an 
understanding of how hepatic host cells meet the energy demands imposed by the 
parasite’s huge replication rate. Such an understanding may help identify 
strategies to control energy production by infected cells and thereby limit parasite 
development and survival. 
 
 
 
GLUT1-mediated glucose uptake during Plasmodium hepatic infection                                                           Chapter II 
78 
 
Acknowledgements 
We are very grateful to Marc Sitbon and Julie Laval (Institut de Génétique 
Moléculaire de Montpellier CNRS-UMSF, France) for kindly providing the HRBD-
EGFP peptide, to Hiromi Imamura (Graduate School of Biostudies, Kyoto 
University, Japan) for kindly providing the pRSET-AT1.03 plasmid, to Benoit Viollet 
(Institut Cochin, France) for providing the AMPK-KO MEFs, to Maria M. Mota 
(Instituto de Medicina Molecular, Portugal) for critically reviewing the manuscript, 
to Marta Miranda for help with the viral infections, to Ana Parreira and Filipa 
Teixeira for producing the various lines of P. berghei-infected mosquitoes and to 
the Bioimaging, Flow Cytometry and Rodent facilities of iMM Lisboa for technical 
support.  
Chapter III  The role of L-arginine uptake and polyamine production during liver stage 
infection by the malaria parasite 
79 
 
The role of L-arginine uptake and polyamine production 
during liver stage infection by the malaria parasite 
 
 
Patrícia Meireles1, Rita I. Aroeira2, Henry M. Staines3, António M. Mendes1, 
Miguel Prudêncio1  
 
1 Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 
Avenida Professor Egas Moniz, 1649-028, Lisboa, Portugal 
2 Institute of Pharmacology and Neurosciences, Faculty of Medicine and Neurosciences 
Unit,  Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 
Avenida Professor Egas Moniz, 1649-028, Lisboa, Portugal 
3 Institute for Infection & Immunity, St. George’s, University of London, Cranmer Terrace, 
London, UK 
 
 
 
Author Contributions 
PM and MP designed the experiments. PM performed all the experiments. RIA 
helped with the radioactive uptake experiments. AMM and HMS gave intellectual 
input to the work. PM wrote the chapter. MP supervised the work and revised the 
text. 
 
  
The role of L-arginine uptake and polyamine production during liver stage                                                     Chapter III 
 infection by the malaria parasite                                                            
80 
 
Introduction 
Cationic amino acids, including L-arginine (Arg), are transported through biological 
membranes by various distinct transport systems [19, 402]. Among these is the y+ 
system, the main mechanism of cellular uptake of cationic amino acids. The y+ 
system is found almost ubiquitously and specifically transports Arg, L-lysine (Lys), 
and L-ornithine (Orn) through the cationic amino acid transporter (CAT) family of 
proteins, a subfamily of the solute carrier family 7 (SLC7) [18, 19]. The four 
members of the CAT family are the nearly-ubiquitous CAT1, encoded by SLC7A1, 
the two products of SLC7A2, the gene that encodes through alternative splicing 
the liver-abundant low affinity CAT2A and the high affinity CAT2B transporters, the 
brain-specific CAT3, encoded by SLC7A3, and CAT4, encoded by SLC7A4, 
whose function is still unknown [19, 403-406]. 
Once inside the cell, Arg can be degraded via multiple pathways that are initiated 
by arginase, nitric oxide synthase (NOS), Arg:glycine amidinotransferase, and Arg 
decarboxylase. These pathways produce polyamines, nitric oxide (NO), proline, 
glutamate, creatine, and agmatine, each of which has great biological importance 
[407]. Arginase, the arginine hydrolytic enzyme, catalyzes the hydrolysis of Arg 
and its activity is important for maintaining Orn levels for polyamine synthesis. 
There are two isoforms of the enzyme, a cytosolic arginase 1, mostly expressed in 
the liver, and a more widely distributed mitochondrial arginase 2 [408]. 
Plasmodium parasites also express arginase and the structure of the P. falciparum 
enzyme has already been reported [23-25]. The dependency of blood stage P. 
falciparum on polyamines for survival has been well established [26-28]. Possibly 
the most distinctive feature of polyamine biosynthesis in Plasmodium parasites is 
that the two rate-limiting decarboxylase activities are found in a unique protein 
known as AdoMetDC/ODC, whose bifunctionality is important for the regulation of 
polyamine pools in the parasite [336-338]. 
Arg and the arginase pathway have been implicated in several infections, including 
Trypanosoma spp.,  Leishmania spp., Toxoplasma gondii, Shistosoma mansoni, 
Candida albicans, and Helicobacter pylori (reviewed in [22]). Most studies 
concerning the use of Arg by Plasmodium parasites have concentrated on the 
blood stages of infection. Plasmodium spp. parasites are incapable of de novo 
amino acid biosynthesis and must therefore acquire the amino acids they require 
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for protein synthesis and growth [24, 305, 409]. A metabolomics study of P. 
falciparum blood stages has shown that Arg is significantly depleted while Orn and 
citrulline accumulate in the culture medium during the parasite’s trophozoite and 
schizont stages [24]. This depletion has been associated with the reduced plasma 
Arg levels observed in severe malaria patients [410]. 
To overcome the scarcity of information regarding the uptake and role of Arg in 
Plasmodium liver stages we employed a well-established rodent P. berghei model 
of in vitro, ex vivo and in vivo infection [41]. Our results reveal an important role for 
the CAT2 transporter in the uptake of Arg by infected cells and show that Arg 
plays an essential role in the development of hepatic parasites by fueling the 
polyamine synthesis pathway of the parasite and of the infected cell. 
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Materials and Methods 
Chemicals 
RPMI 1640, William’s E, PBS pH 7.4, trypsin, FBS, non-essential amino acids, 
penicillin/streptomycin, glutamine, HEPES pH 7, liver perfusion medium (LPM), 
liver digestion medium (LDM), OptiMEM and Lipofectamine RNAiMAX were 
purchased from Gibco/Invitrogen. All other chemicals were obtained from Sigma, 
unless otherwise specified. 
Cells 
Huh7 cells, a human hepatoma cell line were cultured in RPMI 1640 medium 
supplemented with 10% FBS, 1% non-essential amino acids, 1% 
penicillin/streptomycin, 1% Glutamine and 1% HEPES, pH 7 and maintained at 
37°C with 5% CO2. Mouse primary hepatocytes were cultured in William’s E 
medium supplemented with 4% FBS and 1% penicillin/streptomycin and 
maintained at 37°C with 5% CO2.  
Mice 
C57BL/6 mice were purchased from Charles River. A breeding trio of Slc7a2+/- 
mice was kindly provided by Lesley G. Ellies (University of California, San Diego 
School of Medicine) and the animals were housed and bred in the facilities of the 
Instituto de Medicina Molecular to obtain Slc7a2-/- and corresponding littermate 
Slc7a2+/+ mice [411]. All animal experiments were performed in strict compliance 
to the guidelines of our institution´s animal ethics committee and the Federation of 
European Laboratory Animal Science Associations (FELASA). 
Parasites 
WT, arginase-KO, GFP- or luciferase-expressing P. berghei ANKA sporozoites 
were dissected in non-supplemented RPMI medium from the salivary glands of 
infected female A. stephensi mosquitoes, bred at Instituto de Medicina Molecular 
(Lisbon, Portugal), prior to being employed for in vitro, ex vivo and in vivo 
infections [25, 358, 359]. 
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RNAi screen of hepatic transporters on Plasmodium infection 
Down-modulation of the genes encoding the transporters whose expression was 
shown to be altered upon P. berghei infection was obtained by employing 
shRNAs. All shRNAs were purchased from the MISSION TRC library (Sigma) in 
the form of bacterial glycerol stocks which were grown to obtain the purified 
plasmids.  Each gene was targeted by using one to three distinct shRNAs, used 
individually (Table 3.1). For the lentiviral production, HEK 293FT cells (2.0x104 per 
well) were seeded in 96-well plates. On the following day, cells were transfected 
with the packaging vectors and each individual shRNA plasmid in a final 
concentration of 100 ng/well using the FuGENE 6 reagent (Promega), according to 
the manufacturer’s instructions. The lentiviral particles were collected in the 
supernatant of these cells approximately 60 hours after transfection and stored at - 
80°C. For the transduction of Huh7 cells and subsequent generation of cell lines 
with stable knockdown of the genes of interest, Huh7 cells (1.0x105 per well) were 
seeded in 12-well plates. On the following day, the medium was replaced by 400 
µL of supplemented RPMI with 8 µg/mL of polybrene, on top of which were added 
100 µL of lentiviral particles-containing supernatant (approximate MOI of 1:1) and 
the plates were centrifuged for 30 minutes at 1200xg and 37°C. Twenty-four hours 
after transduction, the medium was replaced by supplemented RPMI with 5 µg/mL 
of puromycin (Calbiochem) for the selection of the transduced cells which were 
allowed to grow for at least a week before being used for infections. Cells 
transduced with lentiviral particles carrying a negative control shRNA (SHC002) 
not targeting any annotated gene in the human genome were used as negative 
control. A stable cell line with the knockdown of SR-BI was used as positive 
control in the luminescence assays [210]. The efficiency of knockdown of each 
shRNA sequence was assessed by qPCR using specific primers (Table 3.2). 
  
 
Table 3.1 - List of shRNA sequences used, with the corresponding knockdowns. 
Gene Gene ID Sequence Clone ID Oligonucleotide Sequence Knockdown 
SCARB1 NM_005505  TRCN0000056966 CCGGGCAAGGTTGACTTCTGGCATTCTCGAGAATGCCAGAAGTCAACCTTGCTTTTTG 85% 
SLC1A4 NM_003038  TRCN0000038639 CCGGCCATGTTATTCATGGAGGAATCTCGAGATTCCTCCATGAATAACATGGTTTTTG 50% 
SLC3A2 NM_002394  TRCN0000043384 CCGGCGAGAAGAATGGTCTGGTGAACTCGAGTTCACCAGACCATTCTTCTCGTTTTTG 40% 
SLC6A9 NM_006934 
#01 TRCN0000043503 CCGGCCCGCCATCATCTTCTTTATTCTCGAGAATAAAGAAGATGATGGCGGGTTTTTG 25% 
#02 TRCN0000043505 CCGGGACGGCATCATGTACTACCTACTCGAGTAGGTAGTACATGATGCCGTCTTTTTG 65% 
#03 TRCN0000043507 CCGGCATGTTCAAAGGAGTGGGCTACTCGAGTAGCCCACTCCTTTGAACATGTTTTTG 0% 
SLC7A2 NM_003046 
#01 TRCN0000042973 CCGGGCCCAAATGTTCTCCTGAGAACTCGAGTTCTCAGGAGAACATTTGGGCTTTTTG 70%* 
#02 TRCN0000042974 CCGGGCTGGGTTTGTGAAAGGAAATCTCGAGATTTCCTTTCACAAACCCAGCTTTTTG 90%* 
#03 TRCN0000042976 CCGGCGTATGTGATAGGTACATCAACTCGAGTTGATGTACCTATCACATACGTTTTTG N.I. 
SLC7A5 NM_003486  TRCN0000043010 CCGGGCCGTGGACTTCGGGAACTATCTCGAGATAGTTCCCGAAGTCCACGGCTTTTTG 70% 
SLC7A11 NM_014331  TRCN0000043125 CCGGCCTGCGTATTATCTCTTTATTCTCGAGAATAAAGAGATAATACGCAGGTTTTTG 55% 
SLC25A12 NM_003705  TRCN0000044588 CCGGGCCATTAAACTGACTGTTAATCTCGAGATTAACAGTCAGTTTAATGGCTTTTTG N.I. 
SLC38A2 NM_018573 
#01 TRCN0000020239 CCGGCCTCCAATCCTCTGGCTATTTCTCGAGAAATAGCCAGAGGATTGGAGGTTTTT 60% 
#02 TRCN0000020240 CCGGCCTGAACAATGAATTCCCATTCTCGAGAATGGGAATTCATTGTTCAGGTTTTT 20% 
#03 TRCN0000020242 CCGGTCTGGCTATTTAAGGTTCAAACTCGAGTTTGAACCTTAAATAGCCAGATTTTT 50% 
SLC38A4 NM_018018 
#01 TRCN0000044709 CCGGCGGAACCACTTCCTTTGGAATCTCGAGATTCCAAAGGAAGTGGTTCCGTTTTTG 50% 
#02 TRCN0000044710 CCGGCCCAATTCGTACATCAGTGATCTCGAGATCACTGATGTACGAATTGGGTTTTTG 75% 
#03 TRCN0000044711 CCGGGCAGCAATGAGCAGTCAATTTCTCGAGAAATTGACTGCTCATTGCTGCTTTTTG 70% 
SLC38A7 NM_018231 
#01 TRCN0000060153 CCGGCTGTGCCTCATTCAAGCCAAACTCGAGTTTGGCTTGAATGAGGCACAGTTTTTG 90% 
#02 TRCN0000060154 CCGGCCCTTGGTACACAGACCGCAACTCGAGTTGCGGTCTGTGTACCAAGGGTTTTTG 80% 
#03 TRCN0000060157 CCGGCGGCAAGGTGATCTCAGTCATCTCGAGATGACTGAGATCACCTTGCCGTTTTTG 80% 
SCN1A NM_006920 
#01 TRCN0000044308 CCGGCGCATCAATCTGGTGTTCATTCTCGAGAATGAACACCAGATTGATGCGTTTTTG N.D. 
#02 TRCN0000044310 CCGGGCCAATGTCCAGAGGGATATACTCGAGTATATCCCTCTGGACATTGGCTTTTTG N.D. 
#03 TRCN0000044311 CCGGCGGAAGACTTTAGTAGTGAATCTCGAGATTCACTACTAAAGTCTTCCGTTTTTG N.D. 
CLCA1 NM_001285 
#01 TRCN0000044884 CCGGCGAGTACAATAATGATGAGAACTCGAGTTCTCATCATTATTGTACTCGTTTTTG N.D. 
#02 TRCN0000044885 CCGGGCCCTGAGTAATTCACTCATTCTCGAGAATGAGTGAATTACTCAGGGCTTTTTG N.D. 
#03 TRCN0000044887 CCGGGCACAACATGTTGATTCTATACTCGAGTATAGAATCAACATGTTGTGCTTTTTG N.D. 
CLCA2 NM_006536 
#01 TRCN0000044288 CCGGCCCTTACACTTTGGCTATGAACTCGAGTTCATAGCCAAAGTGTAAGGGTTTTTG N.D. 
#02 TRCN0000044289 CCGGGCCGAGTGTTTGTCCATGAATCTCGAGATTCATGGACAAACACTCGGCTTTTTG N.D. 
#03 TRCN0000044291 CCGGGCTGACTTTCACCACAGCTTTCTCGAGAAAGCTGTGGTGAAAGTCAGCTTTTTG N.D. 
SLC12A2 NM_001046  TRCN0000042944 CCGGGCTCTCTACATGGCATGGTTACTCGAGTAACCATGCCATGTAGAGAGCTTTTTG 50% 
SLC20A1 NM_005415  TRCN0000043057 CCGGCCATCAGTACAACACATTGTACTCGAGTACAATGTGTTGTACTGATGGTTTTTG 55% 
ATP2A2 NM_001681  TRCN0000038531 CCGGCCCTTGGTTGTACTTCTGTTACTCGAGTAACAGAAGTACAACCAAGGGTTTTTG 90% 
ATP2B1 NM_001001323 
#01 TRCN0000043069 CCGGCCAGAGAAAGAGGGTGGATTACTCGAGTAATCCACCCTCTTTCTCTGGTTTTTG 0% 
#02 TRCN0000043070 CCGGGCCTCTCATCTCACGTACAATCTCGAGATTGTACGTGAGATGAGAGGCTTTTTG 70% 
#03 TRCN0000043071 CCGGGCAGATTTAGAAAGAAGAGAACTCGAGTTCTCTTCTTTCTAAATCTGCTTTTTG 45% 
CACNA2D1 NM_000722 
#01 TRCN0000043768 CCGGCCCATCATGTAACGCGGATTTCTCGAGAAATCCGCGTTACATGATGGGTTTTTG 0% 
#02 TRCN0000043770 CCGGGCCAGGGATATTGAGAAACTTCTCGAGAAGTTTCTCAATATCCCTGGCTTTTTG 15% 
#03 TRCN0000043771 CCGGGCACGATTTGTTGTGACTGATCTCGAGATCAGTCACAACAAATCGTGCTTTTTG 0% 
N.I. not included in the RNAi screen due to cytotoxicity; N.D. knockdown was not possible to determine; * average knockdown of both splice variants.
8
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Overall in vitro infection by luminescence 
Overall hepatic infection was determined by measuring the luminescence intensity 
in Huh7 cells infected with a ﬁreﬂy luciferase-expressing P. berghei line, as 
previously described [358]. Brieﬂy, Huh7 cells (1.0x104 per well) were seeded in 
96-well plates the day before infection. Sporozoite addition was followed by 
centrifugation at 1800xg for 5 minutes and the medium was replaced 
approximately 2 hours after infection by the appropriate medium. Parasite infection 
load was measured 48 hours after infection by a bioluminescence assay (Biotium) 
using a multiplate reader Infinite M200 (Tecan). The effect of the different 
treatments on the viability of Huh7 cells was assessed by the CellTiter-Blue assay 
(Promega) according to the manufacturer's protocol. 
Quantification of P. berghei invasion and development by flow 
cytometry 
Invasion of hepatoma cells and intracellular parasite development were assessed 
by determining the percentage of GFP+ cells 2 hours after infection with a GFP-
expressing P. berghei line and by measuring the intensity of the GFP signal of the 
infected cells 48 hours after infection, respectively, as previously described [163]. 
Huh7 cells (5.0x104 per well) were seeded in 24-well plates the day before 
infection. The medium was replaced by the appropriate medium 1 hour prior or 2 
hours after infection, for invasion and development quantification, respectively. 
Cells were then collected for flow cytometry analysis at 2 hours or 48 hours after 
infection and analyzed on a Becton Dickinson FACSCalibur. Data acquisition and 
analysis were carried out using the CELLQuest (version 3.1.1 f1, Becton 
Dickinson) and FlowJo (version 6.4.7, FlowJo) software packages, respectively. 
Immunofluorescence imaging of P. berghei-infected cells 
For  immunofluorescence microscopy analyses,  cells  were  seeded  on   glass 
coverslips  in  24‐well  plates  and  infected  with  sporozoites  as described above. 
Forty-eight hours after infection, cells were rinsed with 1x PBS and fixed with 4% 
paraformaldehyde (PFA; Santa Cruz Biotechnology) for 20 minutes at room 
temperature and stored at 4°C in PBS 1x until being stained. Cells were incubated 
with the permeabilization/blocking solution (0.1% triton X-100, 1% bovine serum 
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albumin (BSA) in 1x PBS) for 30 minutes at room temperature. Parasites were 
stained with a parasite specific anti-Hsp70 (2E6) antibody (dilution 1:100) and an 
anti-UIS4 antibody (dilution 1:1000) for 1 hour at room temperature, followed by 
three washes with permeabilization/blocking solution. Cells were further incubated 
in a 1:400 dilution of anti‐mouse Alexa‐Fluor 488 (Jackson ImmunoResearch 
Laboratories) or anti-goat Alexa-Fluor 568 (Life Technologies) secondary 
antibodies in the presence of a 1:1000 dilution of Hoechst 33342 (Invitrogen) for 
nuclei staining. An additional three washes were carried out with 
permeabilization/blocking solution. Coverslips were mounted on microscope slides 
with Fluoromount (SouthernBiotech). Confocal images were acquired using a 
Zeiss LSM 710 confocal microscope. Widefield images for size determination were 
acquired in a Zeiss Axiovert 200M microscope. Images were processed with 
ImageJ software (version 1.47). 
P. berghei sporozoites in vivo infection and quantification of parasite 
liver load by qPCR 
Mice were infected i.v., through retro-orbital injection, with 1.0x104 P. berghei 
sporozoites. The livers were collected at 44 hpi and homogenized in 3 mL of 
denaturing solution (4 M guanidine thiocyanate; 25 mM sodium citrate pH 7, 
0.5% N-lauroylsarcosine and 0.7% β mercaptoethanol in DEPC-treated water). 
Total RNA was extracted from the livers with the NZY Total RNA Isolation Kit 
(NZYTech), according to the manufacturer's protocol, and parasite load was 
quantified by qPCR using primers specific to P. berghei 18S RNA (Table 3.2). 
Mouse Hprt expression was used for normalization. 
In vivo inhibition of NO production 
Six weeks old male C57BL/6 mice were injected daily with 50 mg/kg of Nω-Nitro-L-
arginine methyl ester (L-NAME) i.p. in saline, or with saline (0.9% NaCl) alone, 
starting 3 days before and until the day of P. berghei sporozoite i.v. injection. The 
livers were collected at 44 hpi and processed as previously described, for 
quantification of parasite liver load. 
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L-Arg in vivo supplementation 
The drinking water of 4 weeks old male C57BL/6 mice was replaced by sterilized 
water with 2.5% (w/v) L-arginine hydrochloride (Fisher Scientific) and the mice 
were allowed to drink ad libitum for 4 weeks. Control mice drank sterilized water 
alone. Mice were then infected i.v. with 1.0x104 P. berghei sporozoites and the 
livers were collected at 45 hpi and processed as previously described, for 
quantification of parasite liver load. 
Blood Parasite Load 
The presence of luciferase-expressing erythrocytic-stage parasites was monitored 
daily by Giemsa-stained blood smears and luminescence. For luminescence 
measurements, 5 μL of blood was collected from the tail vein into 50 μL of lysis 
buffer [412]. Luminescence was determined by adding 50 μL of D-luciferin 
dissolved in firefly luciferase assay buffer (according to the manufacturer’s 
instructions) to 30 μL of lysate and immediately measured using a multiplate 
reader (Tecan, Switzerland). Values of luciferase activity are expressed as relative 
luminescence units. 
Isolation and infection of mouse primary hepatocytes 
Mouse primary hepatocytes were isolated using a modified two-step perfusion 
protocol followed by a Percoll purification step [168, 413, 414]. Briefly, mice were 
euthanized by CO2 inhalation and immediately processed for cannulation of the 
portal vein using a 26-gage needle. Upon successful cannulation, the inferior vena 
cava (IVC) was cut to allow fluid to drain. Liver perfusion medium (LPM) was 
perfused at 8–9 mL/min for 10 minutes followed by liver digestion medium (LDM) 
at the same rate. Intermittent clamping of the IVC (3 seconds clamp every 30 
seconds) was performed during LDM perfusion to improve tissue digestion. After 
digestion, the liver was excised and the cells were liberated by tearing and shaking 
of the liver with forceps. The cell suspension was then sequentially filtered through 
a 100 μm and a 70 μm cell strainer and spun at 50xg for 3 min. The cell pellet was 
resuspended in Williams's Medium E with 10% of FBS and carefully overlaid on a 
60% Percoll solution (1:1). The cell suspension was fractionated by centrifugation 
at 750xg for 20 minutes, without break, at 20 °C. Viable hepatocytes deposited in 
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the pellet were washed with Williams's Medium E with 10% FBS, spun at 50xg for 
3 minutes and resuspended in complete Williams's Medium E (supplemented with 
4% FBS and 1% penicillin/streptomycin). Hepatocytes were then plated at a 
density of 2.0x104 in 96-well plates or 1.0x105 in 24-well plates and infected 16 
hours later with 1.0x104 or 5.0x104 P. berghei sporozoites, respectively.  Viability 
and yield were assessed by trypan blue staining. 
FACS-sorting of P. berghei-infected and non-infected Huh7 cells 
Huh7 cells (1.0x105 per well) were seeded in 24-well plates and infected 24 hours 
later with 1.0x105 GFP-expressing P. berghei sporozoites. Cells were collected at 
2 hpi and FACS-sorted on a BD FACSAria III Cell Sorter (BD Biosciences). Non-
infected and GFP-expressing P. berghei-infected cells were gated on the basis of 
their different fluorescence intensity, as previously established, and collected 
simultaneously [11, 163]. Immediately after FACS-sorting, both infected and non-
infected cells were washed and seeded in 24-well plates at a density of 1.5x105 
per well. Infected cells were diluted 1:1 with non-infected cells to allow replicates. 
Cells were then incubated until being collected at 18, 30 or 48 hpi. In the case of 
the 6 hpi time point, P. berghei-infected cells were FACS-sorted at this time, 
diluted 1:1 with non-infected cells, pelleted, snap-frozen and stored until RNA 
extraction using the High Pure RNA Isolation kit (Roche) according to the 
manufacturer´s instructions. 
[3H] Arginine Uptake 
Arg uptake analysis was performed in naïve and sorted infected and non-infected 
Huh7 cells at 24 hpi, with CAT2 knockdown (SLC7A2#02 cell line) and 
corresponding control (scrambled cell line). The [3H] Arg (specific activity 47.7 
Ci/mmol; PerkinElmer) transport was initiated by the addition of 100 nM [3H] Arg 
and 200 µM cold Arg in KHR transport buffer (containing in mM: 137 NaCl, 5.4 
KCl, 1.8 CaCl2.2H2O, 1.2 MgSO4 and 10 HEPES, pH 7.40) for 1 minute. Uptake 
was stopped by washing the cells twice with ice cold stop buffer (containing in mM: 
137 NaCl and 10 HEPES, pH 7.40). Cells were subsequently solubilized with lysis 
buffer (100 mM NaOH and 0.1 % SDS) at 37°C for 1 hour and scraped from the 
plates. Protein concentration was quantified using Bio-Rad DC protein assay. The 
amount of [3H] Arg taken up by the cells was quantified by liquid scintillation 
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counting (MicroBeta Trilux, PerkinElmer) [415]. The specific CAT2-mediated 
transport was calculated as the difference between the [3H] Arg uptake in the 
scrambled cell line (total transport) and in the SLC7A2#02 cell line. 
siRNA transfection 
4.0x104 Huh7 cells were reverse-transfected with 30nM of target specific (human 
ODC: ref. L-006668-00-0005; human arginase 1: ref. L-009922-00-0005) or control 
siRNA sequence pools (ON-TARGETplus SMARTpool, Dharmacon), using 
Lipofectamine RNAiMAX (Gibco/Invitrogen) according to the manufacturer´s 
instructions. Twenty-four hours after transfection, the cells were infected with 
3.0x104 GFP-expressing P. berghei sporozoites. Cells were collected for flow 
cytometry analysis at 48 hpi and analyzed on a BD LSR Fortessa flow cytometer 
with the DIVA software (version 6.2). Analysis was carried out using the FlowJo 
software (version 6.4.7, FlowJo). The efficiency of knockdown was assessed by 
qPCR using specific primers (Table 3.2). 
 
RNA extraction and quantification   
RNA was extracted from cultured Huh7 cells using the High Pure RNA Isolation kit 
(Roche) according to the manufacturer´s instructions. The amount of RNA in each 
sample was assessed with a NanoDrop® ND‐1000 spectrophotometer.  
cDNA synthesis and qPCR   
Complementary DNA (cDNA) was synthesized from 1 μg of RNA using the Roche 
cDNA synthesis kit, according to the manufacturer´s instructions. The cDNA was 
synthesized employing the following thermocycling parameters: 25°C for 10 
minutes, 55°C for 30 minutes, and 85°C for 5 minutes. qPCR reaction was 
performed in a total volume of 20 µL in a ABI Prism 7500 Fast system (Applied 
Biosystems) using the iTaqTM Universal SYBR® Green kit (BioRad) as follows: 
50°C for 2 minutes, 95°C for 10 minutes, 40 cycles at 95°C for 15 seconds and 
60°C for 1 minute, melting stage was done at 95°C for 15 seconds, 60°C for 1 
minute, and 95°C for 30 seconds. Primers for the housekeeping gene 
hypoxanthine-guanine phosphoribosyltransferase (HPRT) were used for 
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normalization in all experiments (Table 3.2). For qPCR, the delta-delta 
CT relative quantification method was used. 
Table 3.2 - List of primer sequences used. 
Gene forward primer (5’ - 3’) reverse primer (5’ - 3’) 
Pb18S AAGCATTAAATAAAGCGAATACATCCTTAC GGAGATTGGTTTTGACGTTTATGTG 
HPRT TTTGCTGACCTGCTGGATTAC CAAGACATTCTTTCCAGTTAAAGTTG 
SCARB1 AGAATAAGCCCATGACCCTGAA TGAGCTCAGCAAATAATCCGAA 
SLC1A4 
TGTTTGCTCTGGTGTTAGGAGT CGCCTCGTTGAGGGAATTGAA 
SLC3A2 
AGTGCCAACATGACTGTGAAG CCTTACTCCGCTGGTCACTCAG 
SLC6A9 CAGATCGAGTTTGTACTGACGAG GCGATAGCAGAGGTATGGGAAG 
SLC7A2 var1 TCACCAGTTGCTGCCACGTTGA 
AGCCAGGCTGGTACCTGAGGATGAG 
SLC7A2 var2 CGGGTGCAGTGGCAGCTTTGATGG 
SLC7A5 CCAAGCTCGTGGCCTGCCT GATTGGACACATCACCCTTCCCGA 
SLC7A11 TGCTGGCTGGTTTTACCTCAAC CCAATGGTGACAATGGCCAT 
SLC25A12 TGGCGGTCAAGGTGCAGACAACTA TCCTGCCAAGAGCTGCACGATCTT 
SLC38A2 TTGGTTTTATTGGTGCATCTGCAGC GCCATGCTTCCGGTCATCACCA 
SLC38A4 ATTACACCCACCGCAATCCTG CGTCCGGGAGTTGAATACAAAG 
SLC38A7 TTCCCAGGGCTGTGCCTCATTC TGTTCCCTGGGAGGCAGTGGT 
SLC12A2 TCCCACTGGAGAGCAAGAAGCCA TGGCTGACTGAGGATCTGCAAGA 
SLC20A1 TCTTGGTTCGTGTCCCCACTGCTT TTGTCAAAGCCCAGCAACGGTGC 
ATP2A2 AGAACGTGCAAATGCCTGCAACTCA ATGACACCTTCAGGAGCACCCTTCA 
ATP2B1 TGGAAGGCTCTGGAAGAATGGTAGT CCTGGGCTTTTGCTTTGTTGCGA 
CACNA2D1 CGTTCCCTTCGGCCGTCACTATC GCAATTTCTACCAGCTGGCGTGC 
ODC ATGGCTTCCAGAGGCCGAC TTGCTGCATGAGTTGCCACGCA 
Arginase 1 GAAGTGTCAGAGCATGAGCG AGCAGACCAGCCTTTCTCAA 
mouse Slc7a2 TGCTGCTCGTCCAACCTTC TGGAATCTTCAAGGCTGTCC 
 
Statistical Analyses 
Statistical analyses were performed using the GraphPad Prism 5 software. One-
way ANOVA, Two-way ANOVA, Survival Test Gehan-Breslow-Wilcoxon, Mann-
Whitney U test or Unpaired t-test were used for significance of the differences 
observed, as indicated in each figure. ns – not significant, * p < 0.05, ** p < 0.01 
and *** p < 0.001. 
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Results 
SLC7A2 plays an important role during P. berghei intra-hepatic development  
Previous microarray results obtained by the laboratory have shown that the 
expression of several transport proteins is altered during infection of hepatoma 
cells by P. berghei parasites [11]. To investigate the functional role of these 
proteins during the liver stage of Plasmodium life cycle, we employed an RNAi-
based strategy to monitor the effect of their down-modulation on P. berghei 
infection. The screen proceeded in 3 consecutive steps, employing different 
established methods to measure hepatic infection by Plasmodium.  In the first 
step, 1 to 3 shRNA sequences were used to silence each of the 18 selected genes 
and the resulting stable cell lines were infected with luciferase-expressing P. 
berghei sporozoites. Forty-eight hours later, the parasite load in these cells was 
determined by measuring the bioluminescence of cell lysates. Each sequence was 
used in at least 4 independent experiments and a shRNA targeting SR-BI was 
employed as a positive control for infection decrease [210]. Our results showed 
that the knock-down of 10 of those genes consistently led to a decrease in overall 
parasite load, as measured by the luminescence of infected cell lysates (Fig. 
3.1A). Based on the correlation between the effect on infection and the level of 
knockdown of gene expression by the different sequences, 7 genes were selected 
for the second step of the RNAi screen. Then, the stable cells lines with the 
knockdown of these genes were infected with GFP-expressing P. berghei 
parasites and the extent of the impairment of the parasite’s intra-hepatic 
development was assessed 48 hours later by flow cytometry determination of GFP 
intensity [163]. Our data showed that down-modulation of both splice variants of 
the SLC7A2 gene leads to the strongest impairment of parasite development 
among the genes assessed, indicating that the transporter encoded by this gene 
might play an important role in the ability of the parasite to replicate inside hepatic 
cells (Fig. 3.1B). Therefore, the SLC7A2 gene was selected for a final confirmation 
step using two shRNA sequences and through assessment of parasite 
development by immunofluorescence microscopy (Fig. 3.1C). These imaging data 
demonstrated that parasite size correlates with the average expression levels of 
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both variants of SLC7A2, suggesting that CAT2A and CAT2B, the two transporters 
encoded by this gene, are involved in the parasite’s hepatic development. 
 
Figure 3.1 – SLC7A2 knockdown significantly impairs P. berghei intra-hepatic 
development. (A) Huh7 cells with stable knockdown of the selected genes were infected 
with luciferase-expressing P. berghei sporozoites and parasite load (luminescence) was 
assessed 48 hours later. A scrambled shRNA sequence was used as a negative control 
and a cell line with stable knockdown of SR-BI was used as positive control. Error bars 
represent SEM. (B) Huh7 cells with the knockdown of the 7 genes selected on the 
previous step were infected with GFP-expressing P. berghei sporozoites and parasite 
development was assessed by flow cytometry at 48 hpi. Error bars represent SEM. (C) 
Quantification of the area of the EEFs in the 2 different cell lines with SLC7A2 knockdown 
at 48 hpi by immunofluorescence microscopy. The knockdown efficiency of each shRNA 
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sequence is indicated. All panels: Pool of 3 independent experiments. One-way ANOVA 
with post-test Dunnett. ns - not significant, * p < 0.05, ** p < 0.01 and *** p < 0.001. 
Further evidence of a role for SLC7A2 in Plasmodium hepatic development was 
obtained in in vivo and ex vivo experiments employing Slc7a2-/- mice. In the in vivo 
experiments, male and female Slc7a2-/- (KO), Slc7a2+/- (heterozygous) and 
Slc7a2+/+ (WT) littermate mice were infected by i.v. injection of 1.0x104 P. berghei 
sporozoites. Our results show that, in males, parasite burden assessed by qPCR 
44 hours after infection was approximately 65% lower in the livers from KO mice 
compared with their WT counterparts, with the heterozygous mice exhibiting a 
smaller and non-significant reduction that correlates with Slc7a2 expression in 
these mice (Fig. 3.2A, C). In female mice, even though there is an approximately 
50% reduction in parasite load in the livers of the KO mice, the difference is not 
statistically significant (Fig. 3.2B). Additionally, heterozygous female mice do not 
exhibit an intermediate reduction in infection as observed for the males, although 
the expression of the gene is reduced by around 40% (Fig. 3.2D). 
 
 
Figure 3.2 - P. berghei liver load is reduced in Slc7a2-/- mice. Slc7a2+/+, Slc7a2+/- and 
Slc7a2-/- littermate mice were infected with 1.0x104 P. berghei sporozoites and the 
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parasite liver load at 44 hpi was determined by qPCR. (A) Liver load in males. WT: n= 12; 
heterozygous: n = 14; KO: n = 9. (B) Liver load in females. WT: n= 13; heterozygous: n = 
21; KO: n = 9. (C) Expression of both variants of Slc7a2 in the livers of male mice. Error 
bars represent SD.  (D) Expression of both variants of Slc7a2 in the livers of female mice. 
Error bars represent SD. Pool of 2 independent experiments. Panels (A) and (B): One-
way ANOVA with Dunnett. ns - not significant and ** p < 0.01. 
To exclude possible effects of the absence of expression of Slc7a2 in non-
parenchymal liver cells on the observed phenotype, primary hepatocytes were 
collected from the livers of KO, heterozygous and WT mice and infected with GFP-
expressing P. berghei parasites. Our ex vivo results show that, 48 hours after 
sporozoite addition, the overall parasite load in KO hepatocytes is approximately 
60% lower than in WT liver cells (Fig. 3.3A), in perfect agreement with our in vivo 
observations. Similarly, parasite load in primary hepatocytes from heterozygous 
mice is reduced when compared with the WT but the reduction is milder. 
Immunofluorescence microscopy analyses of infected primary hepatocytes further 
confirmed that in the absence of both transporters encoded by Slc7a2 the 
parasite’s ability to develop intracellularly is significantly impaired (Fig. 3.3B). 
 
Figure 3.3 – Absence of Slc7a2 in hepatocytes impairs P. berghei development. (A) 
Primary hepatocytes from Slc7a2+/+, Slc7a2+/- and Slc7a2-/- littermate mice were infected 
ex vivo with P. berghei sporozoites and parasite load at 48 hpi was determined by qPCR. 
(B) Immunofluorescence microscopy quantification of EEF areas in primary hepatocytes 
from Slc7a2+/+, Slc7a2+/- and Slc7a2-/- littermate mice at 48 hpi. Pool of 3 independent 
experiments. Both panels: One-way ANOVA with post-test Dunnett. * p < 0.05 and *** p 
< 0.001. 
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Absence of Slc7a2 does not impact blood stage P. berghei infection 
Finally, to determine if the absence of Slc7a2 expression would affect P. berghei 
blood parasite load and mouse survival, both male and female WT and KO mice 
were injected i.v. with 1.0x104 luciferase-expressing P. berghei sporozoites. Blood 
parasite load was monitored daily, starting on day 2, by a bioluminescence assay 
[412]. No difference in blood parasite load was observed between the 2 groups of 
mice (Fig. 3.4A). The survival of the mice was also not affected by the absence of 
Slc7a2 (Fig. 3.4B). These data suggest that, contrarily to what we observed in 
hepatocytes, the two transporters encoded by Slc7a2 are not important for 
Plasmodium survival inside RBCs and that its absence does not improve the 
outcome of infection. This is not surprising because, contrarily to hepatocytes, in 
which CAT2A is the main Arg transporter, RBCs uptake Arg via the ubiquitous 
CAT1. 
 
Figure 3.4 – Effect of the absence of Slc7a2 on blood parasite load and mouse 
survival. (A) Blood parasite load in WT and KO mice following i.v. injection of 1.0x104 
luciferase-expressing P. berghei sporozoites, assessed by a bioluminescence assay. 
Representative experiment out of 2 independent experiments. WT: n = 4; KO: n = 7 mice. 
Two-way ANOVA with post-test Bonferroni. (B) Survival of WT and KO mice infection. 
Pool of 2 independent experiments. WT: n = 8; KO: n = 15 mice. Gehan-Breslow-
Wilcoxon Survival test. ns – not significant. 
Arg availability is essential for Plasmodium hepatic infection 
Since Arg has been shown to play an important role in various infections [416-
419], we sought to investigate the effect of the depletion of this amino acid on the 
outcome of Plasmodium infection. We started by showing that a decrease in Arg 
The role of L-arginine uptake and polyamine production during liver stage                                                     Chapter III 
 infection by the malaria parasite                                                            
  
96 
 
availability in the cell culture medium of Huh7 cells infected by luciferase-
expressing P. berghei sporozoites leads to a decrease in overall parasite load, as 
measured by the luminescence assay of infected cell lysates, for Arg 
concentrations below 2.5 µM (Fig. 3.5A). Likewise, addition of increasing 
concentrations of NG-NG-dimethyl-L-arginine (L-SDMA), a competitor for Arg 
transport, to the culture medium leads to a decrease in parasite load (Fig. 3.5B). 
Overall, these data indicate that Arg uptake is essential to sustain Plasmodium 
hepatic infection. 
 
Figure 3.5 – Effect of Arg availability on Plasmodium hepatic infection. (A) Huh7 
cells were infected with luciferase-expressing P. berghei sporozoites and cultured in 
medium with different concentrations of Arg. Parasite load was assessed by 
bioluminescence 48 hours after infection. Representative experiment out of 3 independent 
experiments. Error bars represent SD. (B) Huh7 cells were infected with luciferase-
expressing P. berghei sporozoites and cultured in medium with increasing concentrations 
of the competitor L-SDMA. Parasite load was assessed 48 hours after infection by 
bioluminescence. Pool of 2 independent experiments. Error bars represent SD. Both 
panels: One-way ANOVA with post-test Dunnett. ns - not significant and *** p < 0.001. 
SLC7A2 expression and function are not enhanced in Plasmodium-infected 
cells 
Having established a role for SLC7A2 and for the availability of Arg during 
Plasmodium hepatic infection, we decided to investigate if the expression of any of 
the splice variants of this transporter was altered in Plasmodium-infected cells, as 
was previously observed by microarray analysis [11]. To address this, we 
assessed their expression levels in sorted non-infected and infected Huh7 cells at 
6, 18, 30 and 48 hpi with GFP-expressing P. berghei parasites. Our results show 
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that hepatoma cells express both the liver-expressed, low affinity variant 1 (that 
originates CAT2A), and the inducible, high affinity variant 2 (that encodes CAT2B) 
(Fig. 3.6A). However, no significant differences in expression were observed for 
any of the variants between infected and non-infected cells at the selected time 
points (Fig. 3.6A). 
We then sought to determine whether Plasmodium infection influenced the uptake 
of Arg by the host cells via CAT2 transporters. To this end, we determined the 
specific uptake of [3H] Arg by sorted P. berghei-infected and non-infected cells at 
24 hpi. Huh7 cells with the knockdown of SLC7A2 (the SLC7A2#02 cell line) were 
used as control for non-specific transport (in these cells, SLC7A2 expression is 
very low and, therefore, their Arg uptake is mainly mediated by other transporters). 
Of note, in the conditions used, only CAT2A-mediated Arg transport can be 
assessed. Once again, no significant differences were observed, suggesting that 
although Arg is essential for Plasmodium hepatic infection, CAT2A-mediated Arg 
uptake is not increased in infected cells (Fig. 3.6B). Finally, we used [3H] Arg 
uptake to assess the extent to which CAT2A and CAT2B contribute to the total 
uptake of Arg by Huh7 cells. Our data show that Arg uptake by the SLC7A2#02 
cell line, which has a 90% knockdown of SLC7A2 expression, is reduced by 50%, 
implying that CAT2A and CAT2B are responsible for at least half of the total Arg 
uptake by Huh7 cells (Fig. 3.6C). 
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Figure 3.6 – Plasmodium infection does not alter SLC7A2 expression and CAT2-
mediated Arg uptake by infected cells. (A) Quantification of the transcriptional 
expression of both variants of SLC7A2 on sorted infected and non-infected Huh7 cells by 
qPCR. Each time point corresponds to a pool of 2 independent sorting experiments. Error 
bars represent SD. Two-way ANOVA with Bonferroni. (B) Specific [3H] Arg uptake by 
sorted P. berghei-infected cells and non-infected cells at 24 hpi. Pool of 2 independent 
experiments. Unpaired t-test. (C) [3H] Arg uptake by control cells and cells with the stable 
knockdown of SLC7A2. Pool of 3 independent experiments. Mann-Whitney test. ns - not 
significant and ** p < 0.01. 
Successful Plasmodium development depends on polyamine synthesis 
A significant amount of the Arg taken up by the infected host cell will likely be 
employed in one of the two main metabolic pathways that have been described in 
the context of infections by other pathogens, the iNOS and the arginase pathways, 
which lead to the synthesis of NO and polyamines, respectively (Fig. 3.7) [22]. 
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Figure 3.7 – Arg metabolic pathways and their influence on Plasmodium infection. 
In a first attempt to uncover which pathway uses the Arg taken up by Plasmodium-
infected cells, we assessed the expression levels of the key enzymes from both 
pathways in sorted non-infected and infected Huh7 cells at 6, 18, 30 and 48 hpi by 
qPCR, employing specific primers for each gene (see Table 3.2). No significant 
differences in expression of the enzymes were observed between infected and 
non-infected cells at the selected time points (Fig. 3.8). 
 
Figure 3.8 – Expression of the enzymes involved in Arg metabolism is not altered in 
Plasmodium-infected cells. Quantification of the transcriptional expression of iNOS, 
ODC, arginase 1 and arginase 2 on sorted infected and non-infected Huh7 cells by qPCR. 
Each time point corresponds to a pool of 2 independent sortings. Error bars represent SD. 
Two-way ANOVA with Bonferroni. ns – not significant. 
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We then investigated the role of the NO production pathway on Plasmodium liver 
stages. To this end, we assessed the impact of L-NAME, a well-known inhibitor of 
iNOS, on hepatic infection. Our in vitro and ex vivo results showed that inhibition of 
iNOS does not affect Plasmodium infection of hepatic cells (Fig. 3.9A, B). 
Similarly, the administration of L-NAME to mice did not have an impact on in vivo 
P. berghei liver load (Fig. 3.9C). These results are in agreement with published 
data employing the L-NAME inhibitor in vivo and with results of infection of iNOS-
KO mice [232]. 
 
Figure 3.9 – Chemical inhibition of NO production does not impact Plasmodium 
hepatic infection. (A) Huh7 cells were infected with luciferase-expressing P. berghei 
sporozoites and 2 hours later the culture medium was replaced by medium with increasing 
concentrations of L-NAME. Parasite load (luminescence) was assessed at 48 hpi. 
Representative experiment out of 2 independent experiments. Error bars represent SD. 
One-way ANOVA with post-test Dunnett. (B) Mouse primary hepatocytes were infected 
with luciferase-expressing P. berghei sporozoites and 2 hours later the culture medium 
was replaced by medium with increasing concentrations of L-NAME. Parasite load 
(luminescence) was assessed at 48 hpi.  Representative experiment out of 2 independent 
experiments. Error bars represent SD. One-way ANOVA with post-test Dunnett. (C) 
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C57BL/6 mice received four daily doses of 50 mg/kg of L-NAME i.p., starting 3 days 
before infection and until the day of sporozoite i.v. injection. Parasite load was assessed 
at 44 hpi by qPCR. Pool of 2 independent experiments. Saline: n = 10 mice; L-NAME-
treated: n = 10 mice. Two-tailed Mann-Whitney test. ns - not significant. 
Since the inhibition of NO production did not affect Plasmodium hepatic infection, 
we wondered if its stimulation would have any effect in this regard. Some studies 
of Plasmodium-infected mice reported that increasing the circulating levels of Arg 
enhances NO production [32, 33]. With this in mind, we attempted to stimulate NO 
production in hepatocytes by supplementing the drinking water of the mice with 
2.5% Arg (w/v) for 4 weeks. Livers were then collected 44 hours after infection with 
P. berghei sporozoites and parasite load was determined by qPCR. No difference 
was observed between the group drinking the supplemented water and the group 
drinking normal water (Fig. 3.10). These results suggest that providing extra Arg 
might not be sufficient to stimulate NO production by hepatocytes and thereby 
affect Plasmodium infection, or that the extra Arg provided is being employed by 
other pathways. 
Taking together the results of the inhibition of NO production by L-NAME and the 
attempt of its stimulation through Arg supplementation, it would seem that the Arg 
being taken up by Plasmodium-infected cells is not being used for NO production. 
 
Figure 3.10 – Arg supplementation 
does not affect Plasmodium hepatic 
infection. Mice were allowed to drink a 
2.5% (w/v) Arg solution ad libitum for 4 
weeks before infection with P. berghei 
sporozoites. Parasite load was assessed 
at 44 hpi by qPCR. Pool of 3 
independent experiments. Control: n = 
14 mice; L-Arg: n = 15 mice. Two-tailed 
Mann-Whitney test. ns - not significant. 
 
We then decided to investigate whether Arg is being used for polyamine synthesis. 
To this end, we inhibited the rate-limiting enzyme of this pathway, ODC, with the 
well-known inhibitor α-difluoromethylornithine (DFMO), by adding it to Huh7 cells 2 
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hours after infection with luciferase-expressing P. berghei sporozoites. Our results 
show that the addition of increasing concentrations of DFMO to the culture 
medium leads to a decrease in parasite load (Fig. 3.11A). Using GFP-expressing 
P. berghei parasites, we also observed by flow cytometry that a pre-treatment of 
the cells with DFMO inhibits cell invasion by these parasites, as shown by the 
significantly lower number of GFP+ cells detected 2 hpi (Fig. 3.11B). Importantly, 
the development of P. berghei liver stage parasites is significantly affected by the 
addition of DFMO, in agreement with previous reports of a cytostatic effect of this 
compound on P. falciparum blood stages [340, 420]. Overall, these data suggest 
that polyamine synthesis plays an important role during Plasmodium hepatic 
growth. 
 
Figure 3.11 – ODC inhibition affects P. berghei invasion and development inside 
hepatoma cells. (A) Huh7 cells were infected with luciferase-expressing P. berghei 
sporozoites and 2 hours later the culture medium was replaced by medium with increasing 
concentrations of DFMO. Parasite load (bioluminescence) and cell viability were assessed 
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at 48 hpi. Representative experiment out of 2 independent experiments. Error bars 
represent SD. (B) The culture medium of Huh7 cells was replaced by medium with 1.25 or 
2.50 mM of DFMO 1 hour prior to infection with GFP-expressing sporozoites. Cell invasion 
was quantified by determining the percentage of GFP+ cells 2 hpi by flow cytometry. Pool 
of 3 independent experiments. Error bars represent SD. (C) Huh7 cells were infected with 
GFP-expressing P. berghei sporozoites and the culture medium was replaced 2 hpi by 
media with 1.25 or 2.50 mM of DFMO. Parasite development was assessed by flow 
cytometry by determining the fluorescence intensity of GFP+ cells at 48 hpi. Pool of 3 
independent experiments. Error bars represent SD. All panels: One-way ANOVA with 
post-test Dunnett. *** p < 0.001. 
Both Plasmodium and the host cells express the enzymes of the polyamine 
synthesis pathways (Fig. 3.7). In addition, the ODC activity of Plasmodium 
AdoMetDC/ODC catalyzes the same reaction as mammalian ODC, and can also 
be inhibited by DFMO [340]. Therefore, we sought to deconvolute the effect of the 
host and parasite polyamine synthesis pathways on infection, using an RNAi 
approach to down-modulate the expression of ODC and arginase 1 in the host 
cell. Our results show that down-modulation of the expression of host ODC and 
arginase 1 has no impact on cell invasion and on Plasmodium development (Fig. 
3.12A, B), suggesting that Plasmodium parasites rely mainly on their own pathway 
to synthesize polyamines. The efficiency of knockdown was confirmed by qPCR 
employing specific primers for these genes (Table 3.2). 
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Figure 3.12 – Inhibition of polyamine synthesis by the host cell through down-
modulation of its enzymes ODC and arginase 1 does not affect P. berghei invasion 
and development. (A) Huh7 cells with the knockdown of ODC and arginase 1 were 
infected with GFP-expressing P. berghei sporozoites and cell invasion was quantified by 
determining the percentage of GFP+ cells 2 hpi by flow cytometry. Pool of 3 independent 
experiments. Error bars represent SD. One-way ANOVA with post-test Dunnett. (B) Huh7 
cells with the knockdown of ODC and arginase 1 were infected with GFP-expressing P. 
berghei sporozoites and parasite development was assessed by flow cytometry at 48 hpi. 
Pool of 3 independent experiments. Error bars represent SD. One-way ANOVA with post-
test Dunnett. (C) Knockdown efficiency upon transfection of Huh7 cells with the siRNAs 
targeting the host’s ODC and arginase 1. Error bars represent SD. ns - not significant. 
The unexpected behavior of the arginase-KO parasite 
To further investigate the dependence of the parasite on its own polyamine 
synthesis pathway, we compared the in vitro and in vivo infectivity of an available 
arginase-KO P. berghei parasite with that of its WT counterpart. We observed that, 
of a total 6 independent experiments in vitro, the arginase-KO displayed a 
significantly lower infection in 3 of those experiments and a similar infection in the 
remaining 3 experiments (Fig. 3.13A, B). This bimodal pattern was also 
reproduced in an in vivo setting. We carried out 8 independent rodent infection 
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studies where we compared the liver parasite loads of mice infected with WT or 
arginase-KO P. berghei parasites and also found a drastically lower liver infection 
in 4 of them and no significant differences in the remaining 4 experiments (Fig. 
3.13C, D). 
 
Figure 3.13 – The arginase-KO parasite displays a bimodal behavior both in vitro 
and in vivo. (A) Huh7 cells were infected with WT and arginase-KO P. berghei 
sporozoites and parasite load was assessed at 48 hpi by qPCR. In 3 out of 6 independent 
experiments, infection by the arginase-KO parasite was reduced by 70%. Error bars 
represent SEM. (B) In the remaining 3 out of 6 experiments, no difference was observed. 
Error bars represent SEM. (C) Mice were infected with WT and arginase-KO P. berghei 
sporozoites and parasite liver load was assessed at 44 hpi by qPCR. In 4 out of 8 
independent experiments, infection by the arginase-KO was reduced by 65%. Wild Type: 
n = 20 mice; arginase-KO: n = 20 mice. (D) In the remaining 4 out of 8 experiments, no 
difference was observed. Wild Type: n = 20 mice; arginase-KO: n = 20 mice. All panels: 
Mann-Whitney test. ns - not significant and *** p < 0.001. 
In the experiments in which the infection by the arginase-KO parasite is reduced 
we also investigated whether the effect was due to a reduction in the number of 
parasites or in their development. We found that the observed reduction in 
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parasite load 48 hpi can be fully explained by a reduction in the percentage of 
infected cells, suggesting that the survival of the arginase-KO parasite might be 
impaired (Fig. 3.14A). The surviving arginase-KO parasites do not show any 
impairment in their hepatic development, as confirmed by their similar average 
EEF size in comparison with the WT parasite (Fig. 3.14B). 
 
Figure 3.14 – The reduced infection by the arginase-KO parasite observed in half of 
the experiments is caused by a reduction in the percentage of infected cells and not 
by an impairment of parasite development. (A) Huh7 cells were infected with WT and 
arginase-KO P. berghei sporozoites and the percentage of infected cells was quantified by 
immunofluorescence microscopy 48 hpi. Representative experiment out of 2 independent 
experiments. Error bars represent SD. (B) Parasite size was determined by 
immunofluorescence microscopy at 48 hpi. Representative experiment out of 2 
independent experiments. Both panels: Unpaired t-test. ns - not significant and *** p 
< 0.001. 
Finally, in the experiments in which the infectivities of both parasites were similar, 
the knockdown of the expression of the host’s ODC or arginase I led to a 30% 
decrease in parasite load (Fig. 3.15A). In the experiments in which the infection by 
the arginase-KO parasite is reduced, the knockdown of the host’s enzymes did not 
have any further effect on the parasite (Fig. 3.15B).  
Collectively, these results suggest that the parasite needs polyamines for its 
hepatic development and that it relies primarily on its own polyamine synthesis 
pathway, as the knockdown of the host’s polyamine synthesis enzymes does not 
affect its development. However, the results obtained with the arginase-KO 
parasite suggest that, under some circumstances, the parasite might circumvent 
the absence of its own polyamine biosynthesis machinery by acquiring, at least 
partially, the polyamines it needs to develop from its host. 
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Figure 3.15 – The knockdown of the host’s enzymes ODC and arginase 1 only 
affects the infection of the arginase-KO parasite when it behaves similarly to the 
WT. (A) Huh7 cells with or without the knockdown of host’s ODC and arginase 1 were 
infected with WT and arginase-KO P. berghei sporozoites and parasite load was 
assessed at 48 hpi by qPCR. (A) In the experiments in which the arginase-KO parasite 
displayed a behavior similar to the WT parasite, ODC and arginase 1 knockdown led to a 
30% reduction in parasite load. Pool of 4 independent experiments. Error bars represent 
SEM. (B) In the experiments in which the infection by the arginase-KO parasite was 
already reduced relative to the WT control, no further decrease was observed upon ODC 
and arginase 1 knockdown. Pool of 2 independent experiments. Error bars represent 
SEM. Both panels: Two-way ANOVA with post-test Bonferroni. ns - not significant and *** 
p < 0.001. 
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Discussion 
Plasmodium parasites are incapable of de novo amino acid biosynthesis and, 
during the intraerythrocytic stage of their life cycle, obtain most of their supply of 
amino acids from the digestion of hemoglobin [305, 409]. Although Arg 
supplementation is unnecessary to support P. falciparum blood-stage growth, this 
amino acid was found to be significantly depleted during the parasite’s trophozoite 
and schizont stages [24, 421]. The resulting hypoargininemia contributes to 
several aspects of disease severity, such as limited NO production, reduced RBC 
deformability and adherence of parasitized RBCs to endothelium [24, 410, 422, 
423]. This Arg depletion has been attributed to the action of the parasite’s arginase 
and results in the production of significant amounts of the polyamine synthesis 
precursor, ornithine [24]. As a result, it is not surprising that polyamines have been 
shown to be among the major metabolites present within P. falciparum blood-
stage malaria parasites [334]. 
Hepatic Plasmodium spp. parasites cannot rely on hemoglobin degradation to 
obtain the amino acids they require and must, therefore, acquire them from the 
host hepatocyte. Here, we show that the normal developmental process of liver-
stage P. berghei is dependent on Arg availability (Fig. 3.5). This Arg is acquired by 
the host cell mostly via the CAT2A and CAT2B transporters (Fig. 3.1, 3.2, 3.3 and 
3.6C). Furthermore, it seems that the normal Arg uptake by the cells is sufficient to 
sustain Plasmodium development. This hypothesis is supported by the similar Arg 
uptake and SLC7A2 expression observed in infected cells in comparison with non-
infected (Fig. 3.6A, B). 
Additionally, we show that the Arg taken up by the infected cell is mainly being 
used as a source of polyamines, to promote parasite growth (Fig. 3.11). The 
inhibition of polyamine production by the host cell alone, accomplished through the 
down-modulation of the expression of the host’s arginase I or ODC enzymes, has 
no impact on P. berghei development in Huh7 cells. When the pathways from both 
the host and the parasite are inhibited simultaneously with the ODC inhibitor, 
DFMO, parasite development is significantly impaired (Fig. 3.11). These results 
suggested that the parasite relies mostly on its own polyamine synthesis pathway.  
To test this hypothesis, we used an arginase-KO P. berghei parasite, which 
displayed a clear bimodal behavior in terms of its hepatic infectivity (Fig. 3.13). In 
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half of the experiments (both in vitro and in vivo), the absence of the parasite’s 
arginase led to a significant decrease in parasite load, due to a marked reduction 
in the percentage of infected cells at 48 hpi. In the remaining half of the 
experiments, no difference in infectivity could be detected between the arginase-
KO parasite and its WT counterpart, unless there was a simultaneous impairment 
in the host’s polyamine pathway (Fig. 3.15A). Collectively, these data suggest that 
the parasite preferentially uses its own biosynthesis pathway to obtain the 
polyamines it requires and when this pathway is compromised, if the parasites do 
not use some other compensatory mechanisms to guarantee their survival, most 
of them perish inside hepatocytes. Part of these compensatory mechanisms might 
involve the expression of transporters that will allow the uptake of polyamines and 
their precursors from the host cell (Fig. 3.15A). However, the existence of other 
compensatory mechanisms should also be expected, as the impairment of the 
host’s polyamine synthesis pathway through the down-modulation of arginase 1 
and ODC impacts P. berghei hepatic infection by only 30% (Fig. 3.15A). Finally, 
our results suggest that these compensatory mechanisms are induced during the 
parasite’s life cycle in the mosquito vector. This notion is supported by our 
observation that each batch of arginase-KO parasites consistently displayed 
similar behaviors in in vitro and in vivo infections, which seems to exclude a host-
dependent effect. However, further studies are clearly required to fully clarify this 
matter.  
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Introduction 
As described in the previous chapter, L-arginine (Arg) can be employed by cells as 
a precursor of both polyamines and nitric oxide (NO). Polyamines mediate several 
important cellular processes, including differentiation and proliferation, and 
assume particular importance for rapidly proliferating cells, such as cancer cells 
and protozoan parasites [323-329]. Most commonly, polyamine metabolism is 
targeted by preventing intracellular polyamine biosynthesis with enzyme inhibitors 
[324, 329, 424]. α-difluoromethylornithine (DFMO), an irreversible ornithine 
decarboxylase (ODC) inhibitor, is the most widely studied inhibitor of polyamine 
metabolism and it was approved by the Food and Drug Administration (FDA) for 
the treatment of African trypanosomiasis [424]. Its efficacy has been demonstrated 
against several tumors in vitro and in vivo, such as neuroblastoma, lung carcinoma 
and prostate cancer [424-426]. Clinical trials in cancer patients have shown that 
this inhibitor is well tolerated, even at high doses, with only the occasional 
occurrence of reversible ototoxicity, nausea and mild neutropenia. However, to 
date it has failed to translate to the clinic [324, 424, 426].  
Inducible nitric oxide synthase (iNOS)-derived NO is involved in both the 
pathogenesis and control of several types of viral, bacterial and parasitic infections 
[427-429]. Bacterial lipopolysaccharides (LPS) and inflammatory cytokines, such 
as IFN-ɣ and TNF-α, are well-known stimulators of the production of NO via up-
regulation of iNOS [429-433]. In malaria, increased NO production has been 
reported in both laboratory models of infection and human patients [434-436]. 
Early during a Plasmodium blood-stage infection, increased production of 
endogenous NO has been found to correlate with protection [437, 438]. 
Additionally, NO and NO donors have been shown to mediate in vitro killing of 
both hepatic and blood forms of malaria parasites [34-39]. However, controversy 
exists as to the role of NO in malaria because NO has also been reported to 
contribute to the development of cerebral malaria pathology [430, 439, 440]. 
It has been reported that an increase in the circulating levels of Arg in 
Plasmodium-infected mice leads to enhanced NO production [32, 33]. Yet, while in 
one of these studies Arg supplementation significantly decreased parasitaemia 
and improved survival of P. yoelii-infected Balb/c mice [33], none of these effects 
were observed in P. berghei-infected C57BL/6 mice [32]. In individuals with 
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moderately severe malaria, Arg infusion was shown to be safe, and effectively 
increased plasma Arg concentrations and NO production, leading to improved 
endothelial function [441, 442]. More recently, in a pilot study with patients with 
severe P. falciparum malaria in which Arg infusion was used as an adjunctive 
treatment, its safety was confirmed but no increase on NO bioavailability was 
observed [443]. 
Arg metabolism can be regulated by multiple factors that include dietary amino 
acids [407]. L-lysine (Lys), L-ornithine (Orn) and L-valine (Val) have been 
described as arginase inhibitors [30, 31]. Additionally, Lys and Orn also compete 
with Arg for entry into cells via cationic amino acid transporters [444]. Having 
shown in the previous chapter that Arg uptake via CAT2A and CAT2B and Arg-
dependent polyamine synthesis play an important role on parasite hepatic 
development, we wondered whether Plasmodium infection could be impaired and 
NO production stimulated by appropriate amino acid supplementation.   
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Materials and Methods 
Chemicals 
RPMI 1640, William’s E, PBS pH 7.4, trypsin, FBS, non-essential amino acids, 
penicillin/streptomycin, glutamine, HEPES pH 7, liver perfusion medium (LPM) and 
liver digestion medium (LDM) were purchased from Gibco/Invitrogen. All other 
chemicals were obtained from Sigma, unless otherwise specified. 
Cells 
Huh7 cells, a human hepatoma cell line, were cultured in RPMI 1640 medium 
supplemented with 10% FBS, 1% non-essential amino acids, 1% 
penicillin/streptomycin, 1% Glutamine and 1% HEPES, pH 7 and maintained at 
37°C with 5% CO2. Mouse primary hepatocytes were cultured in William’s E 
medium supplemented with 4% FBS and 1% penicillin/streptomycin and 
maintained at 37°C with 5% CO2.  
Mice 
C57BL/6 mice were purchased from Charles River and housed in the facilities of 
the Instituto de Medicina Molecular. All animal experiments were performed in 
strict compliance to the guidelines of our institution´s animal ethics committee and 
the Federation of European Laboratory Animal Science Associations (FELASA). 
Parasites 
GFP- or luciferase-expressing P. berghei ANKA sporozoites were dissected in 
non-supplemented RPMI medium from the salivary glands of infected female A. 
stephensi mosquitoes, bred at Instituto de Medicina Molecular (Lisbon, Portugal), 
prior to being employed for in vitro, ex vivo and in vivo infections [358, 359]. 
Overall in vitro infection by luminescence 
Overall hepatic infection was determined by measuring the luminescence intensity 
in cells infected with a ﬁreﬂy luciferase-expressing P. berghei line, as previously 
described [358]. Brieﬂy, Huh7 cells (1.0x104 per well) or mouse primary 
hepatocytes (2.0x104 per well) were seeded in 96-well plates the day before 
    Chapter IV  Inhibition of Plasmodium liver infection by amino acid supplementation and 
modulation of arginine metabolism 
115 
 
infection. Sporozoite addition (1.0x104 per well) was followed by centrifugation at 
1800xg for 5 minutes and the medium was replaced approximately 2 hours after 
infection by the appropriate medium. Parasite infection load was measured 48 
hours after infection by a bioluminescence assay (Biotium) using a multiplate 
reader Infinite M200 (Tecan). The effect of the different treatments on the viability 
of the cells was assessed by the CellTiter-Blue assay (Promega) according to the 
manufacturer's protocol. 
Isolation and infection of mouse primary hepatocytes 
Mouse primary hepatocytes were isolated using a modified two-step perfusion 
protocol followed by a Percoll purification step [168, 413, 414]. Briefly, mice were 
euthanized by CO2 inhalation and immediately processed for cannulation of the 
portal vein using a 26-gage needle. Upon successful cannulation, the inferior vena 
cava (IVC) was cut to allow fluid to drain. Liver perfusion medium (LPM) was 
perfused at 8–9 mL/min for 10 minutes followed by liver digestion medium (LDM) 
at the same rate. Intermittent clamping of the IVC (3 seconds clamp every 30 
seconds) was performed during LDM perfusion to improve tissue digestion. After 
digestion, the liver was excised and the cells were liberated by tearing and shaking 
of the liver with forceps. The cell suspension was then sequentially filtered through 
a 100 μm and a 70 μm cell strainer and spun at 50xg for 3 min. The cell pellet was 
resuspended in Williams's E Medium with 10% of FBS and carefully overlaid on a 
60% Percoll solution (1:1). The cell suspension was fractionated by centrifugation 
at 750xg for 20 minutes, without break, at 20 °C. Viable hepatocytes deposited in 
the pellet were washed with Williams's E Medium with 10% FBS, spun at 50xg for 
3 minutes and resuspended in complete Williams's E Medium (supplemented with 
4% FBS and 1% penicillin/streptomycin). Hepatocytes were then plated at a 
density of 2.0x104 in 96-well plates and infected 16 hours later with 1.0x104 P. 
berghei sporozoites.  Viability and yield were assessed by trypan blue staining. 
Quantification of the percentage of P. berghei-infected cells and 
parasite development by flow cytometry 
The percentage of infected cells corresponds to the percentage of GFP+ cells 48 
hours after infection with a GFP-expressing parasite line. Intracellular parasite 
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development was assessed by measuring the intensity of the GFP signal of the 
infected cells 48 hours after infection, as previously described [163]. Huh7 cells 
(5.0x104 per well) were seeded in 24-well plates. On the following day, cells were 
infected with 3.0x104 freshly dissected GFP-expressing P. berghei sporozoites. 
Culture medium was replaced by the appropriate medium 2 hours after infection. 
Cells were collected for flow cytometry analysis at 48 hpi and analyzed on a 
Becton Dickinson FACSCalibur. Data acquisition and analysis were carried out 
using the CELLQuest (version 3.1.1 f1, Becton Dickinson) and FlowJo (version 
6.4.7, FlowJo) software packages, respectively. 
In vivo amino acid supplementation 
The drinking water of 4 weeks old male C57BL/6 mice was replaced by sterilized 
water with 2.5% (w/v) L-arginine hydrochloride (Fisher Scientific), 2.5% (w/v) L-
lysine (Sigma), 2.5% (w/v) L-valine (Sigma) or 2.5% (w/v) L-ornithine (Sigma) 
alone, in combinations of 2 amino acids, and a triple combination with Arg, Lys 
and Val. Control mice were provided with sterilized water alone. Mice were 
allowed to drink ad libitum for 4 weeks, unless otherwise indicated, and then were 
infected as described on the following section. 
P. berghei sporozoites in vivo infection and quantification of parasite 
liver load by qPCR 
Mice were infected i.v., through retro-orbital injection, with 1.0x104 P. berghei 
sporozoites. Livers were collected at 45 hpi and homogenized in 3 mL of 
denaturing solution (4 M guanidine thiocyanate; 25 mM sodium citrate pH 7, 
0.5% N-lauroylsarcosine and 0.7% β mercaptoethanol in DEPC-treated water). 
Total liver RNA was extracted with the NZY Total RNA Isolation Kit (NZYTech), 
according to the manufacturer's protocol, and parasite load was quantified by 
qPCR using primers specific to P. berghei 18S RNA (Table 4.1). Mouse Hprt 
expression was used for normalization. 
Immunohistochemical staining of liver sections 
For microscopy, PFA-fixed liver lobes were cut in 50μm sections and were 
incubated in permeabilization/blocking solution (1% BSA, 0,5% Triton-X100 in 
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PBS) at room temperature for 1 hour. Parasites were stained with an anti-UIS4 
antibody (dilution 1:500) for 90 minutes at room temperature, followed by three 
washes with permeabilization/blocking solution. Slices were further incubated in a 
1:300 dilution of anti-goat Alexa-Fluor 568 (Life Technologies) in the presence of a 
1:1000 dilution of Hoechst 33342 (Invitrogen) for nuclei staining. Additional 
washes were carried out with permeabilization/blocking solution and, finally, with 
PBS. Coverslips were mounted on microscope slides with Fluoromount 
(SouthernBiotech). Confocal images were acquired using a Zeiss LSM 710 
confocal microscope. Widefield images for size and number determination were 
acquired in a Leica DM5000B microscope. Images were processed with ImageJ 
software (version 1.47). 
RNA extraction, cDNA synthesis and qPCR 
RNA was extracted from cultured Huh7 cells using the High Pure RNA Isolation kit 
(Roche) according to the manufacturer´s instructions. The amount of RNA in each 
sample was assessed with a NanoDrop® ND‐1000 spectrophotometer.  
Complementary DNA (cDNA) was synthesized from 1 μg of RNA using the Roche 
cDNA synthesis kit, according to the manufacturer´s instructions. The cDNA was 
synthesized employing the following thermocycling parameters: 25°C for 10 
minutes, 55°C for 30 minutes, and 85°C for 5 minutes. qPCR reaction 
was performed in a total volume of 20 µL in a ABI Prism 7500 Fast system 
(Applied Biosystems) using the iTaqTM Universal SYBR® Green kit (BioRad) as 
follows: 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles at 95°C for 15 seconds 
and 60°C for 1 minute, melting stage was done at 95°C for 15 seconds, 60°C for 1 
minute, and 95°C for 30 seconds. Primers for the housekeeping gene 
hypoxanthine-guanine phosphoribosyltransferase (Hprt) were used for 
normalization in all experiments (Table 4.1). The delta-delta CT relative 
quantification method was used for analysis of qPCR results. 
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Table 4.1 - List of primer sequences used. 
Gene forward primer (5’ - 3’) reverse primer (5’ - 3’) 
Pb18S AAGCATTAAATAAAGCGAATACATCCTTAC GGAGATTGGTTTTGACGTTTATGTG 
Hprt TTTGCTGACCTGCTGGATTAC CAAGACATTCTTTCCAGTTAAAGTTG 
Clec4f TGAGTGGAATAAAGAGCCTCCC TCATAGTCCCTAAGCCTCTGGA 
CD68 
AGCTGCCTGACAAGGGACACT AGGAGGACCAGGCCAATGAT 
F4/80 
CCCCAGTGTCCTTACAGAGTG GTGCCCAGAGTGGATGTCT 
 
Statistical Analyses 
Statistical analyses were performed using the GraphPad Prism 5 software. One-
way ANOVA, Two-way ANOVA, Survival Test Gehan-Breslow-Wilcoxon, Mann-
Whitney U test or Unpaired t-test were used for significance of the differences 
observed, as indicated in each figure. ns – not significant, * p < 0.05, ** p < 0.01 
and *** p < 0.001. 
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Results 
Amino acid supplementation impacts Plasmodium hepatic infection in vitro 
and ex vivo 
Having demonstrated that Arg uptake via CAT2A and CAT2B, as well as Arg-
dependent polyamine synthesis, are important for parasite hepatic development, 
we wondered whether Plasmodium infection could be impaired by appropriate 
amino acid supplementation. Lys, Orn and Val have been described as arginase 
inhibitors, suggesting they could be employed to inhibit the polyamine synthesis 
pathway [30, 31]. We also decided to evaluate the effect of Arg on infection 
because it has been described that increasing the amount of available Arg can 
enhance NO production, which was shown to kill malaria parasites in vitro [32-39]. 
We started by culturing Huh7 cells in RPMI and infecting them with luciferase-
expressing P. berghei sporozoites. Two hours later, the medium was replaced by 
Arg-free medium supplemented with either 100 µM Arg, the physiological 
concentration of this amino acid, or 1 mM Arg, the approximate supraphysiological 
concentration of this amino acid present in RPMI. Additional supplementations 
with 20 mM Lys, 20 mM Val or both, which have been shown to completely inhibit 
arginase activity at physiological concentrations of Arg, were also assayed [31]. 
Parasite load was assessed 48 hours after sporozoite addition by luminescence. 
Our data show that supplementation of the medium with Lys or Lys and Val leads 
to a decrease in infection, particularly at physiological levels of Arg (Fig. 4.1A), 
suggesting an impairment of polyamine synthesis in these conditions due to 
arginase inhibition. Notably, infection was not affected when Arg concentration 
was increased in the absence of any additional supplementation. The 
supplementation with Lys or Lys and Val in the presence of supraphysiological 
concentrations of Arg led to a more moderate decrease in infection, possibly due 
to the competition of Arg and Lys for their transporters.   
We then performed a similar experiment under ex vivo conditions, employing 
mouse primary hepatocytes as host cells (Fig. 4.1B). Similarly to what was 
observed for Huh7 cells, supplementation with Lys or with Lys and Val impacted 
Plasmodium infection the most, with a 99% decrease in parasite load in the case 
of supplementation with Lys alone, indicating that arginase inhibition by Lys or by 
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Lys and Val is also effective ex vivo. In agreement with our in vitro data, the 
observed effects are more pronounced if Arg is present at physiological 
concentrations. Finally, we observed a non-statistically significant tendency for 
increased parasite load in the presence of supraphysiological concentrations of 
Arg, which could suggest an increase in polyamine production by hepatocytes in 
this condition. 
In order to further dissect how these amino acid supplementations influence 
hepatic infection, we employed an established flow cytometry-based approach that 
makes use of GFP-expressing P. berghei parasites to determine the number of 
infected cells and to measure parasite development [163]. Supplementation with 
Orn was also included in these experiments due to its reported ability to inhibit 
arginase activity [30]. We observed that, in mouse primary hepatocytes, Lys 
supplementation at physiological concentrations of Arg leads to a 65% reduction in 
the number of infected cells at 48 hpi (Fig. 4.1C). Supplementation with Lys and 
Val also impacts the number of infected cells at 48hpi, especially at physiological 
concentrations of Arg, but the effect is milder than with Lys alone. The number of 
infected cells was not significantly affected in any of the other conditions tested. 
Supplementation with Lys and supplementation with Lys and Val at physiological 
concentrations of Arg were also the most effective at reducing parasite 
development (Fig. 4.1D). On the other hand, supplementation with Orn 
significantly increased parasite development, at both Arg concentrations tested 
(Fig. 4.1D). This is not entirely surprising because even though Orn was described 
to have an inhibitory effect on arginase, it is also the product of Arg degradation by 
this enzyme and the substrate for polyamine synthesis. Plasmodium development 
was also highly enhanced at supraphysiological concentrations of Arg, suggesting 
that higher concentrations of Arg probably stimulate polyamine synthesis in mouse 
primary hepatocytes (Fig. 4.1D).  
Overall, our data show that Plasmodium hepatic infection can be modulated in 
vitro and ex vivo by amino acid supplementation in the cell culture medium. More 
specifically, our results show that supplementation of the cell culture medium with 
Lys, Val, or a combination of both amino acids leads to a marked decrease in 
hepatic cell infection by the malaria parasite. 
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Figure 4.1 - Modulation of hepatic Plasmodium infection by amino acid 
supplementation in vitro (A) and ex vivo (B-D). (A) Huh7 cells were infected with 
luciferase-expressing P. berghei sporozoites and the culture medium was replaced 2 hpi 
by medium supplemented with 20 mM Lys, 20 mM Val or 20 mM Lys and 20 mM Val, at 
physiological (100 µM) or supraphysiological (1 mM) Arg concentrations. Parasite load 
(luminescence) was assessed 48 hpi. Pool of 2 independent experiments. (B) Similar 
experiments were performed in mouse primary hepatocytes. Parasite load (luminescence) 
was assessed 48 hpi. Pool of 3 independent experiments. (C) Mouse primary hepatocytes 
were infected with GFP-expressing sporozoites. Culture medium was replaced 2 hpi with 
the appropriate medium and the percentage of GFP+ cells was quantified by flow 
cytometry 48 hpi. Pool of 3 independent experiments. (D) Parasite development in mouse 
primary hepatocytes was assessed by determining the fluorescence intensity of GFP+ 
cells by flow cytometry at 48 hpi. Pool of 3 independent experiments. For all panels, 
results were normalized to the infection load of the control group with physiological Arg 
concentration (taken as 100% infection) and error bars represent SEM. One-way ANOVA 
with post-test Dunnett. ns - not significant, * p < 0.05, ** p < 0.01 and *** p < 0.001. 
Amino acid supplementation impacts Plasmodium hepatic infection in vivo 
We then sought to investigate whether the observed modulating effect of amino 
acids on Plasmodium infection in vitro and ex vivo could serve to inhibit 
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Plasmodium liver infection in vivo. To this end, the drinking water of C57Bl/6 mice 
was supplemented with Lys, Orn, Val or Lys and Val, in an attempt to inhibit 
arginase activity and, consequently, impair polyamine production in vivo. After 4 
weeks of supplementation, mice were infected with P. berghei sporozoites and the 
parasite liver load was assessed 45 hours later by qPCR. Our data show that 
supplementation with Lys, Val or Lys and Val leads to a small and non-statistically 
significant decrease in Plasmodium liver load (Fig. 4.2A), which indicates that the 
inhibitory effect of these amino acids is not sufficient to significantly impair 
Plasmodium infection in vivo. Orn supplementation did not have any impact on P. 
berghei liver infection. 
It has been described that, upon inhibition of arginase activity, Arg 
supplementation significantly increases NO production by hepatocytes [31]. 
Therefore, we wondered if we could further decrease Plasmodium liver infection 
by adding Arg to the Lys, Orn, Val or Lys and Val supplementations. Indeed, we 
observed that the impact on Plasmodium liver infection is enhanced when Arg is 
combined with these amino acids, with the exception of Val (Fig. 4.2B). Most 
notably, combining Arg with Lys and Val highly impacts Plasmodium infection, 
leading to a 70% decrease on parasite liver load.  
 
Figure 4.2 – Modulation of Plasmodium liver infection by amino acid 
supplementation in vivo. The drinking water of the mice was replaced by sterilized water 
supplemented with 2.5% (w/v) of each amino acid, individually or in combination, and the 
mice were allowed to drink ad libitum for 4 weeks. Mice were infected with P. berghei 
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sporozoites and parasite load was assessed by qPCR at 45 hpi. (A) Parasite liver load 
following infection of mice supplemented with arginase-inhibiting amino acids. (B) Parasite 
liver load following infection of mice supplemented with Lys, Orn, Val, and Lys and Val in 
combination with Arg, to stimulate NO production. Both panels: Pool of 2 to 7 independent 
experiments. Control: n = 34; Lys: n = 15; Orn: n = 10; Val: n = 15; Lys + Val: n = 20; Arg 
+ Lys: n = 8; Arg + Orn: n = 9; Arg + Val: n = 13; Arg + Lys + Val: n = 29 mice. One-way 
ANOVA with post-test Dunnett. ns - not significant and *** p < 0.001. 
In vivo supplementation with Lys, Val and Arg inhibits polyamine synthesis 
and stimulates NO production by hepatocytes 
The results outlined above suggest that in vivo Plasmodium liver infection can be 
modulated by the concurrent inhibition of polyamine synthesis by supplementation 
with Lys and Val and stimulation of NO production by supplementation with Arg. 
To further clarify the effect of the Lys/Val/Arg supplementation on Plasmodium 
liver infection, 50μm liver sections were analyzed by fluorescence microscopy in 
order to compare the number and size of hepatic parasites in control and 
supplemented mice. The results obtained show a relatively small but clearly 
significant reduction on parasite size in the livers of supplemented mice, showing 
that the supplementation employed impairs parasite development (Fig. 4.3A). 
Crucially, however, a drastic reduction in the number of parasites per liver area is 
also observed in supplemented mice, suggesting parasite elimination in the livers 
of these mice (Fig. 4.3B). These results support our hypothesis that Lys and Val 
are inhibiting arginase and, consequently, the production of polyamines required 
for parasite growth, while the extra Arg supplied is being channeled to the 
production of NO, leading to parasite elimination.  
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Figure 4.3 - In vivo dietary supplementation with Lys/Val/Arg decreases the number 
of P. berghei parasites in the liver of C57BL/6 mice. (A) Immunofluorescence 
microscopy quantification of EEF areas in the liver sections of control or supplemented 
mice. Two-tailed Mann-Whitney test. (B) Immunofluorescence microscopy quantification 
of the number of parasites per liver area of control or supplemented mice. Error bars 
represent SD. Unpaired t-test. Both panels: pool of 1 mouse per group from 2 
independent experiments. *** p < 0.001. 
In order to confirm that Lys and Val are indeed inhibiting arginase, a well-known 
arginase inhibitor, Nω-hydroxy-nor-arginine (nor-NOHA) [445-448], was employed 
in combination with Arg supplementation. The drinking water of the mice was 
supplemented as previously described and, in the last week of supplementation, 
200 µL of a 20 mg/kg nor-NOHA solution were injected i.p. every other day, 
starting on day 7 before infection and finishing one day after infection. Our results 
show that the administration of nor-NOHA to mice drinking Arg-supplemented 
water decreases liver parasite load to a very similar extent to that observed upon 
supplementation with Lys, Val and Arg (Fig. 4.4). The fact that the nor-NOHA/Arg 
treatment recapitulated the effect on infection of the Lys/Val/Arg supplementation 
strongly suggests that Lys and Val indeed function as arginase inhibitors in the 
latter supplementation. Additionally, when the Lys/Val/Arg supplementation was 
combined with the administration of nor-NOHA, a cumulative effect on infection 
was not observed, suggesting that Lys and Val might compete with nor-NOHA for 
the active site of the arginase enzyme.  
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Figure 4.4 – Lys and Val function as arginase inhibitors in the Lys/Val/Arg 
supplementation. Mice received five doses of a 20 mg/kg nor-NOHA solution i.p. every 
other day for one week. Parasite load was assessed by qPCR at 45 hpi. One experiment 
with 5 mice per group. Error bars represent SD. One-way ANOVA with post-test Dunnett. 
ns - not significant and ** p < 0.01. 
Having confirmed the role of Lys and Val on the Lys/Val/Arg supplementation, we 
then aimed at confirming that the supplemented Arg is indeed being employed for 
NO production by iNOS. To this end, we used Nω-Nitro-L-arginine methyl ester (L-
NAME), a well-known inhibitor of iNOS [445, 449, 450]. Mice were allowed to drink 
control water or water supplemented with Lys/Val/Arg for 4 weeks and 50 mg/kg of 
L-NAME or saline were injected daily i.p., starting 3 days before and until the day 
of i.v. injection of P. berghei sporozoites. Our results show that administration of L-
NAME to mice on Lys/Val/Arg supplementation abolishes the decrease in parasite 
load observed in the livers of mice supplemented with Lys/Val/Arg and treated with 
saline (Fig. 4.5). This result supports the notion that the supplemented Arg is 
employed to produce NO that contributes to parasite death and elimination. 
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Figure 4.5 – Arg in the Lys/Val/Arg 
supplementation stimulates the iNOS 
pathway. Mice received 4 daily doses of a 
50 mg/kg L-NAME solution i.p., starting 3 
days before infection with P. berghei 
sporozoites. Parasite load was assessed by 
qPCR at 45 hpi. One experiment with 5 mice 
per group. Error bars represent SD. One-
way ANOVA with post-test Dunnett. ns - not 
significant. 
Finally, we sought to identify the cells where the iNOS pathway is stimulated by 
the Lys/Val/Arg supplementation. As described in the general introduction, the liver 
is composed by several types of cells. Among these, Kupffer cells, similarly to 
other phagocytic cells, are the main producers of NO. To investigate their role in 
the mechanism of action of the Lys/Val/Arg supplementation, Kupffer cells were 
depleted in vivo through the administration of clodronate-filled liposomes. Once 
delivered into phagocytic cells using liposomes as vehicles, clodronate is released 
and, because it cannot escape from the cell, it accumulates intracellularly leading 
to cell death [451]. Mice were allowed to drink control water or water 
supplemented with Lys/Val/Arg for 4 weeks and 200 µL of clodronate liposomes or 
PBS liposomes were then injected i.v. 48 hours before infection with P. berghei 
sporozoites. Liver parasite load was assessed by qPCR at 45 hpi. The efficiency 
of the depletion was assessed by quantifying the expression of three specific 
markers: Clec4f, which is specifically expressed by Kupffer cells; CD68, which is a 
marker of the macrophage lineage; and F4/80, which is expressed by mature 
macrophages (Fig. 4.6A). While Kupffer cells were completely eliminated by the 
administration of clodronate liposomes, as shown by the absence of expression of 
Clec4f, some expression of the CD68 and F4/80 markers could be detected, which 
probably results from monocytes and macrophages that were recruited to the liver 
because of Plasmodium infection. Importantly, our liver infection results show that 
depleting liver phagocytes does not abolish the reduction in parasite liver load 
typically observed with the Lys/Val/Arg supplementation (Fig. 4.6B). This result 
suggests that the stimulation of the iNOS pathway by the Lys/Val/Arg 
supplementation occurs in hepatocytes, which is in agreement with a previous 
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report in which immunofluorescence analysis of livers from Brown Norway rats 
infected with P. berghei showed that iNOS expression was found in infected 
hepatocytes, rather than on Kupffer or endothelial cells [452]. 
 
Figure 4.6 – Lys/Val/Arg supplementation stimulates the iNOS pathway of 
hepatocytes. Mice received 200 µL of the PBS- or clodronate-filled liposome formulation 
by i.v. injection 48 hours before infection with P. berghei sporozoites. (A) Assessment of 
hepatic phagocyte depletion by qPCR at 45 hpi. Clec4f is a specific marker for Kupffer 
cells, CD68 is a marker of the macrophage lineage, and F4/80 is a marker of mature 
macrophages. (B) Liver parasite load was assessed by qPCR at 45 hpi. One experiment 
with 5 mice per group. Error bars represent SD. One-way ANOVA with post-test Dunnett. 
ns - not significant and ** p < 0.01. 
Effect of Lys/Val/Arg supplementation for different periods of time on P. 
berghei liver infection  
Finally, we wondered whether the impact of the Lys/Val/Arg supplementation on 
liver P. berghei load would be dependent on the amount of time the mice were 
allowed to drink the supplemented water and, consequently, on the total amount of 
amino acids ingested. To assess this, we infected mice after 1, 2, 3, 4, 5 and 6 
weeks of supplementation and quantified liver parasite load by qPCR at 45 hpi. 
Our results show that the effect on infection is similar for all the supplementation 
periods tested (Fig. 4.7), with no correlation being observed between liver parasite 
liver load and the duration of supplementation. These results suggest that the 
duration of Lys/Val/Arg supplementation can be decreased from 4 weeks in future 
experiments, without any significant loss of impact on the infection impairment 
phenotype.  
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Figure 4.7 – Effect of the length of Lys/Val/Arg supplementation on P. berghei liver 
load. Mice were infected through i.v. injection of P. berghei sporozoites after drinking 
control or supplemented water for 1, 2, 3, 4, 5 and 6 weeks. Liver load was determined by 
qPCR at 45 hpi. Pool of 2-3 independent experiments. n = 12 mice in all groups except 5 
weeks (n = 7) and 6 weeks (n = 10). One-way ANOVA with Dunnett. ** p < 0.01 and *** p 
< 0.001. 
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Discussion 
Dietary amino acid supplementation has been employed in several clinical and 
non-clinical applications. In some instances, amino acid supplementation is used 
solely to balance nutritional needs or deficiencies. In other cases, amino acids or 
their metabolic products can be used to interfere with the function of enzymes or 
receptors, modulating those pathways. 
Lysine can be found as a dietary supplement in the form of L-lysine-HCl. This 
amino acid has an anxiolytic action through its effects on serotonin receptors in the 
intestinal tract, and through serotonin regulation in the amygdale [453-455]. Lysine 
supplementation exerts positive effects in patients with ornithine aminotransferase 
(OAT) deficiency [456, 457], with lysinuric protein intolerance (LPI) [458-461], and 
has been proposed for hyperammonaemia-hyperornithinaemia-homocitrullinuria 
(HHH) syndrome treatment, but its benefits are unclear [462]. On the other hand, 
this amino acid should be avoided in cases of glutaric aciduria type I (GA-I) [463]. 
High doses of lysine have been associated with some side-effects, such as 
abdominal cramps and diarrhea [458, 459]. 
Valine is an essential, branched-chain amino acid (BCAA) and is always used in 
combination with leucine and isoleucine, the other two BCAAs. Dietary BCAA 
supplementation has been suggested to aid in the recovery of burn victims [464] 
and has beneficial effects before and after exercise for decreasing exercise-
induced muscle damage and promoting muscle-protein synthesis [465, 466]. 
Valine supplementation, usually in combination with isoleucine, is also used in 
some aminoacidopathies, such as methylmalonic acidemia (MMA) [467], propionic 
acidemia (PA) [468] and maple syrup urine disease (MSUD) [469-471], to 
ameliorate the effects of the dietary protein restriction imposed to these patients. 
Arginine is becoming an increasingly popular ingredient in dietary supplements 
and is generally recognized as safe at intakes of up to 20 g/day [472]. As a 
precursor of nitric oxide (NO), arginine supplementation is effective in the 
treatment of some conditions where vasodilation is required, such as hypertension 
[473, 474], erectile dysfunction [475, 476] and high blood pressure as part of pre-
eclampsia in pregnant women [477]. Supplementation with this amino acid is 
employed for the treatment of some aminoacidopathies, such as GA-I [478, 479], 
homocystinuria (HCU) [480, 481], LPI [482-485] and HHH syndrome [462, 486-
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488]. However, it should be avoided in cases of OAT and guanidinoacetate 
methyltransferase (GAMT) deficiencies [489], worsening such conditions. 
Interestingly, arginine was also shown to stimulate the secretion of growth 
hormone when administered i.v. [490, 491]. 
Arg supplements are the only amino acid-based supplementation that has been 
employed in malaria infection. Arg administration was reported to increase the 
circulating levels of Arg in Plasmodium-infected mice, leading to enhanced NO 
production [32, 33]. Yet, while in one of these studies Arg supplementation 
significantly decreased parasitaemia and improved survival of P. yoelii-infected 
Balb/c mice [33], none of these effects were observed in P. berghei-infected 
C57BL/6 mice [32]. In individuals with moderately severe malaria, Arg infusion was 
shown to be safe, and effectively increased plasma Arg concentrations and NO 
production, leading to improved endothelial function [441, 442]. 
Having established an important role for Arg metabolism and polyamine 
production during Plasmodium hepatic development in the previous chapter, we 
wondered whether we could employ adequate amino acid supplementations as an 
alternative, drugless approach to inhibit Plasmodium liver infection. We decided to 
study the effect of supplementation with Lys, Orn and Val due to their described 
role as arginase inhibitors [30, 31]. Furthermore, we employed Arg 
supplementation to increase the amount of Arg available in circulation and 
enhance NO production [32-39]. 
Both our in vitro and ex vivo data showed that supplementing the medium with Lys 
or Lys and Val, at physiological concentrations of Arg, markedly impacts P. 
berghei infection (Fig. 4.1A, B). The observed decrease in parasite load is mainly 
due to an impaired P. berghei development (Fig. 4.1D), which is consistent with an 
inhibition of polyamine synthesis. In fact, a previous report showed that these 
concentrations of Lys or Val almost completely abolish arginase activity in rat 
hepatocytes [31]. As human arginase 1 and arginase 2 inhibitors have also been 
shown to inhibit Plasmodium arginase [25, 492], it is possible that Lys and Val are 
also hindering polyamine production by the parasite itself. Interestingly, Arg 
supplementation in mouse primary hepatocytes highly increases parasite 
development, suggesting that, in these cells, the extra Arg might be used for 
polyamine production. Supporting this hypothesis is the fact that hepatocytes 
abundantly express arginase 1 and that, in mammalian cells, Arg is mainly 
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catabolized by the arginase pathway rather than by the iNOS pathway [407, 493, 
494]. 
We then evaluated if we would be able to modulate Plasmodium liver infection in 
vivo through supplementation of the drinking water of mice. Our data shows that 
supplementation with Lys, Val or Lys and Val leads to a small and non-statistically 
significant decrease in Plasmodium liver load (Fig. 4.2A), which indicates that 
supplying the mice with these amino acids is not sufficient to impair Plasmodium 
infection in vivo. This can be explained by a lower amount of amino acids that 
actually reach the hepatocytes. The bioavailability of amino acids provided orally 
might be lower than that achieved by cell culture medium supplementation, and 
therefore their effective concentration in hepatocytes might not be enough to 
inhibit arginase activity. Alternatively, it might be that inhibiting polyamine 
synthesis alone in vivo is not sufficient to impact Plasmodium infection. In fact, α-
difluoromethylornithine (DFMO) has been shown to be more effective at inhibiting 
P. falciparum AdoMetDC/ODC enzyme than the mammalian ODC; however, it has 
only a cytostatic effect on the parasite, slowing down parasite growth but not 
leading to parasite death [340].  
It has been described that, upon inhibition of arginase activity, Arg 
supplementation significantly increases NO production by hepatocytes [31]. 
Therefore, in order to try to further impact Plasmodium infection, we decided to 
add Arg to Lys, Orn, Val, and Lys and Val supplementations. We observed that 
combining Arg with Lys and Val leads to a striking decrease in Plasmodium liver 
infection (Fig 4.2B), which is due to an impairment in parasite development (Fig. 
4.3A) and to a decrease in the number of P. berghei-infected hepatocytes (Fig. 
4.3B). To confirm the inhibitory effect of Lys and Val in the Lys/Val/Arg 
supplementation, a similar effect on Plasmodium liver infection was recapitulated 
by combining a well-known arginase inhibitor, nor-NOHA, with Arg alone (Fig. 4.4). 
Additionally, the administration of an iNOS inhibitor following Lys/Val/Arg 
supplementation reverted the characteristic decrease in P. berghei liver load, 
directly implicating iNOS-mediated NO production on infection inhibition (Fig. 4.5). 
Finally, we excluded Kupffer cells and other phagocytic cells as the producers of 
NO, as the depletion of liver phagocytic cells did not abolish the reduction obtained 
with the Lys/Val/Arg supplementation (Fig. 4.6), suggesting that NO production 
might be stimulated in hepatocytes themselves. These results are in agreement 
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with a previous report in Brown Norway rats infected with P. berghei that showed 
that iNOS expression was found in infected hepatocytes, not Kupffer or endothelial 
cells [452]. However, it is possible that NO production by hepatocytes is being 
stimulated by cytokines produced by immune cells. This hypothesis is supported 
by our ex vivo data that shows that supplementation with Lys and Val in the 
presence of supraphysiological concentrations of Arg leads to only 20% decrease 
in the number of infected hepatocytes, while we observed a 80% reduction with 
the Lys/Val/Arg supplementation in vivo. Future experiments will aim at identifying 
the immune cells and cytokines involved in the stimulation of NO production by 
hepatocytes. 
Overall, our results support a model in which the Lys/Val/Arg supplementation 
blocks polyamine synthesis by inhibiting arginase activity and, concurrently, 
stimulates NO production by iNOS, contributing to parasite elimination (Fig. 4.8). 
Adequate amino acid supplementation may therefore constitute a novel, drugless 
approach to modulate liver-stage of Plasmodium infection, which could be 
employed as a prophylactic strategy against malaria. 
 
Figure 4.8 – Model of the Lys/Val/Arg supplementation-mediated modulation of Arg 
metabolism in Plasmodium-infected hepatocytes. (A) In a normal infection, the Arg 
taken up via CAT2A and CAT2B by the infected hepatocyte is used for the production of 
polyamines, both by the host cell and by the parasite, contributing to parasite 
development. (B) Upon Lys/Val/Arg supplementation, Lys and Val inhibit arginase and, 
therefore, block polyamine synthesis. The extra arginine provided is then channeled to the 
NO production pathway, leading to parasite killing. 
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General Discussion 
Plasmodium parasites are obligate intracellular pathogens within their mammalian 
hosts, infecting and replicating inside hepatocytes during the asymptomatic stage 
of the infection and, later, inside red blood cells (RBCs), originating the symptoms 
of malaria. Despite its asymptomatic nature, the intrahepatic stage of infection is 
an obligatory step of Plasmodium life cycle and involves a massive multiplication 
of each parasite, with 104- to 105-fold replication of its genome, while the 
erythrocytic stage typically only involves 4 rounds of replication [5, 6, 495]. This 
remarkable cellular and genomic expansion inside hepatocytes is possible 
because the parasite takes advantage of the extremely metabolite- and nutrient-
rich environment of these cells. Plasmodium parasites scavenge nutrients from the 
host hepatocyte both by passive diffusion through pores in the parasitophorous 
vacuole membrane (PVM) and by active processes, such as those that take up 
glucose, fatty acids and cholesterol [7-10]. Parasite utilization of host cell nutrients 
makes them unavailable for the host cell and leads to a metabolic adaptation of 
the latter in order to ensure its own survival. Indeed, microarrays of P. berghei-
infected hepatoma cells and P. yoelii-infected mouse hepatocytes revealed that 
the transcriptome of an infected cell favors biosynthetic pathways including 
carbohydrate and fatty acid metabolism [11]. 
Several nutrients derived by the parasite from the host hepatocyte have already 
been identified. These include phosphatidylcholine [228], phosphatidylinositol 3,5-
bisphosphate (PI(3,5)P2) [229-231], iron [232], fatty acids [9], cholesterol [10] and 
glucose [7, 8, 322]. With this work, we deepened our understanding on the role of 
glucose for Plasmodium liver-stage development and added another essential 
nutrient to this list, the amino acid L-arginine (Arg). 
Glucose is the main carbon source for Plasmodium blood stage parasites [296, 
297]. Therefore, it is not surprising that it plays a similar role in the liver stage of 
infection. However, while the glucose consumption rate of an infected RBC is 
estimated to be up to 100-fold higher than that of a non-infected RBC [297, 298], 
our results show a modest 2-fold increase in glucose uptake by P. berghei-infected 
hepatoma cells. As these cells are rapidly proliferating cancer cells, they already 
have a very high glucose uptake and, therefore, only need to double their glucose 
uptake to meet the needs of the dividing parasite and their own. Interestingly, we 
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were able to link the increased glucose uptake by infected cells to parasite 
replication because the former is only observed from 30 hpi onwards, when 
schizogony is occurring, and is not observed in cells containing non-developing 
parasites. 
We also showed that glucose transporter 1 (GLUT1), which is the most abundant 
glucose transporter on the RBC membrane [315, 316], is also responsible for the 
increased glucose uptake by infected hepatoma cells. The extensive parasite 
replication inside these cells promotes the depletion of intracellular glucose levels, 
ultimately leading to a phosphoinositide 3-kinase (PI3K)-independent translocation 
of GLUT1 to the plasma membrane to re-establish the energy status of the cell. 
GLUT2 is the major glucose transporter in hepatocytes, being involved in both 
glucose uptake and release. On the other hand, despite being expressed by all 
hepatocytes, GLUT1 is only localized at the membrane of perivenous hepatocytes 
[12, 349, 350, 390, 391]. Nevertheless, we showed that in vivo chemical inhibition 
of GLUT1-mediated glucose uptake has a substantial impact on the number of P. 
berghei-infected hepatocytes. There are two possible explanations for this 
observation. The first is that the inhibitor will only inhibit GLUT1-mediated glucose 
on perivenous hepatocytes and, therefore, will only have an effect on the parasites 
inside these hepatocytes. In a liver cell plate, which contains 15–25 hepatocytes, 
only around 10% are hypoxic, perivenous hepatocytes and have membranar 
GLUT1 [245]. However, it has been reported that the survival of parasites inside 
hypoxic hepatocytes is improved up to three times in comparison with non-hypoxic 
hepatocytes and that these parasites also develop considerably more than the 
ones in non-hypoxic conditions [394]. Thus, inhibition of GLUT1-mediated glucose 
uptake by these hepatocytes only would be enough to explain the 40% reduction 
in liver parasite load observed. Another possible explanation stems from our in 
vitro results that show that Plasmodium development inside hepatoma cells leads 
to GLUT1 translocation to the plasma membrane. After reaching the liver, 
sporozoites invade hepatocytes randomly, without preference for periportal or 
perivenous hepatocytes [496]. This means that a significant proportion of parasites 
will invade periportal hepatocytes, which have GLUT2 at the membrane but also 
express GLUT1, although it is kept in their endosomal compartments. The 
replication of the parasite inside these hepatocytes could lead to a depletion of the 
cellular glucose pool and trigger the translocation of GLUT1 to the plasma 
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membrane, as has been described in other cell types [497-499]. This would 
increase the percentage of infected hepatocytes with GLUT1 at the plasma 
membrane and, therefore, the percentage of cells targeted by the inhibitor. 
Overall, our results establish glucose as an essential nutrient for Plasmodium 
intrahepatic development and survival in vitro and in vivo, and unveil GLUT1 as an 
important player in hepatic infection by providing the glucose necessary for both 
the parasite and the host cell. 
Whereas glucose appears to be key for energy production by Plasmodium-
infected cells, amino acids are also likely to play a pivotal role during the parasite’s 
intracellular development process. Thus, besides glucose-transporting molecules, 
several amino acid transporters were also included in our RNAi study aimed at 
identifying host cell membrane transporters with a role during the liver stage of the 
parasite’s life cycle. This approach led to the identification of the CAT2 transporter 
of Arg, a precursor of the biosynthesis of polyamines, which constitute key 
nutrients for replicating cells. 
Polyamines are synthesized from Arg by all cells but occur in particularly high 
concentrations in rapidly proliferating cells, such as cancer cells and protozoan 
parasites [323-325]. In the case of Plasmodium parasites, polyamines account for 
14% of the total metabolome of isolated intraerythrocytic parasites and their 
availability was proven essential for the parasite’s survival and rapid proliferation 
[328, 329, 334]. As Plasmodium parasites are incapable of amino acid 
biosynthesis, they were shown to rely on hemoglobin catabolism and amino acid 
uptake from the host cell [305, 421] and to have developed a mechanism to 
respond to low amino acid availability by entering into a hibernation state [500]. 
Arginine, the precursor of polyamines, was shown to be depleted to almost 
undetectable levels from the extracellular medium during the erythrocytic 
development of Plasmodium parasites, with the concomitant accumulation of its 
product, ornithine, due to the action of the parasite’s arginase [24]. In fact, 
hypoargininemia is one of the hallmarks of malaria pathogenesis and several 
clinical studies have demonstrated a correlation between reduced plasma arginine 
levels and advanced malaria in malaria patients [410, 441, 501]. However, the 
growth rate of blood stage Plasmodium parasites in vitro is not affected by the 
absence of Arg in the culture medium [421]. Additionally, the vast majority of the 
ornithine is excreted into the extracellular environment, suggesting that the 
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parasite might deplete the host arginine pool in order to decrease NO production 
by the host’s iNOS and, therefore, avoid being eliminated [24]. 
Our results show that arginine uptake and metabolism are also pivotal for 
Plasmodium liver stage development. Arg uptake into cells is mainly mediated by 
the cationic amino acid transporter (CAT) family of proteins, a subfamily of the 
solute carrier family 7 (SLC7) [18, 19]. The four members of the CAT family are 
the nearly-ubiquitous CAT1, encoded by SLC7A1, the two products of SLC7A2, 
the gene that encodes through alternative splicing the low affinity CAT2A and the 
high affinity CAT2B transporters, the brain-specific CAT3, encoded by SLC7A3, 
and CAT4, encoded by SLC7A4, whose function is still unknown [19, 403-406]. In 
hepatocytes, basal Arg uptake is mainly mediated by the low-affinity CAT2A 
transporter, but they are also able to express the cytokine-inducible, high affinity 
variant CAT2B [19, 403-406]. The knockdown of the expression of the SLC7A2 
gene decreases the amount of Arg taken up by hepatoma cells by around 50%. 
When these cells are infected with P. berghei sporozoites, parasite development is 
significantly decreased, suggesting that the reduced Arg availability in these cells 
is impairing the normal parasite development. In agreement with these data, when 
Arg concentration in the culture medium is decreased or a competitor for Arg 
transport is employed, P. berghei infection is significantly decreased. However, 
and contrarily to what was reported for blood stage infection [421], our results 
suggest that P. berghei-infected hepatic cells do not uptake more Arg than non-
infected cells. This is in agreement with the fact that the expression of CAT2A and 
CAT2B is not increased in infected cells relative to non-infected cells. Altogether, 
these results suggest that the amount of Arg that is normally taken up by hepatic 
cells is sufficient to sustain the polyamine needs of both the parasite and the host 
cell, so there is no need to increase the expression of the transporters and Arg 
uptake. 
Once inside hepatocytes, which abundantly express arginase 1, Arg is mainly 
catabolized by the arginase pathway rather than the iNOS pathway [407, 493, 
494]. This seems to also be true for infected hepatocytes as neither inhibition nor 
stimulation of NO production via iNOS appear to have an impact on P. berghei 
hepatic infection. As arginase and iNOS compete for the same substrate, if most 
Arg is being metabolized by the arginase pathway, it becomes unavailable for 
iNOS thereby limiting NO production [24, 25, 502]. Several pathogens, including 
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Trypanosoma spp., Leishmania spp., Toxoplasma gondii, Shistosoma mansoni, 
Candida albicans, and Helicobacter pylori ([416-419, 503] and reviewed in [22, 
504]), take advantage of this competition to limit NO production and escape 
elimination. 
In an infected hepatocyte, Arg can be converted into polyamines by both the host 
cell and the parasite pathways. Our results show that the RNAi-mediated 
impairment of the host cell polyamine synthesis pathway alone has no effect on 
Plasmodium hepatic infection. Only when both pathways are inhibited 
simultaneously, by employing a well-known host’s ODC and parasite’s 
AdoMetDC/ODC inhibitor, is P. berghei development significantly impaired. Thus, 
it seems that the parasite relies preferentially on its own polyamine synthesis 
pathway rather than on the host’s. Interestingly, an arginase-KO P. berghei 
parasite, whose polyamine synthesis pathway is compromised, displays a clear 
bimodal behavior in terms of its hepatic infectivity. Either most of the parasites 
perish inside hepatocytes or, through some unknown compensatory mechanism, 
they overcome the lack of this pathway and are able to survive and develop 
normally. 
In the blood stage of Plasmodium infection, arginase-KO parasites exhibit a slight 
delay in ascending parasitaemia but eventually develop high blood parasitaemias 
comparable to those of WT parasites, and exhibit no difference in the onset of 
morbidity [24]. A possible explanation for this blood stage behavior is that 
arginase-KO parasites may acquire sufficient amounts of ornithine and polyamines 
either from the plasma or through the activity of the host cell arginase [24, 328, 
329]. Indeed, both putrescine and spermidine have been shown to be taken up by 
the parasite via a saturable process, dependent on pH and temperature but 
independent of extracellular Na+ concentration, with competition between different 
polyamines, the ornithine precursor, and other basic amino acids [346]. 
Interestingly, it has been reported that P. falciparum encodes 6 putative amino 
acid transporters; among them, three are members of the amino acid/auxin 
permease (AAAP) family and mediate H+- and/or Na+-dependent amino acid 
transport [505]. It is possible that one or more of these transporters might be 
involved in the compensatory mechanism proposed for the arginase-KO parasite 
during the blood stage of infection and be responsible for the bimodal behavior 
displayed by the parasite in the liver stage of infection. 
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Overall, we have established the crucial role of Arg uptake and metabolism for 
Plasmodium liver-stage development, which can be explored to find new 
prophylactic approaches for the control of Plasmodium infection. Most commonly, 
Arg metabolism and, more specifically, polyamine synthesis can be modulated by 
interfering with enzymatic activity through the use of appropriate inhibitors [324, 
329, 424]. α-difluoromethylornithine (DFMO), an irreversible ODC inhibitor, is the 
most widely studied inhibitor of polyamine metabolism and was approved by the 
Food and Drug Administration (FDA) for the treatment of African trypanosomiasis 
[424]. However, DFMO was shown to only have a cytostatic effect on P. 
falciparum proliferation in vitro, and is not curative of in vivo P. berghei infection 
[26, 328, 340, 341]. Additionally, our results show that inhibition of ODC by DFMO 
decreases parasite development but does not lead to parasite elimination. 
Our results suggest that inhibition of polyamine synthesis alone is not sufficient to 
eliminate Plasmodium parasites. However, combining the inhibition of polyamine 
synthesis with the stimulation of NO production might constitute an efficacious 
strategy to impair hepatic infection. Ideally this would be achieved without 
resorting to the use of drugs or drug-like compounds. We thus wondered whether 
appropriate amino acid supplementation could be employed to suppress liver 
stage infection by the Plasmodium parasite, as such an approach might constitute 
an appealing prophylactic strategy. 
Dietary amino acid supplementation is commonly employed to balance nutritional 
needs or deficiencies, especially in individuals with metabolic diseases that require 
a protein restrictive diet. Amino acids or their metabolic products can also be used 
to interfere with the function of enzymes or receptors, modulating the pathways in 
which they intervene. Arg metabolism has been shown to be regulated by dietary 
amino acids, such as Lys, Orn and Val, which have been described as arginase 
inhibitors [30, 31, 407]. On the other hand, Arg administration leads to enhanced 
NO production in Plasmodium-infected mice and malaria patients [32, 33, 441, 
442]. Our results show that a Lys/Val/Arg supplementation is effective at blocking 
polyamine synthesis through the inhibition of arginase activity, while 
simultaneously stimulating NO production by iNOS, contributing to parasite 
elimination by hepatocytes. Adequate amino acid supplementation may therefore 
constitute a novel, drugless approach to modulate liver-stage of Plasmodium 
infection, which could be employed as a prophylactic strategy against malaria. 
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In this dissertation, we established the pivotal role of glucose and Arg uptake by 
GLUT1 and CAT2 transporters, respectively, and of their downstream metabolic 
pathways in Plasmodium infection of hepatic cells. Additionally, we explored 
dietary amino acid supplementation as a new drugless approach to modulate 
Plasmodium development and survival during the hepatic stage of the parasite’s 
life cycle. Our results provide new insights into the host-parasite interactions at 
play during liver-stage infection by malaria parasites and pave the way for the 
development of novel intervention strategies against this disease. 
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Miles P. Davenport,b Miguel Prudêncioa
Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugala; Centre for Vascular Research, UNSW Australia, Sydney, NSW, Australiab
Following transmission through a mosquito bite to the mammalian host, Plasmodium parasites first invade and replicate inside
hepatocytes before infecting erythrocytes and causing malaria. The mechanisms limiting Plasmodium reinfections in humans
living in regions of malaria endemicity have mainly been explored by studying the resistance induced by the blood stage of infec-
tion. However, epidemiologic studies have suggested that in high-transmission areas, preerythrocytic stages also activate host
resistance to reinfection. This, along with the recent discovery that liver infections trigger a specific and effective type I inter-
feron (IFN) response, prompted us to hypothesize that this pre-erythrocyte-stage-induced resistance is linked to liver innate im-
munity. Here, we combined experimental approaches andmathematical modeling to recapitulate field studies and understand
the molecular basis behind such resistance. We present a newly established mouse reinfectionmodel and demonstrate that ro-
dent malaria liver-stage infection inhibits reinfection. This protection relies on the activation of innate immunity and involves
the type I IFN response and the antimicrobial cytokine gamma IFN (IFN-). Importantly, mathematical simulations indicate
that the predictions based on our experimental murine reinfectionmodel fit available epidemiological data. Overall, our study
revealed that liver-stage-induced innate immunity may contribute to the preerythrocytic resistance observed in humans in re-
gions of malaria hyperendemicity.
Malaria accounts for over half a million deaths per year and isthus the most prevalent parasitic human disease worldwide
(1). The disease is caused by an intracellular protozoan parasite of
the genus Plasmodium that infects multiple hosts, such as Anoph-
elesmosquitoes andhumans and othermammalians (2). Infection
begins with a bite of a female mosquito that injects a few Plasmo-
dium sporozoites, which represent themosquito-transmitted par-
asite form, into the skin of the mammalian host. After migrating
through skin cells (3), sporozoites enter the bloodstream and are
then rapidly and specifically retained in the liver sinusoids. Sporo-
zoites then cross the sinusoidal barrier (4) and traverse several
liver cells until individual parasites invade a final hepatocyte with
the formation of a parasitophorous vacuole (5). Inside this vacu-
olar niche, sporozoites asymptomatically develop and replicate
into thousands of erythrocyte-infective parasites, termedmerozo-
ites (6). Finally, merozoites are released into the bloodstream and
rapidly infect erythrocytes, initiating the blood stage and the clin-
ical phase of infection (7).
Malaria reinfections are common, especially in regions of high
malaria transmission. Plasmodium parasites present an extraordi-
narily high rate of polymorphism; consequently, the host can be
reinfected by different parasites that repeatedly escape the im-
mune response (8). Therefore, efficient immunity to reinfection
in one individual is obtained only after many years of facing re-
current infections with many different parasite strains (9, 10).
Most of our knowledge of immune defense mechanisms acting
against Plasmodium reinfection relies on studies focusing on the
blood stage of infection. These studies have revealed that host
resistance to blood-stage infection is complex and mediated by
both the innate immune system, which limits the initial growth of
all blood-stage parasites, irrespective of Plasmodium species or
strain, and adaptive immunity, which is genotype specific (re-
viewed in references 9, 10, and 11). In addition, recent studies have
suggested that high levels of blood-stage parasitemia protect the
host from secondary or superinfection, by inhibiting liver-stage
reinfection (12, 13). In mice, this increased resistance seems to be
mediated by the iron-regulatory hormone hepcidin, which im-
pairs parasite growth by restricting iron availability in the liver
(12). Thus, antimalarial host responses induced during the eryth-
rocytic stage of infection are effective against reinfection of both
the blood and the liver.
Interestingly, epidemiological and mathematical modeling
studies have also suggested that, in addition to these blood-stage-
induced defenses, resistance mechanisms must exist which are
triggered by infection stages that precede blood-stage infection
(14–16). However, the immune responses raised during these ini-
tial stages of infection remain poorly explored (reviewed in refer-
ences 17 and 18). Recently, we have shown that Plasmodium liver-
stage parasites are sensed by the host and specifically activate a
type I interferon (IFN) response (19). This response controls par-
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asite load during this first obligatory step of infection and medi-
ates host resistance when experimentally induced prior to infec-
tion (19). In regions of hyperendemicity, the entomological
inoculation rate (EIR), which indicates the number of infective
mosquito bites within a given time interval (20), can reach several
hundred infective bites per person per year (21–24). Since liver-
stage infection lasts 7 to 13 days in humans (25, 26), a person living
in these regions of hyperendemicity is likely to be reinfected while
parasites from a previous infection are still in the liver. On the
basis of our recent results, we speculated that this reinfection is less
efficient than the primary infection as it occurs in the context of a
type I IFN response triggered by the first infection and that this
effect could participate in the resistance mechanism observed in
epidemiological studies.
To test this hypothesis, we have established a mouse reinfec-
tion model. We show that innate immunity induced by a primary
Plasmodium berghei liver-stage infection contributes significantly
to host resistance to reinfection, not only after intravenous injections
of high sporozoite doses but, crucially, also following mosquito bite
infections. Our data indicate that the mechanisms of inhibition of a
secondary infection depend on the activation of type I IFN signaling
andgammaIFN(IFN-) expression.Last,weutilizedamathematical
modeling approach tounderstandwhether the resistanceobserved in
themurinemodelmight explain epidemiological observations of the
rates of P. falciparum infection. We showed that the host resistance
observed in our murine model is consistent with the observed
changes in infection rates seen in epidemiological studies of human
infection with P. falciparum.
MATERIALS AND METHODS
Supplemental experimental information is available in the supplemental
material.
Ethics statement. All in vivo protocols were approved by the internal
animal care committee of the Instituto de Medicina Molecular (IMM)
and performed according to national and European regulations (project
license AEC_2010_034_MP_Rdt_General).
Mice. Mice were housed in the facilities of the IMM. C57BL/6J wild-
type (WT) mice were purchased from Charles River Breeding Laborato-
ries. Ifnar1/ mice were bred in specific-pathogen-free facilities at the
InstitutoGulbenkian deCiência. Ifn-/micewere purchased fromThe
Jackson Laboratories (27). Mice used in this work were in the C57BL/6J
background and had been backcrossed at least 10 times.
Parasite strains, liver infection, and blood parasitemia. Green fluo-
rescent protein (GFP)-expressing P. berghei ANKA (28) sporozoites were
obtained by dissection ofAnopheles stephensi-infectedmosquitoes bred at
the IMM.Micewere injected intravenously with 50,000 sporozoites.Mos-
quito bite infection was performed with 10 mosquitoes per mouse. Para-
site liver load was quantified by quantitative real-time PCR (qRT-PCR) in
extracts of total livers. The presence of erythrocyte-stage parasites was
monitored by flow cytometry. Measurements were performed on a
Fortessa (BD Biosciences) flow cytometer. A drop of blood in 1 phos-
phate-buffered saline (PBS) was used tomeasure the blood parasitemia of
GFP-expressing parasites. Flow cytometry data were analyzed using
FlowJo software (version 9.0.2, Tree Star Inc., OR, USA).
RNA isolation of total livers and qRT-PCR quantification. For
mouse liver RNA extraction, whole livers were homogenized in 3 ml de-
naturing solution (4Mguanidine thiocyanate, 25mMsodium citrate [pH
7], 0.5%N-lauroylsarcosine, 0.7%mercaptoethanol, diethyl pyrocarbon-
ate [DEPC]-treated water). RNA was extracted using an RNeasy minikit
(Qiagen). cDNA was synthesized using a Transcriptor first-strand cDNA
synthesis kit (Roche). Gene expression analysis was performed using Bio-
Rad kits. For analysis, the expression levels of all target genes were nor-
malized against the hypoxanthine guanine phosphoribosyltransferase
(Hprt) housekeeping gene using the delta threshold cycle (CT) method.
Changes in gene expression valueswere calculated using the Pfafflmethod
(29). We used the following oligonucleotide primer pairs to detect target
gene transcripts: Hprt-F (CATTATGCCGAGGATTTGGA) and Hprt-R
(AATCCAGCAGGTCAGCAAAG), Ifit1-F (CCTTTACAGCAACCATG
GGAGA) and Ifit1-R (GCAGCTTCCATGTGAAGTGAC), Ifi44-F (TCG
ATTCCATGAAACCAATCAC) and Ifi44-R (CAAATGCAGAATGCCAT
GTTTT), Usp18-F (CGTGCTTGAGAGGGTCATTTG) and Usp18-R (G
GTCGGGAGTCCACAACTTC), Ifit3-F (CTGAACTGCTCAGCCCA
CAC) and Ifit3-R (TGGACATACTTCCTTCCCTGA), Irf7-F (CTTCAG
CACTTTCTTCCGAGA) and Irf7-R (TGTAGTGTGGTGACCCTTGC),
Ifn--F (CACACTGCATCTTGGCTTTG) and Ifn--R (TCTGGCTCTG
CAGGATTTTC), and P. berghei 18S rRNA-F (AAGCATTAAATAAAGC
GAATACATCCTTAC) and P. berghei 18S rRNA-R (GGAGATTGGTTT
TGACGTTTATGTG).
Statistical analyses.Data are expressed as means standard errors of
the means (SEM). Statistically significant differences between two differ-
ent groups were analyzed using the Mann-Whitney test. Statistical tests
involving three groups or more were analyzed using the nonparametric
Kruskal-Wallis test with posterior Dunn’s multiple comparison tests. Re-
sults with a P value of 0.05 were considered statistically significant.
Significances are represented in the figures as follows: *, P 0.05; **, P
0.01; ***, P 0.001. All statistic tests were performed using Graph Prism
5.0 software.
Mathematical simulations. (i) Estimating themaximum“blocking”
of the liver stage. In order to estimate the extent to which prior liver-stage
infection is able to block subsequent liver stages, we analyzed the data
from our murine experiments. There are two ways to estimate the level of
blocking. First, we might consider simply the reduction in liver infection
load in the second infection (Fig. 1B and C). However, this may underes-
timate the reduction in subsequent blood-stage infection because, al-
though liver cells may contain Plasmodium DNA, this may not result in
fully infectiousmerozoites. Therefore, themost direct way to estimate the
reduction in release of infectious merozoites from the liver is to estimate
the delay in infection dynamics in a second infection compared to a first
infection (Fig. 2B). In order to estimate the initial number of infectious
merozoites that were released from liver, we fitted the logistic growth
function to the mean level of parasitemia observed in the experimental
data. This function is a good approximation of the growth of the concen-
tration of parasites over time (threshold cycle [CT]) in blood until the
concentration reaches a maximal value:
C(t)
MPert
M P(ert 1)
(1)
where P is the initial concentration of parasites in blood,M is the asymp-
totic maximum of the concentration of parasites in blood, and r is the
initial growth rate of parasites. We used GraphPad Prism 6.04 (GraphPad
Software Inc. La Jolla, CA), to fit function 1 to the mean of experimental
data. We assumed that the only parameter that is different in groups with
single and repeated infections is the initial concentration of parasites (P);
let us call the concentrations P1 and P2, respectively. Parameters M and r
are shared between groups. The graphs of the best-fit function (equation
1) to the data are shown in Fig. S2A in the supplemental material, and the
best-fit parameters are as follows: P1 2.28% 10
5 infected red blood
cells (RBC), P2 9.1% 10
7 infected RBC,M 3.296% infected RBC,
and r  2.345 parasites per day. Comparing P1 and P2, we find the con-
centration of merozoites released from the liver after reinfection is ap-
proximately 25-fold less than after the single infection.
(ii) Deterministic model of the impact of the innate liver-stage im-
munity on the force of infection.Wedeveloped amathematicalmodel in
order to investigate whether the effects of innate immunity blocking sub-
sequent liver-stage infections could contribute to the relationship be-
tween the entomological inoculation rate (EIR) and the force of infection
(FOI) that was observed in field studies. In the absence of induced resis-
tance, we would expect that the proportion of infected bites reaching the
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FIG 1 Role of type I IFN and IFN- in a P. berghei liver-stage reinfection model. (A) Schematic representation of the reinfection protocol. Mice were injected
intravenously (i.v.) with 50,000 P. berghei sporozoites or an equivalent amount of noninfected (NI) salivary glands on day 0. Both groups of animals were treated
with 700 	g of chloroquine (CQ) on days 2, 3, and 4 after injection. On day 3, mice were reinfected by the i.v. injection of 50,000 P. berghei sporozoites.
Alternatively, mice were subjected to bites of infected Anophelesmosquitoes or an equivalent number of noninfected mosquitoes, treated with CQ on days 2, 3,
and 4 after inoculation, and infected or reinfected on day 3 by mosquito bite. The amount of parasite 18S ribosomal small-subunit transcripts (18S rRNA),
corresponding to the parasite liver load of the second infection, was measured by qRT-PCR 44 h after reinfection. (B) Parasite liver loads in reinfectedWTmice,
measured by qRT-PCRofP. berghei 18S rRNA44 h after the second infectionwithP. berghei sporozoites and plotted as the percentages of theP. berghei 18S rRNA
levels in control WTmice. The results shown represent the means and SEM of the results of two independent experiments (single infection, n 14; reinfection,
n 14). The Mann-Whitney test demonstrated a statistically significant difference between control and reinfected mice (P 0.001). (C) Parasite liver loads in
reinfected WT mice, measured by qRT-PCR of P. berghei 18S rRNA, 44 h after two consecutive mosquito bite infections (10 mosquitoes/mouse) plotted as
percentages of the levels in control WTmice. The results shown represent the means and SEM of the results of three independent experiments (single infection,
n  16; reinfection, n  18). The Mann-Whitney test demonstrated a statistically significant difference between control and reinfected mice (P  0.05). (D)
Expression of genes Ifit1, Ifi44, Usp18, Ifit3, and Irf7 in total liver extracts of WT mice collected at multiple time points after infection with 50,000 P. berghei
sporozoites (SPZ). For each time point, the values shown are the means and SEM of the results of two independent experiments (NI, n 10; 42 h, n 8; 48 h,
n  8; 52 h, n  16; 62 h, n  11; 68 h, n  10; 72 h, n  10; 82 h, n  10). The Kruskal-Wallis test followed by Dunn’s multiple-comparison test revealed
statistically significant differences between uninfected control samples and liver samples 42 h, 68 h, 72 h, and 82 h after infection (P 0.05). (E) Parasite liver
loads in reinfected Ifnar1/mice, measured by qRT-PCR of P. berghei 18S rRNA, 44 h after two consecutive mosquito bite infections (10 mosquitoes/mouse)
plotted as percentages of the levels in control Ifnar1/mice. The results shown represent the means and SEM of the results of two independent experiments
(single infection, n  14; reinfection, n  13). The Mann-Whitney test demonstrated no statistically significant difference between control and reinfected
Ifnar1/mice. (F) Ifn- gene expression in whole livers ofWTmice collected at multiple time points after infection with 50,000 P. berghei sporozoites. For each
time point, the values represented are the means and SEM of the results of four (42 h, 48 h, and 52 h) and two (62 h, 72 h, and 82 h) independent experiments
(NI, n  38; 42 h, n  20; 48 h, n  37; 52 h, n  20; 62 h, n  10; 68 h, n  10; 72 h, n  10; 82 h, n  10). The Kruskal-Wallis test followed by Dunn’s
multiple-comparison test revealed statistically significant differences between uninfected control samples and liver samples 48 h, 52 h, 62 h, 72 h, and 82 h after
infection (P 0.001). (G) Parasite liver loads in reinfected Ifn-/mice, measured by qRT-PCR of P. berghei 18S rRNA, 44 h after two consecutive mosquito
bite infections (10 mosquitoes/mouse), plotted as percentages of the levels in control Ifn-/ mice. The results shown represent the means and SEM of the
results of two independent experiments (single infection, n 8; reinfection, n 8). TheMann-Whitney test demonstrated no statistically significant difference
between control and reinfected Ifn-/mice.
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liver would be constant at different biting rates and that the slope of this
would be determined by the baseline success rate of an infected bite reach-
ing the blood stage (r). In this case, the relation between EIR and FOI
would be a straight line:
y rx (2)
where x represents EIR and y represents FOI.
In the case of induced immunity that blocks infections from subse-
quent bites, we can also find the expected relationship between EIR and
FOI. For a given EIR, the waiting times between infected bites have an
exponential distribution. If we again assume a baseline success of an in-
fection from a bite reaching the blood stage of r, then the waiting time
between instances of “successful” liver-stage infection is rx. Therefore, the
cumulative distribution function (CDF) of an exponential distribution
with parameter rx at point T gives us the probability that next bite would
occur during the period T from a previous infection—and would be
blocked by the innate immune response. Thus, the relation between EIR
and FOI can be expressed by the following formula:
y rx[1 p CDFexp (rx, T)] (3)
where p is the probability that a liver-stage infection will be blocked by the
innate immune response induced by a previous bite, given that it occurred
during the period T of the active immunity response. We then fitted
model 2 andmodel 3 to the experimental data and compared the fits using
the Akaike information criterion (AIC).
(iii) Stochastic model of the impact of the innate liver-stage immu-
nity on the force of infection.We also developed a stochastic model that
is able to take into account a more complex infection kinetics than the
deterministic model, such as multiple consecutive bites and gradual ac-
quisition and loss of immunity. This allows us to investigate whether the
effects of innate immunity blocking subsequent liver-stage infections
would produce the same relationship between entomological inoculation
rate (EIR) and force of infection (FOI) as that predicted by the determin-
istic model and observed in field studies (30–33). This model simulated
biting at different rates and the proportion of infectious bites that success-
fully initiated blood-stage infections.
(iv) Modeling infection. The simulation takes into account 3 possible
types of infection: (i) infections that survive the liver stage and pass on to
the blood stage, which induce strong innate liver stage resistance to sub-
sequent liver-stage infections (with the maximal level of Rs  1); (ii)
infections that are cleared at the liver stage by the innate liver-stage im-
munity induced by previous infections—we assume that they would in-
duce a lower level of resistance than completed liver-stage infections (at a
level of Rp, which we assume to be 25% of the maximal inhibition [i.e.,
Rp 0.25 Rs]); and (iii) bite infections that do not reach the liver stage.
We assume that there is a baseline probability (Rb) that infectious bites
would fail to result in liver-stage infection. They do not induce liver-stage
immunity. According to model 2, Rb is equal to 0.93 (rate of progression
to blood-stage infection r 0.07).
(v) Simulation of biting rates. The model assumes that for a given
EIR, infective bites arrive randomly with exponentially distributed wait-
ing times (13, 34, 35). Each bite infection then has a probability of reach-
ing the blood stage, which is determined by the baseline probability of
success (Rb) and the level of induced resistance at a given time [R(t)]. After
a successful bite infection, the level of induced resistance rises to its max-
FIG 2 Effect of a primary P. berghei liver infection on the blood stage of a subsequent sporozoite-initiated reinfection. (A) Schematic representation of the
reinfection protocol. Mice were injected with 50,000 P. berghei sporozoites or noninfected salivary glands on day 0. Both groups of animals were treated with 700
	g of chloroquine (CQ) on days 2, 3, and 4 after injection. On day 3, mice were reinfected with 50,000 P. berghei GFP-expressing sporozoites. Parasitemia
(percentage of red blood cells infected with GFP-expressing parasites) was measured by flow cytometry starting at day 3 after the second infection. Survival was
monitored daily. (B and C) Parasitemia and survival in reinfected WT mice after mosquito bite infection (10 mosquitoes/mouse). The results shown represent
the means and SEM of the results of two independent experiments (single infection, n  11; reinfection, n  12). The Mann-Whitney test demonstrated a
statistically significant difference in parasitemia levels between control and reinfected mice (P 0.01). The log-rank test demonstrated a statistically significant
difference in survival rates between control and reinfected mice (P 0.001).
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imum and then falls over time (see formula 4 below). Thus, for each
simulated bite, a uniformly distributed randomnumber
 is assigned to it.
The value of this number and the current level of induced resistance de-
termine which of categories 1 to 3 this infection belongs to as follows. (i)
If R(t) plus Rb is 
, where R(t) is the current level of the liver stage
resistance, then the infection is considered of type 1 and induces subse-
quent resistance to infection. (ii) If Rb is less than 
 and 
 is less than R(t)
plus Rb, where R(t) is the current level of liver stage resistance, then the
infection is considered of type 2. (iii) If
 is less thanRb, then the infection
does not reach the liver stage and the infection is considered of type 3 and
does not contribute to the innate liver-stage immunity.
(vi) Modeling changes in induced resistance. The dynamics of in-
duced resistance to liver-stage infection in humans is unknown.However,
we can estimate the likely duration of resistance using the data from the
studies in P. berghei and scaling for the longer duration of the intrahepatic
stage of infection in P. falciparum. We assume that resistance in P. falcip-
arum infection has a duration of 12 days and is induced over time during
liver-stage infection (peaking at d1 days after the initial infection; we as-
sume d1 6 days) and then decays over some period (for d2 days after the
peak; we assume d2  6 days). We chose the logistic growth function to
describe the growth and decay of liver stage resistance over time. For this
function, we need an initial level of resistance immediately after initiation
of the liver stage (R0 0.05) and a peak level of resistance (M, the asymp-
totic maximum resistance [which will never be attained], which we as-
sume to be slightly larger than the maximum resistance M Rmax/0.98).
The function that describes both the growth and decay is defined by for-
mula 4.
f(t)
MR0e
r1(tt0)
M R0(e
r1(tt0) 1)
, t0  t  t0 d1,
MRmaxe
r2(tt0d1)
M Rmax(e
r2(tt0d1) 1)
, t0 d1 t t0 d1 d2,
0, t t0 d1 d2
(4)
where ri ln[(R0Rmax)MRmax)/R0(MRmax)]/di, i 1, 2, andRmax is
themaximal level of induced liver-stage immunity, which can take a value
ofRs orRp, depending on conditions i to iii as described above. Fig. S2B in
the supplemental material shows the trajectory of resistance over time
after a successful bite.
The total level of induced resistance R(t) induced by all previous in-
fections is calculated using formula 5.
R(t)Min
i1
n
fi(t), Rmax (5)
where function fi(t) is the immunity induced by the i-th infection (i 1,
. . ., n).
Using this stochasticmodel, we can then simulate different biting rates
and analyze the observed FOI that we obtain in the simulation. We com-
pared the relationship of EIR to FOI predicted by the simulationswith that
observed in a published field study presented in Table 2 in a study by Beier
et al. (30). We ran simulations with EIR values ranging from 0.01 to 5
infective bites/day and observed the rate of infection expected. The sto-
chastic simulation showed the same relationship between EIR and FOI as
in model 3, namely, as the EIR increases, infections from an increasing
proportion of bites are blocked by induced resistance, and we see a de-
creasing proportion of infections frombitesmaking it to the blood. This is
shown in Fig. 3B. A sample of the simulation calculated with an EIR of 1 is
shown in Fig. S2C in the supplemental material.
RESULTS
Induction of type I IFN and IFN- by a first P. berghei liver
infection protects against reinfection.To test the hypothesis that
a primary Plasmodium liver infection induces protection from
reinfection, we set up an assay in which mice were first injected
withP. bergheiparasites or, for control animals, with an equivalent
amount of salivary gland material from noninfected mosquitoes.
Three days later, mice were reinfected and the liver parasite bur-
den 42 h after the rechallenge was monitored by quantitative real-
time PCR, targeting the parasite 18S ribosomal small-subunit
transcripts (Fig. 1A). Since a primary liver-stage infection lasts 2 to
3 days in our rodent model (see Fig. S1 in the supplemental ma-
terial), we were able to attribute the measured liver parasite bur-
den to the second infection. To minimize the influence of blood-
stage-induced immune responses, mice were treated with
chloroquine from day 2 to day 5 after the primary infection, effec-
tively killing developing erythrocyte-stage parasites without af-
fecting the liver stages (36–38) (Fig. 1A). This was also confirmed
by the absence of blood-stage parasitemia on day 2 after the sec-
ond sporozoite infection, when any blood-stage parasites would
likely have resulted from the first infection (observation of Gi-
emsa-stained blood smears; data not shown). When mice were
FIG 3 Linking murine reinfection data to epidemiological observations. (A) Deterministic modeling of the experimental relationship between the EIR (ento-
mological inoculation rate; average number of infectious bites per person per unit time) and the FOI (force of infection; number of infections per person per unit
of time). Using published data on EIR and FOI from a field study in western Kenya (extracted from Table 2 of reference 30; red dots), we fitted either a baseline
model (fixed proportion of infectious bites progressing to blood stage) (dashed line) or a model with induced liver-stage immunity (solid line). The model of
induced liver-stage immunity showed a better fit to the experimental data compared by AIC. The best-fit parameters for the models are as follows: for model 2,
r 0.022; for model 3, r 0.069, p 0.85, t 12.2 days. (B) Results of the stochastic simulation of the relation between EIR and FOI in the presence of induced
resistance. Red dots represent the field study data (extracted from Table 2 of reference 30); crosses represent the estimates from the simulation.
Liehl et al.
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infected by intravenous injection of 50,000 sporozoites, we found
that primed mice were significantly more resistant to a second
challenge with 50,000 sporozoites than control animals (Fig. 1B).
Thus, our data indicate that, within 3 days, a primary exposure to
a high number of sporozoites activates a significant host resistance
to a malaria liver-stage reinfection. We next carried out a similar
experiment in which mice were infected by mosquito bites. A sig-
nificant 2-fold decrease of liver parasite load in reinfected mice
was also observedwhen infections were performed via this natural
route (Fig. 1C). Overall, our data show that, 3 days after an initial
liver-stage infection, the host benefits from increased defenses
against Plasmodium sporozoite reinfection. Notably, this protec-
tion is observed not only after a primary infection by intravenous
injection with (nonphysiologically) high numbers of sporozoites
but also when sporozoites are delivered by mosquito bites.
We next sought to understand the molecular mechanisms un-
derlying this phenomenon. Recently, we have shown that a pri-
mary liver-stage infection induces a hepatic type I IFN signature
(19). The recognition mechanism relies on the detection of Plas-
modiumRNA by the cytosolic RNA sensorMDA5 and likely other
as-yet-unidentified receptors. The signaling cascade involves the
mitochondrial antiviral signaling protein (MAVS) adapter mole-
cule and transcription factors interferon regulatory factor 3
(IRF3) and IRF7. Our data further suggested a model in which
released type I IFN binds, in both an autocrine manner and a
paracrine manner, to the heterodimeric alpha interferon receptor
(IFNAR, composed of IFNAR1 and IFNAR2), activating tran-
scription of IFN-inducible genes, with a peak of expression at 42 h
after infection (19, 39). Here we have extended our analysis of the
liver type I IFN response to later time points. We challenged mice
with 50,000 P. berghei sporozoites and treated them with chloro-
quine on the second, third, and fourth days after infection. We
first confirmed a significant expression of several type I IFN-in-
ducible genes (Ifit1, Ifi44,Usp18, Ifit3, and Irf7) at 42 h after infec-
tion, followed by a progressive decline of the response (Fig. 1D).
Strikingly, we found another significant and strong induction at
68 and 72 h after infection, which suggests that the liver reinitiates
de novo type I IFN signaling at those later time points (Fig. 1D). To
analyze the in vivo contribution of type I IFN-dependent signaling
to host resistance to sporozoite reinfection, wemonitored the liver
parasite load in reinfected IFNAR1-deficient (Ifnar1/)mice fol-
lowing infections by mosquito bites. In contrast to wild-type
(WT) mice, preinfected Ifnar1/ mice did not display a de-
creased liver parasite load after a secondary challenge by P. berghei
sporozoites (Fig. 1E). This result demonstrates that the type I IFN
response in the liver is physiologically relevant in host defense
against sporozoite reinfection in mice.
Next, we sought to approach the effector mechanisms that are
involved in the observed phenotype downstream of the type I IFN
response. Previously, we have provided evidence that the hepato-
cyte-mediated type I IFN response per se is not able to eliminate
the parasite during a primary infection. However, this response is
critical for the recruitment of immune cells to the infected hepa-
tocyte, which leads to Plasmodium elimination (19). As IFN- has
been identified as a cytokine that is able to mediate the killing of
intrahepatic Plasmodium parasites (40–42), we hypothesized that
themechanismof parasite elimination in the liver after reinfection
is IFN- dependent. We monitored transcript expression of the
gene encoding this cytokine in whole-liver extracts at different
time points after infection, using the previously established infec-
tion protocol and chloroquine treatment. Ifn- expression started
to be induced by 48 h after P. berghei liver infection, followed by a
slow but steady increase in transcript levels until 52 h postchal-
lenge. Interestingly, and similarly to the observation of the type I
IFN response, we observed a peak of Ifn- gene induction at 68 h
after infection (Fig. 1F). To assess the functional role of IFN- in
innate immunity to Plasmodium reinfection, IFN--deficient
(Ifn-/) mice were reinfected bymosquito bites after a primary
mosquito bite infection.We found that, in contrast toWTanimals
but similarly to Ifnar1/ mice, Ifn-/ mutants lost their pro-
tection against sporozoite reinfection (Fig. 1G). Taken together,
our data suggest that liver-stage infection by P. berghei first stim-
ulates type I IFN pathway activation and later stimulates IFN-
expression, both of which play a critical role in host defense
against reinfection.
A primary liver infection affects the blood stage of a sporo-
zoite reinfection. In contrast to the liver stage, which is asymp-
tomatic, the blood stage of infection is responsible for all the
symptoms associated with malaria. Thus, we next investigated
whether P. berghei-induced host protection also impacts the de-
velopment of the subsequent blood-stage infection and the asso-
ciated pathogenesis. We performed both primary and secondary
infections by mosquito bites, following the same protocol as pre-
viously described, and used P. berghei parasites expressing green
fluorescence protein (GFP) for reinfection (Fig. 2A). First, we
measured the length of the prepatent period, i.e., the time between
sporozoite injection and the appearance of blood-stage parasites,
by observing Giemsa-stained blood smears under a light-fieldmi-
croscope. Strikingly, we observed that 50% of the reinfected mice
demonstrated a 1-day delay in the appearance of blood-stage par-
asites from the secondary infection compared to primary-infected
controls (data not shown). As the prepatent period is a good in-
dicator of the number of infective merozoites produced in the
liver (43), this result suggests that fewer merozoites are released
from reinfected mice than from control mice. Next, we measured
the percentage of GFP-expressing infected red blood cells (blood-
stage parasitemia of the second infection) by flow cytometry. Our
results indicate that growth of blood-stage parasites from a sec-
ondary infection in primed mice was significantly delayed com-
pared to that seen in nonprimed, control animals (Fig. 2B).More-
over, reinfected mice presented a delay in malaria-associated
mortality compared to control animals (Fig. 2C). These data in-
dicate that the host resistance activated by a primary sporozoite
liver infection is physiologically relevant as it not only inhibits
liver infection but also delays blood-stage patency, resulting in a
decrease in the associated mortality.
Mathematical modeling of murine reinfection correlates
with epidemiological data. Several studies carried out in low-,
medium-, and high-transmission areas have measured the time
required for Plasmodium parasites to reappear in the blood of
individuals after parasitemia has been cleared with blood-stage-
specific antimalarial compounds (14, 15, 21, 30, 44–47). Interest-
ingly, these and other modeling studies have revealed a discrep-
ancy between the estimated number of infective bites per human
per time unit (i.e., the EIR) and the resulting force of infection
(FOI; i.e., the rate of new blood-stage infections) (16, 33). These
data indicate that, first, even at a low EIR, not all infective bites
translate into subsequent infections, and second, as the transmis-
sion rate increases (i.e., when EIR increases), the proportion of
infective bites that result in blood-stage infection progressively
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decreases (33). Thus, the observed FOI is lower than what would
be expected if it remained proportional to the rate of infective
bites. These data suggest that a high proportion of sporozoite re-
infections are blocked under high-transmission conditions and
that the preerythrocytic stage and/or early blood stage of infection
may activate effective host defenses. Therefore, we decided to test
whether our experimental data could explain the increased
preerythrocytic resistance with increasing FOI observed in hu-
mans (33).
We created twomodels linking FOI to EIR, onewith a constant
proportion of infections from bites reaching the blood stage and
another in which infections from bites could be blocked by innate
liver-stage immunity. The reduction in the infection thatwould be
induced by a prior liver-stage infectionwas estimated based on the
analysis of the reduction in the numbers of blood-stage parasites
observed after primary and secondary murine infections (for
more details, see Materials and Methods; also see Fig. S2A in the
supplementalmaterial). In order to determinewhichmodel better
explains the field study data, we compared the results of the fitting
of the two models to experimental data on P. falciparum EIR and
FOI from a field trial in western Kenya published in reference 30.
The results of fitting are shown in Fig. 3A. Using the Akaike infor-
mation criterion (AIC) to compare the twomodels, we found that
the model taking into account induced liver-stage immunity pro-
vided a significantly better fit to the field data (the AICs for con-
stant-proportion model 2 and for innate-immunity model 3 are
660 and700, respectively).
This deterministic model assumed a constant level of blocking
of new infections for a fixed period after the first infection. How-
ever, it is likely that innate immunity is induced and subsequently
decays over time. To take these dynamics into consideration, we
developed a stochastic model of malaria infection that takes into
account more-complex factors such as multiple consecutive bites
and gradual acquisition and loss of immunity. Ourmodel is based
on four assumptions: (i) infective bites arrive randomly at a given
biting rate (13, 34, 35); (ii) only a proportion of bites result in
infection (e.g., in a number of cases, mosquito injection of sporo-
zoites is unsuccessful or sporozoites remain in the skin); (iii) a
successful liver-stage infection (i.e., an infection that progresses to
the blood stage) induces strong host resistance and thus inhibits
the establishment of a subsequent liver-stage infection; and (iv) a
liver-stage infection that is blocked by innate immunity and does
not progress to a blood-stage infection nonetheless induces a
small amount of resistance to subsequent infections.
To parameterize the model, we estimated the baseline propor-
tion of infectious bites that result in blood-stage infection (base-
line FOI/EIR ratio) at 7%, based on the best-fit parameters of
deterministic model 2. Finally, we estimated how the reduction in
infectivity (or increase in host resistance) changes over time after
infection. Fig. S2B in the supplementalmaterial illustrates how the
probability of success of a reinfection changes with time after a
preceding successful infective bite, based on our assumptions. Full
details of the parameters and mathematical formalism of the
model are provided in Materials and Methods.
Based on this model, we were able to simulate different rates of
infectious biting (the EIR) and observed the expected number of
blood-stage infections arising from this (the FOI). We then over-
laid our simulated data onto the EIR and FOI relationship ob-
served in field studies. We found that the stochastic simulation
predicts that, similarly to the deterministicmodel of the inhibitory
effect of prior liver-stage infection, the number of infections per
bite does not remain proportional to EIR but instead reduces with
increasing biting rates, as was observed in regions of hyperende-
micity (Fig. 3B).Overall, our combinedmodeling and experimen-
tal data suggest for the first time that inhibition of reinfection in
high-transmission areas can be at least partly explained by the
activation of innate immunity in the liver.
DISCUSSION
We have established a mouse reinfection model and shown that
the innate immunity induced by a primary P. berghei liver-stage
infection impairs a second sporozoite reinfection. Importantly,
we also observed a significant inhibition of reinfection when both
infections were initiated by mosquito bites, as well as a delay in
blood-stage parasitemia and in malaria-associated mortality. Us-
ing an interdisciplinary approach, we incorporated our experi-
mental data into amathematicalmodel andwere able to show that
the predictions based on our experimental results are sufficient to
explain the available epidemiological data.
The issue treated in this study deals with a situation experi-
enced daily by the populations living in areas of high malaria
transmission, which face regular and repeated reinfections. Inter-
estingly, in regions of malaria hyperendemicity, individuals in
whom blood parasitemia has been cleared with blood stage-spe-
cific antimalarial compounds resist a large number of consecutive
mosquito bite infections before parasites become detectable in the
blood smears compared to individuals living in areas of medium
or low transmission (14–16, 21, 33). Several attempts have been
made to explain this phenomenon, including genetic factors and
heterogeneous mosquito biting preferences that would result in a
few people receivingmost of the infective bites (33). However, the
observed resistance could also be the consequence of human im-
mune defenses triggered by the preerythrocyte stage and/or early
blood stage of infection. As this resistance was also associated with
the age of study participants, a role for acquired adaptive immu-
nity has been suggested (18), although an explanation of how it
would participate in this protection remains elusive (9, 18). Our
murine reinfection model, combined with mathematical simula-
tions, suggests for the first time that liver innate immunity in-
duced by hepatic Plasmodium infection can also account for these
observed protective effects. Our data show that this kind of inter-
disciplinary approach can improve the mechanistic understand-
ing of the antimalarial resistance operating in humans.
Importantly, our findings seem to extend to other Plasmodium
species, as another recent study with another rodent parasite
strain, P. yoelii, showed that a first liver infection inhibits a second
reinfection (48). In regions of malaria endemicity, the prevalence
of multiple distinct genetic Plasmodium variants and species is the
norm (49) and humans can be successively infected with several
different genotypes (50, 51) or even with different parasite species
(52, 53) at one time. A major problem in fighting malaria is the
poor cross-reactivity of adaptive immune responses to different
Plasmodium species (54). Dissecting the level of cross-protective
effects of innate immune responses between different parasite
strains and species would contribute to a better understanding of
the relevance of innate immunity during liver-stage reinfections
in the field and could be of medical interest as this knowledge
could be exploited to improve the efficiency of currently available
antimalarial therapies.
Our report provides genetic evidence of an important role for
Liehl et al.
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the type I IFN response and IFN- in the host defense against
malaria liver-stage reinfection. IFN- treatment is known to effi-
ciently kill intrahepatic parasites (40–42), but we provide the first
evidence of a biologically relevant IFN- response in vivo after
mosquito bite-transmitted malaria infection (P. berghei). Our
data are in accordancewith the recent report of an IFN- response
in mice injected intravenously with high numbers of P. yoelii
sporozoites (48). As hepatocytes are not substantial producers of
IFN- (55), we hypothesize that the type I IFN response likely
recruits myeloid cells, in particular, NK andNK-T cells, which are
known to secrete large amounts of IFN-, to the infected hepato-
cytes (56). Interestingly, Miller et al. have shown that NK-T cells
constitute the only effector cell population that is crucial for host
resistance to sporozoite reinfection (48). However, more data will
be critical to gain further insight into the effector molecules me-
diating the IFN--dependent host resistance to reinfections and to
pinpoint when exactly these defense mechanisms are most effec-
tive in eliminating parasites during liver reinfection. Indeed, the
decrease in parasite loadwe observed in comparisons of reinfected
mice to nonprimed animalswas of considerably highermagnitude
at the early blood stage (10-fold decrease) than at the liver stage
(2- to 3-fold decrease at 44 h after infection). This suggests that the
observed resistance could be linked to amore efficient elimination
of parasites in their last maturation steps in the liver, i.e., when
they start to egress from hepatocytes and transition to blood-stage
infection. Taken together, our data strongly suggest that the liver-
stage-induced type I IFN and IFN- response is a major host de-
fense mechanism against sporozoite reinfection in our mouse
model. A detailed characterization of the mechanisms by which
the host detects and kills intrahepatic parasites will be helpful to
pave the way for innovative strategies in the development of effec-
tive preerythrocyte-based vaccines and prophylactic immuno-
therapies.
ACKNOWLEDGMENTS
We thank A. Parreira for Anopheles stephensi production and infection
and A. Zaidman-Rémy for critical reading of the manuscript.
This work was supported by Fundação para a Ciência e Tecnologia
(FCT, Portugal) grants PTDC-SAU-MIC-117060-2010 (to Miguel
Prudêncio) and EXCL/IMI-MIC/0056/2012 (to M.M.M.). P.L. was sup-
ported by Fondation pour la Recherche Médicale and FCT (fellowship
SFRH/BPD/41547/2007). P.M. was supported by FCT (fellowship SFRH/
BD/71098/2010).Miguel Prudêncio andM.P.D. are supported by anAus-
tralian Research Council Discovery Grant (DP120100064). M.P.D. is an
NHMRC Senior Research Fellow.
REFERENCES
1. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring
D, Fullman N, Naghavi M, Lozano R, Lopez AD. 2012. Global malaria
mortality between 1980 and 2010: a systematic analysis. Lancet 379:413–
431. http://dx.doi.org/10.1016/S0140-6736(12)60034-8.
2. Prudêncio M, Rodriguez A, Mota MM. 2006. The silent path to thou-
sands of merozoites: the Plasmodium liver stage. Nat Rev Microbiol
4:849–856. http://dx.doi.org/10.1038/nrmicro1529.
3. Amino R, Giovannini D, Thiberge S, Gueirard P, Boisson B, Dubremetz
JF, Prevost MC, Ishino T, Yuda M, Menard R. 2008. Host cell traversal
is important for progression of the malaria parasite through the dermis to
the liver. Cell Host Microbe 3:88–96. http://dx.doi.org/10.1016/j.chom
.2007.12.007.
4. Tavares J, Formaglio P, Thiberge S, Mordelet E, Van Rooijen N,
Medvinsky A, Menard R, Amino R. 2013. Role of host cell traversal by the
malaria sporozoite during liver infection. J Exp Med 210:905–915. http:
//dx.doi.org/10.1084/jem.20121130.
5. Mota MM, Pradel G, Vanderberg JP, Hafalla JC, Frevert U, Nussenz-
weig RS, Nussenzweig V, Rodriguez A. 2001. Migration of Plasmodium
sporozoites through cells before infection. Science 291:141–144. http://dx
.doi.org/10.1126/science.291.5501.141.
6. Sturm A, Amino R, van de Sand C, Regen T, Retzlaff S, Rennenberg A,
Krueger A, Pollok JM, Menard R, Heussler VT. 2006. Manipulation of
host hepatocytes by the malaria parasite for delivery into liver sinusoids.
Science 313:1287–1290. http://dx.doi.org/10.1126/science.1129720.
7. Haldar K, Murphy SC, Milner DA, Taylor TE. 2007. Malaria: mecha-
nisms of erythrocytic infection and pathological correlates of severe dis-
ease. Annu Rev Pathol 2:217–249. http://dx.doi.org/10.1146/annurev
.pathol.2.010506.091913.
8. Takala SL, Plowe CV. 2009. Genetic diversity and malaria vaccine design,
testing and efficacy: preventing and overcoming ‘vaccine resistant ma-
laria’. Parasite Immunol 31:560–573. http://dx.doi.org/10.1111/j.1365
-3024.2009.01138.x.
9. Marsh K, Kinyanjui S. 2006. Immune effector mechanisms in malaria.
Parasite Immunol 28:51–60. http://dx.doi.org/10.1111/j.1365-3024.2006
.00808.x.
10. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. 2008. Immunity to
malaria: more questions than answers. Nat Immunol 9:725–732. http://dx
.doi.org/10.1038/ni.f.205.
11. Stevenson MM, Riley EM. 2004. Innate immunity to malaria. Nat Rev
Immunol 4:169–180. http://dx.doi.org/10.1038/nri1311.
12. Portugal S, Carret C, Recker M, Armitage AE, Goncalves LA, Epiphanio
S, Sullivan D, Roy C, Newbold CI, Drakesmith H, Mota MM. 2011.
Host-mediated regulation of superinfection in malaria. Nat Med 17:732–
737. http://dx.doi.org/10.1038/nm.2368.
13. Pinkevych M, Petravic J, Chelimo K, Vulule J, Kazura JW, Moormann
AM, Davenport MP. 9 September 2013, posting date. Density-dependent
blood stage Plasmodium falciparum suppressesmalaria super-infection in
amalaria holoendemic population. Am J TropMedHyg http://dx.doi.org
/10.4269/ajtmh.13-0049.
14. Sokhna CS, Rogier C, Dieye A, Trape JF. 2000. Host factors affecting the
delay of reappearance of Plasmodium falciparum after radical treatment
among a semi-immunepopulation exposed to intense perennial transmis-
sion. Am J Trop Med Hyg 62:266–270.
15. Tall A, Sokhna C, Perraut R, Fontenille D, Marrama L, Ly AB, Sarr FD,
Toure A, Trape JF, Spiegel A, Rogier C, Druilhe P. 2009. Assessment of
the relative success of sporozoite inoculations in individuals exposed to
moderate seasonal transmission. Malar J 8:161. http://dx.doi.org/10.1186
/1475-2875-8-161.
16. Smith T, Maire N, Dietz K, Killeen GF, Vounatsou P, Molineaux L,
Tanner M. 2006. Relationship between the entomologic inoculation rate
and the force of infection for Plasmodium falciparummalaria. Am J Trop
Med Hyg 75(2 Suppl):11–18.
17. Liehl P, Mota MM. 2012. Innate recognition of malarial parasites by
mammalian hosts. Int J Parasitol 42:557–566. http://dx.doi.org/10.1016/j
.ijpara.2012.04.006.
18. Offeddu V, Thathy V, Marsh K, Matuschewski K. 2012. Naturally
acquired immune responses against Plasmodium falciparum sporozoites
and liver infection. Int J Parasitol 42:535–548. http://dx.doi.org/10.1016/j
.ijpara.2012.03.011.
19. Liehl P, Zuzarte-Luis V, Chan J, Zillinger T, Baptista F, Carapau D,
Konert M, Hanson KK, Carret C, Lassnig C, Muller M, Kalinke U,
Saeed M, Chora AF, Golenbock DT, Strobl B, Prudencio M, Coelho LP,
Kappe SH, Superti-Furga G, Pichlmair A, Vigario AM, Rice CM,
Fitzgerald KA, Barchet W, Mota MM. 2014. Host-cell sensors for Plas-
modium activate innate immunity against liver-stage infection. Nat Med
20:47–53. http://dx.doi.org/10.1038/nm.3424.
20. Macdonald G. 1956. Epidemiological basis of malaria control. Bull World
Health Organ 15:613–626.
21. Charlwood JD, Smith T, Lyimo E, Kitua AY, Masanja H, Booth M,
Alonso PL, Tanner M. 1998. Incidence of Plasmodium falciparum infec-
tion in infants in relation to exposure to sporozoite-infected anophelines.
Am J Trop Med Hyg 59:243–251.
22. Beier JC, Killeen GF, Githure JI. 1999. Short report: entomologic inoc-
ulation rates and Plasmodium falciparum malaria prevalence in Africa.
Am J Trop Med Hyg 61:109–113.
23. Rogier C, Tall A, Diagne N, Fontenille D, Spiegel A, Trape JF. 1999.
Plasmodium falciparum clinical malaria: lessons from longitudinal stud-
ies in Senegal. Parassitologia 41:255–259.
24. Bloland PB, Boriga DA, Ruebush TK, McCormick JB, Roberts JM, Oloo
AJ, Hawley W, Lal A, Nahlen B, Campbell CC. 1999. Longitudinal
Innate Immunity and Malaria Reinfections
March 2015 Volume 83 Number 3 iai.asm.org 1179Infection and Immunity
 o
n
 January 15, 2016 by B-O
N FCCN TRIAL
http://iai.asm
.org/
D
ow
nloaded from
 
cohort study of the epidemiology of malaria infections in an area of in-
tense malaria transmission II. Descriptive epidemiology of malaria infec-
tion and disease among children. Am J Trop Med Hyg 60:641–648.
25. Epstein JE, Rao S, Williams F, Freilich D, Luke T, Sedegah M, de la
Vega P, Sacci J, Richie TL, Hoffman SL. 2007. Safety and clinical out-
come of experimental challenge of human volunteers with Plasmodium
falciparum-infected mosquitoes: an update. J Infect Dis 196:145–154.
http://dx.doi.org/10.1086/518510.
26. Verhage DF, Telgt DS, Bousema JT, Hermsen CC, van Gemert GJ, van
der Meer JW, Sauerwein RW. 2005. Clinical outcome of experimental
humanmalaria induced by Plasmodium falciparum-infectedmosquitoes.
Neth J Med 63:52–58.
27. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA.
1993. Multiple defects of immune cell function in mice with disrupted
interferon-gamma genes. Science 259:1739–1742. http://dx.doi.org/10
.1126/science.8456300.
28. Franke-Fayard B, Trueman H, Ramesar J, Mendoza J, van der Keur M,
van der Linden R, Sinden RE, Waters AP, Janse CJ. 2004. A Plasmodium
berghei reference line that constitutively expresses GFP at a high level
throughout the complete life cycle. Mol Biochem Parasitol 137:23–33.
http://dx.doi.org/10.1016/j.molbiopara.2004.04.007.
29. Pfaffl MW. 2001. A newmathematical model for relative quantification in
real-time RT-PCR. Nucleic Acids Res 29:e45. http://dx.doi.org/10.1093
/nar/29.9.e45.
30. Beier JC, Oster CN, Onyango FK, Bales JD, Sherwood JA, Perkins PV,
Chumo DK, Koech DV, Whitmire RE, Roberts CR, Diggs CL, Hoffman
SL. 1994. Plasmodium falciparum incidence relative to entomologic in-
oculation rates at a site proposed for testing malaria vaccines in western
Kenya. Am J Trop Med Hyg 50:529–536.
31. Bekessy A, Molineaux L, Storey J. 1976. Estimation of incidence and
recovery rates of Plasmodium falciparum parasitaemia from longitudinal
data. Bull World Health Organ 54:685–693.
32. Pull JH, Grab B. 1974. A simple epidemiological model for evaluating the
malaria inoculation rate and the risk of infection in infants. Bull World
Health Organ 51:507–516.
33. Smith DL, Drakeley CJ, Chiyaka C, Hay SI. 2010. A quantitative analysis
of transmission efficiency versus intensity for malaria. Nat Commun
1:108. http://dx.doi.org/10.1038/ncomms1107.
34. Pinkevych M, Petravic J, Chelimo K, Kazura JW, Moormann AM,
Davenport MP. 2012. The dynamics of naturally acquired immunity to
Plasmodium falciparum infection. PLoS Comput Biol 8:e1002729. http:
//dx.doi.org/10.1371/journal.pcbi.1002729.
35. Pinkevych M, Petravic J, Chelimo K, Vulule J, Kazura JW, Moormann
AM, Davenport MP. 2014. Decreased growth rate of P. falciparum blood
stage parasitemia with age in a holoendemic population. J Infect Dis 209:
1136–1143. http://dx.doi.org/10.1093/infdis/jit613.
36. Peters W. 1974. Recent advances in antimalarial chemotherapy and drug
resistance. Adv Parasitol 12:69–114. http://dx.doi.org/10.1016/S0065-308X
(08)60387-5.
37. Yayon A, Vande Waa JA, Yayon M, Geary TG, Jensen JB. 1983.
Stage-dependent effects of chloroquine on Plasmodium falciparum in
vitro. J Protozool 30:642–647. http://dx.doi.org/10.1111/j.1550-7408
.1983.tb05336.x.
38. Belnoue E, Costa FT, Frankenberg T, Vigario AM, Voza T, Leroy N,
Rodrigues MM, Landau I, Snounou G, Renia L. 2004. Protective T cell
immunity against malaria liver stage after vaccination with live sporozo-
ites under chloroquine treatment. J Immunol 172:2487–2495. http://dx
.doi.org/10.4049/jimmunol.172.4.2487.
39. Decker T, Muller M, Stockinger S. 2005. The yin and yang of type I
interferon activity in bacterial infection. Nat Rev Immunol 5:675–687.
http://dx.doi.org/10.1038/nri1684.
40. Schofield L, Ferreira A, Altszuler R, Nussenzweig V, Nussenzweig RS.
1987. Interferon-gamma inhibits the intrahepatocytic development of
malaria parasites in vitro. J Immunol 139:2020–2025.
41. Vergara U, Ferreira A, Schellekens H, Nussenzweig V. 1987. Mechanism
of escape of exoerythrocytic forms (EEF) of malaria parasites from the
inhibitory effects of interferon-gamma. J Immunol 138:4447–4449.
42. Mellouk S, Green SJ, Nacy CA, Hoffman SL. 1991. IFN-gamma inhibits
development of Plasmodium berghei exoerythrocytic stages in hepato-
cytes by an L-arginine-dependent effector mechanism. J Immunol 146:
3971–3976.
43. Zuzarte-Luis V, Sales-Dias J, Mota MM. 2014. Simple, sensitive and
quantitative bioluminescence assay for determination of malaria pre-
patent period. Malar J 13:15. http://dx.doi.org/10.1186/1475-2875-13-15.
44. Owusu-Agyei S, Koram KA, Baird JK, Utz GC, Binka FN, Nkrumah FK,
Fryauff DJ, Hoffman SL. 2001. Incidence of symptomatic and asymp-
tomatic Plasmodium falciparum infection following curative therapy in
adult residents of northern Ghana. Am J Trop Med Hyg 65:197–203.
45. Moormann AM, Sumba PO, Chelimo K, Fang H, Tisch DJ, Dent AE,
John CC, Long CA, Vulule J, Kazura JW. 2013. Humoral and cellular
immunity to Plasmodium falciparum merozoite surface protein 1 and
protection from infection with blood-stage parasites. J Infect Dis 208:
149–158. http://dx.doi.org/10.1093/infdis/jit134.
46. Sokhna CS, Faye FBK, Spiegel A, Dieng H, Trape JF. 2001. Rapid
reappearance of Plasmodium falciparumafter drug treatment among Sen-
egalese adults exposed tomoderate seasonal transmission. Am JTropMed
Hyg 65:167–170.
47. Sagara I, Sangare D, Dolo G, Guindo A, Sissoko M, Sogoba M, Niam-
bele MB, Yalcoue D, Kaslow DC, Dicko A, Klion AD, Diallo D, Miller
LH, Toure Y, Doumbo O. 2002. A high malaria reinfection rate in chil-
dren and young adults living under a low entomological inoculation rate
in a periurban area of Bamako, Mali. Am J Trop Med Hyg 66:310–313.
48. Miller JL, Sack BK, Baldwin M, Vaughan AM, Kappe SH. 3 April 2014,
posting date. Interferon-mediated innate immune responses against ma-
laria parasite liver stages. Cell Rep http://dx.doi.org/10.1016/j.celrep.2014
.03.018.
49. Richie TL. 1988. Interactions betweenmalaria parasites infecting the same
vertebrate host. Parasitology 96(Pt 3):607–639.
50. Greenhouse B, Myrick A, Dokomajilar C, Woo JM, Carlson EJ,
Rosenthal PJ, Dorsey G. 2006. Validation of microsatellite markers for
use in genotyping polyclonal Plasmodium falciparum infections. Am J
Trop Med Hyg 75:836–842.
51. Juliano JJ, Porter K, Mwapasa V, Sem R, Rogers WO, Ariey F, Wong-
srichanalai C, Read A, Meshnick SR. 2010. Exposing malaria in-host
diversity and estimating population diversity by capture-recapture using
massively parallel pyrosequencing. Proc Natl Acad Sci U S A 107:20138–
20143. http://dx.doi.org/10.1073/pnas.1007068107.
52. Black J, Hommel M, Snounou G, Pinder M. 1994. Mixed infections with
Plasmodium falciparum and P malariae and fever in malaria. Lancet 343:
1095.
53. Bruce MC, Macheso A, Kelly-Hope LA, Nkhoma S, McConnachie A,
Molyneux ME. 2008. Effect of transmission setting and mixed species
infections on clinical measures of malaria in Malawi. PLoS One 3:e2775.
http://dx.doi.org/10.1371/journal.pone.0002775.
54. Doolan DL, Dobano C, Baird JK. 2009. Acquired immunity to malaria.
Clin Microbiol Rev 22:13–36, table of contents. http://dx.doi.org/10.1128
/CMR.00025-08.
55. Horras CJ, Lamb CL, Mitchell KA. 2011. Regulation of hepatocyte fate by
interferon-gamma. Cytokine Growth Factor Rev 22:35–43. http://dx.doi
.org/10.1016/j.cytogfr.2011.01.001.
56. Schoenborn JR, Wilson CB. 2007. Regulation of interferon-gamma dur-
ing innate and adaptive immune responses. Adv Immunol 96:41–101.
http://dx.doi.org/10.1016/S0065-2776(07)96002-2.
Liehl et al.
1180 iai.asm.org March 2015 Volume 83 Number 3Infection and Immunity
 o
n
 January 15, 2016 by B-O
N FCCN TRIAL
http://iai.asm
.org/
D
ow
nloaded from
 
 
Loss-of-function analyses deﬁnes vital and redundant
functions of the Plasmodium rhomboid protease family
Jing-wen Lin,1 Patrícia Meireles,3 Miguel Prudêncio,3
Sabine Engelmann,5 Takeshi Annoura,1
Mohammed Sajid,1 Séverine Chevalley-Maurel,1
Jai Ramesar,1 Carolin Nahar,6
Cristina M. C. Avramut,2 Abraham J. Koster,2
Kai Matuschewski,5,6 Andrew P. Waters,7
Chris J. Janse,1 Gunnar R. Mair4** and
Shahid M. Khan1*
1Leiden Malaria Research Group (Parasitology), and
2Section Electron Microscopy (Molecular Cell Biology),
Leiden University Medical Centre, Leiden, The
Netherlands.
3Malaria Unit, and 4Molecular Parasitology Unit, Instituto
de Medicina Molecular, Faculdade de Medicina,
Universidade de Lisboa, Lisboa, Portugal.
5Parasitology, Department of Infectious Diseases,
University of Heidelberg Medical School, Heidelberg,
Germany.
6Max Planck Institute for Infection Biology, Parasitology
Unit, Berlin, Germany.
7Division of Infection and Immunity, Institute of
Biomedical Life Sciences & Wellcome Centre for
Molecular Parasitology, Glasgow Biomedical Research
Centre, University of Glasgow, Glasgow, UK.
Summary
Rhomboid-like proteases cleave membrane-anchored
proteins within their transmembrane domains. In api-
complexan parasites substrates include molecules
that function in parasite motility and host cell invasion.
While two Plasmodium rhomboids, ROM1 and ROM4,
have been examined, the roles of the remaining six
rhomboids during the malaria parasite’s life cycle are
unknown. We present systematic gene deletion analy-
ses of all eight Plasmodium rhomboid-like proteins
as a means to discover stage-specific phenotypes
and potential functions in the rodent malaria model,
P. berghei. Four rhomboids (ROM4, 6, 7 and 8) are
refractory to gene deletion, suggesting an essential
role during asexual blood stage development. In con-
trast ROM1, 3, 9 and 10 were dispensable for blood
stage development and exhibited no, subtle or severe
defects in mosquito or liver development. Parasites
lacking ROM9 and ROM10 showed no major pheno-
typic defects. Parasites lacking ROM1 presented a
delay in blood stage patency following liver infection,
but in contrast to a previous study blood stage para-
sites had similar growth and virulence characteristics
as wild type parasites. Parasites lacking ROM3 in
mosquitoes readily established oocysts but failed to
produce sporozoites. ROM3 is the first apicomplexan
rhomboid identified to play a vital role in sporogony.
Introduction
Rhomboid-like proteins are intramembrane serine pro-
teases that hydrolyse a substrate within its transmembrane
(TM) spanning domain (Freeman, 2004). The first rhom-
boid protease described was Drosophila melanogaster
Rhomboid-1 that initiates cell signalling by cleaving the
membrane-resident Spitz, an epidermal growth factor
(EGF)-like ligand precursor, releasing it as an activated
molecule from the membrane and promoting subsequent
EGF-receptor signalling (Urban et al., 2001). With the
exception of viruses, rhomboid-like proteins are found in all
kingdoms of life and share a conserved core structure of six
TM domains that contains the catalytic serine-histidine
diad (Koonin et al., 2003; Wang et al., 2006; Wu et al.,
2006; Ben-Shem et al., 2007; Lemberg and Freeman,
2007). Interestingly, as a family of proteins, they share only
around 5% sequence identity in the core region (Urban
et al., 2002b) and have highly variable amino termini.
Some members have additional TM domains at either N-
or C-termini of the core six, but their precise functions
are unknown. Rhomboids function in cell–cell signalling
in metazoans (Urban et al., 2002a; Sundaram, 2004),
quorum sensing between bacteria (Stevenson et al.,
2007), facilitate mitochondrial membrane fusion in yeast
(McQuibban et al., 2003) and regulate apoptosis (Cipolat
et al., 2006).
Many eukaryotic organisms contain large rhomboid
gene families. Multiple rhomboid-like enzymes are also
found in the genomes of apicomplexan parasites such as
Toxoplasma gondii, Plasmodium spp., Eimeria tenella,
Cryptosporidium spp., Theileria spp. and Babesia bovis.
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Based on a phylogenetic clustering of rhomboid-like pro-
teins, a nomenclature has been defined according to the
initial assignment of T. gondii rhomboids (Dowse and
Soldati, 2005) which expresses six rhomboid-like proteins
TgROM1–6. Only four TgROMs (i.e. ROM1, 3, 4 and 6)
have direct Plasmodium homologues (Dowse and Soldati,
2005); there are no direct homologues of TgROM2 and
TgROM5 in Plasmodium and ROM7–10 are only present
in Plasmodium but not in T. gondii. Although Plasmodium
species do not have a direct TgROM5 homologue, P. fal-
ciparum ROM1 and ROM4 share substrate specificities
with TgROM5 (Baker et al., 2006). Apicomplexan ROM6
is most likely an evolutionarily ancient mitochondrial
PARL-like rhomboid, whereas all the others seem to be
unique to apicomplexan parasites (Dowse and Soldati,
2005). Interestingly, Plasmodium ROM9 also has a puta-
tive mitochondrial-targeting sequence and clusters with
PARL-like rhomboids (Santos et al., 2011b).
Although in vitro certain rhomboids of apicomplexan
parasites can cleave adhesins that are known to mediate
recognition of, and attachment to host cells, their in vivo
substrate specificities are largely unknown (Freeman,
2009; Santos et al., 2011b). Understanding the biological
functions of apicomplexan rhomboids is an active area of
research because of the critical roles identified for several
of these molecules in host cell invasion and pathogenesis
(Freeman, 2009; Buguliskis et al., 2010; Santos et al.,
2011b). In T. gondii, TgROM4 has been shown to process
surface adhesins including MIC 2, 3 (microneme proteins)
and apical membrane antigen 1 [AMA1 (Buguliskis et al.,
2010)]; this TgROM4-mediated AMA1 cleavage critically
regulates the parasite’s switch from an invasive to a rep-
licative mode (Santos et al., 2011a). TgROM1 is localized
in micronemes (Brossier et al., 2005) and although it is
critical for parasite growth, TgROM1 is not essential for
parasite invasion (Brossier et al., 2008). From the eight
Plasmodium rhomboids, only ROM1 and ROM4 have
been analysed in more detail. In vitro substrates of the
P. falciparum proteins include the merozoite-specific pro-
teins AMA1 and proteins of the EBL (erythrocyte binding
ligands) and RBL (reticulocyte binding ligands) families
as well as several proteins of the invasive ookinete-
and sporozoite-stages, such as TRAP (thrombospondin-
related anonymous protein), CTRP (circumsporozoite-
and TRAP-related protein) and MAEBL (merozoite
adhesive erythrocytic binding protein) (Baker et al.,
2006). Structural analysis of the RBL protein EBA175
(Erythrocyte-binding antigen 175) and TRAP provided evi-
dence for shedding of these proteins by a rhomboid-like
protease (O’Donnell et al., 2006) and indeed both pro-
teins are cleaved in vitro by ROM4 (O’Donnell et al., 2006;
Ejigiri et al., 2012). In P. falciparum only a small fraction of
AMA1 is shed by ROM1 and the intramembrane cleavage
can be reduced to undetectable levels by mutagenesis
without discernible phenotypic consequences (Olivieri
et al., 2011). The successful generation of P. berghei and
P. yoelii mutants that lack expression of ROM1 also dem-
onstrated that ROM1 is not essential for blood stage
multiplication (Srinivasan et al., 2009; Vera et al., 2011).
Blood stages of these mutants suffer only from a minor
reduction in growth, again indicating that intramembrane
cleavage of AMA1 by ROM1 is not essential for invasion
of erythrocytes. ROM1 mutants in P. yoelii also showed a
slight growth defect during liver stage development which
has been attributed to reduced cleavage of the parasito-
phorous vacuole protein UIS4 (upregulated in sporozoites
4) by ROM1 (Vera et al., 2011). Whether additional pro-
teins are processed by Plasmodium ROM4 or ROM1 in
vivo is still unknown. The non-essential nature of ROM1
during the complete life cycle indicates that other rhom-
boids or proteases from other families can cleave sub-
strates of ROM1. ROM4 on the other hand has been
reported to be essential for blood stage growth as
attempts to mutate the rom4 gene of P. falciparum failed
(O’Donnell et al., 2006). However, differences in cellular
localization and in vitro substrate specificities of ROM1
and ROM4 (Baker et al., 2006; O’Donnell et al., 2006)
raise questions as to whether these rhomboids cleave the
same substrates in vivo. In blood stage P. falciparum
ROM1 is located in micronemes of merozoites and ROM4
is embedded into the merozoite plasma membrane
(O’Donnell et al., 2006).
Due to the absence of data defining Plasmodium
rhomboid expression, cellular localization, or importance
during the parasite’s life cycle, it is largely unknown which,
if any rhomboids are biologically essential, redundant or
perhaps share overlapping functions. We therefore under-
took a genetic screen of all eight rhomboids by targeting
each gene for deletion by homologous recombination
using the genetically most tractable malaria parasite,
P. berghei. Multiple attempts to disrupt genes encoding
ROM4, ROM6, ROM7 and ROM8 failed, suggesting that
these proteins have essential, non-redundant functions
during blood stage development. We show that in addition
to ROM1, three other rhomboid-like proteases – ROM3,
ROM9 and ROM10 – are redundant for asexual blood
stage development in mice. Parasites lacking ROM9 and
ROM10 showed no major phenotypic defects during
the entire life cycle; however, parasites lacking ROM1
were slightly compromised with respect to their ability to
develop in the liver. Although already transcribed strongly
in the female gametocyte, ROM3 is crucial during oocyst
development inside the mosquito. Parasites lacking
ROM3 produce normal numbers of ookinetes that readily
establish oocysts in the mosquito. Although normal in size
and number, oocysts fail to sporulate, suggesting that
ROM3 plays a key role in the regulation of cytokinesis and
production of individual sporozoites.
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Results
The gene expression profiles of rhomboids across the
parasite life cycle
The genome of the rodent malaria parasite P. berghei
contains eight genes encoding rhomboid proteases
(Dowse and Soldati, 2005) (Gene IDs are shown in
Table 1). Each member shows a high level of sequence
identity (70–85%) with its rhomboid orthologue from the
human malaria parasite P. falciparum and shares a syn-
tenic location in the genome (http://www.plasmodb.org)
with an identical exon/intron gene structure.
We compared expression data of all rhomboid genes
in P. berghei and P. falciparum in publicly available litera-
ture as well as transcriptome and proteome datasets
across the life cycle (Table 1) (http://www.plasmodb.org
and Khan et al., 2005). Immunofluorescence assays
(IFA) on HA-tagged ROM1 and ROM4 show expression
of these proteins in dividing schizonts and merozoites in
P. falciparum (O’Donnell et al., 2006). A similar pattern of
expression of P. berghei and P. yoelii ROM1 has been
shown in schizonts and merozoites by IFA (Srinivasan
et al., 2009; Vera et al., 2011). In both P. berghei
and P. falciparum ROM1 is located in the micronemes.
P. berghei ROM1 and ROM4 of P. falciparum and
P. berghei have been detected in the sporozoite stage
(Srinivasan et al., 2009; Ejigiri et al., 2012) (Table 1). Our
RT-PCR analyses (Fig. S1) demonstrate transcription of
P. berghei rom1 and rom4 in blood stages and sporo-
zoites. These different observations indicate that both
ROM1 and ROM4 of human and rodent parasites have
comparable patterns of expression and cellular location.
For other rhomboids the information on stage-specific
expression is much more limited. Proteome analyses
indicate that ROM6, ROM9 and ROM10 are expressed
in P. falciparum gametocytes (Table 1); however, pro-
teome evidence for expression of these proteins in
P. berghei gametocytes or other blood stages is absent.
ROM7 and ROM8 are absent in all P. falciparum and
P. berghei proteomes and ROM3 is only detected in
P. falciparum blood stages. EST, RNAseq (Table 1) and
RT-PCR analyses (Fig. S1), however, indicate that
ROM3, ROM7 and ROM8 are expressed in blood stages
and therefore the absence in proteomes may suggest
that rhomboids are relatively low abundant proteins,
although we have to take into account the difficulties of
proteomic sequencing multi-pass TM proteins. P. falci-
parum RNAseq analyses indicate that transcription of
rom3 and rom4 is upregulated in gametocytes compared
with asexual stages (Table 1). RNAseq analyses of dif-
ferent P. berghei blood stages also showed strongly
increased transcripts levels of rom3 and rom4 in game-
tocytes (W.A.M. Hoeijmakers, A. Religa, C.J. Janse, A.P.
Waters and H.G. Stunnenberg, unpubl. data). We con-
Table 1. Expression profile of Plasmodium rhomboids.
Protein Gene ID mRNA Protein
P. berghei Asa,b Gcta,b Ooka Spa,b Asc Gctd Spc
ROM1 PBANKA_093350 + (-) + (-) ++ + (++) - (+e)  - (+e)
ROM3 PBANKA_070270 - (++) + (-) - - (-) - - -
ROM4 PBANKA_110650 + (++) + (-) ++ + (++) - (+f) - - (+f)
ROM6 PBANKA_135810 + (-) + (-) - - (+) - - -
ROM7 PBANKA_113460 + (-) - (-) - - (+) - - -
ROM8 PBANKA_103130 + (-) - (-) - - (-) - - -
ROM9 PBANKA_111470  (-)  (-) - + (-) - - -
ROM10 PBANKA_111780 + (++)  (-) + - (-) - - -
P. falciparum Asg Gctg Sph Asc Gctc Oocc Spc
ROM1 PF3D7_1114100 +  + + - - -
ROM3 PF3D7_0828000  ++   - - -
ROM4 PF3D7_0506900 + ++ + ++ - - +
ROM6 PF3D7_1345200    -  - -
ROM7 PF3D7_1358300  - - - - - -
ROM8 PF3D7_1411200 + + + - - - -
ROM9 PF3D7_0515100    -  - -
ROM10 PF3D7_0618600 +    + - -
a. RT-PCR results in this study (see Fig. S1).
b. PlasmoDB EST data in parentheses (–, no data; +, 1 EST; ++, 2–7 ESTs).
c. PlasmoDB proteome data (–, no data; , 1–2; +, 3–10; ++, > 10).
d. PbANKA Male vs female gametocyte proteome (Khan et al., 2005).
e. IFA evidence using anti-PbROM1 serum (Srinivasan et al., 2009).
f. Western and IFA evidence using anti-PbROM4 serum (Ejigiri et al., 2012).
g. PlasmoDB RNAseq data (–, no data; , 0–6; +, 6–10) RPKM (log2).
h. PlasmoDB oligo array (–, no data; , 1–100; +, 100–1000; ++, > 1000) RMA value.
AS, asexual stages; Gct, gametocytes; Ook, ookinetes; Ooc, oocysts; Sp, sporozoites.
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firmed transcription of these rhomboids in P. berghei
gametocytes by RT-PCR (Fig. S1).
The similarities between the eight rhomboid genes of
P. falciparum and P. berghei and similarities in expression
patterns and cellular locations of several rhomboids point
towards a conserved function between rhomboid ortho-
logues across the parasites’ life cycle in both species.
Since most rhomboids appear to be expressed in multiple
life cycle stages, the expression pattern is, however, not a
good indicator for a putative role at a distinct life cycle
stage.
Evidence for an essential role of ROM4, 6, 7 and 8 in
asexual blood stage parasites – ROM1, 3, 9 and
10 are dispensable
As a first step towards understanding the roles of
rhomboid proteases during the Plasmodium life cycle,
we undertook a systematic, individual gene deletion
approach for each of the eight P. berghei rhomboid genes
and provide here a detailed analysis of the growth char-
acteristics of gene deletion mutants for four rhomboids.
Using well-established standard assays, the following
phenotypes of the gene deletion mutants were character-
ized throughout the complete life cycle including blood,
mosquito and liver stages: in vivo asexual blood stage
multiplication rate, in vivo gametocyte production, in vitro
ookinete formation, oocyst and sporozoite development in
Anopheles stephensi mosquitoes and the prepatent
period in mice after injection of sporozoites. The prepatent
period is defined as the time taken to achieve a 0.5–2%
blood stage parasitemia in mice after intravenous inocu-
lation of 104 sporozoites.
Standard genetic modification technologies used to
replace entire rhomboid genes by double cross-over inte-
gration with a drug resistant marker resulted in gene dele-
tion mutants for rom1, 3, 9 and 10, while multiple attempts
to disrupt rom4, 6, 7 and 8 were unsuccessful (see Tab-
les S1, S2 and S3 for details of these unsuccessful gene-
deletion attempts including primers used to amplify the
targeting sequences, generate the gene-deletion con-
structs and genotype). We demonstrated by RT-PCR that
rom4, 6, 7 and 8 are transcribed in blood stages (Fig. S1)
and the multiple unsuccessful attempts to disrupt rom4, 6,
7 and 8 may indicate that these genes have a critical
function for asexual blood stage growth and multiplication.
While a failure to disrupt a gene is not an unequivocal
proof that the encoded protein is essential for blood stage
growth/multiplication for rom4 we show that the failure of
disruption is not due to refractoriness of the genetic locus
to genetic modification by creating a transgenic mutant
(rom4::mCherry) that expresses a C-terminally mCherry-
tagged ROM4 (Fig. S2). Genotype analysis of the
rom4::mCherry parasites and analysis of ROM4::mCherry
expression (Fig. S2) demonstrates that correct genetic
modification of the rom4 locus is possible. Immunofluo-
rescence analysis of ROM4::mCherry revealed its expres-
sion in gametocytes (Fig. S2); however, the very weak
fluorescence signals in asexual blood stages prevented
confirmation of merozoite surface location observed in
P. falciparum (Fig. S2). The normal asexual multiplication
rate (Table 2) indicates that the mCherry-tagged ROM4
functions normally during blood stage development. All
information on the failed attempts to disrupt rom4, 6, 7
and 8, including DNA constructs and primers have been
submitted to the RMgmDB database of genetically modi-
fied rodent malaria parasites (http://www.pberghei.eu).
The correct integration of the constructs and successful
disruption of the other rhomboids, rom1, 3, 9 and 10, were
confirmed by diagnostic PCR and Southern analysis of
separated chromosomes (Figs 1 and 2). Northern analy-
ses showed transcription of all four genes in blood stages
of wild type P. berghei ANKA parasites and confirmed the
lack of transcription in the blood stages of the respective
gene-deletion mutants (Figs 1 and 2). The clonal lines of
the gene-deletion mutants Drom1, Drom3, Drom9 and
Drom10 showed no change in asexual growth rates in vivo
(Table 2). Despite the evidence for transcription and
protein expression of ROM1, 9 and 10 in asexual blood
stages (Figs 1, 2 and S1; Table 1) this indicates a non-
essential, redundant function for these proteins during
asexual blood stage multiplication.
ROM9 and ROM10 are dispensable for the entire
life cycle
Two independent gene-deletion mutants were generated
for rom9: Drom9-a and Drom9-b (Fig. 2C). Asexual blood
stage multiplication, gametocyte production and ookinete
production of both Drom9 mutants were similar to that of
wild type P. berghei parasites.
We analysed Drom9-a parasites during development in
mosquitoes and in hepatocytes. The Drom9 parasites pro-
duced wild type levels of oocysts (Table 2). Although we
showed that rom9 is transcribed in salivary gland sporo-
zoites (Fig. S1), we found no significant differences
between Drom9 parasites and wild type parasites with
respect to the production of sporozoites, their gliding motil-
ity (data not shown), traversal and invasion of hepatocytes
and in the prepatent period in mice after injection of spo-
rozoites (Table 2). Immunofluorescence analyses of liver
stage parasites stained with antibodies against markers for
parasite development (HSP70), parasitophorous vacuole
membrane (PVM) (UIS4 and EXP1) and merozoite forma-
tion (MSP1), also revealed no distinct differences in mor-
phology between Drom9 and wild type liver stage parasites
at 24 h or 48 h after sporozoite invasion (Fig. 3A).
However, Drom9 parasite loads between 53 and 57 h after
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infection (measured by RT-PCR, FACS and luciferase
assay) were consistently lower both in vitro and in vivo
(Fig. 3B and C) which may indicate that this enzyme plays
a (minor) role during liver stage development.
We generated one gene deletion mutant for rom10 and
analysed this mutant throughout the entire life cycle. The
phenotype of Drom10 parasites was similar to that of wild
type parasites in all developmental assays (Table 2), spe-
cifically in vivo asexual multiplication rate, in vivo game-
tocyte production, in vitro ookinete production, oocyst and
sporozoite production and in vivo liver stage develop-
ment. In addition, Drom10 sporozoites showed normal
rates of gliding (data not shown), in vitro hepatocyte inva-
sion rate and prepatent period (Table 2). These results
indicate that this protein is redundant and/or that its func-
tion can be fulfilled by other (rhomboid) proteases.
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Fig. 1. Generation of mutants lacking expression of P. berghei rhomboid 1.
A. Schematic representation of the constructs Mg031 and pL1533 targeting rhomboid-1 for gene deletion by double cross-over homologous
recombination at the target regions (hatched boxes), and the locus before and after disruption. Each construct contains the tgdhfr/ts selection
cassette (black box). Mg031 replaces the 3rd and 4th exons (red arrows) of the ORF but retains 1st and 2nd exons in mutant Drom1-p.
pL1533 replaces the complete ORF in Drom1-c. Primer positions for diagnostic PCRs, amplicon sizes and the location of two PCR probes for
the Northern blot analyses are shown (see Table S3 for primer sequences).
B. Diagnostic PCRs (left) and Southern analyses of separated chromosomes (right) confirm the correct integration of the constructs in
Drom1-p and Drom1-c. Primer pairs and amplicon sizes are shown in A: 5′/3′ in, integration PCR; SM, amplification of the tgdhfr/ts selection
cassette; ORF, deleted ORF. For Southern analyses, pulsed field gel-separated chromosomes were hybridized with a 3′UTR pbdhfr probe that
recognizes the constructs integrated into rom1 locus on chromosome 9 and the endogenous dhfr/ts locus on chromosome 7; in the Drom1-c
line, the probe also hybridizes to the GFP-luciferase reporter cassette in the 230p locus on chromosome 3.
C. Northern blot analyses of mRNA from mixed blood stage parasites confirm the loss of wild type rom1 transcripts in Drom1-p and Drom1-c.
Locations of the PCR probes used for hybridization were shown in A (PCR probes were generated by PCR-amplification from wild type
P. berghei genomic DNA using primers 2084/2085 for Probe 1, and primers 2082/2085 for Probe 2; see Table S3 for primer sequences). In
blood stages of Drom1-p, truncated transcripts were detected with Probe 2, recognizing exons 1 and 2 of rom1. In Drom1-c, no transcripts
were detected. As a loading control, hybridization was performed with probe L644R that recognizes the large subunit ribosomal RNA. wt,
wild-type P. berghei ANKA.
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Drom1 parasites have wild type blood stage growth
and virulence characteristics, but show delayed liver
stage development
In the course of this study we generated two independent
P. berghei Drom1 mutants; the first mutant Drom1-p is a
partial gene deletion lacking the 3rd and 4th exons of
rom1 that contain the catalytic diad (Fig. 1A and B); the
second mutant Drom1-c lacks the entire open reading
frame (ORF) (Fig. 1A and B). Northern analyses of rom1
transcripts in blood stages using two PCR-amplified
probes specific to 3rd and 4th exons, or to the whole ORF,
showed that Drom1-p lacks transcripts containing the 3rd
and 4th exons but still produces stable, truncated tran-
scripts consisting of the 1st and 2nd exons. As expected,
Drom1-c had no detectable rom1 transcripts (Fig. 1C).
Both Drom1-p and Drom1-c showed in vivo multiplication
rates that were similar to wild type P. berghei parasites
when analysed in the cloning-assay (Table 2). To deter-
mine possible differences in growth rate and virulence
during prolonged infections in mice, we analysed the
growth rate of Drom1 and wild type parasites in C57BL/6
and in BALB/c mice (Fig. 4A and B). C57BL/6 mice are
sensitive to experimental cerebral malaria (ECM) and cer-
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ebral complications develop 6–8 days post-infection with
P. berghei ANKA parasites, whereas BALB/c mice are
ECM-resistant and develop fulminating (and lethal) para-
sitemias peaking 2–3 weeks after infection. In both
C57BL/6 and BALB/c mice Drom1 parasites showed
infection patterns that were highly similar to infections
initiated with wild parasites (Fig. 4A and B); all Drom1
infected C57BL/6 mice developed ECM symptoms at day
6 or 7 after infection (Fig. 4A).
Drom1 parasites were next examined during mosquito
and liver stage development. These parasites produced
numbers of ookinetes, oocysts and salivary gland sporo-
zoites similar to those of wild type parasites (Table 2).
However, liver-stage development was reduced as shown
by a 1-day extension of the prepatent period in mice
following the inoculation with 104 purified sporozoites.
While gliding motility (data not shown) and the rate of cell
traversal of sporozoites were similar to wild type parasites
(Table 2), we observed in two out of three experiments a
reduction in sporozoite in vitro invasion rates (Table 2)
that could explain (in part) the delay in the prepatent
period. Immunofluorescence analyses of liver stage para-
sites stained with antibodies against markers for parasite
development (HSP70), PVM (UIS4 and EXP1) and mero-
zoite formation (MSP1), revealed no distinct differences in
morphology and size between Drom1 and wild type liver
stages at 24 h or 48 h after sporozoite invasion (Fig. 4C).
Although a significant reduction in parasite loads and
expression of UIS4 have been reported for liver stages of
P. yoelii mutants lacking expression of ROM1 (Vera et al.,
2011), we only observed a slight, but not significant,
reduction in numbers of liver stages as determined by
anti-UIS4 antibody staining (Fig. 4D) and we did not
observe that these mutants had unusual PVM morphol-
ogy. Liver stages of Drom1 and wild-type parasites were
also comparable in size at 48 h post-infection (Fig. 4D).
Drom3 parasites establish oocysts but fail to
produce sporozoites
Two independent gene-deletion mutants, Drom3-a and
Drom3-b, were generated (Fig. 2B). Asexual blood stage
multiplication rates of both mutants determined in the
cloning assay were normal and Drom3 parasites pro-
duced wild type levels of gametocytes, ookinetes and
oocysts (Table 2). By light microscopy, Drom3 ookinetes
have the characteristics of fully mature wild-type ooki-
netes such as an elongated ‘banana’ shape, hemozoin
clusters and a centrally located, enlarged nucleus and
the Drom3 and wild type ookinetes show a similar (tetra-
ploid) DNA content (Fig. S3). In addition, by electron
microscopy analyses we were unable to detect differ-
ences in the ultrastructural morphology of wild-type and
Drom3 ookinetes, with respect to the nucleus, crystalloid
body and the structure of the apical complex (Fig. S5).
All membranes of these organelles exhibit a normal
structure and the apical complex of Drom3 ookinetes
had the characteristic features of abundant micronemes,
and the presence of microtubules and the inner mem-
brane complex.
However, no sporozoites were detected in salivary
glands of mosquitoes infected with Drom3-a or Drom3-b in
three independent experiments. Inspection of Drom3
oocysts by light-microscopy revealed normal oocyst pro-
duction but a complete absence of sporozoite formation;
mature oocysts had clearly vacuolated cytoplasm and
there were no signs of sporulation (Fig. 5A). Western
analysis of circumsporozoite protein (CSP) expression
using anti-CSP antibody in oocysts-containing midguts at
day 10 after infection, showed that CSP is almost absent
in the Drom3 oocysts (Fig. 5B). An indirect IFA on wild
type and Drom3 oocysts confirmed the strongly reduced
CSP levels in Drom3 oocysts (Fig. 5C). There was also
Fig. 2. Generation of mutants lacking expression of P. berghei rhomboid 3, 9 and 10.
A. Schematic representation of the DNA construct used for targeting rhomboid genes for deletion and the gene locus before and after
disruption. The constructs which contain a drug-selectable marker cassette (SM; black box) disrupt the genes by double cross-over
homologous recombination at the target regions (hatched boxes). The locations of primers for diagnostic PCRs are shown.
B. Diagnostic PCRs, Southern and Northern analyses confirm correct disruption of rhomboid 3 (rom3) in 2 independent mutants, Drom3-a and
Drom3-b. For diagnostic PCRs (left), the following primers were used: 5′ integration (5′ in): 2389/695; 3′ integration: (3′ in) 4239/1886;
amplification of the tgdhfr/ts selection cassette (SM): 4598/4599; deleted ORF (ORF): 1812/1813. For Southern analyses of separated
chromosomes (middle), pulsed field gel-separated chromosome were hybridized using a tgdhfr/ts probe that recognizes the construct
integrated into rom3 locus on chromosome 7. Northern blot analysis (right) of mRNA of different blood stages shows transcripts only present
in wild type gametocytes (gct). No transcripts are detected in trophozoites (troph) or schizonts (schz). The analysis also confirms the loss of
rom3 transcripts in gct of Drom3. Hybridization was performed using a PCR probe recognizing rom3 ORF (primers 1812/1813). As a loading
control, hybridization was performed with probe L644R that recognizes the large subunit ribosomal RNA.
C. Analysis of two independent mutants, Drom9-a and Drom9-b, lacking expression of ROM9. For diagnostic PCRs (left), the following primers
were used: 5′ in: 7083/4906; 3′ in: 4239/7084; SM (hdfhr::yfcu): 4698/4699; ORF: 7085/7086. For Southern analyses (middle), chromosomes
were hybridized using a 3′UTR pbdhfr probe that recognizes the construct integrated into rom9 on chromosome 11, the dhfr/ts on
chromosome 7 and the GFP-luciferase reporter cassette in the 230p locus on chromosome 3. Northern blot was hybridized with a PCR probe
recognizing rom9 ORF (primers 7085/7086) (right).
D. Analysis of Drom10 lacking expression of ROM10. For diagnostic PCRs (left), the following primers were used: 5′ in: 6939/4179; 3′ in:
4239/2088; SM (tgdhfr/ts): 4598/4599; ORF: 6940/2066. Chromosomes were hybridized using a 3′UTR pbdhfr probe that recognizes the
construct integrated into rom10 on chromosome 11 and the dhfr/ts on chromosome 7 (middle). Northern blot was hybridized with a PCR probe
recognizing rom10 ORF (primers 6940/2066) (right). See Table S3 for all primer sequences and product sizes.
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reduced intensity of Hoechst DNA-staining indicating
decreased DNA replication in these oocysts (Fig. 5C). The
crucial role of ROM3 in oocyst maturation/sporogony is
unexpected given the high transcript levels detected in
gametocytes (Table 1, Fig. S1B). When we analysed
ROM3::GFP expression in rom3::gfp parasites (with
the endogenous rom3 C-terminally tagged with GFP), we
observed GFP signal in all female gametocytes (but not in
male gametocytes) that persisted into mature ookinetes
but was undetectable in oocysts (days 6–17) and sporo-
zoites (Fig. 5D).
The normal development throughout the life cycle
(Fig. 5D, Table 2) indicates that the C-terminal GFP-tag
does not affect the essential function of ROM3 during
sporozoite formation. We attempted to use the rom3::gfp
parasites to gain a better understanding of the localization
of ROM3 in female gametocytes and ookinetes. Specifi-
cally, we extracted soluble and insoluble protein fractions
of rom3::gfp gametocytes and ookinetes and then exam-
ined the presence of ROM3 protein using antibodies
against the GFP tag. Unfortunately, we were unable to
unambiguously identify ROM::GFP in either fraction,
presumably due to the very low expression of ROM3 in
these stages (data not shown).
Discussion
The discovery of critical roles for certain rhomboid pro-
teins in motility, host cell invasion and pathogenesis of
apicomplexan parasites has attracted considerable atten-
tion. However, 10 years after their initial discovery, only
two of the eight rhomboids of malaria parasites, ROM1
and ROM4, have been analysed in more detail. Multiple
roles have been suggested for ROM1 and ROM4: inva-
sion of red blood cells (RBC) (O’Donnell et al., 2006),
sporozoite gliding motility (Ejigiri et al., 2012) and the
formation of the PVM in infected hepatocytes (Vera et al.,
2011). In this study, we investigated expression patterns
of all eight P. berghei rhomboids and examined the effects
of rhomboid gene deletion across the entire life cycle of
the parasite in order to pinpoint additional, new role for
this intramembrane protease family. In line with previously
published work, our studies support the observations that
ROM1 is dispensable for parasite development through-
out the life cycle (Srinivasan et al., 2009; Vera et al., 2011)
and that ROM4 is essential for asexual blood stage devel-
opment (O’Donnell et al., 2006). We identified three
more rhomboids that are dispensable for asexual blood
stage development: ROM3, ROM9 and ROM10. Mutants
lacking expression of ROM9 and ROM10 can complete
the entire life cycle without major developmental defects.
These observations indicate functional redundancy for
several rhomboids (ROM1, 9 and 10) and suggest that
processing of essential substrates may be fulfilled by
more than one protease. ROM4 and ROM1 are targeted
to different cellular locations in the merozoite – surface
and microneme (O’Donnell et al., 2006) – making it
unlikely that they process identical substrates that would
allow ROM4 to compensate for ROM1 in the Drom1
mutant, and clearly not vice versa.
The repeated failure to delete ROM4, ROM6, ROM7
and ROM8 genes indicate that these rhomboids play key
and most likely independent roles during blood stage
development that cannot be met by other proteins.
Located on the merozoite surface, P. falciparum ROM4 is
strongly implicated in the shedding of the erythrocyte
binding antigen 175 (EBA175) during merozoite invasion
(O’Donnell et al., 2006). Rodent malaria parasites lack
EBA175 but express a homologue of EBA140 (BAEBL)
which also belongs to the same EBL (erythrocyte-binding-
like) TM protein family. Similar to EBA175, P. falciparum
EBA140 is also an in vitro substrate of ROM4 (Baker
et al., 2006), and in P. yoelii EBA140 (PY04764) is essen-
tial for RBC invasion (Otsuki et al., 2009). Interestingly,
in P. berghei the related protein, PBANKA_133270, also
contains a putative cleavage site, similar to the one
found in EBA140. Our successful C-terminal tagging of
P. berghei ROM4 strengthens the notion that the failure to
disrupt rom4 is not due to inaccessibility of this specific
locus to genetic modification, but is due to its key role in
the enzymatic processing of surface molecules like
EBA140. Combined these data suggest that ROM4
shares essential roles in both human and rodent malaria
parasites through cleavage of one or more merozoite
surface proteins involved in RBC invasion, which cannot
be compensated by other rhomboid or non-rhomboid
Fig. 3. Liver stage development of Drom9 parasites.
A. Immunofluorescence assays of liver stages of Drom9 and the wild type (wt) control PbGFP-Lucschz at 24 h and 48 h after sporozoite
infection of cultured Huh7 cells show a comparable morphology of Drom9 and wild type parasites. Anti-HSP70 (red) antibody highlights the
parasite’s cytoplasm while anti-UIS4 (green) antibody decorates the PVM. Anti-MSP1 (red) antibody recognizes developing merozoites and
anti-EXP1 (green) antibody the PVM. Nuclei were stained with Hoechst-33342 (Blue). BF, bright field; scale bars equals 10 mm.
B. Parasite loads at 57 h in cultured Huh7 cells after infection with 5 ¥ 104 Drom9 or wild type control PbGFP-Lucschz sporozoites as
determined by luciferase assay (left), qRT-PCR (middle) and FACS (right). All assays show a slight reduction of mutant parasite loads,
however, only the relative infection value determined by qRT-PCR shows significant reduction (Student’s t-test: n.s: not significant; *P < 0.5).
C. Parasite loads in C57BL/6 mice at 53 h after injection of 1 ¥ 104 Drom9 sporozoites or wild type control PbGFP-Lucschz sporozoites as
determined by in vivo imaging (left and middle) and qRT-PCR (right). Representative rainbow images of luminescence in livers of live mice
(left) and the corresponding luminescence levels (photons s-1) of livers in whole mice (middle) are shown (Student’s t-test: n.s: not significant).
The lines indicate mean values and the error bars indicate standard deviations. This figure is available in colour online at
wileyonlinelibrary.com.
Loss-of-function analyses of Plasmodium rhomboids 327
© 2013 Blackwell Publishing Ltd, Molecular Microbiology, 88, 318–338
BALB/cB
P
ar
as
it
e 
d
en
si
ty
 (
R
L
U
) 
0 5 10 15 20
102
103
104
105
106
rom1
wt
Δrom1-c
t
1 2 3 4 5 6
0
5
10
15
20
25
rom1-c
rom1-p
wt
0 1 2 3 4 5 6 7
0
50
100
538cl2
1496cl4
wildtypeP
ar
as
it
em
ia
 (
%
)
Days post infection
C57BL/6A
Days post infectionDays post infection
S
u
rv
iv
al
 (
%
)
Δr 1-c
Δrom1-p
wt
Δrom1-c
Δrom1-p
t
D
0
500
1000
1500
2000
t 1
0
100
200
300
400
n.s
Δrom1-cwt Δrom1-cwt
E
E
F
 n
u
m
b
er
s
E
E
F
 s
iz
es
 (
µ
m
2 )n.s
24hr after infection
48hr after infection
C
BF αHSP70 αUIS4 Hoechst Merge
wt
Δrom1-c 
BF αMSP1 αEXP1 Merge
wt
Hoechst
Δrom1-c 
328 J. Lin et al. 
© 2013 Blackwell Publishing Ltd, Molecular Microbiology, 88, 318–338
proteases. ROM4 from another apicomplexan parasite,
T. gondii, has been established as a sheddase during
gliding motility and invasion (Parussini et al., 2012). In
addition to ROM1 and ROM4, P. falciparum ROM7 and
ROM8 are also expressed in merozoites (Baker et al.,
2006). It is, however, unlikely that these proteins process
the same TM spanning proteins as ROM1 or ROM4,
because they do not show the same in vitro substrate
specificities as ROM1 or ROM4 (Baker et al., 2006). Plas-
modium ROM7 only has orthologues in the apicomplexan
parasites, Babesia bovis and Theileria annulata, while
ROM8 does not cluster with any other apicomplexan
rhomboids (Santos et al., 2011b).
Plasmodium ROM6 is the orthologue of T. gondii
ROM6, which clusters with the PARL-like mitochondrial
rhomboids and localizes to the single mitochondrion
(Santos et al., 2011b); however, a mitochondrial location
in Plasmodium has yet to be confirmed. These ROM6
proteins share common features in their TM domains
and catalytic sites, which are characteristic for PARL-type
rhomboids (Lemberg and Freeman, 2007), and contain
predicted mitochondrial-targeting sequence (Verma et al.,
2010). Known conserved substrates of PARL-type rhom-
boids are dynamin-related proteins (McQuibban et al.,
2003; Dowse and Soldati, 2005). Plasmodium species
express two conserved dynamins: DYN1 (PBANKA_
090360) and DYN2 (PBANKA_052040). Interestingly,
phylogenetic analyses show that Plasmodium DYN2 clus-
ters with dynamins of other species that are mainly impli-
cated in the division of the mitochondrial outer membrane
(Charneau et al., 2007). Attempts to disrupt the dyn2 gene
were unsuccessful (Gunnar R. Mair and Chris J. Janse,
unpubl. data; http://www.pberghei.eu/index.php?rmgm=
765), suggesting its essential role in asexual stage para-
sites. Further research is needed to determine whether
DYN2 is the substrate of ROM6 and protein localization
studies with tagged proteins or antibodies may reveal
whether both proteins are indeed located in the mitochon-
dria in blood stages.
Although ROM1 is not essential for blood stage para-
sites, it has been reported that P. berghei and P. yoelii
mutants lacking ROM1 exhibit a slight growth delay and
appear less virulent in mice than wild type parasites
(Srinivasan et al., 2009; Vera et al., 2011). In contrast, we
were unable to detect either a growth or virulence-
attenuation phenotype in experiments conducted with two
independent P. berghei Drom1 lines. The cause for these
discrepancies in blood stage phenotypes between our
and the P. berghei mutant reported by Srinivasan et al.
(2009) is unknown. In the study of Srinivasan et al.
(2009), the mutant clone examined was derived from a
single transfection experiment that generated a 3′ end
truncation of the gene encoding ROM1, preserving a large
part of the ROM1 protein. We were able to detect a stable,
although truncated, transcript transcribed from the 5′ end
of the gene in the Drom1-p mutant; whether these are
translated into stable, truncated proteins that are inserted
into the membrane exerting a dominant-negative effect is
unknown. Cloned lines of wild type P. berghei ANKA para-
sites are known to differ in growth and virulence charac-
teristics (Amani et al., 1998) and environmental factors
have been shown to influence the course of infections in
mice (Levander et al., 1995); such differences between
laboratories may influence the outcome of phenotypic
analyses of genetically identical mutants. Therefore, the
reported growth and virulence phenotype may be unre-
lated to the disruption of rom1.
In contrast to normal blood stage infections of the
mutants reported in this study, we found that Drom1 para-
sites have a slight defect in liver stage development with
a consistent delay of 1 day in blood stage patency follow-
ing sporozoite infection. A prolonged prepatent period was
also observed by Srinivasan et al. (2009). This finding
was confirmed by a twofold reduction in liver stage devel-
opment of P. yoelii Drom1 parasites (Vera et al., 2011). It
has been suggested that this reduction in P. yoelii liver
development results from reduced cleavage of the PVM
protein UIS4 (upregulated in sporozoites 4) (Vera et al.,
Fig. 4. Blood and liver stage development of Drom1 parasites.
A. The course of infection (left panel) and survival curve (right panel) in C57BL/6 mice (n = 6) infected with 105 wild-type (wt, cl15cy1),
Drom1-p or Drom1-c. The parasitemia developed in mice infected with wt, Drom1-p and Drom1-c parasites are highly comparable during the
whole course of infection (left). All C57BL/6 mice infected with wild-type (wt, cl15cy1), Drom1-p and Drom1-c parasites developed ECM
complications on day 6–7 as indicated by a drop in body temperature below 34°C; mice were sacrificed at this point (right).
B. The course of infection in BALB/c mice (n = 6) infected with 104 parasites of wild-type (wt, GPF-luccon) or Drom1-c parasites. Parasite
densities were determined by measuring luciferase activity indicated as relative light unit (RLU) in the IVDL-assay. Error bars indicate standard
deviations in A and B.
C. Immunofluorescence analyses of Drom1-c and the wild type (wt, GFP-Luccon) exo-erythrocytic forms (EEF) at 24 h and 48 h after infection
with 1 ¥ 104 Drom1-c or wild type (GFP-Luccon) parasites show normal development of Drom1-c parasites compared with wild type control.
Anti-HSP70 (red) and anti-UIS4 (green) antibodies recognize the parasite’s cytoplasm and the PVM. Anti-MSP1 (red) antibodies recognize
developing merozoites and anti-EXP1 (green) antibodies stain the PVM. Nuclei were stained with Hoechst-33342 (Blue). BF, bright field; scale
bars equals 10 mm.
D. EEF numbers per well of cultured Huh7 cells at 24 h (left) and the sizes of EEFs at 48 h (right) after sporozoite infection. The numbers of
EEFs were determined by counting anti-UIS4 staining positive EEFs in the immunofluorescence assay, and the EEF sizes were determined by
measuring the sizes of anti-Hsp70 staining positive parasites. The lines indicate mean values and the error bars indicate standard deviations.
This figure is available in colour online at wileyonlinelibrary.com.
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2011). However, when we analysed liver stage develop-
ment of P. berghei Drom1 parasites, we did not find
evidence for the aborted liver stage development or para-
sites with unusual PVM morphology. In addition to the
prolonged prepatent period, we did observe a decrease in
sporozoite invasion rate in two out of three experiments.
However, since there are discrepancies in Drom1-c
sporozoite-hepatocyte invasion rates, we cannot con-
clude that a reduction in invasion is responsible for the
delay in the prepatent period. Altogether, the phenotypic
observations of different Drom1 parasites prove that
ROM1 is not essential throughout the complete life cycle
in both P. berghei and P. yoelii. In addition to ROM1, our
loss-of-function analyses indicate that there is large
degree of functional redundancy of Plasmodium rhom-
boids. We identified two other rhomboids, ROM9 and
ROM10, which are dispensable throughout the complete
life cycle. Both rhomboids are exclusive to Plasmodium
(Santos et al., 2011b). Interestingly, ROM9 carries a mito-
chondrial targeting sequence (MitoProtII http://ihg.gsf.de/
ihg/mitoprot.html) but its predicted topology is atypical
of mitochondrial PARL-like rhomboids (Lemberg and
Freeman, 2007). ROM10 lacks key residues predicted to
be critical to rhomboid proteolysis (Baker et al., 2006;
Lemberg and Freeman, 2007) and is therefore likely an
inactive rhomboid. Although the expression of ROM10
was detected in multiple stages in P. falciparum, and our
RT-PCR and Northern analyses also confirmed its expres-
sion in blood stage, the gene-deletion mutant showed no
phenotypic defect throughout the entire life cycle.
In contrast to the Drom1, Drom9 and Drom10 parasites,
mutants lacking ROM3 expression exhibit a strong and
distinct phenotype. The gene encoding ROM3 is highly
transcribed in gametocytes and in the rom3::gfp mutant,
the GFP signal was clearly observed in female gameto-
cytes through to the ookinete stage but was absent from
developing oocysts and sporozoites. P. berghei mutants
lacking ROM3 are capable of producing normal numbers
of oocysts; however, these oocysts show a complete
absence of sporozoite formation. This is the first apicom-
plexan rhomboid identified to play such a vital role in
sporogony. Mutant oocysts show clear signs of stalled
DNA replication and a failure to form individual sporo-
zoites, and remain highly vacuolated. This ‘delayed
phenotype’ in mutants which lack proteins normally
expressed in female gametocytes/gametes but only mani-
fest the consequences of the loss-of-function in maturing
oocysts is not unique. Examples include several members
of the LCCL/lectin adhesive-like protein (CCp/LAP) family
with their distinct Lgl1(LCCL)-lectin adhesive domains
(Raine et al., 2007). Deletion of these also female game-
tocyte expressed genes produces a phenotype in matur-
ing oocysts comparable to the one observed in the Drom3
parasites; vacuolated oocysts and absence of sporozoite
formation (Raine et al., 2007; Ecker et al., 2008; Lavazec
et al., 2009). CCp/LAP proteins have no TM domains and
therefore are unlikely ROM3 substrates. They are local-
ized to the crystalloid body in ookinetes which has been
postulated to constitute a reservoir of proteins synthe-
sized by the gametocyte to be used during oocyst growth
and sporozoite development (Garnham et al., 1962; 1969;
Saeed et al., 2010). However, ultrastructure analysis of
the Drom3 and wild-type ookinetes revealed no distinct
differences with respect to their crystalloid bodies. In
addition, although we observed a punctate location
of ROM3::GFP in ookinetes, we did not observe the
crystalloid-type location that was shown for LAP2 and
LAP3 (Saeed et al., 2010). A failure of oocysts to sporu-
late also occurs in the absence of three other membrane-
bound proteins: glycosyl phosphatidyl inositol (GPI)
anchored CSP (PBANKA_040320) (Menard et al., 1997),
or TM domain containing plasmepsin VI (PBANKA_
040970) (Ecker et al., 2008) and PBANKA_130960
(Lasonder et al., 2008). CSP is localized on the oocyst
plasma membrane and on the inner surface of the oocyst
capsule; when budding begins, large amounts of CSP
cover the surface of sporoblasts and sporozoites (Thathy
et al., 2002). Our analyses of CSP expression and
processing in Drom3 parasites show that although CSP
expression is strongly reduced (Figs 5B and S4), process-
Fig. 5. Rhomboid 3 is essential for sporozoite formation in oocysts.
A. Phase contrast microscopy of wild type and aberrant, vacuolated Drom3 oocysts on day 12 after mosquito infection. Mutants lack any signs
of sporozoite formation (white arrow) whereas wild type (wt) oocysts collected on the same day show clear sporulation (black arrow). Scale
bar 10 mm.
B. Western blot analysis of midguts from infected mosquitoes. Midguts from mosquitoes infected with Drom3 (1 or 2 midguts, day 10) and
wild-type (wt, day 10) were separated on SDS-PAGE and stained with anti-CSP and anti-HSP70 antibodies. A longer exposure of the
anti-CSP blot is also shown.
C. Developmental defects of Drom3 parasites examined by immunofluorescence assays. Compared with wild-type (wt), Drom3 oocyst show
decreased CSP expression as shown by staining oocysts with anti-CSP (green) antibody and reduced staining with the DNA-specific dye
Hoechst-33342 (blue), indicating less DNA replication. BF, bright field. Scale bar 10 mm.
D. All rom3::gfp female gametocytes (F gct; n = 50) and ookinetes (n > 100) exhibited a GFP signal that was significantly above background
values (***P < 0.0001, Student’s t-test). No GFP signals above background were detected in either male gametocyte (M gct; n = 30) or
asexual blood stages. In the mosquito vector no GFP signals were detected in either rom3::gfp oocysts (6–17 days after mosquito infection) or
in salivary gland sporozoites (sgs, day 21). Nuclei are stained with Hoechst-33342 (blue). BF, bright field. Scale bar 10 mm. n.s, not significant,
Student’s t-test. This figure is available in colour online at wileyonlinelibrary.com.
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ing appears to be normal (Fig. S4). Given that CSP con-
tains a GPI anchor it is unlikely to be processed by ROM3.
As most identified natural substrates of rhomboid pro-
teases contain only a single TM domain, it is questionable
if PBANKA_130960 is a substrate since it has several
putative TM domains (http://www.plasmodb.org). In
Table S5 we provide a list of putative substrates of ROM3,
based on the published proteome data of oocysts and
sporozoite proteins (http://www.plasmoDB.org), which are
predicted to contain a single TM domain and encode a
signal peptide. Whether plasmepsin VI is the substrate of
ROM3 and contributes to the phenotype observed in
ROM3-deficient mutants remains to be investigated.
Since we observe expression of ROM3 in gametocytes
and ookinetes and not in developing and mature oocysts,
it is very much possible that the ROM3 substrate(s) is
(are) also present and cleaved in gametocytes/ookinetes.
In this study we have examined all eight rhomboid
proteases encoded by P. berghei and found four of them
(ROM4, 6, 7 and 8) to be critical for asexual development,
and one (ROM3) essential for mosquito development.
While some member of these rhomboids may govern
processes common to a large number of eukaryotic
species (for example, the mitochondrial PARL-like rhom-
boid ROM6), most of them are unique to Apicomplexa and
some unique to Plasmodium. These specific rhomboids
and their substrates offer themselves as targets for
anti-parasite interventions. While the exact nature of the
function of most rhomboids and their substrate range
remain to be elucidated, this study helps provide a clear
framework of expression, function in parasite develop-
ment and the specific and redundant enzymatic activities
of this important class of proteases.
Experimental procedures
Experimental animals and P. berghei ANKA
reference lines
Female C57BL/6, BALB/c and Swiss OF1 mice (6–8 weeks)
and male C57BL/6 (6–8 weeks) from Charles River were
used. All animal experiments performed at the LUMC were
approved by the Animal Experiments Committee of the
Leiden University Medical Center (DEC 07171; DEC 10099).
The Dutch Experiments on Animal Act is established under
European guidelines (EU directive no. 86/609/EEC regarding
the Protection of Animals used for Experimental and Other
Scientific Purposes). Animals used at the Instituto de
Medicina Molecular, Faculdade de Medicina, Universidade
de Lisboa, were housed in the Specific Pathogen Free facili-
ties of the Institute. All experimental procedures were carried
strictly within the rules of the Portuguese official Veterinary
Directorate (Direcção Geral de Veterinária), which complies
with the European Guideline 86/609/EC and follows the
FELASA (Federation of European Laboratory Animal Science
Associations) guidelines and recommendations concerning
laboratory animal welfare.
Three reference P. berghei ANKA parasite lines were used
for generation of the gene-deletion mutants and the trans-
genic parasites: the ‘wild type’ (wt) line cl15cy1 (Janse et al.,
2006b) and two reporter lines, i.e. PbGFP-LUCcon (line
676m1cl1; mutant RMgm-29; http://www.pberghei.eu) and
PbGFP-Lucschz (line 1037cl1; mutant RMgm-32; http://
www.pberghei.eu). Both reporter lines were generated in the
cl15cy1 parent line and express the fusion protein GFP-
Luciferase either under the control of the constitutive eef1a
promoter or the schizont-specific ama1 promoter respec-
tively. The gfp-luc expression cassette is stably integrated
into the pb230p locus without introduction of a drug-
selectable marker (Janse et al., 2006a; Spaccapelo et al.,
2010).
RT-PCR analyses
To investigate the transcription pattern of the different rhom-
boid genes, RT-PCR was performed for each gene using
cDNA from (i) asexual blood stages of a non-gametocyte
producer P. berghei ANKA parasite line (HPE) (Janse et al.,
1989), (ii) purified gametocytes of wild type P. berghei ANKA
(cl15cy1) parasites and (iii) salivary gland sporozoites of wild
type P. berghei ANKA (cl15cy1). Primers were designed spe-
cific to the ORF of each gene and across introns when
possible in order to distinguish amplicons from gDNA and
cDNA. Details of the primers and expected sizes are shown
in Table S4.
Generation of gene deletion mutants
To disrupt the rhomboid genes, the following replacement
constructs were generated. Plasmid constructs targeting
rom1, 3, 4, and 10 were constructed in the generic plasmid
pL0001 (http://www.mr4.com) which contains the pyrimeth-
amine resistant Toxoplasma gondii (tg) dihydrofolate
reductase-thymidylate synthase (dhfr/ts) as a selectable
marker (SM) under the control of P. berghei dhfr/ts promoter.
Targeting regions for homologous recombination were PCR-
amplified from P. berghei ANKA (cl15cy1) genomic DNA
using primers specific for the 5′ or 3′ ends of each rhomboid
gene (see Table S2 for the primer sequences) and cloned in
upstream and downstream, respectively of the SM; this
allows integration of the construct into the targeting regions
by double cross-over homologous recombination and com-
plete replacement of the ORF. For transfection the gene-
deletion constructs were linearized with the appropriate
restriction enzymes (Table S2).
Constructs targeting rom6, 8 and 9 were generated using a
modified two-step PCR method (Lin et al., 2011). Briefly, in
the first PCR reaction two fragments of 5′ and 3′ targeting
regions (TR) were amplified from P. berghei ANKA (cl15cy1)
genomic DNA with the primer sets shown in Table S2. The
reverse primers of 5′TR and the forward primers of 3′TR have
5′ extensions homologous to the hdhfr::yfcu selectable
marker cassette from pL0048. In the second PCR reaction,
the 5′TR and 3′TR were annealed to either side of the
selectable marker cassette, and the joint fragment was ampli-
fied by the external anchor-tag primers 4661/4662, resulting
in the PCR-based targeting constructs. Before transfection,
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the PCR-based constructs were digested with NruI (as
indicated in primer sequences in Table S2) to remove the
‘anchor-tag’ and with DpnI that digests any residual uncut
pL0048 plasmid.
Transfection and selection of transformed parasites with
pyrimethamine was performed using standard technology for
the genetic modification of P. berghei (Janse et al., 2006b).
All information on the generation of gene-deletion mutants
(as well as unsuccessful disruption attempts), such as DNA
constructs and primers, has been submitted to the RMgmDB
database of genetically modified rodent malaria parasites
(http://www.pberghei.eu).
Clonal parasite lines were obtained from all gene-deletion
mutants by the method of limiting dilution. Correct integration
of DNA constructs and disruption of the genes was verified by
diagnostic PCR analyses (see Table S3 for primers used) and
Southern analyses of chromosomes separated by pulsed-
field gel electrophoresis hybridized with probes specific for
the selectable maker (see Table S3 for primers used) (Janse
et al., 2006b).
Generation and analyses of parasites expressing
ROM3::GFP and ROM4::mCherry
To tag ROM3 C-terminally with GFP, 1.6 kb upstream of the
stop codon of rom3 containing the entire ORF were PCR-
amplified from wild-type P. berghei ANKA genomic DNA,
TOPO-cloned and sequence analysed (see Table S2 for the
primers). The fragment was released from pCR2.1-TOPO
(Invitrogen) through digestion with EcoRV and BamHI and
ligated into the generic GFP-tagging plasmid pL1200 (Mair
et al., 2010), resulting in construct pL1079 containing the
pyrimethamine resistant tgdhfr/ts as a selectable marker. To
tag ROM4 with mCherry, the complete ORF of rom4 (except
the stop codon) was PCR-amplified from wild type P. berghei
ANKA genomic DNA (see Table S2 for the primers used). This
ORF was digested with SpeI and BglII, and ligated into SpeI/
BamHI digested vector pL1646 (containing a C-terminal
mCherry tag and the tgdhfr/ts selectable marker cassette),
resulting in construct pL1920. Before transfection, pL1709
was linearized with SpeI, and pL1920 was linearized with
BamHI. Transfection, selection and cloning of transgenic
parasites with pyrimethamine was carried out as described
above, generating the following transgenic lines, rom3::gfp
(line 654cl1) and rom4::mCherry (line 2143cl1) that express
endogenous C-terminally tagged ROM3 and ROM4 respec-
tively. The live GFP or mCherry signals of parasites of the
transgenic mutants were examined by fluorescence micros-
copy (Leica DM-IRBE Flu) after staining with Hoechst-33342
(2 mmol l-1, Sigma, NL) for 15 min at room temperature. The
fluorescence intensity was measured using ImageJ software.
Analysis of transcription of rhomboid genes in blood
stages of wild type and gene-deletion parasites
Transcript levels were analysed by standard Northern blot
analyses. Total RNA was isolated from mixed blood stages or
different stages of wild type P. berghei ANKA (cl15cy1), non-
gametocyte producer line (HPE) and the different gene-
deletion mutant lines. Northern blots were hybridized with
probes specific for each rhomboid ORF, which had been
PCR-amplified from wild-type P. berghei ANKA genomic DNA
(primers shown in Table S3). As a loading control, Northern
blots were hybridized with the oligonucleotide probe L644R
that recognizes the large subunit ribosomal RNA (van
Spaendonk et al., 2001).
In vivo multiplication rate of asexual blood stages
The multiplication rate of asexual blood stages in mice is
determined during the cloning procedure of each gene-
deletion mutant (Spaccapelo et al., 2010) and is calculated
as follows: the percentage of infected erythrocytes in Swiss
OF1 mice injected with a single parasite is quantified at days
8–11 on Giemsa-stained blood films. The mean asexual mul-
tiplication rate per 24 h is then calculated assuming a total of
1.2 ¥ 1010 erythrocytes per mouse (2 ml of blood). The per-
centage of infected erythrocytes in mice infected with refer-
ence lines of the P. berghei ANKA strain consistently ranges
between 0.5 and 2% at day 8 after infection, resulting in a
mean multiplication rate of 10 per 24 h (Janse et al., 2003;
Spaccapelo et al., 2010).
Course of parasitemia, virulence and experimental
cerebral malaria in mice infected with Drom1 parasites
The course of parasitemia was determined in BALB/c mice.
Groups of six mice were intraperitoneally (i.p) infected with
104 Drom1-c parasites or equal numbers of the parental
reporter line PbGFP-LUCcon. The course of parasitemia
was determined in a luciferase assay (IVDL-assay)
(Franke-Fayard et al., 2008); in vivo parasite growth in mice
is quantified by measuring the luciferase activity of GFP-
Luciferase expressing parasites in tail blood. The IVDL-assay
generates growth-curves that are identical to those obtained
by manual counting of parasites in Giemsa-stained smears.
In brief, 10 ml tail blood was collected daily from all mice using
heparinized capillaries. Samples were stored at -80°C in
Eppendorf tubes till further processing for the luciferase
assay. Luciferase activity (luminescence) in the samples was
measured as described (Franke-Fayard et al., 2008; Lin
et al., 2013).
The capacity of Drom1 to induce features of ECM was
analysed in C57BL/6 mice. Groups of six mice were infected
with 105 P. berghei ANKA (cl15cy1), Drom1-p or Drom1-c
parasites. Onset of ECM in P. berghei infection was deter-
mined by measurement of a drop in body temperature below
34°C (Spaccapelo et al., 2010). The body temperature of
infected mice was measured twice a day from day 5 to day 8
after infection using a laboratory thermometer (model BAT-
12, Physitemp Instruments, Clifton, NJ) with a rectal probe
(RET-2) for mice. When infected mice showed a drop in
temperature (below 34°C) the mice were sacrificed.
Gametocyte and ookinete production
Gametocyte production is defined as the percentage of ring
forms developing into mature gametocytes during synchro-
nized infections (Janse and Waters, 1995). Ookinete produc-
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tion was determined in standard in vitro fertilization and
ookinete maturation assays and is defined as the percentage
of female gametes that develop into mature ookinetes under
standardized in vitro culture conditions (van Dijk et al., 2001).
Female gamete and mature ookinete numbers were deter-
mined in Giemsa-stained blood smears made 16–18 h post-
activation.
Electron microscopy
Ookinetes were cultured in vitro as previously described (van
Dijk et al., 2001); briefly, gametocytes for these assays were
obtained from infected mice that had been pretreated with
phenylhydrazine and treated with the antimalarial drug sul-
fadiazine (dissolved in the drinking water at a concentration
of 30 mg l-1) to obtain highly pure gametocyte populations
(Beetsma et al., 1998). Ookinetes from these cultures were
purified using a Nycodenz density gradient centrifugation.
The purified ookinetes were diluted in RPMI medium (without
serum) and fixed by resuspending them in an equal amount
of 3% glutaraldehyde (Electron Microscopy Sciences, Hat-
field, PA) in 0.2 M sodium cacodylate pH 7.4 (1 h at RT),
washed twice with cacodylate buffer (spinning for 2 min at
425 g), post-fixed with 1% osmium tetroxide (Electron Micro-
scopy Sciences, Hatfield, PA) in cacodylate buffer (1 h at RT),
and washed again with cacodylate buffer. Subsequently, the
samples were stained with an aqueous solution of 1% uranyl
acetate for 40 min at RT, washed twice with demineralized
water, resuspended in 3% agar (Difco Laboratories, Detroit,
Michigan; in demineralized water at 60°C), centrifuged (for
2 min at 425 g) and stored at 4°C until the agar became solid.
The samples were dehydrated in series of washes 70%
(overnight), 80% (10 min), 90% (10 min) and 100% ethanol
(1 h, refreshing two times), infiltrated with a 1:1 mixture of
epon LX 112/propylene oxide (1 h) and pure epon (3 h), fol-
lowed by embedding in epon and polymerization for 48 h at
60°C. The samples were cut using a Leica UC6 ultramicro-
tome at RT into 100nM sections with a Diatome ultra
45°diamond knife (Diatome, Switzerland) at a cutting speed
of 1 mm s-1. The sections were attached to slot copper grids
(Stork Veco BV, Eerbeek, the Netherlands), covered with 1%
formvar film and a 7 nm carbon layer; no post-staining was
applied prior to data collection. Imaging was performed in a
Tecnai 12 Twin transmission electron microscope (FEI
Company). Transmission electron microscope was operated
at an acceleration voltage of 80 kV, and binned images
(2k ¥ 2k) were acquired with a FEI Eagle CCD camera (FEI
Company).
Oocyst and sporozoite production in Anopheles
stephensi mosquitoes
For mosquito transmission experiments female A. stephensi
mosquitoes were fed on mice infected with wild-type para-
sites or mutants. Oocyst development, oocyst production and
sporozoite production was monitored in infected mosquitoes
as described (Sinden, 1997). Oocyst and sporozoites
numbers were counted in infected mosquitoes at 11–14 days
and 19–22 days after infection respectively. Salivary gland
sporozoites were isolated and counted as described
(Annoura et al., 2012).
For Western blot analysis of CSP expression in oocysts or
sporozoites, we isolated oocysts containing midguts from
infected mosquitoes, or 100 000 midgut sporozoites, and pro-
teins were separated on 8% polyacrylamide gels and trans-
ferred to nitrocellulose membranes by electroblotting. CSP
expression was detected by incubation of membranes with
monoclonal anti-CSP antibody (Potocnjak et al., 1980) fol-
lowed by incubation with horseradish-peroxidase-conjugated
anti-mouse antibody (Sigma). Immunostained protein com-
plexes were visualized by enhanced chemiluminescence
(Amersham). For the IFA, midguts of infected mosquitoes
were isolated in RPMI-Medium and immobilized with 2%
formaldehyde, 0.2% glutaraldehyde, 2 mM magnesium
chloride, 0.02% Triton X-100 in phosphate-buffered saline
(PBS). Subsequently midguts were permeabilized, using 2%
Saponin in PBS and oocysts stained with monoclonal anti-
CSP antibody and monoclonal Alexa-Fluor® 488 goat anti-
mouse antibody. DNA was stained with Hoechst-33342.
Sporozoite infectivity and liver stage development
Sporozoites were collected at days 19–25 after infection by
hand-dissection of the salivary glands as described (Annoura
et al., 2012). Gliding motility of sporozoites was determined in
assays that were performed on anti-P. berghei CSP antibody
(3D11, monoclonal mouse antibody 25 mg ml-1, 100 ml per
well) pre-coated 10-well cell-line diagnostic microscope
slides (7 mm, Thermo Scientific) to which 1 ¥ 104 sporozoites
were added (van Dijk et al., 2005). After 30 min of incubation
at 37°C sporozoites were fixed with 4% paraformaldehyde
and after washing with PBS, the sporozoites and the trails
(‘gliding circles’) were stained with anti-CSP-antiserum
(Yoshida et al., 1980) and anti-rabbit IgG-secondary antibody
(Alexa Fluor® 488 Goat Anti-rabbit IgG; Molecular Probes®,
Invitrogen). Slides were mounted with Vectorshield (Vector
Laboratories) and ‘gliding circles’ were analysed using a
Leica DMR fluorescence microscope at 1000¥ magnification.
Huh-7 cells, a human hepatoma cell line, were used in
in vitro analysis of sporozoite infectivity. Huh-7 cells were
cultured in ‘complete’ RPMI 1640 medium supplemented
with 10% (vol/vol) fetal bovine serum (FBS), 1% (vol/vol)
penicillin-streptomycin, 1% (vol/vol) GultaMAX (Invitrogen),
and maintained at 37°C with 5% CO2. Sporozoite hepatocyte
traversal was determined in assays as described previously
(Mota et al., 2001). Briefly, Huh-7 cells were suspended in
1 ml of ‘complete’ medium and were seeded in 24-well plates
(105 cells ml-1). After the Huh7 monolayers were > 80% con-
fluent, 105 sporozoites were added with the addition of FITC-
or Alexa-647-labelled dextran (Invitrogen, NL) for 2 h. No
sporozoites were added to the negative control wells. In vitro
invasion rates of mutants lacking expression of rhomboids
and wild type parasites were determined by the ratio between
the number of sporozoites inside the cells and the total
number of sporozoites (both inside and outside of cells).
Huh-7 cells (5 ¥ 104 cells per well) were seeded into cover-
slips in 24-well plates and on the following day, cells were
infected with 5 ¥ 104 sporozoites. Three hours after infection,
cells were fixed with 4% paraformaldehyde in PBS for 20 min.
For the double staining, cells were incubated for 30 min in
blocking buffer (10% FBS in PBS) followed by 1 h incubation
with anti-CSP serum against P. berghei CSP protein (Yoshida
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et al., 1980) diluted 1:500 in the same buffer. Cells were then
washed with PBS and incubated for 45 min with a secondary
antibody (anti-rabbit Alexa Fluor® 568) diluted 1:500 in block-
ing buffer. This procedure only stained the parasites outside
the cells. After washing with PBS, cells were fixed with 4%
paraformaldehyde in PBS for 30 min, then incubated in for
30 min in permeabilization buffer (1% Triton X-100 in PBS)
followed by 1 h incubation with anti-CSP serum diluted 1:500
in the same buffer. Cells were then washed with PBS and
incubated for 45 min with a secondary antibody (anti-rabbit
Alexa Fluor® 488) diluted 1:500 in blocking buffer. This
second staining allows visualization of all the parasites,
whether inside or outside the cells. Nuclei were stained with
Hoechst-33342. The parasites in both green and red chan-
nels were analysed using a DM-IRBE Flu Leica fluorescence
microscope.
For analysis of in vitro EEF (exo-erythrocytic form) devel-
opment, 5 ¥ 104 sporozoites were added to a monolayer of
Huh7 cells on coverslips in 24-well plates in ‘complete’ RPMI
1640 (see above). At different time points after infection, cells
were fixed with 4% paraformaldehyde, permeabilized with
0.5% Triton X-100 in PBS, blocked with 10% FBS in PBS,
and subsequently stained with primary and secondary anti-
bodies for 2 h and 1 h respectively. Primary antibodies used
were anti-PbEXP1 [raised in chicken (Sturm et al., 2006)] and
anti-UIS4 [raised in rabbit (Mueller et al., 2005)], detecting
the PVM-resident proteins; anti-PbHSP70 [raised in mouse
(van Dijk et al., 2005)], detecting the cytoplasmic heat shock
protein 70 (PBANKA_081890); and anti-MSP1 (mouse;
MRA-78 from MR4; http://www.MR4.org) detecting MSP1 of
P. yoelii and P. berghei. Anti-mouse, -chicken and -rabbit sec-
ondary antibodies, conjugated to Alexa Fluor® 488 and 594,
were used for visualization (Invitrogen). Nuclei were stained
with Hoechst-33342. Cells were mounted in Vectashield
(Vector Laboratories) and examined using a DM-IRBE Flu
Leica fluorescence microscope.
In addition, intracellular parasite development was deter-
mined by measuring the area of the EEFs inside fixed Huh-7
hepatoma cells. Huh-7 cells (5 ¥ 104 cells per well) were
seeded into coverslips in 24-well plates and, the following
day, cells were infected with 4 ¥ 104 sporozoites. Forty-eight
hours after infection, cells were fixed with 4% paraformalde-
hyde in PBS for 20 min. Cells were stained by incubation
for 30 min in blocking/permeabilization buffer (0.5% Triton
X-100, 1% BSA in PBS) followed by 1 h incubation with
monoclonal antibody 2E6 against P. berghei HSP70 diluted
1:500 in the same buffer. Cells were then washed with 0.5%
Triton X-100 in PBS and incubated for 45 min with a second-
ary antibody (anti-mouse Alexa488) diluted 1:400 in blocking/
permeabilization buffer. Nuclei were stained with DAPI.
Images were acquired with a Zeiss Axiovert 200 M widefield
fluorescence microscope and processed using ImageJ.
Hepatocyte infection was determined by measuring the
luminescence intensity in Huh-7 cells infected with either the
firefly luciferase-expressing Drom9 and the corresponding
control line PbGFP-Lucschz. Huh-7 cells infection and culture
conditions were as described above. At 57 h after infection,
50 ml of D-Luciferin (Firefly Luciferase Assay Kit, Biotium)
were added to 30 ml of lysed samples in white 96-well plates.
Luminescence intensity of the samples was measured using
a microplate reader (Tecan Infinite M200). The viability of
Huh-7 cells was assessed by the AlamarBlue assay (Invitro-
gen, UK) according to the manufacturer’s protocol.
To determine parasite loads by qRT-PCR, sporozoites
(5 ¥ 104) were added to a monolayer of Huh7 cells (seeded
the day before with 105 cells) in 24-well plates in ‘complete’
DMEM (Dulbecco’s modified Eagle’s medium) (see above).
At different time-points after adding the sporozoites, culture
medium was removed, cells washed once with PBS, and
cells were resuspended in 200 ml of RLT buffer (Quiagen’s
MicroRNeasy kit). RNA from these samples was extracted
following the manufacturer’s instructions. The transcriptor
first-strand cDNA synthesis kit (Roche) was used according
to the manufacturer’s recommendations to make single-
stranded cDNA. Real time PCR analysis of P. berghei 18S
rRNA and human b-actin was performed as described
(Ploemen et al., 2009).
Flow cytometry analysis was used to determine the para-
site load of Drom9 in Huh-7 cell (57 h p.i) compared the wild
type control (PbGFP-Lucschz). The infection and culture con-
dition was as described above. Fifty-seven hours after infec-
tion, samples for were washed with PBS, incubated with
trypsin for 5 min at 37°C and collected in 400 ml of 10% v/v
FBS in PBS. Cells were then centrifuged at 0.1 g for 5 min,
resuspended in 300 ml of 2% v/v FBS in PBS. All samples
were analysed on a LSR Fortessa cytometer with the appro-
priate settings for the fluorophores used. Data acquisition and
analysis were carried out using the BD FACSDiva (BD Bio-
sciences) and FlowJo (v6.4.7, FlowJo) software packages
respectively.
To determine in vivo infectivity of sporozoites, Swiss OF1
mice were infected with 1 ¥ 104 salivary gland sporozoites by
intravenous injection, as previously described (Sinden,
1997). Blood stage infections were monitored by analysis of
Giemsa-stained thin smears of tail blood collected on days
4–8 after inoculation of sporozoites. The prepatent period
(measured in days post sporozoite infection) is defined as the
day when a blood stage infection with a parasitemia of
0.5–2% is observed. In addition we determined parasite
loads in livers of infected mice by in vivo imaging as
described (Ploemen et al., 2009). In addition, a group of 10
male C57BL/6 mice were inoculated by i.v. injection of 1 ¥ 104
freshly isolated sporozoites of Drom9 or its wild type control
PbGFP-Lucschz. Luciferase activity in the livers of the animals
was visualized 44 h after infection using an in vivo Imaging
System (IVIS Lumina), following i.p injection of D-luciferin
dissolved in PBS (100 mg kg-1). Animals were kept under
anesthesia during the measurements, which were performed
within 3–5 min after the injection of D-luciferin. Biolumines-
cence imaging was acquired with a 10 cm field of view,
medium binning factor and an exposure time of 180 s. Quan-
titative analysis of bioluminescence was performed by meas-
uring the luminescence signal intensity using the ROI settings
of the Living Image® 3.0 software. ROI measurements are
expressed in total flux of photons. qRT-PCR is also used to
determine the in vivo parasite load in liver. After measuring
luminescence, livers from 5 mice were collected, homog-
enized in 4 ml denaturing solution (4 M guanidine thiocy-
anate; 25 mM sodium citrate pH 7, 0.5% sarcosyl and 0.7%
b-Mercaptoethanol in DEPC-treated water) and total RNA
was extracted using the RNeasy Mini kit (Qiagen). cDNA was
obtained by reverse transcription (First-strand cDNA synthe-
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sis kit, Roche) and qRT-PCR using the SybrGreen method
(DyNAmoTM HS SYBR® Green qPCR Kit, Finnzymes) was
performed with primers specific for P. berghei 18S rRNA for
quantification of parasite load in the liver of each mouse.
Relative amounts of P. berghei mRNA were calculated
against the Hypoxanthine Guanine Phosphoribosyl Trans-
ferase (HPRT) housekeeping gene (Ploemen et al., 2009).
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ABSTRACT: The use of artemisinin or other endoperoxides
in combination with other drugs is a strategy to prevent
development of resistant strains of Plasmodium parasites. Our
previous work demonstrated that hybrid compounds, compris-
ing endoperoxides and vinyl sulfones, were capable of high
activity proﬁles comparable to artemisinin and chloroquine
while acting through two distinct mechanisms of action:
oxidative stress and falcipain inhibition. In this study, we adapted this approach to a novel class of falcipain inhibitors:
peptidomimetic pyrimidine nitriles. Pyrimidine tetraoxane hybrids displayed potent nanomolar activity against three strains of
Plasmodium falciparum and falcipain-2, combined with low cytotoxicity. In vivo, a decrease in parasitemia and an increase in
survival of mice infected with Plasmodium berghei was observed when compared to control. All tested compounds combined
good blood stage activity with signiﬁcant eﬀects on liver stage parasitemia, a most welcome feature for any new class of
antimalarial drug.
■ INTRODUCTION
Although the number of deaths caused by Plasmodium
falciparum malaria has probably decreased in recent years, the
disease remains a huge problem in much of the developing
world.1,2 Drug resistance is a major threat, and reports of
resistance to artemisinins are alarming, as we are now highly
dependent on the use of artemisinin-based combination
therapies (ACTs) to treat falciparum malaria.3−5 Semisynthetic
artemisinin derivatives (Figure 1) were a major breakthrough in
malaria chemotherapy because they produce a very rapid
therapeutic response against malaria parasites. ACT, the current
recommended treatment for uncomplicated falciparum malaria
in most of the world, includes ﬁve standard regimens, each
incorporating a rapid acting artemisinin derivative plus a slower
acting drug to kill parasites that may escape the rapid action of
the artemisinin and to limit selection of artemisinin-resistant
parasites.6 Artemisinins and other endoperoxides, such as
tetraoxane 2 (Figure 1), are highly active against the asexual
erythrocytic stage of infection. These compounds are
reductively activated in the presence of high concentrations
of iron(II) accumulated inside the parasite food vacuole after
the digestion of large quantities of host hemoglobin. Although
the mechanism of action of artemisinins is still a matter of
debate,7 it is generally accepted that the resulting radicals of this
activation can alkylate several targets in the parasite, leading to
its death.
A key feature of hybrid drugs is the presence of diﬀerent
mechanisms of action, against either a single target or diﬀerent
targets.8 A recent publication associates artemisinin resistance
Received: March 22, 2014
Published: May 13, 2014
Figure 1. Structures of artemisinin, 1, its derivatives dihydroartemi-
sinin (DHA), artemether (AM), and artesunate (AS) and the
tetraoxane RKA182, 2.
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to a form of antioxidant defense system,9 so it is particularly
important that a distinct mechanisms of action is combined
with endoperoxide drugs in the treatment of highly adaptable
parasites.10 We recently reported that tetraoxane−peptide vinyl
sulfone hybrids, 3 (Figure 2), are rapidly activated by iron(II),
releasing a potent irreversible inhibitor of falcipains inside the
parasitedigestive vacuole.11 Falcipain-2 and falcipain-3 are
cysteine proteases from P. falciparum involved in the digestion
of host hemoglobin in the digestive vacuole of the parasite,
providing amino acids for its survival and development.12
Although hybrid compounds 3 displayed weak to moderate
falcipain inhibitory activity, they were able to inhibit
hemoglobin digestion at low nanomolar concentrations,
consistent with the release of the parent peptide vinyl sulfone
triggered by iron(II).
To overcome selectivity issues often associated with
irreversible inhibitors, it is desirable to develop nonpeptidic
reversible inhibitors.12,13 Nitriles inhibit cysteine proteases by
forming a reversible thioimidate intermediate resulting from the
nucleophilic attack of the catalytic cysteine residue.14−18 Several
heterocyclic and peptidomimetic compounds containing a
nitrile warhead displayed excellent inhibitory activity against
falcipain-2 and against cultured P. falciparum.19 In particular,
appropriately decorated pyrimidine and triazine scaﬀolds were
shown to position vectors for the S1, S2, and S3 binding pockets
and to direct the thioimidate adduct toward the oxyanion hole
of the enzyme.18,19 An interesting feature of pyrimidine nitriles
is the possibility to accommodate a wide variety of substituents
at P3, without signiﬁcantly compromising enzyme inhibition.
19
This observation prompted us to hypothesize that tetraoxane−
pyrimidine nitrile constructs with the general structure 4
(Figure 2), in which the peroxide moiety occupies the P3
position, could be endowed with both falcipain and P.
falciparum inhibitory activities, in contrast to their hybrid
vinyl sulfone counterparts 3.11 This approach could provide a
new class of hybrid compounds whose ability to inhibit
falcipains would not be dependent on the rate of peroxide
activation triggered by theiron(II) present in the digestive
vacuole of the malaria parasite. We now report the synthesis of
tetraoxane−pyrimidine nitrile hybrids 4, and the evaluation of
these compounds against the blood and liver stages of malaria
infection, against falcipain-2, against mammalian cells, and in
vivo using a murine model of malaria. The adamantane-based
tetraoxane moiety was selected throughout this study, as it is
known to provide adequate metabolic stability.
■ RESULTS AND DISCUSSION
Synthesis. Tetraoxane−pyrimidine nitrile hybrids were
synthesized as depicted in Schemes 1 and 2. The tetraoxane
moiety was prepared by reacting the appropriate ketone 5 with
hydrogen peroxide 50% in acidic conditions to form a gem-
dihydroperoxide intermediate, which was then reacted with 2-
adamantanone in the presence of rhenium(VII) catalyst to give
6a−b (Scheme 1).20,21 The synthesis of the pyrimidine nitrile
moiety followed the procedure reported by Coteroń et al.19
Reductive amination of tert-butyl carbazate, 8, with the
appropriate aldehyde or ketone and subsequent nucleophilic
aromatic substitution reaction of the appropriate 2,4-dichlor-
opyrimidine with hydrazines 9a−c aﬀorded the 5- and 6-
substituted 2-chloropyrimidines 10a−f (Scheme 2). Cyanation
of 10a−f using potassium cyanide gave the corresponding 2-
cyanopyrimidines 11a−f.19 Boc removal with p-toluenesulfonic
acid and subsequent coupling with the acid chloride derived
from 7 yielded the ﬁnal products 4 with poor to moderate
yields (Scheme 2, method A). Alternatively, deprotection of the
hydrazine 10a−f followed by coupling with the acid chloride
derived from 7 and cyanation of the 2-chloropyrimidine hybrid
precursors 12 aﬀorded the ﬁnal products in moderate to good
yields (Scheme 2, method B).
Iron(II) Activation. Compound 13, lacking the tetraoxane
core, was prepared from the reductive cleavage of tetraoxane 4a
using iron(II) bromide in dichloromethane (Scheme 3).22 This
reaction is intended to simulate the intraparasitic endoperoxide
iron(II) mediated bioactivation process in the digestive vacuole
of the parasite.11,22 To conﬁrm the proposed mechanism, an
aqueous solution of 4a was treated with high concentration of
iron(II) sulfate, and the resulting mixture was analyzed by LC-
MS.22 Decomposition of 4a into ketone 13 followed ﬁrst-order
decay kinetics, with a half-life of 5.1 h (Figure 3). This value is
of the same order of magnitude as those observed with
tetraoxanes and 1,2,4-trioxolane analogues with basic side
chains, suggesting that the nature of the endoperoxide side
chain does not signiﬁcantly aﬀect the rate of iron(II)-triggered
activation.22
As depicted in Figure 3, ketone 13 accounts for 50% of the
initial concentration of 4a, indicating that another decom-
position pathway is operating under the conditions used.
Tetraoxane activation may involve coordination of iron(II)
either with O2, leading to the formation of 13, or with O1,
which leads to 2-adamantanone (Supporting Information
Scheme S1). Although we were not able to detect 2-
Figure 2. General structures: tetraoxane−vinyl sulfone hybrids 3;
tetraoxane−pyrimidine nitrile hybrids 4.
Scheme 1. Synthesis of Tetraoxanes 6 and 7a
aReagents and conditions: (a) (1) HCO2H, H2O2 50%, ACN, rt, 45
min, (2) 2-adamantanone, Re2O7, DCM, rt, 3 h; (b) NaOH, MeOH/
H2O (2:1), 80 °C, 1 h 30 s.
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adamantanone, these results are in agreement with similar
assays, where radicals derived from both activation pathways
were trapped with TEMPO and identiﬁed.20,22
Falcipain-2 Inhibition. Compounds 4 were screened
against recombinant falcipain-2. They displayed a wide range
of inhibitory activities, with IC50s ranging from 978 nM for 4g
to 3.4 nM for 4e (Table 1). These results suggest that
pyrimidine nitriles, in contrast to their vinyl sulfone hybrid
counterparts 3,11 can accommodate the bulky adamantane−
tetraoxane moiety at P3 without signiﬁcantly aﬀecting the
enzyme inhibitory activity. Structure−activity data revealed that
substituents at C-5 of the pyrimidine, which interact with the S1
pocket, markedly aﬀect the potency, with compounds bearing a
chlorine and bromine 270 and 55 times more potent than their
unsubstituted counterparts, respectively (4a and 4e versus 4f).
In contrast, a chlorine atom at C-6 had a deleterious eﬀect on
the inhibitory capacity, compared to the unsubstituted
compound (4g versus 4f), suggesting that substituents at this
position do not interact adequately with the S1 binding site.
Extending the linker between the two pharmacophoric moieties
decreased the activity by 6-fold (4a versus 4b). Finally, varying
the P2 moiety suggested that the isobutyl and cyclohexyl groups
are well accommodated by the S2 binding pocket, a result in
line with that reported by Coteroń et al.19
The predicted binding modes of hybrids 4 were further
supported by covalent molecular docking calculations. The
Scheme 2. Synthesis of Tetraoxanes−Pyrimidine Nitrile Hybrids 4a−ga
aReagents and conditions: (a) (1) aldehyde, dry DCM, molecular sieves 3 Å (2) Et3SiH, Pd/C, dry MeOH; (b) aldehyde or ketone, dry DCM,
glacial AcOH, NaBH(OAc)3, rt, ov; (c) 2,4-dichloropyrimidines, DIPEA, iPrOH, reﬂux, ov; (d) KCN, DABCO, DMSO/H2O (9:1), rt, 3 h; (e) (1)
pTsOH, ACN, rt, ov, (2) acid chloride of tetraoxane 7a−b, DIPEA, dry THF, rt, ov; (f) (1) pTsOH, ACN, rt, ov, (2) acid chloride of tetraoxane 7a,
DIPEA, dry THF, rt, ov; (g) KCN, DABCO, DMSO/H2O (9:1), rt, 3 h.
Scheme 3. Synthesis of Pyrimidine Nitrile 13a
aReagents and conditions: (a) FeBr2, ACN/DCM (1:1), rt, 24 h.
Figure 3. Time-dependence proﬁle for the activation of hybrid 4a by
18 equiv of FeSO4 in aqueous acetonitrile.
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm5004528 | J. Med. Chem. 2014, 57, 4916−49234918
crystal structure of FP-2 complexed with the epoxysuccinate
E64 at a resolution of 2.9 Å (PDB code: 3BPF) was employed
in the docking calculations. Inspection of the top ranking
solutions of 4a, 4b, 4e−g, and 13 inside the falcipain-2 binding
pocket (Figure 4A; see Supporting Information for a closer
view), selected according to their goldscore ﬁtness function,
revealed that these compounds present the pyrimidine
thioimidate adduct resulting from the nucleophilic attack of
the active site cysteine sitting in the S1 binding pocket, while
the isobutyl group and tetraoxane moiety ﬁt into the S2 and S3
binding sites, respectively. Remarkably, the parent ketone 13
adopts the same pose as 4a and 4e (Figure 4B), indicating that
the adamantane group do not signiﬁcantly disturb the
positioning of the pyrimidine inside the active site. The best
poses reveal that nitrogen atom of the thioimidate adduct is
stabilized by hydrogen bonding with Gln36 (N···H ∼ 2.4 Å)
and Cys42 (N···H ∼ 1.8 Å), while the carbonyl oxygen atom
establishes a hydrogen bond with Gly83 (O···H ∼ 1.3 Å). But
the most prominent feature observed for derivatives 4a, 4b, and
4e is the strong halogen bond established between 5-Br/5-Cl
and the Asn81 oxygen atom, ranging from 2.8 to 3.2 Å (Figure
4C). These values are lower than the sum of the van der Waals
radii of 3.27 Å23 and contrasts with the value of 3.54 Å
observed for the less potent 6-Cl counterpart 4g.
Target engagement in the parasites was conﬁrmed by the
observation that cultured parasites incubated with compounds
4 at 123 nM for 24 h beginning at the ring stage developed
swollen digestive vacuoles with the staining characteristics of
erythrocyte cytoplasm (Table 1). It has been previously shown
that this speciﬁc abnormality is indicative of a block in
hemoglobin hydrolysis caused by inhibition of falcipains.24
Remarkably, compounds 4 with low nanomolar IC50 values
against falcipain-2 were able to block hemoglobin degradation
Table 1. Antiplasmodial Activity against Chloroquine-Sensitive (3D7), Chloroquine-Resistant (W2), and Atovaquone-Resistant
(FCR3) Strains of P. falciparum, Falcipain-2 (FP-2) Inhibition, and Digestive Vacuole (DV) Swelling Induced by Hybrids 4a−g
and Ketone 13
IC50 (nM)
compd X R1 R2 3D7 W2 FCR3 FP-2 DV swelling (123 nM)a
4a CO −CH2CH(CH3)2 5-Br 58.1 ± 7.8 9.8 ± 1.5 NDb 16.4 ± 4.2 yes
4b CH2CO −CH2CH(CH3)2 5-Br 18.9 ± 4.2 22.8 ± 2.8 NDb 95.1 ± 0.4 yes
4c CO −CH2CH(CH2)4 5-Br 70.7 ± 1.2 29.5 ± 11.7 NDb 112 ± 9 NDb
4d CO −CH(CH2)5 5-Br 78.5 ± 8.4 22.4 ± 12.3 81.2 ± 7.2 25.3 ± 7.1 yes
4e CO −CH2CH(CH3)2 5-Cl 80.9 ± 17.2 33.8 ± 0 53.3 ± 7.6 3.4 ± 0.6 yes
4f CO −CH2CH(CH3)2 5-H 13.1 ± 0.6 47.3 ± 1.7 30.3 ± 9.4 909 ± 93 no
4g CO −CH2CH(CH3)2 6-Cl 28.4 ± 7.9 48.9 ± 2.5 37.7 ± 6.4 978 ± 205 no
13 48.2 ± 11.1 48.1 ± 3.2 NDb 58.4 ± 0.4 yes
ART 36.2 ± 4.7 14.1 ± 1.4 7.7 ± 8.7
CQ 9.25 ± 3.5 64.7 ± 5.5 36.2 ± 0.4
aObservation of DV swelling at 123 nM concentration. bND: not determined.
Figure 4. (A) Superimposition of docked conformations of hybrids 4a (green) and 4e (light-gray) inside FP-2 binding pocket. (B) Docked
conformation of ketone 13 inside FP-2 binding pocket. (C) Closer view of the interactions between compound 4e and residues present in the FP-2
binding pocket.
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at 123 nM to the same extent as the parent pyrimidine nitrile
13.
In Vitro Antimalarial Activity. Hybrid compounds 4 were
screened against chloroquine-sensitive (3D7), chloroquine-
resistant (W2), and atovaquone-resistant (FCR-3) P. falciparum
strains to assess their potential as blood stage antimalarials
(Table 2). Compounds 4a−g inhibited the growth of the three
P. falciparum strains with IC50 values ranging from 9.8 to 81.2
nM, while displaying negligible cytotoxicity, with EC50 values
against HEK293T mammalian cells ranging from 85 to >100
μM.
Activity against liver-stage malaria parasites is highly
desirable, in particular for radical cure of Plasmodium vivax
and Plasmodium ovale infections and in drugs used for the
prevention of malaria.25,26 Thus, compounds 4 were also
evaluated for their activity against liver stages of the rodent
parasite Plasmodium berghei and for cytotoxicity to Huh-7
human hepatoma cells, employing previously reported
methods.27 Primaquine, the only approved drug to treat liver
stage/relapsing malaria, and atovaquone were also included as
positive controls for liver stage activity. Most hybrid
compounds 4 signiﬁcantly decreased the parasite load in
Huh-7 cells when compared to untreated controls and were
more active than primaquine at 10 μM (Figure 5) but less
active than atovaquone at 2 μM (see Figure S3 in Supporting
Information). A similar activity proﬁle was observed for the
parent compound 13. The endoperoxide artemisinin was
inactive at both dose levels. To our knowledge, this is the
ﬁrst report of endoperoxides and pyrimidine nitriles active
against liver stage malaria. So far, only hybrid compounds based
on known liver stage antimalarials27−29 were noted to have
both blood and liver stage activity.
In Vivo Eﬃcacy. Hybrid 4e was selected to evaluate the in
vivo eﬃcacy in a murine model of infection as it displayed
excellent FP-2 inhibitory activity, high potency against all P.
falciparum strains, low cytotoxicity, and very good activity in the
liver stage assay. Hybrid 4e was tested at 30 mg/kg/day,
administered intraperitoneally for ﬁve consecutive days
beginning when parasitemia reached 4% at day 4 postinfection.
Infected mice receiving compound 4e responded initially to the
treatment, but parasitemia increased after day 8, to reach a
mean valueof 51% at day 18 postinfection. However, all animals
treated with compound 4e survived to day 18 after initial
inoculation with parasites (Figure 6).
■ CONCLUSIONS
In conclusion, we developed a series of tetraoxane−pyrimidine
nitrile hybrids 4 endowed with two distinct mechanisms of
action, a feature predicted to help prevent selection of drug
resistance. Remarkably, appending a large adamantane-based
tetraoxane moiety to the P3 position of the pyrimidine scaﬀold
did not aﬀect inhibitory potency against falcipain-2 or general
structure−activity relationship trends when compared to
previously reported pyrimidine nitriles. Although this enzyme
inhibitory proﬁle translated into excellent in vitro potency
against the erythrocytic stage malaria parasites, there was only
moderate in vivo eﬃcacy. Overall, this new class of hybrid
antimalarial compounds displayed good activity against the
blood and liver stages of malaria parasites and it is thus
deserving of further exploration.26
Table 2. In Vitro Cytotoxicity and Selectivity Index of
Hybrids 4a−g and Ketone 13
CC50 (μM) selectivity index (SI)
a
compd Hek293T NIH3T Hek293T NIH3T
4a >100 8.0 ± 0.7 >10000 816
4b 85.5 ± 6.7 2.3 ± 1.0 3750 101
4c >100 5.5 ± 0.5 >3390 186
4d >100 1.4 ± 0.1 >4464 63
4e >100 4.5 ± 1.3 >2959 133
4f >100 0.9 ± 0.1 >2114 19
4g >100 1.7 ± 0.8 >2045 35
13 >100 >100 >2079 >2079
aSI was calculated as the ratio of IC50 for in vitro cytotoxicity on
Hek293T and NIH3T to the IC50 of plasmodial inhibition against the
strain W2.
Figure 5. In vitro antimalarial activity against the liver stage of infection. In vitro inhibition of hepatic P. berghei infection by compounds 4a−g and
13. Compounds were added to Huh-7 hepatoma cells 1 h before infection with luciferase-expressing sporozoites. An amount of DMSO equivalent to
that in the highest compound concentration tested was used as a control. Then 48 h after the addition of P. berghei sporozoites, cell conﬂuence (dots
on bar plots) was assessed by AlamarBlue ﬂuorescence, and the infection rate (bars) was measured by quantifying the luciferase activity by
luminescence. The eﬀects of two concentrations (2 and 10 μM) of compounds 4a−g and 13 are shown. Results are expressed as means ± standard
deviations.
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■ EXPERIMENTAL SECTION
Chemistry. All chemicals and solvents were of analytical reagent
grade and were purchased from Alfa Aesar or Sigma-Aldrich.
Tetrahydrofuran was dried before use. Thin layer chromatography
was performed using Merck silica gel 60F254 aluminum plates and
visualized by UV light, iodine, potassium permanganate dip, and/or p-
anisaldehyde dip. Flash column chromatography was performed using
Merck silica gel 60 (230−400 mesh ASTM) eluting with various
solvent mixtures and using an air aquarium pump to apply pressure.
NMR spectra were recorded on a Bruker 400 Ultra-Shield (400 MHz)
in CDCl3; chemical shifts, δ, are expressed in ppm, and coupling
constants, J, are expressed in Hz. Mass analyses were determined using
a Micromass Quattro Micro API spectrometer, equipped with a
Waters 2695 HPLC module and Waters 2996 photodiode array
detector. High resolution mass spectra were performed in Unidade de
Espectrometria de Masas (HMRS-ESI-TOF), Santiago de Composte-
la, Spain. All compounds tested in the biological assays were
determined to be >95% pure by elemental analysis (for C, H, and
N). Melting points were determined using a Koﬂer Bock Monoscop M
and are uncorrected.
Preparation of Compounds 4 (Method A). (1) To a solution of
compound 11a−f (0.2 mmol) in ACN (1.5 mL) was added p-
toluenesulfonic acid (0.8 mmol). The mixture was stirred overnight at
room temperature. Then the solvent was removed under reduced
pressure and the crude taken up in EtOAc (30 mL) and washed with 1
M solution of Na2CO3 (30 mL). The aqueous phase was further
extracted with EtOAc (2 × 20 mL). The combined organic phases
were dried over Na2SO4, ﬁltered, and concentrated to give the free
amine. (2) A solution of tetraoxane 7a−b (0.24 mmol) in thionyl
chloride (2 mL) was reﬂuxed for 2 h. The mixture was concentrated
under reduced pressure, and then the acid chloride was taken up in dry
THF (1 mL) in nitrogen atmosphere. A solution of the appropriate
free amine (0.2 mmol) in dry THF (1 mL) was added to the acid
chloride. After stirring for 30 min at room temperature under nitrogen,
DIPEA (0.6 mmol) was added, followed by overnight stirring in the
same conditions. The mixture was diluted with DCM (30 mL) and
water (30 mL), and the phases were separated. The aqueous phase was
further extracted with DCM (2 × 20 mL). The combined organic
extracts were dried over Na2SO4, ﬁltered, and concentrated.
Puriﬁcation by ﬂash chromatography gave the pure compound.
Preparation of Compounds 4 (Method B). To a solution of
compound 12a−e (0.2 mmol) and DABCO (0.2 mmol) in DMSO/
water (9:1, 2 mL) was added KCN (0.22 mmol). The solution was
stirred for 5 h at room temperature. Then the mixture was poured into
ice water (30 mL) and extracted with EtOAc (2 × 30 mL). The
combined organic phases were washed with saturated solution of
NaHCO3 (30 mL), dried over Na2SO4, ﬁltered, and concentrated.
Puriﬁcation by ﬂash chromatography gave the pure compound.
Compound 4a. White solid (method A: 38% yield/method B: 60%
yield); mp 113−114 °C. 1H NMR (400 MHz, CDCl3) δ = 8.47 (s,
1H), 7.79 (s, 1H), 3.67 (bs, 2H), 2.38 (bs, 1H), 2.11−1.46 (m, 23H),
0.99 (d, J = 6.5 Hz, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ =
171.9, 160.7, 160.7, 141.6, 115.4, 110.7, 106.7, 106.2, 59.0, 41.6, 36.9,
33.1, 27.0, 26.3, 20.2 ppm. HRMS-ESI: m/z [M + Na]+ calcd for
C26H34BrN5O5, 598.1641; found, 598.1618.
Compound 4b. White solid (method A: 27% yield); mp 94−96 °C.
1H NMR (400 MHz, CDCl3) δ = 8.46 (s, 1H), 7.63 (s, 1H), 3.67 (bs,
2H), 2.19 (d, J = 6.7 Hz, 2H), 2.09−1.46 (m, 22H), 1.41−1.20 (m,
2H), 0.96 (d, J = 6.7 Hz, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ =
169.6, 160.7, 160.6, 141.6, 115.4, 110.6, 107.5, 106.0, 59.1, 39.5, 36.9,
33.3, 33.1, 33.1, 27.0, 27.0, 26.3, 20.2 ppm. HRMS-ESI: m/z [M + H]+
calcd for C27H37BrN5O5, 590.1978; found, 590.1961.
Compound 4c. White solid (method A: 10% yield/method B: 66%
yield); mp 190−191 °C. 1H NMR (400 MHz, CDCl3) δ = 8.44 (s,
1H), 7.69 (s, 1H), 3.75 (bs, 2H), 2.42−2.31 (m, 1H), 2.25−2.15 (m,
1H), 2.07−1.47 (m, 26H), 1.27 (m, 4H) ppm. 13C NMR (101 MHz,
CDCl3) δ = 172.0, 160.7, 160.7, 141.8, 115.5, 110.9, 106.8, 106.2, 56.4,
41.7, 37.5, 37.0, 33.2, 30.7, 27.1, 27.1, 25.2 ppm. HRMS-ESI: m/z [M
+ H]+ calcd for C28H37BrN5O5, 602.1978; found, 602.1962.
Compound 4d. White solid (method A: 8% yield); mp 148−149
°C. 1H NMR (400 MHz, CDCl3) δ = 8.41 (s, 1H), 7.47 (s, 1H), 4.54
(bs, 1H), 2.42 (bs, 1H), 2.13−1.20 (m, 31H), 1.20−1.01 (m, 2H)
ppm. 13C NMR (101 MHz, CDCl3) δ = 172.5, 160.4, 159.6, 141.7,
115.5, 110.7, 106.7, 106.3, 59.6, 36.9, 33.1, 27.0, 25.5 ppm. HRMS-
ESI: m/z [M + H]+ calcd for C28H37BrN5O5, 602.1978; found,
602.1971.
Compound 4e. White solid (method B: 57% yield); mp 134−137
°C. 1H NMR (400 MHz, CDCl3) δ = 8.28 (s, 1H), 7.79 (s, 1H), 3.66
(bs, 2H), 2.40−2.27 (m, 1H), 2.08−1.46 (m, 23H), 0.97 (d, J = 6.7
Hz, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ = 172.2, 159.8, 157.7,
141.1, 117.7, 115.3, 110.7, 106.7, 59.2, 41.6, 36.9, 33.1, 27.0, 27.0, 26.4,
20.2 ppm. HRMS-ESI: m/z [M + H]+ calcd for C26H35ClN5O5,
532.2327; found, 532.2312.
Compound 4f. White solid (method B: 43% yield); mp 196−197
°C. 1H NMR (400 MHz, CDCl3) δ = 8.22 (d, J = 6.0 Hz, 1H), 8.06
(bs, 1H), 6.61 (d, J = 6.0 Hz, 1H), 3.97−3.25 (m, 2H), 2.47−2.33 (m,
1H), 2.07−1.47 (m, 23H), 0.93 (d, J = 6.5 Hz, 6H) ppm. 13C NMR
(101 MHz, CDCl3) δ = 158.5, 156.2, 144.1, 116.0, 110.7, 106.7, 105.6,
Figure 6. In vivo mouse eﬃcacy studies for compound 4e in the P. berghei mouse model. Mice were infected with parasites on day 0, and compound
4e dosing began on day 4 and lasted for a total of 5 consecutive days (indicated by the arrows). Dosing was by ip administration at 30 mg/kg bw. (A)
Parasitemia curve; (B) survival curve.
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41.8, 36.9, 33.1, 29.7, 27.0, 26.7, 20.1 ppm. HRMS-ESI: m/z [M −
H]− calcd for C26H34N5O5, 496.2560; found, 496.2568.
Compound 4g. White solid (method B: 37% yield); mp 106−108
°C. 1H NMR (400 MHz, CDCl3) δ = 7.58 (s, 1H), 6.60 (s, 1H),
3.98−3.13 (m, 2H), 2.40 (bs, 1H), 2.14−1.46 (m, 23H), 0.95 (d, J =
6.4 Hz, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ = 160.7, 143.5,
115.0, 110.8, 106.6, 104.6, 41.9, 36.9, 33.1, 27.0, 26.7, 20.1 ppm.
HRMS-ESI: m/z [M − H]− calcd for C26H33ClN5O5, 530.2170;
found, 530.2173.
In Vitro Activity Assay against Blood Stage of Infection.
Synchronized ring-stage P. falciparum strain W2 parasites were
cultured with multiple concentrations of test compounds (added
from 1000× stocks in DMSO) in RPMI 1640 medium with 10%
human serum. After 48 h of incubation, when control cultures
contained new rings, parasites were ﬁxed with 1% formaldehyde in
phosphate-buﬀered saline (PBS), pH 7.4, for 48 h at room
temperature; then they were labeled with YOYO-1 (1 nM; Molecular
Probes) in 0.1% Triton X-100 in PBS. Parasitemia was determined
from dot plots (forward scatter versus ﬂuorescence) acquired on a
FACSort ﬂow cytometer using CellQuest software (Becton Dick-
inson). Fifty percent inhibitory concentrations (IC50 values) for
growth inhibition were determined with GraphPad Prism software
from plots of the percentage of parasitemia of the control relative to
the inhibitor concentration. In each case, the goodness of the curve ﬁt
was documented by R2 values of 0.95.
In Vitro Activity against Liver Stage of Infection. Inhibition of
liver-stage infection by test compounds was determined by measuring
the luminescence intensity in Huh-7 cells infected with a ﬁreﬂy
luciferase expressing P. berghei line, PbGFP-Luccon, as previously
described.30 Huh-7 cells, from a human hepatoma cell line, were
cultured in 1640 rpmI medium supplemented with 10% v/v fetal calf
serum, 1% v/v nonessential amino acids, 1% v/v penicillin/
streptomycin, 1% v/v glutamine, and 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), pH 7, and maintained at 37
°C with 5% CO2. For infection assays, Huh-7 cells (1.2 × 10
4 per well)
were seeded in 96-well plates the day before drug treatment and
infection. The medium was replaced by medium containing the
appropriate concentration of each compound approximately 1 h prior
to infection with sporozoites freshly obtained through disruption of
salivary glands of infected female Anopheles stephensi mosquitoes.
Sporozoite addition was followed by centrifugation at 1700g for 5 min.
Then 24 h after infection, the medium was replaced by fresh medium
containing the appropriate concentration of each compound. Parasite
infection load was measured 48 h after infection. The eﬀect of the
compounds on the viability of Huh-7 cells was assessed by the
AlamarBlue assay (Invitrogen, U.K.) using the manufacturer’s
protocol.
Falcipain-2 Inhibition Assay. IC50s against falcipain-2 were
determined as described earlier.24 Brieﬂy, equal amounts (∼1 nM) of
recombinant falcipain-2 were incubated with diﬀerent concentrations
of vinyl sulfones (added from 100× stocks in DMSO) in 100 mM
sodium acetate (pH 5.5)−10 mM dithiothreitol for 30 min at room
temperature before addition of the substrate benzoxycarbonyl-Leu-
Arg-7-amino-4-methyl-coumarin (ﬁnal concentration, 25 μM). Fluo-
rescence was continuously monitored for 30 min at room temperature
in a Labsystems Fluoroskan II spectroﬂuorometer. IC50s were
determined from plots of activity over enzyme concentration with
GraphPad Prism software.
In Vivo Assay. C57Bl/6J mice were infected by intraperitoneal
inoculations of 2 × 106 GFP-expressing P. berghei ANKA-infected
erythrocytes. Parasitemias were monitored daily by microscopy and
ﬂow cytometry. Drug treatment was initiated when blood parasitemias
were ca. 3.9%. At this point, 30 mg/kg bw of compound 4a were
administered once daily by intraperitoneal injection for 5 days. An
equivalent amount of drug vehicle was injected in control mice.
Parasitemias, disease symptoms, and survival were monitored daily
from the onset of treatment until the end of the experiment. The
experiment was terminated following 10 consecutive of growing blood
parasitemia in treated mice. Parasitemias of control mice increased
steadily until day 6 postinfection, when all mice died with symptoms of
experimental cerebral malaria.
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ABSTRACT: In a search for eﬀective compounds against both the blood- and
liver-stages of infection by malaria parasites with the ability to block the
transmission of the disease to mosquito vectors, a series of hybrid compounds
combining either a 1,2,4-trioxane or 1,2,4,5-tetraoxane and 8-aminoquinoline
moieties were synthesized and screened for their antimalarial activity. These
hybrid compounds showed high potency against both exoerythrocytic and
erythrocytic forms of malaria parasites, comparable to representative trioxane-
based counterparts. Furthermore, they eﬃciently blocked the development of the sporogonic cycle in the mosquito vector. The
tetraoxane-based hybrid 5, containing an amide linker between the two moieties, eﬀectively cleared a patent blood-stage P.
berghei infection in mice after i.p. administration. Overall, these results indicate that peroxide-8-aminoquinoline hybrids are
excellent starting points to develop an agent that conveys all the desired antimalarial multistage activities in a single chemical
entity and, as such, with the potential to be used in malaria elimination campaigns.
KEYWORDS: Antimalarials, endoperoxide, sporogonic cycle, P. berghei
Malaria is a potentially life-threatening disease caused byinfection with parasites of the genus Plasmodium and
transmitted to humans through the bite of infected female
Anopheles mosquitoes.1 Among the ﬁve Plasmodium species that
commonly infect humans, P. falciparum is responsible for most
of the mortality worldwide.2 Parasite resistance to antimalarial
drugs remains a real and ever-present danger. For this reason,
the WHO recommends that P. falciparum malaria should be
treated with artemisinin (ART, 1)-based combination therapies
(ACT), in which the ART-based component is combined with
a second, longer-acting agent.1,3 Artemisinin and its derivatives
are potent blood schizontocides, acting rapidly against parasitic
forms that invade erythrocytes and cause disease symptoms.4
The ultimate goal of eradicating malaria will beneﬁt greatly
from a drug that eliminates all life cycle stages of parasites.5
Malaria parasites undergo an asymptomatic, obligatory
developmental phase in the liver, which precedes the formation
of red blood cell-infective forms.6 Thus, the liver stage of
infection oﬀers important potential for disease prevention, as
intervention at this stage acts before the onset of symptoms,
providing a true causal prophylactic strategy.7 In addition, P.
vivax, the second most prevalent species causing human
malaria, and P. ovale infections can generate cryptic parasite
forms called hypnozoites that persist in the liver for long
periods of time and that, upon reactivation, are responsible for
relapses of malaria.8 Thus, antiliver stage drugs would also be
beneﬁcial for a malaria eradication campaign through
elimination of the long-lived hypnozoites of P. vivax and P.
ovale in the liver.8,9 Primaquine (2, PQ, Chart 1) is the only
drug currently used for the radical cure of P. vivax and P. ovale
malaria and is active against the transient liver forms of all
Plasmodium species. Moreover, PQ is also used as a
gametocytocidal, i.e., it is active against the blood-circulating
sexual forms of the parasite that are transmitted to the
mosquito upon a blood meal, and in this way, it is able to block
the transmission of infection from the human host to mosquito
vectors.10,11 The liver and sporogonic stages of malaria parasites
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have remained largely underexploited as antimalarial targets due
to the poorly understood biology of these life-cycle stages and
the inherent technical diﬃculties in studying them.7,11 Only
recently have systematic eﬀorts toward the identiﬁcation of
novel liver schizontocidal and transmission blocking scaﬀolds
been reported.4,12−14
Endoperoxide-based hybrid compounds represent an attrac-
tive alternative to ACTs.15−19 ART contains a 1,2,4-trioxane
core that is reductively activated by iron(II) heme, a byproduct
of host hemoglobin degradation, to form carbon-centered
radicals capable of reacting with heme and proteins.20 An
alternative model for the antimalarial mechanism of endoper-
oxides has been put forward by Haynes and Monti whereby
endoperoxides mediate their antimalarial activity through
interaction with cofactors. The tetraoxanes reported here are
also likely to be capable of oxidizing cofactors such as FADH2
and diﬀerences in activity between trioxanes and tetraoxanes
may reﬂect the diﬀerent oxidizing capacities of the two
heterocycles.21,22
We recently reported, for the ﬁrst time, the ability of PQ-
ART hybrid molecules, e.g., 3, to impair the liver and
erythrocyte stages of Plasmodium, a result that paves the way
for the exploitation of this approach for malaria control and
eradication.23 We now extend this hybrid-based strategy to fully
synthetic 1,2,4,5-tetraoxanes, a class of peroxides with potent
blood schizontocidal activity.24 The aims of this study were (i)
to evaluate the eﬃcacy of hybrid compounds 5, 8, 10, and 12
(Scheme 1) against Plasmodium liver and erythrocyte stages
and compare their activities to those of their 1,2,4-trioxane
counterparts 16 and 18 (Schemes 2 and 3), and (ii) to
determine their potential as transmission-blocking agents.
The preparation of hybrid compounds 5, 8, 10, and 12 is
outlined in Scheme 1. Compounds 5 and 10, containing an
amide linker between the two pharmacophoric moieties, were
synthesized by reacting tetraoxanes 4 and 9 with PQ, using
TBTU and methyl chloroformate as coupling agents,
respectively. Tetraoxanes 4 and 9 as starting materials were
prepared via a rapid three-step synthesis that was previously
reported.24−26
The synthesis of hybrid 8, the amine counterpart of 5, started
with the conversion of tetraoxane 4 to the Weinreb amide 6,
which was then reduced to the corresponding aldehyde 7 with
LiAlH4.
27−29 Reductive amination of 7 with PQ and NaBH-
(AcO)3 gave compound 5 in moderate yield. Hybrid 12 was
synthesized by reductive amination of tetraoxane 11 with PQ
and NaBH(AcO)3.
30 The 1,2,4-trioxane-based hybrid 16, the
amine counterpart of the previously reported amide 17, was
prepared as outlined in Scheme 2.23 The synthetic pathway
started with ART, which was converted to 10β-carboxymethyl-
10-desoxy-dihydroartemisinin 13.31,32 Following the same
procedure used for 6, compound 13 was converted to the
Weinreb amide 14 and then reduced to the corresponding
aldehyde 15 with LiAlH4. Reductive amination of 15 with PQ
in acetic acid gave compound 16 in moderate yield. Finally,
hybrid 18, the amide counterpart of 3, was prepared by reacting
artelinic acid with PQ and TBTU.
Chart 1. Structures of Arteminisin, 1, Primaquine, 2, and an
Artemisinin−Primaquine Hybrid, 3
Scheme 1. Synthesis of Tetraoxane-Primaquine Hybridsa
aReagents and conditions: (i) a, TBTU, DCM, TEA, 0 °C, 1 h; b, PQ,
DCM, TEA, rt. (ii) CH3NHOMe, TBTU, DCM, TEA, rt, 7 h. (iii)
LiAlH4, THF, 0 °C, 1 h. (iv) a, PQ, DCM, rt, 30 min; b,
NaBH(AcO)3, AcOH, rt, 16 h. (v) a, CH3OCOCl, TEA, DCM, 0
°C 1 h; b PQ, 0 °C 30 min, rt, 1.5 h.
Scheme 2. Synthesis of Trioxane−Primaquine Hybrid 16 and
Structure of Hybrid 17a
aReagents and conditions: (i) CH3NHOMe, TBTU, DCM, TEA, rt, 7
h. (ii) LiAlH4, THF, 0 °C 2 h. (iii) a, PQ, DCM, rt, 30 min; b,
NaBH(AcO)3, AcOH, rt.
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Tetraoxanes 5, 8, 10, and 12 and semisynthetic trioxanes 16
and 18 were ﬁrst screened for activity against the erythrocyte-
stage of chloroquine-resistant W2-strain P. falciparum (Table
1). Compounds 5, 8, 10, and 12 inhibited the growth of
parasites with IC50 values ranging from 21 to 45 nM, suggesting
that the nature of the linker between the tetraoxane and PQ
moieties does not signiﬁcantly aﬀect antiplasmodial activity.
Trioxanes 16 and 18 were slightly more potent than
tetraoxanes as antiplasmodial agents, with IC50 values of 9
and 5 nM, respectively (Table 1). These values are of the same
order of magnitude as those reported for their counterparts 3,
17, and ART. As expected, PQ showed only modest activity in
this assay.
To evaluate the abilities of hybrids 5, 8, 10, 12, 16, and 18 to
inhibit infection of liver cells by malaria parasites, the
compounds were tested using an in vitro infection model that
employs a human hepatoma cell line (Huh7) and the rodent
malaria parasite P. berghei.7 Parasite load was assessed by
bioluminescence measurements following infection with
luciferase-expressing parasites, as previously described.33 The
results were compared with those obtained for a tetraoxane
lacking the 8-aminoquinoline moiety, the ethyl ester of 4
(Table 1). All hybrids showed high potency against the liver
forms of the parasite, with most of the compounds displaying
IC50 values in the low to mid nM range. In contrast, the parent
tetraoxane showed to be inactive at 10 μM, suggesting that this
scaﬀold is not intrinsically eﬀective against the liver stages of
the parasite. Furthermore, hybrids were signiﬁcantly more
potent than PQ and the 1:1 PQ−ART mixture. This is
consistent with what has been previously reported for
compounds 3 and 17.23 Additionally, none of the compounds
signiﬁcantly aﬀected Huh7 cell proliferation, indicating that
tetraoxane−PQ hybrids are selective and nontoxic antimalarial
agents (Table 1).
Since PQ is known to undergo extensive oxidative
deamination at the primary amine, the metabolic stability of
tetraoxane-based hybrids 5 and 8 was evaluated in rat liver
microsomes, at 37 °C. From the results presented in Table 2 it
is possible to conclude that tetraoxane 5, containing an amide
linker between the two pharmacophoric moieties, displayed a
high rate of metabolism in rat liver microsomes and predicted
in vivo hepatic extraction ratio, EH. In contrast, its amine
counterpart 8 presented an intermediate EH values, suggesting
that metabolic susceptibility of tetraoxane hybrids are aﬀected
by the nature of the linker between the two moieties. Neither
primaquine nor its oxidative deamination product, carbox-
yprimaquine,10 were detected in the incubation mixtures,
suggesting that other metabolic pathways might be operating
for 5 and 8. In addition, these hybrids did not degrade when
incubated in 80% human plasma for 3 days.
Having determined the activity proﬁle of tetraoxane-based
hybrids against the blood- and liver-stage of infection, we then
evaluated the in vivo antimalarial eﬃcacy of compound 5 using
GFP-expressing P. berghei ANKA-infected male C57Bl/6J mice.
This compound was administered i.p. at 30 mg/kg dose once a
day for 5 days. Parasitemias were monitored daily by
microscopy and ﬂow cytometry. Remarkably, compound 5
completely and irreversibly cleared the parasitemia by day 8
postinfection, and all treated animals survived until the end of
the experiment, whereas all control mice succumbed with signs
of experimental cerebral malaria at day 6 postinfection (Figure
1), clearly indicating that tetraoxane-based hybrids have
curative value. Furthermore, no adverse reactions were
observed following administration of 5 at the dosage regimen
used in this study.
The potential of tetraoxane hybrids to inhibit the sporogonic
cycle of the parasite within the mosquito was also evaluated
using an established in vivo infection model consisting of
BALB/c mice infected with P. berghei ANKA-GFP and
Anopheles gambiae mosquitoes.34,35 In this model, mice infected
with parasitised erythrocytes were treated by a single i.p.
injection of each compound at two dose levels (10 and 25
μmol·kg−1). Two hours after administration, glucose-starved
mosquitoes were allowed to feed on the anesthetized mice. The
engorged mosquitoes were maintained at 19 ± 1 °C, for 10
days and then collected and dissected for microscopy detection
of oocysts in midguts. The criteria used to assess the
antimalarial activity of each compound were the percentage
of mosquitoes with oocysts and the mean number of oocysts
per infected mosquito, when compared to nontreated controls.
Scheme 3. Synthesis of Trioxane−Primaquine Hybrid 18a
aReagents and conditions: (i) a, TBTU, DCM, TEA, 0 °C, 1 h; b, PQ,
DCM, TEA, rt.
Table 1. In Vitro Antimalarial Activity and Toxicity of
Tetraoxanes 5, 8, 10, and 12 and Trioxanes 16−18
in vitro activity (IC50/nM) cytotoxicity (IC50/μM)
compd blood-stagea liver-stageb Huh7
3 12.5c 155c ND
5 21.1 538 >100
8 45.2 >1000 5.02
10 36.5 604 2.57
12 21.6 330 8.20
16 9.3 >1000 32.8
17 9.1c 523c ND
18 5.1 67 73.0
4, ethyl ester 128.2 NA ND
PQ 3300 7500 ND
ART 8.2 NA ND
PQ + ART ND 9714 ND
aDetermined against the chloroquine-resistant P. falciparum W2 strain.
bDetermined against P. berghei; ND, not determined; NA, not active
(>10 μM). cRef 23.
Table 2. In Vitro Metabolism of Compounds 5 and 8 in Rat
Liver Microsomes and Predicted in Vivo Metabolism Data
compd
t1/2
(min)
CLint,invitro
(μL/min/mg protein)
predicted
EH
putative
metabolitesa
5 10 132.8 0.81 Not detected
8 27 51.2 0.62 Not detected
aPrimaquine and carboxyprimaquine.
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Inspection of data presented in Table 3 shows that compounds
5, 8, 10, and 12 aﬀected the development of the sporogonic
cycle of P. berghei in A. gambiae mosquitoes at the dose levels of
10 and 25 μmol·kg−1. In particular, compound 5 was superior
to PQ, and completely inhibited the appearance of oocysts in
mosquito midguts when administered at 25 μmol·kg−1.
Compounds 8, 10, and 12 also markedly decreased the
percentage of infected mosquitoes as well as the number of
oocysts at the highest dose tested. Although it should be noted
that this in vivo model cannot speciﬁcally ascribe the drug eﬀect
to either gametocytocidal or sporontocidal activity, the results
clearly show that hybrids 5, 8, 10, and 12 are eﬀective at
interrupting the transmission of malaria parasites to mosqui-
toes.
In conclusion, a new class of hybrid compounds combining
endoperoxides and 8-aminoquinoline pharmacophores was
developed to target both blood- and liver-stages of parasites
and to block the transmission of infection to mosquito vectors.
The in vitro antimalarial proﬁle of these compounds reveals
that they display potent inhibitory activity against the blood
stage of infection, with IC50 values in the nanomolar range, a
level of activity similar to that of artemisinin-based hybrid
compounds. Screening against P. berghei liver stage of infection
revealed that both the tetraoxane- and trioxane-based series are
potent inhibitors of the exoerythrocytic forms of the parasite,
with IC50 values in the submicromolar range, being superior to
a 1:1 PQ−ART mixture.23 In vivo studies revealed that
compound 5 irreversibly cleared the parasitemia from infected
mice, while screening of transmission-blocking activity showed
that the tetraoxanes show potent activity in reducing the
percentage of infected mosquitoes and the mean number of
oocysts per mosquito. These results indicate that these hybrids
are excellent starting points to develop agents with the potential
to be used in malaria eradication campaigns since they display
all the desired antimalarial multistage activities.
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Figure 1. In vivo mouse eﬃcacy studies for compound 5 in the P.
berghei mouse model. Mice were infected with parasites on day 0, and
compound 5 dosing began on day 4 and lasted for a total of 5
consecutive days (indicated by the arrows). Dosing was by i.p.
administration at 30 mg/kg b.w. (A) Parasitemia curve; (B) survival
curve.
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(P < 0.05) using the Mann−Whitney test.
ACS Medicinal Chemistry Letters Letter
dx.doi.org/10.1021/ml4002985 | ACS Med. Chem. Lett. 2014, 5, 108−112111
(3) Martinelli, A.; Moreira, R.; Cravo, P. V. L Malaria combination
therapies: Advantages and shortcomings. Mini-Rev. Med. Chem. 2008,
No. 8, 201−212.
(4) Delves, M.; Plouffe, D.; Scheurer, C.; Meister, S.; Wittlin, S.;
Winzeler, E. A.; Sinden, R. E.; Leroy, D. The activities of current
antimalarial drugs on the life cycle stages of plasmodium: A
comparative study with human and rodent parasites. PLoS Med.
2012, 9, e1001169.
(5) The malERA Consultative Group on Drugs.. A research agenda
for Malaria eradication: Drugs. PloS Med. 2011, 8, e1000402.
(6) Prudencio, M.; Rodriguez, A.; Mota, M. M. The silent path to
thousands of merozoites: the Plasmodium liver stage. Nat. Rev.
Microbiol. 2006, 4, 849−856.
(7) Prudencio, M.; Mota, M. M.; Mendes, A. M. A toolbox to study
liver stage malaria. Trends Parasitol. 2011, 27, 565−74.
(8) Wells, T. N.; Burrows, J. N.; Baird, J. K. Targeting the hypnozoite
reservoir of Plasmodium vivax: the hidden obstacle to malaria
elimination. Trends Parasitol. 2010, 26, 145−51.
(9) Derbyshire, E. R.; Mota, M. M.; Clardy, J. The next opportunity
in anti-malaria drug discovery: the liver stage. PLoS Pathog. 2011, 7,
e1002178.
(10) Vale, N.; Moreira, R.; Gomes, P. Primaquine revisited six
decades after its discovery. Eur. J. Med. Chem. 2009, 44 (3), 937−953.
(11) Rodrigues, T.; Prudencio, M.; Moreira, R.; Mota, M. M.; Lopes,
F. Targeting the liver stage of malaria parasites: A yet unmet goal. J.
Med. Chem. 2012, 55, 995−1012.
(12) Meister, S.; Plouffe, D. M.; Kuhen, K. L.; Bonamy, G. M. C.;
Wu, T.; Barnes, S. W.; Bopp, S. E.; Borboa, R.; Bright, A. T.; Che, J.
W.; Cohen, S.; Dharia, N. V.; Gagaring, K.; Gettayacamin, M.;
Gordon, P.; Groessl, T.; Kato, N.; Lee, M. C. S.; McNamara, C. W.;
Fidock, D. A.; Nagle, A.; Nam, T. G.; Richmond, W.; Roland, J.;
Rottmann, M.; Zhou, B.; Froissard, P.; Glynne, R. J.; Mazier, D.;
Sattabongkot, J.; Schultz, P. G.; Tuntland, T.; Walker, J. R.; Zhou, Y.
Y.; Chatterjee, A.; Diagana, T. T.; Winzeler, E. A. Imaging of
Plasmodium liver stages to drive next-generation antimalarial drug
discovery. Science 2011, 334, 1372−1377.
(13) Cruz, F. P.; Martin, C.; Buchholz, K.; Lafuente-Monasterio, M.
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